<SEC-DOCUMENT>0001062822-21-000035.txt : 20210506
<SEC-HEADER>0001062822-21-000035.hdr.sgml : 20210506
<ACCEPTANCE-DATETIME>20210506163524
ACCESSION NUMBER:		0001062822-21-000035
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		46
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210506
DATE AS OF CHANGE:		20210506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		21898449

	BUSINESS ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lxrx-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:4b8e7fc5-a67e-4e41-8672-ef3fbe451ee1,g:d40e2da2-7e73-4fe0-84fd-1f0cf7fd616c,d:a5892dcce25547a19d63f064d49677ff--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:lxrx="http://www.lexpharma.com/20210331" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80L2ZyYWc6NzM2MzM2NDE4MzZhNGE4NTkzNGViNDA3YjE4ZDhmMjMvdGFibGU6ODI2Zjg2ZGQzOWFiNGVhYzg5Mzg1MGQwYTdmZWVjNzIvdGFibGVyYW5nZTo4MjZmODZkZDM5YWI0ZWFjODkzODUwZDBhN2ZlZWM3Ml81LTQtMS0xLTA_923330d7-ac62-4c93-bd24-3f9a44fc5eeb">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80L2ZyYWc6NzM2MzM2NDE4MzZhNGE4NTkzNGViNDA3YjE4ZDhmMjMvdGFibGU6ODI2Zjg2ZGQzOWFiNGVhYzg5Mzg1MGQwYTdmZWVjNzIvdGFibGVyYW5nZTo4MjZmODZkZDM5YWI0ZWFjODkzODUwZDBhN2ZlZWM3Ml85LTQtMS0xLTA_a15f740d-6d35-422d-8c43-f949e5475742">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80L2ZyYWc6NzM2MzM2NDE4MzZhNGE4NTkzNGViNDA3YjE4ZDhmMjMvdGFibGU6ODI2Zjg2ZGQzOWFiNGVhYzg5Mzg1MGQwYTdmZWVjNzIvdGFibGVyYW5nZTo4MjZmODZkZDM5YWI0ZWFjODkzODUwZDBhN2ZlZWM3Ml8xMC00LTEtMS0w_69b4247d-3684-43d6-8615-452801e8eed6">2021</ix:nonNumeric><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80L2ZyYWc6NzM2MzM2NDE4MzZhNGE4NTkzNGViNDA3YjE4ZDhmMjMvdGFibGU6ODI2Zjg2ZGQzOWFiNGVhYzg5Mzg1MGQwYTdmZWVjNzIvdGFibGVyYW5nZTo4MjZmODZkZDM5YWI0ZWFjODkzODUwZDBhN2ZlZWM3Ml8xMS00LTEtMS0w_ce16ed66-6d19-4d79-80a7-70d84d7dfb74">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80L2ZyYWc6NzM2MzM2NDE4MzZhNGE4NTkzNGViNDA3YjE4ZDhmMjMvdGFibGU6ODI2Zjg2ZGQzOWFiNGVhYzg5Mzg1MGQwYTdmZWVjNzIvdGFibGVyYW5nZTo4MjZmODZkZDM5YWI0ZWFjODkzODUwZDBhN2ZlZWM3Ml8xNC00LTEtMS0w_cd7d56f8-5a85-403b-9146-190c708a36e8">0001062822</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i3242745ce2a44d3f9f9445dc84df1632_I20210504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dca67dbb6624abeb8141b5923482d81_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50ee913592ef4520b5d81d6e189446e8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fdc7cf67e874d559ff410b0ab012041_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e58e312dc3047689801cba0f72629d5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f0724b0fae84864825b9dc62f678c5b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a606756c32f497285a9518996aac3b4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d3a9feed1574e7ab2f1969416fef122_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie90037db436a4b29a12d6bbac4f4cca8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i375cc32ca2c34f1e9336833c1ed0ea7f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i078b6b9a2fc943a09745dbb2ce3a271f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80bed1b60e694ddf8bec5653c1a55108_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia36b6c47696646d39cb6d3753f25f8fc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d2a1d2958c44883b7cb551a566117ba_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i071c8ec8b6154a1e922ede9df8277cc5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6becb50947fe41d7a703d27c05c60d23_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bb8568447be4c9fbfc10b295ff7b33a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if27faa5c3eef4da8a2be4870c962c535_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24e6c722889a4e529025d61dbe7edbca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42dd529b05c74e7cb35485cf486d3ef7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1cdf94e04d943c08450a611bfc2b63f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa953ef8800f442aa472c4b20bef4764_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic60d7c15b6e143cdb8e7f57bad14a09a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04674a820fd84a47af510792ed23d319_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8da06dd15088483d9ddeaea504d86cd7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1df52d1685b845e99310b7cf678d9bc1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i191cef183ce042d78110d9e5f705083b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75076d7889ad4eb8b803991721300015_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie96e698d44f741e8b15ba8a973f9aaaa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e98480c8ab24073a57917c703b340ca_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f7ed8cd8f7b42aeb8bcb7b11be2be35_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b5277bb1cee46b0a0e275f43ab30ecd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05e826ffe0344bbbb51ccbc13eaa4d00_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i146253cab0294e3eae00a7148487429e_I20210301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icef415129a23469b9ec147c98cb56572_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7680cb4d42ed478997941e9bf13624ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c017c3c99f6498daff3ecf3edf83a48_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6aa61cc7aaf43e6bbc474b8505cc3d4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05f812c6327541b6b09fdc249c90d7f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5f92e864c7242d5879f8636e1617415_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c83f6001ecc4b738df4e9c1c3f4412f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f6b3dae24ed4be1a4420f2bc0f76d2f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c1c834ecce44f16b35b81cf92f8af4c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i291ed1f6abf04110bd6f3f96dfaf9687_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f3856fc70db4f0eb8819a27978a3fb5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25913c0c6d894c7284fdf1a62f452c6a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i128725cdccf34310af9e7048fc57e23a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafe798e7d357475783018b7f99e88eef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idce92942910c43e4903e00d0f785c79f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i538c6f098f45484a9093e4c6f76257da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f07d12ec62145c8975b2c25813bcab8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie788a1a6bb1842ee842bbab7098f63f2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id00ac6a719fe4e628278d8c2ce3383db_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01fc13da04a74ba9a24a1954fe5e09d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e16817a1f8b455fa37d4b4d3496642d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia420366f6ef2477b888780f5aa7343c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2fc5a7556d44214b71b2e8a010774b2_D20141101-20141130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-01</xbrli:startDate><xbrli:endDate>2014-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb9c8c0f84be4d2bb3ae691e86ab0e8b_I20141120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2014-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e1514570bdc407c8e2a1b9524eab9cc_I20200928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i683e05dc441240d9a2492d0fd1aa4361_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75c9ca72d87c4541bcbf8632f671f7ae_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0d9a71689364f11b5b23e80ebdf0b0e_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i404c6b80bc36405880a95d223586358a_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2747cad63b6941889a2232ada4034c1e_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0953aa39e2f84e829c3acc2d7f88a6a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9cf39493d3443c4a790590a54c215b8_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia5892dcce25547a19d63f064d49677ff_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF84Mg_4bae2902-df9e-4bbd-8e14-85e91870a1c6">10-Q</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:1.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6NDJiYTUyOGZiZmY1NDExMWIxMDdhMzkzZTY4NDRjZTUvdGFibGVyYW5nZTo0MmJhNTI4ZmJmZjU0MTExYjEwN2EzOTNlNjg0NGNlNV8wLTAtMS0xLTA_4adab47c-8a1e-4a0e-a2c5-664bfe934051">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                       For the Quarterly Period Ended <ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8xNjk_50c4b3c6-3c5c-4c6f-ba55-52d085a5289f">March 31, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:1.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6NTAxYjJiYTNlNDE5NDNmYWFjMzViM2YzODFlMmZhMjQvdGFibGVyYW5nZTo1MDFiMmJhM2U0MTk0M2ZhYWMzNWIzZjM4MWUyZmEyNF8wLTAtMS0xLTA_eb65dec4-1c9c-4c8d-ae95-07bcba855d92">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Transition Period from _____________ to _____________</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8yNjU_a229aa0a-dc04-43b9-a6db-bf617cae4c23">000-30111</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8yNjg_b63efd61-a380-4717-9e7c-1f213cdf7f98">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6N2YwNmEwNDYzMDhkNDUxMWI5ZDRhOWY3YzViMDIzZWMvdGFibGVyYW5nZTo3ZjA2YTA0NjMwOGQ0NTExYjlkNGE5ZjdjNWIwMjNlY18wLTAtMS0xLTA_6a361704-c5c5-4bbc-802e-1962f2d4011a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6N2YwNmEwNDYzMDhkNDUxMWI5ZDRhOWY3YzViMDIzZWMvdGFibGVyYW5nZTo3ZjA2YTA0NjMwOGQ0NTExYjlkNGE5ZjdjNWIwMjNlY18wLTEtMS0xLTA_877fd0f4-1a5b-4cd4-84f1-f79798d0ab7d">76-0474169</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8zMjg_d3aff391-8d67-41d3-b670-8f4923142808">8800 Technology Forest Place</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8zMzE_9b48c604-0e5d-43db-b858-408e9588ef88">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8zMzU_4dc0b39b-7b3e-43b9-8ed7-6bfd3ceae015">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8zMzg_44269fa5-5769-43ea-8476-2be2ea3fa2eb">77381</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of Principal Executive Offices and Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8zOTY_e0151a89-a4ce-4689-8314-15cbd462c451">281</ix:nonNumeric>) <ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF80MDA_baf1b776-db8a-4539-b3c5-1836ddca4fe8">863-3000</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6OWUxNzljOGI0OGVhNDZmN2ExYWRmMDM0YThhY2E5YjkvdGFibGVyYW5nZTo5ZTE3OWM4YjQ4ZWE0NmY3YTFhZGYwMzRhOGFjYTliOV8xLTAtMS0xLTA_9879a8ac-92c3-417f-b1d1-b878b3d57c4a">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6OWUxNzljOGI0OGVhNDZmN2ExYWRmMDM0YThhY2E5YjkvdGFibGVyYW5nZTo5ZTE3OWM4YjQ4ZWE0NmY3YTFhZGYwMzRhOGFjYTliOV8xLTEtMS0xLTA_2f8d1bea-bff6-4ad0-b3be-4a9673aec282">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6OWUxNzljOGI0OGVhNDZmN2ExYWRmMDM0YThhY2E5YjkvdGFibGVyYW5nZTo5ZTE3OWM4YjQ4ZWE0NmY3YTFhZGYwMzRhOGFjYTliOV8xLTItMS0xLTA_573ddee1-fa41-45a9-b09f-2f7291cbd7c6">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:30.263%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6MzcwYWY2ZmE3YTQyNDA0NTk2OTgwMDYwZGI0NTU2YTYvdGFibGVyYW5nZTozNzBhZjZmYTdhNDI0MDQ1OTY5ODAwNjBkYjQ1NTZhNl8wLTAtMS0xLTA_71db5b12-3489-499f-b0f9-8a2dd0d659e3">Yes</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:30.263%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6MDg1NTk2YmFjMmFhNDZkNTllMDhkM2NjYjFiNjZhYjUvdGFibGVyYW5nZTowODU1OTZiYWMyYWE0NmQ1OWUwOGQzY2NiMWI2NmFiNV8wLTAtMS0xLTA_93cadab2-c912-4b0c-a2e9-5b513bd26817">Yes</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;     <ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8xNTY1_c53f3374-b8ab-4153-979a-76b7ac41fe8c">Accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#9745;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          Non-accelerated filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;<ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8yMTY4_c955e644-5a68-4261-8f4e-e9fb11eab0f6">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;<ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8xNjg0_5754cfd2-c5e4-4c61-b604-06d2d87a3c76">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registration has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:30.263%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6MTYzMTkwMjMwMWJlNDg2MzlkNTQ2OTYxN2FjZGMzYzQvdGFibGVyYW5nZToxNjMxOTAyMzAxYmU0ODYzOWQ1NDY5NjE3YWNkYzNjNF8wLTEtMS0xLTA_5c7de822-17af-40d5-894e-e1fae5746150">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;4, 2021, <ix:nonFraction unitRef="shares" contextRef="i3242745ce2a44d3f9f9445dc84df1632_I20210504" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8yMDc3_77f7a174-2b87-4bc5-aed3-cf56d964d218">144,387,799</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.001 per share, were outstanding.  &#9744;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia5892dcce25547a19d63f064d49677ff_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_10">Factors Affecting Forward-Looking Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_10">2</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_13">Part I &#8211; Financial Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_13">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_16">Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_16">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Balance Sheets - March 31, 2021 (unaudited) and December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_19">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Comprehensive Loss (unaudited) - Three Months Ended March 31, 2021 and 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_22">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Stockholders&#8217; Equity (unaudited) - Three Months Ended March 31, 2021 and 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_25">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Cash Flows (unaudited) - Three Ended March 31, 2021 and 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_28">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Condensed Consolidated Financial Statements (unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_31">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_64">Management&#8217;s Discussion and Analysis of Financial Condition and Results&#160;of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_64">15</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_73">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_73">20</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_76">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_73">20</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_79">Part II &#8211; Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_79">21</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_82">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_82">21</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_85">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_85">21</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_88">Unregistered Sales of Equity Secu</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_88">rities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_88">23</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_91">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_91">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_94">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5892dcce25547a19d63f064d49677ff_94">26</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lexicon name and logo are registered trademarks of Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div><span><br/></span></div><div id="ia5892dcce25547a19d63f064d49677ff_10"></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Forward Looking Statements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report on Form 10-Q contains forward-looking statements.  These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology including &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under &#8220;Part&#160;II, Item 1A. - Risk Factors&#8221; and in our annual report on Form 10-K for the year ended December&#160;31, 2020, that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable, future results, levels of activity, performance or achievements may vary materially from our expectations. We are not undertaking any duty to update any of the forward-looking statements after the date of this quarterly report on Form 10-Q to conform these statements to actual results, unless required by law.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ia5892dcce25547a19d63f064d49677ff_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part I &#8211; Financial Information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ia5892dcce25547a19d63f064d49677ff_16"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ia5892dcce25547a19d63f064d49677ff_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except par value)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfNC0yLTEtMS0w_08d5eb59-bfdd-4617-8235-a31e76c7b777">97,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfNC00LTEtMS0w_b3ec9cbc-be3e-4148-925c-ae92543e786e">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfNS0yLTEtMS0w_74ad00ce-aa16-418c-871a-3005356f3590">43,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfNS00LTEtMS0w_a9311b17-8dd7-4bb2-a605-171569fdbef2">26,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfNi0yLTEtMS0w_1a7a81b5-2997-4719-b9eb-72a9bf93c642">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfNi00LTEtMS0w_9ffec7f4-5ded-42ba-b97a-b1f6320a4f50">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfOS0yLTEtMS0w_a04619bf-06c3-498d-8eed-bbabcf974027">3,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfOS00LTEtMS0w_dde114ca-713c-4e35-b9b2-12b8ebced6f6">5,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTAtMi0xLTEtMA_8dee9dbe-682f-496f-8905-e2ef93d91863">145,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTAtNC0xLTEtMA_d4fad955-5686-4854-8d94-36fccd9cd171">157,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization of $<ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjJkMWJlY2ZhN2ZiODQ1YzM4NGE5ODUyNDE0Mzg0Y2FlXzgw_29602ea2-7b5b-443e-8eb8-4277f2394159">5,851</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjJkMWJlY2ZhN2ZiODQ1YzM4NGE5ODUyNDE0Mzg0Y2FlXzg3_15f08e4b-0f5c-4f35-b352-a1c4468aefa8">5,815</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTEtMi0xLTEtMA_7b798cc3-81e5-4eba-8d6a-f172af96b195">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTEtNC0xLTEtMA_c7f45f38-216f-4bca-a206-8e4b8e546ca2">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTItMi0xLTEtMA_d4f05cdb-8159-4734-a752-99cc393c4e8c">44,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTItNC0xLTEtMA_13130e57-add3-4ea7-ad1e-98ddea337d7c">44,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTQtMi0xLTEtMA_26e12403-5e23-46b3-bbf7-0d6b985bb984">3,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTQtNC0xLTEtMA_d13a924a-328c-493d-97e8-47af811eb77b">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTUtMi0xLTEtMA_d7e96e15-fd89-458e-bea3-c0ea00db4883">193,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTUtNC0xLTEtMA_2bf8c93a-c302-423e-90a5-684429715f1e">203,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTgtMi0xLTEtMA_fa991ec4-ac25-46a6-86cc-bd15dcbf6bee">4,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTgtNC0xLTEtMA_460a8cb1-f6ba-441a-a0aa-2141df4c3202">5,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTktMi0xLTEtMA_b684be0d-2236-4a4a-89c9-2cf8572d3b99">22,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTktNC0xLTEtMA_25c6800f-5ac5-4346-b030-93b39a9258ca">29,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, net of deferred issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjEtMi0xLTEtMA_08bb348d-1457-4a36-a09e-d9ccbced58b3">11,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjEtNC0xLTEtMA_96f948ac-a8b8-4c3a-8c55-1accb4a95ab8">11,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjItMi0xLTEtMA_8296ee2f-78c2-4c51-b194-7d5093c3c8f1">38,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjItNC0xLTEtMA_bc2dca65-4000-4207-84f2-b11dcc7221d3">46,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjYtMi0xLTEtMA_15f53dde-2625-4c5d-b7e2-4ce7ed857a36">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjYtNC0xLTEtMA_10f3ffc0-6570-4f6a-bc2b-163244f8b2c0">611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjctMi0xLTEtMA_da59a6ea-8bd4-49a8-97b4-b2d7c3bd68fd">40,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjctNC0xLTEtMA_8c841fa0-77b0-4313-bb96-c88d949b17a9">47,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjgtMi0xLTEtMA_20108018-e957-4991-957a-1ced17d50f68"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjgtNC0xLTEtMA_e58715f8-a323-403e-beee-2df88620b07d"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; Equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzIy_0370998e-e6dd-47bc-9542-fa635a2ab1d6"><ix:nonFraction unitRef="usdPerShare" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzIy_1025b6ce-6e4d-4c56-b682-40564d214f30">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzM2_27c547a3-b40d-41ee-84d8-8e2e5af0621d"><ix:nonFraction unitRef="shares" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzM2_7000c803-2f22-4b2a-8fa1-9ddb93f5f6c1">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzU4_09dd3672-717a-47d4-9ea4-6c082e3aa3ae"><ix:nonFraction unitRef="shares" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzU4_66b5e28a-0eec-4ca7-8abf-a0765c80cd4b"><ix:nonFraction unitRef="shares" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzU4_d490778c-de6d-4091-9960-aac1b6af6027"><ix:nonFraction unitRef="shares" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzU4_f37de82c-35e6-46ea-a9d9-12ff7f94f338">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMi0xLTEtMA_1c38bb46-417d-4ef3-8ef2-753fb13e9933">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtNC0xLTEtMA_240f8354-0510-4341-85ec-a304d37c9067">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjIzMTQwNjhmNGM4MjQ2MTA5ODYxYzAyYjVhOWFhN2UwXzE4_1dd4b6a6-3eed-423e-b96b-e81052db9878"><ix:nonFraction unitRef="usdPerShare" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjIzMTQwNjhmNGM4MjQ2MTA5ODYxYzAyYjVhOWFhN2UwXzE4_4ea943d7-a763-4a78-8498-a150fd821f43">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjIzMTQwNjhmNGM4MjQ2MTA5ODYxYzAyYjVhOWFhN2UwXzMy_93428110-e8ef-4fba-b40a-5801e8de58d2"><ix:nonFraction unitRef="shares" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjIzMTQwNjhmNGM4MjQ2MTA5ODYxYzAyYjVhOWFhN2UwXzMy_f466b945-3893-4749-ab3f-154f0380d6fb">225,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjIzMTQwNjhmNGM4MjQ2MTA5ODYxYzAyYjVhOWFhN2UwXzU0_fd99beba-0703-4def-b5dd-7e72db11a338">145,552</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjIzMTQwNjhmNGM4MjQ2MTA5ODYxYzAyYjVhOWFhN2UwXzYx_269d65f2-4635-421c-979f-99c8319a3897">142,289</ix:nonFraction> shares issued, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtMi0xLTEtMA_f80c01cb-f20c-4303-92f8-caade9c7b33e">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtNC0xLTEtMA_03596f25-3f23-4f3e-9de1-bec2e19344dd">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzItMi0xLTEtMA_fca44f2b-771b-47de-b645-a87e7b135088">1,580,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzItNC0xLTEtMA_3197a247-de26-4905-9a90-eedeb9a7b86a">1,561,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzMtMi0xLTEtMA_4d42f7c3-2fde-4ed9-bb3f-e0312abfe69d">1,420,976</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzMtNC0xLTEtMA_2b321af1-1c85-46f5-b619-679d265768ec">1,400,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzQtMi0xLTEtMA_c05a69bf-4b02-46ac-bab6-e738d73b5f97">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzQtNC0xLTEtMA_d58ac012-a4aa-4c05-aa9d-63c36afec39e">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjhlNzc1OTM4YjY1MTQyM2JhM2Q3OGY2YzAyMjhmNTYyXzI5_eebdaf2b-cb68-4711-9ecc-6f9620169255">1,165</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjhlNzc1OTM4YjY1MTQyM2JhM2Q3OGY2YzAyMjhmNTYyXzM2_7507b07b-6dd7-4059-8425-1dc4ef68dfc3">793</ix:nonFraction> shares, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzUtMi0xLTEtMA_e8bb6ae5-5ef9-4448-99b1-28153e5412fb">7,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzUtNC0xLTEtMA_34b4f2fc-e055-4549-9445-141129337f76">4,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzYtMi0xLTEtMA_06c9e642-21ea-4356-a2cc-91ef21ffca17">152,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzYtNC0xLTEtMA_58bb9e69-3db5-4541-84d9-bab7ed24deae">156,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzctMi0xLTEtMA_48f660fa-82bd-415e-9be0-f6827c6ebd5c">193,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzctNC0xLTEtMA_341e3acc-bf02-4ec8-bbc5-08ea9e2ddcaf">203,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ia5892dcce25547a19d63f064d49677ff_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.385%"><tr><td style="width:1.0%"></td><td style="width:72.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.724%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="lxrx:Netproductrevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMy0yLTEtMS0w_1efa03b6-46aa-4865-8071-e12eb9e99d7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Netproductrevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMy00LTEtMS0w_77d36e20-9917-4078-bd9a-c258e054956f">7,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfNC0yLTEtMS0w_25a81b82-3ed5-46b7-b2fb-987665d59ccb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfNC00LTEtMS0w_6c8be643-5feb-462c-b674-3ea6cef2b461">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfNS0yLTEtMS0w_6b7347cb-85f2-4c65-a816-b04e4ad39c3d">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfNS00LTEtMS0w_bf0f37fa-29f6-4025-a26e-79caa34dd369">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfNi0yLTEtMS0w_c7fb513d-84f8-4075-8e23-ac79bb3197c6">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfNi00LTEtMS0w_44eaaac0-d65a-4fa3-a45e-d00d236032ee">7,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (including finite-lived intangible asset amortization)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfOC0yLTEtMS0w_e2d6c4bd-b7b7-4410-b052-fb8c26bd5428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfOC00LTEtMS0w_c3cf7196-b384-4e81-9438-9f52778085be">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfOS0wLTEtMS0wL3RleHRyZWdpb246MmM5ZTgwZDhkMDllNGM0ZGJhNWVkNmMxZmEwOGU1NTdfNjg_c65d5f34-f27b-4adb-aff6-393c389fda97">1,286</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfOS0wLTEtMS0wL3RleHRyZWdpb246MmM5ZTgwZDhkMDllNGM0ZGJhNWVkNmMxZmEwOGU1NTdfNzI_ae02a8ab-0919-4dc0-9ab4-65c80940710b">2,176</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfOS0yLTEtMS0w_0e9a780a-00a7-44f2-a482-617f6255db25">12,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfOS00LTEtMS0w_e9fe8935-d362-4d20-af53-14214ea6b513">55,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRhZGQwZjI0NDQzMTQ2YWQ4MGUxN2E4ZTA3MmNjZjEzXzc5_731b8fad-39c7-4884-adcb-9c7b931578a1">1,565</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRhZGQwZjI0NDQzMTQ2YWQ4MGUxN2E4ZTA3MmNjZjEzXzgz_f2f68caa-043a-44a2-9687-dd61e047a879">2,256</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Sellinggeneralandadministrativeexpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTEtMi0xLTEtMA_e17f92b4-a855-4cf7-949b-1618913dde94">8,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Sellinggeneralandadministrativeexpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTEtNC0xLTEtMA_4cd1c9a5-8771-4096-8057-432333b97a1a">14,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTUtMi0xLTEtMA_01dbad8f-12ae-4a55-8941-8863f1115b4f">20,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTUtNC0xLTEtMA_2fbe7c1d-1ac9-49bb-be35-f7cf47310ad1">70,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTgtMi0xLTEtMA_35c8b1af-851b-491e-ba0c-219ef972c14a">20,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTgtNC0xLTEtMA_8d0afa19-d03c-440a-8634-aca4b2ab3899">62,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjEtMi0xLTEtMA_c83350e7-2790-41d9-823e-39cc0358d51c">167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjEtNC0xLTEtMA_78bb3273-9fdb-494e-817a-076c543c1099">5,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjItMi0xLTEtMA_e71b2870-cd10-4ae2-9d1b-df130a8fcbfc">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjItNC0xLTEtMA_a5479848-5b25-46f1-840f-a3e389fbdc09">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjUtMi0xLTEtMA_6d594d9f-4e5e-4149-82b8-e53f9e12ad55">20,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjUtNC0xLTEtMA_0d128135-b711-455d-8ab0-8619ce6b3a80">66,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjYtMi0xLTEtMA_32707c9a-d77d-4248-b769-7d3159c5ed22">0.15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjYtNC0xLTEtMA_8a962d17-f9ac-4eae-a780-89a296620d6c">0.63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net loss per common share, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjktMi0xLTEtMA_1e880718-0c2e-4e6b-af59-d0b8ea9881d7">143,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjktNC0xLTEtMA_bc6ca58a-6a2f-4a0b-b1ca-03f6134ea117">106,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMzMtMi0xLTEtMA_fcb63a8c-4ef8-4ae1-8f65-127cf30ee165">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMzMtNC0xLTEtMA_8cf711c2-0c94-4d28-99c6-6b6d67f6c266">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMzQtMi0xLTEtMA_8021340a-6d9a-4946-9236-5b121640b800">20,947</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMzQtNC0xLTEtMA_29566e7c-1903-42fc-a58f-b5825cb48ed1">65,835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ia5892dcce25547a19d63f064d49677ff_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.722%"><tr><td style="width:1.0%"></td><td style="width:37.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.644%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Comprehensive Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2dca67dbb6624abeb8141b5923482d81_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMi0yLTEtMS0w_3510fa78-bc1f-48ef-9724-69f51dc998b3">106,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dca67dbb6624abeb8141b5923482d81_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMi00LTEtMS0w_89dabbac-8f96-47de-85e9-15042e617ba8">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50ee913592ef4520b5d81d6e189446e8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMi02LTEtMS0w_49b0ad34-3b8c-45de-858e-2087cb554512">1,462,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fdc7cf67e874d559ff410b0ab012041_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMi04LTEtMS0w_9df72f6e-35d8-4cf8-a583-a124c4bafee3">1,341,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58e312dc3047689801cba0f72629d5_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMi0xMC0xLTEtMA_fca86db9-ab33-409d-b755-8a9bb5c401d2">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f0724b0fae84864825b9dc62f678c5b_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMi0xMi0xLTEtMA_4954d27f-aafb-47d9-9d07-4c78c6f1153c">3,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a606756c32f497285a9518996aac3b4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMi0xNC0xLTEtMA_41689130-9096-4f6e-bde4-9d96f8fbe75e">117,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3a9feed1574e7ab2f1969416fef122_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNS00LTEtMS0w_70b0f88b-20ef-4fdd-b423-ae2645dfc05e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie90037db436a4b29a12d6bbac4f4cca8_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNS02LTEtMS0w_6bda058c-f40c-402d-8032-b0ba2aaf39a5">4,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375cc32ca2c34f1e9336833c1ed0ea7f_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNS04LTEtMS0w_fb3c3a6f-1139-45cd-ad6e-73a22e381814">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078b6b9a2fc943a09745dbb2ce3a271f_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNS0xMC0xLTEtMA_d8a29d4b-1538-407a-99a8-c2b5057c302a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80bed1b60e694ddf8bec5653c1a55108_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNS0xMi0xLTEtMA_5072857d-6866-4295-b99e-f2f2743170e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNS0xNC0xLTEtMA_759fb30a-dad7-4ad3-a594-84725a26c1cd">4,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d3a9feed1574e7ab2f1969416fef122_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNi0yLTEtMS0w_0d2c59c4-0f5f-4480-9346-67df1e458016">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3a9feed1574e7ab2f1969416fef122_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNi00LTEtMS0w_fa9eacb8-f987-47c3-a35c-a496205e2001">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie90037db436a4b29a12d6bbac4f4cca8_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNi02LTEtMS0w_6bdae9f4-e476-4b91-86ee-daddb3c11c34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375cc32ca2c34f1e9336833c1ed0ea7f_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNi04LTEtMS0w_ec4a6ccc-e849-4e15-8270-8f6adacaecd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078b6b9a2fc943a09745dbb2ce3a271f_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNi0xMC0xLTEtMA_64667a31-bf7e-43fd-9268-b25d953722d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80bed1b60e694ddf8bec5653c1a55108_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNi0xMi0xLTEtMA_45079f05-665a-4b24-844c-aeacf496912b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNi0xNC0xLTEtMA_c7ae40d7-7d0e-4429-b6c1-2d60bf180159">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3a9feed1574e7ab2f1969416fef122_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOC00LTEtMS0w_1f24e5d5-04ed-4d99-8623-9900e58184e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie90037db436a4b29a12d6bbac4f4cca8_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOC02LTEtMS0w_1d01378c-7535-4f0f-a287-96cbdaa79141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375cc32ca2c34f1e9336833c1ed0ea7f_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOC04LTEtMS0w_7e3a77cd-aba6-46c2-8e2c-4f86507272cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078b6b9a2fc943a09745dbb2ce3a271f_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOC0xMC0xLTEtMA_6f7a253e-48b3-428e-b101-011c78194d10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80bed1b60e694ddf8bec5653c1a55108_D20200101-20200331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOC0xMi0xLTEtMA_bb277ec7-d752-4c32-a16d-99a486bf671a">923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOC0xNC0xLTEtMA_00206502-ab4f-4c81-978f-c2527a189e7a">923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3a9feed1574e7ab2f1969416fef122_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOS00LTEtMS0w_39cff951-992b-4e27-a952-779230289639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie90037db436a4b29a12d6bbac4f4cca8_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOS02LTEtMS0w_8a36bc10-cd16-4596-a6e7-921f0868e146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i375cc32ca2c34f1e9336833c1ed0ea7f_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOS04LTEtMS0w_cdcf25b9-c2d2-4e80-86f8-a8797bf78f5c">66,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078b6b9a2fc943a09745dbb2ce3a271f_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOS0xMC0xLTEtMA_3072b429-cc46-4504-887a-6910c9f783e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80bed1b60e694ddf8bec5653c1a55108_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOS0xMi0xLTEtMA_bcd7f505-541d-43ec-b255-c6c1a62240cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i375cc32ca2c34f1e9336833c1ed0ea7f_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOS0xNC0xLTEtMA_9eaed459-5e90-4e0f-a1a7-779378f0cead">66,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3a9feed1574e7ab2f1969416fef122_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTAtNC0xLTEtMA_45ea9789-55a0-4fd0-835f-3a01dc195f4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie90037db436a4b29a12d6bbac4f4cca8_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTAtNi0xLTEtMA_b4ad5dec-d13d-41be-91f1-5cb06a92286b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375cc32ca2c34f1e9336833c1ed0ea7f_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTAtOC0xLTEtMA_55c4a7d5-4a1d-48f9-9e55-18b9025a9893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078b6b9a2fc943a09745dbb2ce3a271f_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTAtMTAtMS0xLTA_dfcefd53-515d-4f3c-9bdf-fd00510ae83d">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80bed1b60e694ddf8bec5653c1a55108_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTAtMTItMS0xLTA_25e65839-39bf-48c5-8a97-e042ca610054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTAtMTQtMS0xLTA_71aed17b-85f6-43ef-bae6-d91e12f0f186">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia36b6c47696646d39cb6d3753f25f8fc_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTItMi0xLTEtMA_85381979-e123-40bd-b5be-3d60889a0414">107,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia36b6c47696646d39cb6d3753f25f8fc_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTItNC0xLTEtMA_5807a132-f350-4fed-8c1d-2d444cbeabba">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d2a1d2958c44883b7cb551a566117ba_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTItNi0xLTEtMA_853c3228-31d6-4568-b7e5-1c9bbdd08d96">1,466,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i071c8ec8b6154a1e922ede9df8277cc5_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTItOC0xLTEtMA_4e634686-5755-409e-8e1f-6447ef6dcef0">1,408,055</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6becb50947fe41d7a703d27c05c60d23_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTItMTAtMS0xLTA_560c7f6a-f671-4e51-a84f-8d646e5cc2c2">860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bb8568447be4c9fbfc10b295ff7b33a_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTItMTItMS0xLTA_d5aad611-fd07-465a-8ace-d38dffa48a91">4,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27faa5c3eef4da8a2be4870c962c535_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTItMTQtMS0xLTA_96e0c860-4005-4b00-9bcd-24347db0d70f">54,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.506%"><tr><td style="width:1.0%"></td><td style="width:37.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Comprehensive Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24e6c722889a4e529025d61dbe7edbca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMi0yLTEtMS0w_56a9eeaf-1d1d-498f-9ec3-fa8e1f607ba2">142,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e6c722889a4e529025d61dbe7edbca_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMi00LTEtMS0w_90e5d74c-65a7-43b6-b64b-cb1e7bd768cd">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42dd529b05c74e7cb35485cf486d3ef7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMi02LTEtMS0w_4ceb9b97-eb4a-4ed5-8ae5-b48412207dc0">1,561,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1cdf94e04d943c08450a611bfc2b63f_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMi04LTEtMS0w_7dae1c02-231d-4624-b608-5db02431dfa9">1,400,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa953ef8800f442aa472c4b20bef4764_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMi0xMC0xLTEtMA_f244afd5-b640-46e7-be24-10df3d1616d2">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic60d7c15b6e143cdb8e7f57bad14a09a_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMi0xMi0xLTEtMA_4e6046c1-ae4d-4dc8-acbe-297dd979f4ca">4,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMi0xNC0xLTEtMA_58b088fb-8631-4afd-8411-99a630fcfe59">156,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNC00LTEtMS0w_21d9be28-6a03-4d44-8b67-58c95d7dfc56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8da06dd15088483d9ddeaea504d86cd7_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNC02LTEtMS0w_2210fb6f-6126-4535-a103-e8f5ee59b662">2,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df52d1685b845e99310b7cf678d9bc1_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNC04LTEtMS0w_fb1f1d09-ab1e-4360-b6da-6d34d187c46a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191cef183ce042d78110d9e5f705083b_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNC0xMC0xLTEtMA_6577aa73-c7db-4acc-a769-e647de7a1f04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75076d7889ad4eb8b803991721300015_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNC0xMi0xLTEtMA_b0e44cd6-06ce-427c-9643-815ef314ab7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNC0xNC0xLTEtMA_dac14415-17ea-48d0-8e21-e5d1818a3c63">2,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNS0yLTEtMS0w_dc1c4edc-dd3d-4c7f-8ead-c02db1718e1b">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNS00LTEtMS0w_141f634d-976a-4fae-be1f-95ad26338209">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8da06dd15088483d9ddeaea504d86cd7_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNS02LTEtMS0w_73e19cbe-ef6c-47bc-a13d-b20a16aba558">547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df52d1685b845e99310b7cf678d9bc1_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNS04LTEtMS0w_d6637cdd-cca5-4e28-bf9d-e39e915b166f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191cef183ce042d78110d9e5f705083b_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNS0xMC0xLTEtMA_68d8b8a1-2d0f-48f3-bddd-d8ad7ae41eb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75076d7889ad4eb8b803991721300015_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNS0xMi0xLTEtMA_26e287e5-f50a-4d8f-8c25-5e687a7b1fee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNS0xNC0xLTEtMA_a56bfe5c-589f-406e-a845-11d28acc051a">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under an Open Market Sale Agreement, net of issuance fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNi0yLTEtMS04NzM_1f215336-14d7-42c9-8e89-1fa27b6ea600">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNi00LTEtMS04NzM_ae3f61c2-9f4a-40d9-9dff-b60f3c8ae2dc">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8da06dd15088483d9ddeaea504d86cd7_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNi02LTEtMS00ODM_60cb0c2e-1369-43c3-bbe7-5101e26cdcb8">16,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df52d1685b845e99310b7cf678d9bc1_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNi04LTEtMS00ODM_392db1a5-34c0-4d0e-a550-2eb39b566ed0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191cef183ce042d78110d9e5f705083b_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNi0xMC0xLTEtODcz_ffbe92e3-5cf5-435d-9fbe-664564942ef4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75076d7889ad4eb8b803991721300015_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNi0xMi0xLTEtODcz_f7bd66d0-9d07-4a58-914d-17def16a3c43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNi0xNC0xLTEtODcz_5aea6eea-d26c-4b30-b160-8be5df733ee3">16,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNy00LTEtMS0w_fadf0106-030a-4ba2-ad88-af2497a117a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8da06dd15088483d9ddeaea504d86cd7_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNy02LTEtMS0w_c09ffe01-cd98-4d97-970d-d83e777eaf54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df52d1685b845e99310b7cf678d9bc1_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNy04LTEtMS0w_c7ea2913-baa5-4da2-a989-ef8046dc3926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191cef183ce042d78110d9e5f705083b_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNy0xMC0xLTEtMA_f12f4657-14f4-41f6-ab68-0b3d0d759db9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75076d7889ad4eb8b803991721300015_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNy0xMi0xLTEtMA_ebb105b8-7800-4c36-8de4-26108231a8fa">2,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNy0xNC0xLTEtMA_7f186c15-0a22-4513-a9dd-1777b1e70c59">2,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfOC00LTEtMS0w_d07482ee-a190-46e9-889a-e99517fa6d06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8da06dd15088483d9ddeaea504d86cd7_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfOC02LTEtMS0w_48d1bfb0-c85e-48df-ba85-5d02c922f4d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df52d1685b845e99310b7cf678d9bc1_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfOC04LTEtMS0w_becfa2a9-df4f-4397-9c82-46fd8d2db249">20,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191cef183ce042d78110d9e5f705083b_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfOC0xMC0xLTEtMA_98a6200c-d155-4859-bab0-e581336f58f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75076d7889ad4eb8b803991721300015_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfOC0xMi0xLTEtMA_a937b469-db13-41cf-8d7e-d138c79266e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfOC0xNC0xLTEtMA_e549cbc9-251b-44b9-af84-dc7e47676c19">20,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTAtNC0xLTEtMA_af0deac5-eab4-4be2-88b5-0daa8c3f827a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8da06dd15088483d9ddeaea504d86cd7_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTAtNi0xLTEtMA_2a87c840-4506-4262-8e0a-3906b4823a4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df52d1685b845e99310b7cf678d9bc1_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTAtOC0xLTEtMA_2e4e767c-2043-43ae-b0f7-92fefe7e615b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191cef183ce042d78110d9e5f705083b_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTAtMTAtMS0xLTA_6724cd0b-b6ac-4c05-b701-24a1d3f102c2">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75076d7889ad4eb8b803991721300015_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTAtMTItMS0xLTA_1566661c-6a09-4e03-9858-f2c5ce4ac272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTAtMTQtMS0xLTA_40de6a7b-57d2-478d-9876-54030103aa0c">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie96e698d44f741e8b15ba8a973f9aaaa_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTEtMi0xLTEtMA_0c3ef585-2092-4cac-b718-eeca7dbfd537">145,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96e698d44f741e8b15ba8a973f9aaaa_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTEtNC0xLTEtMA_773af53e-a88f-4791-9d36-b80e5ae3b751">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e98480c8ab24073a57917c703b340ca_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTEtNi0xLTEtMA_0d3efc8a-a2a8-4879-92d0-4b3ae533a91e">1,580,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f7ed8cd8f7b42aeb8bcb7b11be2be35_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTEtOC0xLTEtMA_c7a7c750-eeeb-40eb-9e05-0fe9eb6798d8">1,420,976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b5277bb1cee46b0a0e275f43ab30ecd_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTEtMTAtMS0xLTA_f2a42e9f-a7e1-480b-ae33-d273c9d2a742">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05e826ffe0344bbbb51ccbc13eaa4d00_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTEtMTItMS0xLTA_e33a848d-42f7-4e75-9548-77965dbfac6b">7,518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTEtMTQtMS0xLTA_7661c05f-ff4d-43d2-8298-7417cbe830ad">152,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ia5892dcce25547a19d63f064d49677ff_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:73.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMy0yLTEtMS0w_77d55a2b-aac8-4b07-b01b-dd8a2164d1d3">20,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMy00LTEtMS0w_4ed99a7d-cfca-437b-a749-f7b1ea03fadc">66,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNS0yLTEtMS0w_d02949bb-5e7d-4dde-b7ad-2aed3cfd31bf">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNS00LTEtMS0w_5417936a-1bc8-48b6-88fa-fd77a5852662">906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNy0yLTEtMS0w_1e9d1aa0-da14-442e-901b-b48ff7cb8b61">2,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNy00LTEtMS0w_feb07f90-3207-4b6b-9b8d-f1361399b315">4,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfOC0yLTEtMS0w_f947ed0c-ee40-4920-888b-b42e7c378789">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfOC00LTEtMS0w_e833e18d-4d0b-4b54-82e8-1acc94da51bb">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTUtMi0xLTEtMA_199b4ef6-603a-47c3-97e6-fd993149e155">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTUtNC0xLTEtMA_f9bf289f-6bac-4540-a57a-79bfee59683f">26,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTYtMi0xLTEtMA_6c5b783e-e80c-4dec-a1d0-fdcc51ca95a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTYtNC0xLTEtMA_76ffce89-8e31-4b24-8c30-9d5af67217f5">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) decrease in prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTctMi0xLTEtMA_e85b7c16-0822-4488-9fcb-b88c6b911e61">1,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTctNC0xLTEtMA_fad8f1cf-aab6-4a10-9fa4-8a4d23ad6862">2,875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) decrease in other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTgtMi0xLTEtMA_6984e332-049c-479d-8947-7c889108527a">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTgtNC0xLTEtMA_ee96d9b2-cde5-4026-ac40-3fab0b88bf2b">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTktMi0xLTEtMA_5903e4a5-f85e-47d5-9071-19942b7e1943">8,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTktNC0xLTEtMA_acbb131f-cb97-42dd-a05b-e72960523bb4">15,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjEtMi0xLTEtMA_dfd423fb-9ad2-41d8-b6b8-5c4d90373b69">25,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjEtNC0xLTEtMA_25bc5c13-5e57-405a-9a97-52d1ce59a63b">22,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjMtMi0xLTEtMA_4440d3c9-060a-4fdc-872c-7937501694f2">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjMtNC0xLTEtMA_c36884d3-edc9-4d53-8f6c-b82bf2f7bff7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjYtMi0xLTEtMA_f420d9c6-aff7-4052-bdda-290d257bc649">21,686</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjYtNC0xLTEtMA_fa985efd-9ee3-42be-ac8b-420e67e00f11">33,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjctMi0xLTEtMA_37f725d1-e79a-4301-918d-014ca25e3b6c">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjctNC0xLTEtMA_721e28d7-4ac1-4fe7-94e3-ec9b2ab001fe">76,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjgtMi0xLTEtMA_82cda8c8-362d-45d5-82c7-2ea541bd630e">17,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjgtNC0xLTEtMA_1d9b1472-c1be-4eb0-ab6b-f81b8804febf">42,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzAtMi0xLTEtMA_ec355bb6-351b-4d53-980c-75b1fd4c657e">16,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzAtNC0xLTEtMA_0121481b-6e54-4bcf-b349-1199b7a1b331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzEtMi0xLTEtMA_e9e371d2-c404-4799-bd3d-35c40a504e00">2,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzEtNC0xLTEtMA_67f1d687-f9b2-46e4-bf9e-53a953af2a6e">923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of debt borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzMtMi0xLTEtMA_1009f2a3-bd03-4769-a97a-2a55c857d988">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzMtNC0xLTEtMA_a06348bf-2e5a-4a85-afef-04c0ad15aedd">321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzUtMi0xLTEtMA_b9f4034d-36e2-4e4e-bba9-3abf6b4d8dc0">14,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzUtNC0xLTEtMA_f2dc4c89-47eb-463f-918e-36e3d3a22d24">1,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzYtMi0xLTEtMA_5631ced3-410f-4485-8f83-5458b630dc2a">28,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzYtNC0xLTEtMA_6a803017-06e5-482e-a30d-2b8957c1d87c">19,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzctMi0xLTEtMA_de958b54-ac61-4faa-8f7f-707765f6240e">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a606756c32f497285a9518996aac3b4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzctNC0xLTEtMA_2c1f0f87-9afb-49dc-bd97-e74fc4d812b6">36,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzgtMi0xLTEtMA_27186214-4df0-498c-86b9-bdd3ea475363">97,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27faa5c3eef4da8a2be4870c962c535_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzgtNC0xLTEtMA_85685d89-dbec-4518-8e32-0bb3133b94c9">55,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNDEtMi0xLTEtMA_cd9c94f6-9952-45b4-9097-40471b27a97a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNDEtNC0xLTEtMA_cf79decb-2683-4623-86ad-0aa107231fcc">3,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Right-of-use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:InitialRecognitionOfRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNDQtMi0xLTEtMTA4Nw_2df17db4-4ad1-4801-b9fe-7d2c6068866a">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:zerodash" name="lxrx:InitialRecognitionOfRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNDQtNC0xLTEtMTA4Nw_06be9bf8-b425-4bf3-922c-8aeead784ffc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ia5892dcce25547a19d63f064d49677ff_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ia5892dcce25547a19d63f064d49677ff_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3ODc_5f63575a-d92d-4930-be82-dba003f73cf1" continuedAt="i865cf28cc8a64d6f94a304c7db39fe2f" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i865cf28cc8a64d6f94a304c7db39fe2f" continuedAt="i18771e9417cc4cb0940f2e8dbe625b83"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month period ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NDk_842e5b59-8b0c-43eb-9d7f-12edd7ece63f" escape="true">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information, refer to the financial statements and footnotes thereto included in Lexicon&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2020, as filed with the SEC.&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NTE_7e53a8dd-f741-4046-ac02-206a298a7e33" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3ODQ_f686a76d-6f7c-473e-b689-b05b8d4d1ee3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2021, short-term investments consisted of U.S. treasury bills and corporate debt securities.  As of December&#160;31, 2020, short-term investments consisted of corporate debt securities.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NzE_3b5af74b-79f3-4e41-b221-4c4aff73c27d" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.163%"><tr><td style="width:1.0%"></td><td style="width:52.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:AccruedResearchAndDevelopmentServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfMy0yLTEtMS0w_cd6fd074-4638-437d-b7f4-88b96040a71c">16,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:AccruedResearchAndDevelopmentServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfMy00LTEtMS0w_4cdfad4b-15da-49de-bc89-f4448ea739dd">21,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:AccruedCompensationAndBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNC0yLTEtMS0w_e6550163-c593-4b71-a053-7521c6f72391">3,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:AccruedCompensationAndBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNC00LTEtMS0w_51fe39dd-f1b0-476a-966a-6653f246371d">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNS0yLTEtMS0w_125dc410-59da-47f3-802d-3e2d689ad7a9">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNS00LTEtMS0w_4989664a-cdb5-4649-84b8-2685c9d455b1">553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNi0yLTEtMS0w_e778b1e8-db7b-4bc4-b6f1-f392c836e7f2">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNi00LTEtMS0w_73d8debe-1bee-4474-a0c6-158e3e76c625">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNy0yLTEtMS0w_828146f3-851e-4326-826f-31e9e2b68a02">22,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNy00LTEtMS0w_7ede1d17-5b5b-4fb5-ae82-b19deb44bfdc">29,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMjE5OTAyMzI3NjM5MQ_a9b8c02b-307f-4e91-9cb3-bd991958d5ca" continuedAt="i7d292550f1ab45c6b48fb59f1b384352" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less.</span></ix:nonNumeric></div></ix:continuation><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i18771e9417cc4cb0940f2e8dbe625b83" continuedAt="id93f7012ec754a8392db8245e268b61e"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7d292550f1ab45c6b48fb59f1b384352">Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future minimum lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon uses its incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="i146253cab0294e3eae00a7148487429e_I20210301" decimals="INF" format="ixt:numdotdecimal" name="lxrx:LexiconIncrementalBorrowingRate" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfOTM0NTg0ODg1NjkzNg_b62cf118-1ef9-43ac-bb67-369ff24e9ff0">9</ix:nonFraction>% at the commencement date in determining the present value of future payments.</ix:continuation> </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NTI_997261c2-db83-48ac-b3d4-1e25ffb17be9" continuedAt="id2c3c33facf04e60a90b60ea0a18ae25" escape="true"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Company&#8217;s sale of XERMELO and related assets to TerSera in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (&#8220;Ipsen&#8221;).  Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#8217;s net product revenues reflected the Company&#8217;s best estimates of the amounts of consideration to which it was entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs were considered a fulfillment activity when control transferred to the Company&#8217;s customers and such costs were included in cost of sales.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Agreements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="id93f7012ec754a8392db8245e268b61e" continuedAt="i92dfb379f910424b80effcd32a43f1f9"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id2c3c33facf04e60a90b60ea0a18ae25">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfOTM0NTg0ODg1NjkzNA_8e4a78d5-def5-47f3-b270-f15e86cfa47b" continuedAt="ib7c13c02b88e4f0dbf7f42461c1a3782" escape="true">Cost of Sales: </ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib7c13c02b88e4f0dbf7f42461c1a3782"> Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Product shipping and handling costs were included in cost of sales. Cost of sales also included the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.</ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3ODk_035379d7-d226-47d8-ba7b-fd2b601045db" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#8217;s estimates of the clinical study costs and costs to transition activities from Sanofi for the development of sotagliflozin for type 2 diabetes and heart failure, as well as the wind down of those activities, were based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that conducted and managed the clinical studies on its behalf.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3OTQ_ad96da6e-a32a-4215-bd56-8846b39fe327" continuedAt="id3f339e5494b4df3b6ab19d6c4f41aba" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id3f339e5494b4df3b6ab19d6c4f41aba">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.</ix:continuation>&#160;&#160;The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the three months ended March&#160;31, 2021 and 2020:</span></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NDY_fb9c43a1-0e87-4472-a946-7afa4e876ac8" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:51.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.916%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMi0yLTEtMS0w_479e90b0-9e6e-467f-b5f0-6ff92bddc42d">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMi00LTEtMS0w_51e17655-5b64-41a8-8af8-eea12042c615">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMi02LTEtMS0w_1d83277c-2565-49f1-8893-1bb725961341">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331" decimals="2" format="ixt:zerodash" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMi04LTEtMS0w_323a6328-ec37-45f9-9822-a182f6d92ff9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMy0yLTEtMS0w_658afecd-5880-43fc-b51b-938e240b2172">90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMy00LTEtMS0w_428b4132-4551-4896-812d-b940d9bf07fc">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMy02LTEtMS0w_db1b7da6-bad4-407e-8f3b-a3c14e40bb41">7</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331" decimals="2" format="ixt:zerodash" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMy04LTEtMS0w_01b120ac-085e-435c-a8c2-67aed3798b38">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNS0yLTEtMS0w_5793820d-340a-45c2-a637-84ff3b3272a1">89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNS00LTEtMS0w_1720ce9a-9949-4b82-8575-e7819a42bf91">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNS02LTEtMS0w_4e946007-b82b-4974-8e47-1ccdb2c893a5">4</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331" decimals="2" format="ixt:zerodash" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNS04LTEtMS0w_471c1112-160b-422a-b872-c9ce45b9e1cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNi0yLTEtMS0w_9a266d34-1b70-4340-9e30-5b1a357da3c8">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNi00LTEtMS0w_91692582-fc78-4251-972e-ef5fb6b80daa">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNi02LTEtMS0w_6cbc053f-3924-4275-b2c8-650051de3d2d">8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331" decimals="2" format="ixt:zerodash" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNi04LTEtMS0w_7836d272-28e0-4bf1-bf87-9e29b42aecae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i92dfb379f910424b80effcd32a43f1f9" continuedAt="i100c0be7fb9e4c7eb2457d5cd0f0bd62"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NDI_7bdd83b1-9052-4e39-87ce-58194bf9b2da" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7680cb4d42ed478997941e9bf13624ac_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfMi0yLTEtMS0w_fc5be4f0-e9da-4f17-8412-f644bdc64ab7">8,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7680cb4d42ed478997941e9bf13624ac_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfMi00LTEtMS0w_26a6b191-ce3f-4661-9cc3-2f85e87e3fb5">7.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c017c3c99f6498daff3ecf3edf83a48_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfMy0yLTEtMS0w_f23722a0-3c2d-42a4-ab9d-164c5833838d">957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c017c3c99f6498daff3ecf3edf83a48_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfMy00LTEtMS0w_f66a0da0-52f2-4106-affb-bff3187c845a">8.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNC0yLTEtMS0w_892e88a9-e0f3-4f2d-bc4b-bb76b5ed6673">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNC00LTEtMS0w_ad82af43-0fb5-4d22-8e14-9fec6040cbf3">5.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1c017c3c99f6498daff3ecf3edf83a48_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNS0yLTEtMS0w_36df5324-1f2f-48e5-9e50-04bb00141515">178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c017c3c99f6498daff3ecf3edf83a48_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNS00LTEtMS0w_6195749d-61e6-485c-9338-4992d607f6dc">12.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1c017c3c99f6498daff3ecf3edf83a48_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNi0yLTEtMS0w_a9b03122-c91a-4ad1-ba79-71f367939d08">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c017c3c99f6498daff3ecf3edf83a48_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNi00LTEtMS0w_eea6bd36-eb26-4fb8-9cd2-fd381f22a4f1">10.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6aa61cc7aaf43e6bbc474b8505cc3d4_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNy0yLTEtMS0w_b56d5d17-e9f4-4f8b-a9ea-5699433b844f">9,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6aa61cc7aaf43e6bbc474b8505cc3d4_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNy00LTEtMS0w_f814f4b0-c1e0-41db-9171-9b6572b9fe5e">7.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6aa61cc7aaf43e6bbc474b8505cc3d4_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfOC0yLTEtMS0w_b9ac9a57-a425-4bab-a39f-ecee4380e5f6">5,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6aa61cc7aaf43e6bbc474b8505cc3d4_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfOC00LTEtMS0w_03a48a4a-7b81-420c-bb5c-d102e6145bc0">8.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, Lexicon also granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three annual installments.  The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2021:</span></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NjE_83333c66-c484-4319-b000-c47b84ebc6ec" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05f812c6327541b6b09fdc249c90d7f2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfMi0yLTEtMS0w_5ad907d1-5c4c-4624-b249-42f81d0662ce">2,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i05f812c6327541b6b09fdc249c90d7f2_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfMi00LTEtMS0w_0398db2d-c491-4914-a4c1-ae1c47557a79">4.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5f92e864c7242d5879f8636e1617415_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfMy0yLTEtMS0w_a914e004-fd89-4d30-ac3f-4d8fadb735c6">631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id5f92e864c7242d5879f8636e1617415_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfMy00LTEtMS0w_c42cdf2d-fff9-4d0d-a144-dc0d5ab71a88">8.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id5f92e864c7242d5879f8636e1617415_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfNC0yLTEtMS0w_71caaa3e-1273-4be7-9ec9-2d407d0b6f9f">1,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id5f92e864c7242d5879f8636e1617415_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfNC00LTEtMS0w_61eaef09-64ff-4304-9e21-6d7a912d78b5">5.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id5f92e864c7242d5879f8636e1617415_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfNS0yLTEtMS0w_d9c47723-8309-4c89-9aeb-de9d6abe8f25">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id5f92e864c7242d5879f8636e1617415_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfNS00LTEtMS0w_5d1930cb-b365-4e6d-867d-b7be9520fe4b">4.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c83f6001ecc4b738df4e9c1c3f4412f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfNi0yLTEtMS0w_dfe5caec-6679-4efc-8850-ac6a34519ffa">2,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c83f6001ecc4b738df4e9c1c3f4412f_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfNi00LTEtMS0w_781f5d25-76c5-4885-ad19-124502fdca9a">5.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i100c0be7fb9e4c7eb2457d5cd0f0bd62" continuedAt="ic1705ad537744921b03df44463a8c316"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NjI_db774248-d1e6-4025-b173-5ac28440a935" continuedAt="i9948a36f30e44a6e9ec6571f3a48ce00" escape="true">Net Loss per Common Share:</ix:nonNumeric></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic1705ad537744921b03df44463a8c316"><ix:continuation id="i9948a36f30e44a6e9ec6571f3a48ce00"> Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</ix:continuation></ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ia5892dcce25547a19d63f064d49677ff_37"></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNy9mcmFnOjYxMWJkMjUyY2FkYzQ2NWQ4NDYxY2U1ZmMxNWJjZmMwL3RleHRyZWdpb246NjExYmQyNTJjYWRjNDY1ZDg0NjFjZTVmYzE1YmNmYzBfMTcyMw_294ebb37-3a79-4e96-b960-76e14e7761de" continuedAt="i15d6832a6ce2492a9666f6de750cadab" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i15d6832a6ce2492a9666f6de750cadab">In December 2019, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, Income Taxes (Topic 740) Simplifying Accounting for Income Taxes, as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, including interim periods therein. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ia5892dcce25547a19d63f064d49677ff_43"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RleHRyZWdpb246MjAzNjQ5OGJiNWUxNDRjMWE2MTdiMDdiYjRjMzM4ZmZfMzQx_40d928a6-6f38-48cd-9706-5237f3d4d483" continuedAt="ie7d6656fafe342ffb6a5f3b349fc24ee" escape="true">Cash and Cash Equivalents and Investments</ix:nonNumeric></span></div><ix:continuation id="ie7d6656fafe342ffb6a5f3b349fc24ee"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents and investments held at March&#160;31, 2021 and December&#160;31, 2020 are as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RleHRyZWdpb246MjAzNjQ5OGJiNWUxNDRjMWE2MTdiMDdiYjRjMzM4ZmZfMzI5_563c9944-013a-462e-aed4-23175e42204e" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f6b3dae24ed4be1a4420f2bc0f76d2f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMy0yLTEtMS0w_296b5022-3bcf-45ad-a2db-836d2f8b0dc7">97,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f6b3dae24ed4be1a4420f2bc0f76d2f_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMy00LTEtMS0w_b5439989-0f8b-4dba-a67b-2397241fc6fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f6b3dae24ed4be1a4420f2bc0f76d2f_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMy02LTEtMS0w_75f2c576-5177-4d10-b965-0cc20d96214f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f6b3dae24ed4be1a4420f2bc0f76d2f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMy04LTEtMS0w_164219e4-26e2-4c02-aa55-e8163d65c0d0">97,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c1c834ecce44f16b35b81cf92f8af4c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNS0yLTEtMS0w_5ea7d1d0-90c2-4b8a-9346-0b2c7a4fb9d9">15,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c1c834ecce44f16b35b81cf92f8af4c_I20210331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNS00LTEtMS0w_f4a5cf97-de2b-44d6-a830-9fbcdb1a6aa9">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c1c834ecce44f16b35b81cf92f8af4c_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNS02LTEtMS0w_df88ee13-6baf-46f2-9077-3e8540487d3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c1c834ecce44f16b35b81cf92f8af4c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNS04LTEtMS0w_c1001a33-c48d-4728-a067-7373525f2197">15,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i291ed1f6abf04110bd6f3f96dfaf9687_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNi0yLTEtMS0w_3a320026-9297-47ad-b396-6988ad8f57c7">28,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i291ed1f6abf04110bd6f3f96dfaf9687_I20210331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNi00LTEtMS0w_577d2179-de61-4a77-90ae-c33bc521f138">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i291ed1f6abf04110bd6f3f96dfaf9687_I20210331" decimals="-3" sign="-" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNi02LTEtMS0w_8693ff7d-b9db-4df5-9ca9-9b4656d3c088">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i291ed1f6abf04110bd6f3f96dfaf9687_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNi04LTEtMS0w_af99e3c3-d9e3-4e1d-9b42-0201c759cd56">28,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f3856fc70db4f0eb8819a27978a3fb5_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNy0yLTEtMS0w_3ee64702-fc6b-4bba-8164-7458f8c6a7d1">43,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f3856fc70db4f0eb8819a27978a3fb5_I20210331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNy00LTEtMS0w_30c161d0-bfeb-4f55-a2f1-cf9cbca4719d">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f3856fc70db4f0eb8819a27978a3fb5_I20210331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNy02LTEtMS0w_a2ed13b5-3f2b-4a4e-a535-6998bab7f439">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f3856fc70db4f0eb8819a27978a3fb5_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNy04LTEtMS0w_70e57a9c-f3e9-49d5-a1cd-ddc631dac339">43,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25913c0c6d894c7284fdf1a62f452c6a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfOC0yLTEtMS0w_23715b06-371f-4ddc-89c3-4a7559f7e958">141,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25913c0c6d894c7284fdf1a62f452c6a_I20210331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfOC00LTEtMS0w_c42cf2b9-8873-4d1b-b4c4-9aa46a5d1320">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25913c0c6d894c7284fdf1a62f452c6a_I20210331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfOC02LTEtMS0w_9f085a0f-4db4-4f95-891c-756a96bfa6b8">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25913c0c6d894c7284fdf1a62f452c6a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfOC04LTEtMS0w_53a6759b-c90e-4165-816f-3d22954766f3">141,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i128725cdccf34310af9e7048fc57e23a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTMtMi0xLTEtMA_601024b8-7a1b-4a0a-b62c-9d672495d720">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i128725cdccf34310af9e7048fc57e23a_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTMtNC0xLTEtMA_204e5124-f56b-4dd8-a118-bc51f99db1bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i128725cdccf34310af9e7048fc57e23a_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTMtNi0xLTEtMA_1c1674bc-7c3a-4287-abf2-16038a98d263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i128725cdccf34310af9e7048fc57e23a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTMtOC0xLTEtMA_5151e479-de70-4fff-ae49-cae273c198e0">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe798e7d357475783018b7f99e88eef_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTYtMi0xLTEtMA_90adb7b8-c7a6-4680-94e2-e18544aa5614">26,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe798e7d357475783018b7f99e88eef_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTYtNC0xLTEtMA_c41f3d7a-42c9-4914-b644-f5b375a16579">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafe798e7d357475783018b7f99e88eef_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTYtNi0xLTEtMA_0e23800a-f6d6-4bd0-85ed-ac885a6b6362">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe798e7d357475783018b7f99e88eef_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTYtOC0xLTEtMA_28615ecd-3823-4fa2-820b-ed54e5f6e19b">26,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce92942910c43e4903e00d0f785c79f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTctMi0xLTEtMA_f7d39b47-11ac-4284-ace0-8c4d7b22fc81">26,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce92942910c43e4903e00d0f785c79f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTctNC0xLTEtMA_f8c5ce2b-9c54-4df7-af7e-a3320a29d6c4">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idce92942910c43e4903e00d0f785c79f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTctNi0xLTEtMA_d52d74d4-563b-4622-905a-95988b8dbf41">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce92942910c43e4903e00d0f785c79f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTctOC0xLTEtMA_6d6e65da-f154-4279-901b-4c9992e850fe">26,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i538c6f098f45484a9093e4c6f76257da_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTgtMi0xLTEtMA_4517f1de-fc81-49c8-ac58-e6126d67f1b1">152,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i538c6f098f45484a9093e4c6f76257da_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTgtNC0xLTEtMA_0919bab1-985a-4314-afd7-687633af3a74">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i538c6f098f45484a9093e4c6f76257da_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTgtNi0xLTEtMA_27102689-c6ea-42ee-be15-9561502a2cca">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i538c6f098f45484a9093e4c6f76257da_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTgtOC0xLTEtMA_d5303031-b9b3-44ed-bea4-8c14fba333b3">152,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RealizedInvestmentGainsLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RleHRyZWdpb246MjAzNjQ5OGJiNWUxNDRjMWE2MTdiMDdiYjRjMzM4ZmZfMTcx_2859c58f-ff8f-4090-9fe5-65e09a1f5e16"><ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RealizedInvestmentGainsLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RleHRyZWdpb246MjAzNjQ5OGJiNWUxNDRjMWE2MTdiMDdiYjRjMzM4ZmZfMTcx_767f91c5-f276-4bd0-bc42-75f7f33b15fa">no</ix:nonFraction></ix:nonFraction> realized losses during either of the three months ended March&#160;31, 2021 and 2020, respectively.  The cost of securities sold is based on the specific identification method.</span></div></ix:continuation><div id="ia5892dcce25547a19d63f064d49677ff_46"></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RleHRyZWdpb246NDIyYTQyZjFhMTQ2NDkzZjkwNDhmMGI1NjM5YmI5NWVfMjE2Nw_7e070745-fc32-4312-946e-3fb783483f3b" continuedAt="i40c6ee2a309149d78d7b67ac7f90f30d" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i40c6ee2a309149d78d7b67ac7f90f30d" continuedAt="i82e8bb926af74c41894b42cbd215b58d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - significant unobservable inputs </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i82e8bb926af74c41894b42cbd215b58d"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of March&#160;31, 2021 and December&#160;31, 2020.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RleHRyZWdpb246NDIyYTQyZjFhMTQ2NDkzZjkwNDhmMGI1NjM5YmI5NWVfMjE1Mw_a2c4cd34-6e83-4b97-85ef-fa5c92195b29" escape="true"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:46.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f07d12ec62145c8975b2c25813bcab8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNC0yLTEtMS0w_40f14489-c3f3-45e3-90bb-16de555f14f0">97,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie788a1a6bb1842ee842bbab7098f63f2_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNC00LTEtMS0w_ae1aacb3-a1e2-44e5-b472-2c7bcb70958c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00ac6a719fe4e628278d8c2ce3383db_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNC02LTEtMS0w_12652c0e-31c9-4a2c-b73b-86317c933415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNC04LTEtMS0w_08c8d200-d0f2-437c-8ad8-c6ff731098d5">97,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f07d12ec62145c8975b2c25813bcab8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNS0yLTEtMS0w_c9f01354-1e08-4f76-9d84-290b507ba821">15,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie788a1a6bb1842ee842bbab7098f63f2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNS00LTEtMS0w_67ebb1b0-2044-4552-86e0-204e17e322f4">28,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00ac6a719fe4e628278d8c2ce3383db_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNS02LTEtMS0w_3a375ce7-2ea2-4667-bc96-f4c260ada7de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNS04LTEtMS0w_9d73f7fa-9de5-4bf0-9787-37cd94a1e24d">43,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f07d12ec62145c8975b2c25813bcab8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNi0yLTEtMS0w_53d31b92-a0cb-4085-88a3-eb119cb6a848">112,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie788a1a6bb1842ee842bbab7098f63f2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNi00LTEtMS0w_8c2d255c-8e65-44f2-96ba-f0e694e2e839">28,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00ac6a719fe4e628278d8c2ce3383db_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNi02LTEtMS0w_7030e007-39f7-4895-85e0-e60e5f9e1a6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNi04LTEtMS0w_a6f94dc6-c406-49b7-a872-d48a70d5463b">141,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:46.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01fc13da04a74ba9a24a1954fe5e09d1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNC0yLTEtMS0w_2255cb66-90cf-4256-951f-342442f1637b">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e16817a1f8b455fa37d4b4d3496642d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNC00LTEtMS0w_58f7472c-dab2-4f56-879d-2ab35c098e11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia420366f6ef2477b888780f5aa7343c4_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNC02LTEtMS0w_ad7287ff-1272-42db-93d2-8e201fbe4c81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNC04LTEtMS0w_c51b942b-570f-4acf-9fc9-22ea8a686147">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01fc13da04a74ba9a24a1954fe5e09d1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNS0yLTEtMS0w_4f7ce04d-4a4c-430d-a652-1463beb2a60a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e16817a1f8b455fa37d4b4d3496642d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNS00LTEtMS0w_ddf4d82b-5400-47f7-92d8-dd516b4b0656">26,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia420366f6ef2477b888780f5aa7343c4_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNS02LTEtMS0w_bea5cbff-3e98-4752-a229-ea3e28d6b795">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNS04LTEtMS0w_20cb257d-bdb0-43e7-9fac-b61126334595">26,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01fc13da04a74ba9a24a1954fe5e09d1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNi0yLTEtMS0w_6b887248-1967-4ec3-877d-5921ea16712c">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e16817a1f8b455fa37d4b4d3496642d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNi00LTEtMS0w_2675cfbf-266f-49e4-a135-fea68b9e2350">26,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia420366f6ef2477b888780f5aa7343c4_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNi02LTEtMS0w_3f1206e0-a7eb-4d63-847d-799250eeb4ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNi04LTEtMS0w_afa88c8f-190f-4d74-9a9f-c3d9b5532ae1">152,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets or liabilities as of March&#160;31, 2021 or December&#160;31, 2020. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5, Debt Obligations, for fair value measurements of debt obligations.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="ia5892dcce25547a19d63f064d49677ff_49"></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfODAwMQ_89160156-33ce-4d63-8582-24412225de66" continuedAt="if661d24cc32241f99458ae6518d7fbd5" escape="true">Debt Obligations</ix:nonNumeric></span></div><ix:continuation id="if661d24cc32241f99458ae6518d7fbd5" continuedAt="iad95cd4edbe94052ab90dfa55d39882a"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Debt.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2014, Lexicon completed an offering of $<ix:nonFraction unitRef="usd" contextRef="ie2fc5a7556d44214b71b2e8a010774b2_D20141101-20141130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfMTAz_7fd85960-57d0-4f22-9fe3-f4dd71cf5b58">87.5</ix:nonFraction> million in aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="icb9c8c0f84be4d2bb3ae691e86ab0e8b_I20141120" decimals="4" name="lxrx:ConvDebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfMTQz_815ceef3-6053-48c3-a743-186ee89ea0fa">5.25</ix:nonFraction>% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s condensed consolidated balance sheets.  </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $<ix:nonFraction unitRef="usd" contextRef="i1e1514570bdc407c8e2a1b9524eab9cc_I20200928" decimals="-3" format="ixt:numdotdecimal" name="lxrx:ConvertibleDebtExchangeTotalPrincipalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfNTU3_6db3762d-fa16-41bf-a5ca-8f8b6ace1abb">75.8</ix:nonFraction> million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principle amount of the Convertible Notes.  As of March&#160;31, 2021, the carrying value of the remaining Convertible Notes was $<ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:ConvertibleDebtExchangeRemainingNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfMTI4OA_c59aa68d-2d18-443f-a108-9be005a3870f">11.7</ix:nonFraction> million and are included in the current portion of long-term debt, net of deferred issuance costs in the accompanying condensed consolidated balance sheet. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The remaining Convertible Notes are governed by an indenture (the &#8220;Indenture&#8221;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="icb9c8c0f84be4d2bb3ae691e86ab0e8b_I20141120" decimals="4" name="lxrx:ConvDebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfMTkxOA_815ceef3-6053-48c3-a743-186ee89ea0fa">5.25</ix:nonFraction>%&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Convertible Notes mature on December&#160;1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.  </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially <ix:nonFraction unitRef="number" contextRef="ie2fc5a7556d44214b71b2e8a010774b2_D20141101-20141130" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfMjY0NQ_e6aec397-f86e-4e1c-b25b-a208690c3a53">118.4553</ix:nonFraction> shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icb9c8c0f84be4d2bb3ae691e86ab0e8b_I20141120" decimals="3" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfMjc2Ng_afa41ad9-8850-45cf-9904-4a57221c50c1">8.442</ix:nonFraction> per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iad95cd4edbe94052ab90dfa55d39882a"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the remaining Convertible Notes was $<ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfNDE3Nw_5911f385-25ac-4f44-9ffd-18be40b13762">12.6</ix:nonFraction>&#160;million as of March&#160;31, 2021 and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="ia5892dcce25547a19d63f064d49677ff_52"></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RleHRyZWdpb246YjdhOGU1YzMwMGIyNDhiM2I2ZGYxYjhlOGRiMjE5Y2JfMjgyNQ_84c16a73-11b0-4b09-bbdb-8c6318a04db1" continuedAt="i0738e395edee4b1fa3665713a05c0f91" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i0738e395edee4b1fa3665713a05c0f91" continuedAt="i88d741787c1c4334bc77ac3f765105d5"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Lease Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;Lexicon&#8217;s operating leases include office space in The Woodlands, Texas and Basking Ridge, New Jersey that will expire in August 2025 and December 2022, respectively. Under its lease agreements, Lexicon is obligated to pay property taxes, insurance, and maintenance costs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the right-of-use assets for the office space leases had a balance of $<ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RleHRyZWdpb246YjdhOGU1YzMwMGIyNDhiM2I2ZGYxYjhlOGRiMjE5Y2JfMjc0ODc3OTA3ODQzMQ_80c21f17-ddaa-47ac-99dd-616c8634b774">2.9</ix:nonFraction> million, which is included in other assets in the condensed consolidated balance sheet, and current and non-current liabilities relating to the assets were $<ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCommitmentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RleHRyZWdpb246YjdhOGU1YzMwMGIyNDhiM2I2ZGYxYjhlOGRiMjE5Y2JfMjc0ODc3OTA3ODQzNw_22173759-1218-45ab-8796-ac7a7bd80ebe">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RleHRyZWdpb246YjdhOGU1YzMwMGIyNDhiM2I2ZGYxYjhlOGRiMjE5Y2JfMjc0ODc3OTA3ODQ0MQ_69967cbc-fdf6-4c3d-afa1-ef48a719a2f8">1.7</ix:nonFraction> million, respectively, which are included in accrued liabilities and other long-term liabilities in the condensed consolidated balance sheet, respectively.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at March&#160;31, 2021:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:80.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.168%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfMi0xLTEtMS0zMjc_41107307-c2c7-4c6a-8b48-480d8e2c000b">644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfMy0xLTEtMS0zMjc_03f85343-4aae-4a39-989f-9d21d625532d">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfNC0xLTEtMS0zMjc_bbec3f85-a336-4fa4-a693-f949e3bf3eda">530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfNS0xLTEtMS0zMjc_ad1453b3-1ba9-49ac-96d5-47a487ca1c38">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfNi0xLTEtMS0zMjc_15d74e3a-d264-46f2-9c0b-ef77da0fe043">369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfOC0xLTEtMS0zMjc_e20af0b5-cc5b-4033-9628-77e7592975d3">3,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfOS0xLTEtMS0zMjc_9d2c7120-df7c-422b-ba24-06038e9e00d4">505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfMTAtMS0xLTEtMzI3_3bbc3048-ef0d-45c2-bc2e-241650bea0e7">2,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: short-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="INF" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfMTEtMS0xLTEtMzI3_894a5d53-23af-49e2-b700-765d6ad22ebb">1,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfMTItMS0xLTEtMzI3_5ff98325-6a5e-4feb-85aa-472de6c6bff2">1,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against the Company and certain of its officers in the U.S. District Court for the Southern District of Texas, Houston Division.  Our motion to dismiss was granted and the action was dismissed with prejudice by the District Court on August 14, 2020.  The lead plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Fifth Circuit on September 11, 2020 and a brief in support of its appeal on December&#160;17, 2020.  We filed a response brief on February 18, 2021 and the lead plaintiffs filed a reply brief on March 11, 2021.  The lawsuit purports to be a class action brought on behalf of purchasers of our securities during the period from March 11, 2016 through July 29, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from our Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi Arbitration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  On October 16, 2020, the Company initiated arbitration proceedings against Sanofi-Aventis Deutschland GmbH (&#8220;Sanofi&#8221;) seeking to recover damages for breach of contract relating to the Termination and Settlement </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i88d741787c1c4334bc77ac3f765105d5" continuedAt="i29af49cba3454334b4bc03d031e4f862">Agreement and Mutual Releases with Sanofi, dated September 9, 2019 (the &#8220;Termination Agreement&#8221;).  In September 2020, Sanofi withheld approximately $<ix:nonFraction unitRef="usd" contextRef="i683e05dc441240d9a2492d0fd1aa4361_D20200901-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Lxrx_Sanofiterminationcashpayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RleHRyZWdpb246YjdhOGU1YzMwMGIyNDhiM2I2ZGYxYjhlOGRiMjE5Y2JfMTg0OQ_496bba5f-b6e6-4fea-aaa5-5041dfe8d1cf">23.2</ix:nonFraction>&#160;million from the final $<ix:nonFraction unitRef="usd" contextRef="i75c9ca72d87c4541bcbf8632f671f7ae_D20200901-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Lxrx_Sanofiterminationcashpayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RleHRyZWdpb246YjdhOGU1YzMwMGIyNDhiM2I2ZGYxYjhlOGRiMjE5Y2JfMTg2OA_57f20955-b998-40ea-a629-d11753a92cb1">26</ix:nonFraction>&#160;million payment due to the Company under the Termination Agreement, offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by the Company under the terms of the Termination Agreement.  The Company disputes that at least a significant portion of such costs are properly reimbursable by the Company under the terms of the Termination Agreement and asserts that, in any event, Sanofi was not permitted to withhold any of such costs under the terms of the Termination Agreement.  The Company is seeking payment of up to $<ix:nonFraction unitRef="usd" contextRef="id0d9a71689364f11b5b23e80ebdf0b0e_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="lxrx:SanofiDisputedCosts" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RleHRyZWdpb246YjdhOGU1YzMwMGIyNDhiM2I2ZGYxYjhlOGRiMjE5Y2JfOTM0NTg0ODg0Nzg2MA_789a1969-b3db-4941-aad2-dd4182dd47c4">23.2</ix:nonFraction> million in such disputed costs, together with late interest and attorneys&#8217; fees and costs.  Sanofi is seeking declaratory judgment that the Company is liable for all disputed costs previously withheld and damages for any additional costs properly reimburseable under the terms of the Termination Agreement in excess of those previously withheld, together with late interest and attorneys&#8217; fees.</ix:continuation></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i29af49cba3454334b4bc03d031e4f862">In addition, Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</ix:continuation>&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ia5892dcce25547a19d63f064d49677ff_55"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81NS9mcmFnOmNmOTc3MzZjMWQyODQ1YTVhYjMyNTIzZjM2M2QxNGI4L3RleHRyZWdpb246Y2Y5NzczNmMxZDI4NDVhNWFiMzI1MjNmMzYzZDE0YjhfOTgwNQ_c59f85dc-a23f-4340-96c6-60bde8d17830" continuedAt="i8fc36c7614944bc0a3bdd76f6deb60f5" escape="true">Collaboration and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i8fc36c7614944bc0a3bdd76f6deb60f5" continuedAt="i5d4856acfe0b4a31a0c35b9e8f84030f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ipsen.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#8220;Ipsen Agreement&#8221;), with Ipsen for the development and commercialization of XERMELO outside of the United States and Japan (the &#8220;Licensed Territory&#8221;).  The Ipsen Agreement was assigned to TerSera in September 2020 in connection with the XERMELO sale.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the XERMELO sale, Lexicon had earned certain milestone payments and royalties from Ipsen.  Revenue, including royalty revenue, recognized under the Ipsen Agreement was $<ix:nonFraction unitRef="usd" contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81NS9mcmFnOmNmOTc3MzZjMWQyODQ1YTVhYjMyNTIzZjM2M2QxNGI4L3RleHRyZWdpb246Y2Y5NzczNmMxZDI4NDVhNWFiMzI1MjNmMzYzZDE0YjhfMjc0ODc3OTA4NjcxMA_1525b865-cbf7-4520-ae8a-b8bf242d63ea">0.1</ix:nonFraction> million for the three months ended March&#160;31, 2020.   </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &#8220;Sanofi Agreement&#8221;), with Sanofi for the worldwide development of Lexicon&#8217;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of September 9, 2019 (the &#8220;Settlement Date&#8221;), Lexicon entered into the Termination Agreement with Sanofi, pursuant to which the Sanofi Agreement was terminated and certain associated disputes between Lexicon and Sanofi were settled.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5d4856acfe0b4a31a0c35b9e8f84030f">Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications. Sanofi paid Lexicon $<ix:nonFraction unitRef="usd" contextRef="i404c6b80bc36405880a95d223586358a_D20190901-20190930" decimals="-6" format="ixt:numdotdecimal" name="lxrx:SettlementPaymentFromTermination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81NS9mcmFnOmNmOTc3MzZjMWQyODQ1YTVhYjMyNTIzZjM2M2QxNGI4L3RleHRyZWdpb246Y2Y5NzczNmMxZDI4NDVhNWFiMzI1MjNmMzYzZDE0YjhfODc3NA_2ea9840f-adf7-4d03-8740-b052849eecfe">208</ix:nonFraction> million in September 2019 and $<ix:nonFraction unitRef="usd" contextRef="i2747cad63b6941889a2232ada4034c1e_D20200301-20200331" decimals="-6" format="ixt:numdotdecimal" name="lxrx:Lxrx_sanofiInitialCashPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81NS9mcmFnOmNmOTc3MzZjMWQyODQ1YTVhYjMyNTIzZjM2M2QxNGI4L3RleHRyZWdpb246Y2Y5NzczNmMxZDI4NDVhNWFiMzI1MjNmMzYzZDE0YjhfODc5OQ_cab57cdc-a476-4600-9b82-7ed3c3a7856d"><ix:nonFraction unitRef="usd" contextRef="i75c9ca72d87c4541bcbf8632f671f7ae_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="lxrx:Lxrx_sanofiInitialCashPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81NS9mcmFnOmNmOTc3MzZjMWQyODQ1YTVhYjMyNTIzZjM2M2QxNGI4L3RleHRyZWdpb246Y2Y5NzczNmMxZDI4NDVhNWFiMzI1MjNmMzYzZDE0YjhfODc5OQ_f96386bc-0cad-450a-a64f-738db56f4082">26</ix:nonFraction></ix:nonFraction> million in each of March and September 2020 (less amounts withheld by Sanofi offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by Lexicon under the terms of the Termination Agreement), and neither party will owe any additional payments pursuant to the Sanofi Agreement. The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions.  See Note 6, Commitments and Contingencies, for additional information.  Beginning in March 2020, Lexicon closed out early the clinical studies related to the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease. Subsequent to the Termination Agreement, Lexicon has no remaining performance obligations to Sanofi.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ia5892dcce25547a19d63f064d49677ff_894"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" name="lxrx:OtherCapitalAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzkzNDU4NDg4MzY5ODk_1878b2d8-5f52-4b6c-a396-42d2dde07034" continuedAt="id46573811ed648fe97e97b6508384f3d" escape="true">Other Capital Agreements</ix:nonNumeric></span></div><ix:continuation id="id46573811ed648fe97e97b6508384f3d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  In 2020, Lexicon entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;sales agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) relating to the shares of its common stock.  Lexicon may offer and sell common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="i0953aa39e2f84e829c3acc2d7f88a6a3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="lxrx:ATMOfferingTotal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzI3NDg3NzkwNzAxMDQ_64ffa68c-c071-42ab-9676-dfe5eb22e33e">50.0</ix:nonFraction>&#160;million from time to time through Jefferies acting as its sales agent.  In 2020, Lexicon sold <ix:nonFraction unitRef="shares" contextRef="i0953aa39e2f84e829c3acc2d7f88a6a3_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="lxrx:SharesSoldInNov2020ATMOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzI3NDg3NzkwNzAxNjI_581888bf-4627-493c-b064-cbf5dde1ea26">3,709,233</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usd" contextRef="ie9cf39493d3443c4a790590a54c215b8_D20201001-20201231" decimals="3" name="lxrx:SharePriceInNovember20ATMOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzI3NDg3NzkwNzAyMTU_cabc7b0a-866f-465f-8ed6-70a4abd37f7a">1.992</ix:nonFraction> per share pursuant to the sales agreement, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i0953aa39e2f84e829c3acc2d7f88a6a3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:ProceedsFromNov2020ATMOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzI3NDg3NzkwNzAyOTE_22181dd5-0541-4f23-aaad-6ff8021f70da">7.0</ix:nonFraction>&#160;million.  In January 2021, Lexicon sold <ix:nonFraction unitRef="shares" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="lxrx:SharesSoldInJanuary2021ATMOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzI3NDg3NzkwNzAxMTE_aaed9182-4b47-4352-aed0-c1ccffb85b1a">2,000,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="shares" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="3" name="lxrx:SharePriceInJanuary2021ATMOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzI3NDg3NzkwNzAxMTU_509717e2-3156-403e-af5c-b94526dc45ba">8.463</ix:nonFraction> per share pursuant to the sales agreement, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:ProceedsFromJanuary2021ATMOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzI3NDg3NzkwNzAxMTk_c2198df8-597d-47b7-a91e-0fcbf72c7daa">16.4</ix:nonFraction>&#160;million.  The net proceeds are reflected as issuance of common stock in the accompanying condensed consolidated financial statements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ia5892dcce25547a19d63f064d49677ff_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives. We are devoting most of our resources to the research and development of our most advanced drug candidates:</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.  We have reported results from two Phase 1 clinical trials of LX9211 and are now conducting a Phase 2 clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase 2 clinical trial of LX9211 in post-herpetic neuralgia.  LX9211 has received Fast Track designation from the FDA for development in diabetic peripheral neuropathic pain.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.  We have reported positive results from two Phase 3 clinical trials evaluating the effect of sotagliflozin on long-term outcomes related to cardiovascular death and heart failure in approximately 10,500 and 1,200 patients, respectively.  We are now working towards an application for regulatory approval to market sotagliflozin for heart failure and seeking a strategic collaboration for the commercialization of sotagliflozin, if approved.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have reported positive results from three Phase 3 clinical trials evaluating the effect of sotagliflozin on type 1 diabetes in approximately 800, 800 and 1,400 patients, respectively.  The FDA issued a complete response letter regarding our application for regulatory approval to market sotagliflozin for type 1 diabetes in the United States and, at our request, has issued a public Notice of Opportunity for Hearing on whether there are grounds for denying approval of our application.  Sotagliflozin has been approved in the European Union for use as an adjunct to insulin therapy in the treatment of type 1 diabetes, but has not yet been commercially launched.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are conducting preclinical research and development and preparing to conduct clinical development of compounds from a number of additional drug programs originating from our internal drug discovery efforts.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> LX9211 originated from our collaborative neuroscience drug discovery efforts with Bristol-Myers Squibb, and sotagliflozin and compounds from a number of additional drug programs originated from our own internal drug discovery efforts.  Those efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets.  We have identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working both independently and through collaborations and strategic alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  We seek to retain exclusive or co-exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians.  We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have derived substantially all of our revenues from strategic collaborations and other research and development collaborations and technology licenses, as well as from commercial sales of our XERMELO product following its commercial launch in February 2017 until our sale of XERMELO and related assets to TerSera in September 2020.  To date, we have generated a substantial portion of our revenues from a limited number of sources. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results and, in particular, our ability to generate additional revenues are dependent on many factors, including the success of our ongoing nonclinical and clinical development efforts and ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; TerSera&#8217;s ability to successfully develop and commercialize XERMELO for biliary tract cancer and our receipt of milestone payments and royalties from such efforts; our success in establishing new collaborations and licenses, particularly for the commercialization of sotagliflozin for heart failure; and general and industry-specific economic conditions which may affect research and development expenditures.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future revenues from our sale of XERMELO to TerSera are uncertain because they depend on the achievement of milestones and payment of royalties we earn from TerSera&#8217;s development and commercialization of XERMELO in biliary tract cancer.  Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.&#160;&#160;We may determine, as we have with certain of our drug candidates, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase expenses.&#160;&#160;Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant losses and, as of March&#160;31, 2021, we had an accumulated deficit of $1.4&#160;billion. Our losses have resulted principally from costs incurred in research and development, selling, general and administrative costs associated with our operations, and non-cash stock-based compensation expenses associated with stock options and restricted stock units granted to employees and consultants. Research and development expenses consist primarily of salaries and related personnel costs, external research costs related to our nonclinical and clinical efforts, material costs, facility costs, depreciation on property and equipment, and other expenses related to our drug discovery and development programs. Selling, general and administrative expenses consist primarily of salaries and related expenses for executive, sales and marketing, and administrative personnel, professional fees and other corporate expenses, including information technology, facilities costs and general legal activities. We expect to continue to incur significant research and development costs in connection with the continuing development of our drug candidates. As a result, we will need to generate significantly higher revenues to achieve profitability. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our condensed consolidated financial statements and accompanying notes.&#160;&#160;Actual results could differ from those estimates.&#160;&#160;We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recent accounting pronouncements that could have a material impact to our condensed consolidated financial statements.   </span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="ia5892dcce25547a19d63f064d49677ff_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues and dollar and percentage changes as compared to the corresponding period in the prior year are as follows (dollar amounts are presented in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%"><tr><td style="width:1.0%"></td><td style="width:64.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar decrease</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage decrease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Net product revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Net product revenue for the three months ended March&#160;31, 2020 was $7.9 million. We sold XERMELO and related assets to TerSera on September 8, 2020. Product revenues were recorded net of estimated product returns, pricing discounts including rebates offered pursuant to mandatory federal and state government programs and chargebacks, prompt pay discounts and distribution fees and co-pay assistance.  Revenue recognition policies require estimates of the aforementioned sales allowances each period.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Royalties and other revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Royalty revenue for the three months ended March&#160;31, 2020 was $0.1 million from the product sales of XERMELO by Ipsen in countries outside the United States.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Cost of sales was $0.6 million for the three months ended March&#160;31, 2020 and included $0.4 million of amortization of intangible assets relating to XERMELO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses and dollar and percentage changes as compared to the corresponding period in the prior year are as follows (dollar amounts are presented in millions):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.134%"><tr><td style="width:1.0%"></td><td style="width:64.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.168%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.642%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar decrease</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage decrease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of third-party and other services principally related to nonclinical and clinical development activities, salaries and other personnel-related expenses, stock-based compensation expense, and facility and equipment costs.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party and other services &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Third-party and other services for the three months ended March&#160;31, 2021 decreased 84% to $7.2 million as compared to the corresponding period in 2020 primarily due to decreases in external clinical development costs relating to sotagliflozin subsequent to the wind down of the activities beginning in March 2020.  Third-party and other services relate principally to our clinical trial and related development activities, such as nonclinical and clinical studies and contract manufacturing.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Personnel &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Personnel costs for the three months ended March&#160;31, 2021 decreased 48% to $2.9 million as compared to the corresponding period in 2020, primarily due to lower employee salaries and benefit costs as a result of the reduction in force of our personnel in September 2020.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Stock-based compensation expense for the three months ended March&#160;31, 2021 decreased 41% to $1.3 million as compared to the corresponding period in 2020, primarily due to cancellation of unvested share-based awards as a result of the reduction in force of our personnel in September 2020.  </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Facilities and equipment &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities and equipment costs for the three months ended March&#160;31, 2021 and 2020 was $0.3 million and $0.7 million, respectively.  </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other costs for the three months ended March&#160;31, 2021 decreased 38% to $0.9 million as compared to the corresponding period in 2020, primarily due to lower costs of travel.   </span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses and dollar and percentage changes as compared to the corresponding period in the prior year are as follows (dollar amounts are presented in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.134%"><tr><td style="width:1.0%"></td><td style="width:64.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.168%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.642%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar decrease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage decrease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel costs to support our research and development activities, professional and consulting fees, stock-based compensation expense, and facility and equipment costs.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Personnel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Personnel costs for the three months ended March&#160;31, 2021 decreased 58% to $3.2 million as compared to the corresponding period in 2020, primarily due to lower employee salaries and benefit costs as a result of the reduction in force of our personnel in September 2020.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Professional and consulting fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Professional and consulting fees for the three months ended March&#160;31, 2021 decreased 16% to $2.4 million as compared to the corresponding period in 2020, primarily due to lower marketing expenses, partially offset by higher legal fees.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Stock-based compensation expense for the three months ended March&#160;31, 2021 decreased 31% to $1.6 million as compared to the corresponding period in 2020, primarily due to cancellation of unvested share-based awards as a result of the reduction in force of our personnel in September 2020. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Facilities and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Facilities and equipment costs for the three months ended March&#160;31, 2021 and 2020 were $0.3 million and $0.5 million, respectively. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other costs for the three months ended March&#160;31, 2021 decreased 50% to $0.8 million as compared to the corresponding period in 2020, primarily due to decreases in travel expenses due to the COVID-19 pandemic. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Interest and Other Income, Net</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;Interest expense decreased 97% to $0.2 million for the three months ended March&#160;31, 2021, primarily due to the $150 million payoff of the BioPharma term loan in September 2020 and the $75.8 million exchange of convertible notes in September and October 2020.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and Other Income, Net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Interest and other income, net for the three months ended March&#160;31, 2021 decreased 95% from $1.0 million in the corresponding period in 2020. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss and Net Loss per Common Share</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net loss and Net loss per Common Share.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss was $21.0 million, or $0.15 per share, in the three months ended March&#160;31, 2021 as compared to $66.6 million, or $0.63 per share, in the corresponding period in 2020.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly operating results have fluctuated in the past and are likely to do so in the future, and we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="ia5892dcce25547a19d63f064d49677ff_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations from inception primarily through sales of common and preferred stock, contract and milestone payments we received under our strategic and other collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts, and financing under debt and lease arrangements.  We have also financed certain of our research and development activities under our agreements with Symphony Icon, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we had $141.4&#160;million in cash, cash equivalents and short-term investments.  As of December&#160;31, 2020, we had $152.3&#160;million in cash, cash equivalents and short-term investments.  We used cash of $25.2&#160;million from operations in the three months ended March&#160;31, 2021.  This consisted primarily of the net loss for the period of $21.0&#160;million and a net decrease in operating liabilities net of assets of $7.1 million, partially offset by non-cash charges of $2.9&#160;million related to stock-based compensation expense. Investing activities used cash of $17.7&#160;million in the three&#160;months ended March&#160;31, 2021, primarily due to net purchases of investments.  Financing activities provided cash of $14.3&#160;million, primarily as a result of $16.9&#160;million net proceeds from the sale of common stock under an Open Market Sale agreement, which was partially offset by $2.7&#160;million used to repurchase common stock. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, sotagliflozin was approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index &#8805; </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 kg/m</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, who could not achieve adequate glycemic control despite optimal insulin therapy.  Upon the achievement of certain European regulatory pricing approvals, we will be required to make certain royalty payments, totaling $4.5 million, in three equal annual installments of $1.5 million. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In December 2020, our subsidiary, Lex-Gen Woodlands, L.P., sold our facilities in The Woodlands, Texas for $11.9 million.  Concurrent with such sale, we entered into a leaseback agreement with respect to 38,000 square feet of such facilities for a period of up to six months, with monthly gross rent payments of $101,000.  In February 2021, we leased a 25,000 square-foot office space in The Woodlands, Texas to which we plan to relocate our corporate offices.  The term of the sublease extends from March 1, 2021 through August 31, 2025, and provides for escalating yearly base rent payments starting at $506,000 and increasing to $557,000 in the final year of the lease.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, our subsidiary Lexicon Pharmaceuticals (New Jersey), Inc. leased a 25,000 square-foot office space in Basking Ridge, New Jersey.  The term of the lease extends from June&#160;1, 2015 through December&#160;31, 2022, and provides for escalating yearly base rent payments starting at $482,000 and increasing to $646,000 in the final year of the lease. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will be substantial and will depend on many factors, including the success of our ongoing nonclinical and clinical development efforts and the ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; TerSera&#8217;s ability to successfully develop and commercialize XERMELO for biliary tract cancer and our receipt of milestone payments and royalties from such efforts; our success in establishing new collaborations and licenses, particularly for the commercialization of sotagliflozin for heart failure; the amount and timing of our research, development and commercialization expenditures; the resources we devote to developing and supporting our products and other factors.&#160;&#160;Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary technologies and businesses.&#160;&#160;We expect to continue to devote substantial capital resources to successfully complete our nonclinical and clinical development efforts with respect to LX9211, sotagliflozin and our other drug candidates; and for other general corporate activities.&#160;&#160;We believe that our current unrestricted cash and investment balances and cash and revenues we expect to derive from strategic and other collaborations and other sources will be sufficient to fund our operations for at least the next 12 months.&#160;&#160;During or after this period, if cash generated by operations is insufficient to satisfy our liquidity requirements, we will need to sell additional equity or debt securities or obtain additional credit arrangements.&#160;&#160;Additional financing may not be available on terms acceptable to us or at all. The sale of additional equity or convertible debt securities may result in additional dilution to our stockholders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our board of directors may authorize us to repurchase shares of our common stock, repurchase, in cash or common stock, our outstanding convertible notes, or make a cash payment to holders of our convertible notes to induce conversion pursuant to the terms of the convertible notes, in each case, in privately negotiated transactions, publicly announced programs or otherwise.  If and when our board of directors should determine to authorize any such action, it would be on terms and under market conditions that our board of directors determines are in the best interest of us and our stockholders.  Any such actions could deplete significant amounts of our cash resources and/or result in additional dilution to our stockholders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure about Market Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to limited market and credit risk on our cash equivalents which have maturities of three months or less at the time of purchase. We maintain a short-term investment portfolio which consists of U.S. Treasury bills and corporate debt securities that mature three to 12 months from the time of purchase, which we believe are subject to limited market and credit risk. We currently do not hedge interest rate exposure or hold any derivative financial instruments in our investment portfolio.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had approximately $141.4&#160;million in cash and cash equivalents and short-term investments as of March&#160;31, 2021.  We believe that the working capital available to us will be sufficient to meet our cash requirements for at least the next 12&#160;months. We are not subject to interest rate sensitivity on our outstanding Convertible Notes as they generally have a fixed rate of 5.25% per annum.  The Convertible Notes interest is payable in cash semi-annually in arrears and matures in December 2021, unless earlier converted or repurchased in accordance with their terms.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operated primarily in the United States and substantially all sales to date have been made in U.S. dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ia5892dcce25547a19d63f064d49677ff_73"></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Disclosure about Market Risk&#8221; under &#8220;Item 2. Management&#8217;s Discussion and Analysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Financial Condition and Results of Operations&#8221; for quantitative and qualitative disclosures about market risk.</span></div><div><span><br/></span></div><div id="ia5892dcce25547a19d63f064d49677ff_76"></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;Controls and Procedures</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective to ensure that the information required to be disclosed by us in the reports we file under the Securities Exchange Act is gathered, analyzed and disclosed with adequate timeliness, accuracy and completeness, based on an evaluation of such controls and procedures as of the end of the period covered by this report. There were no changes in our internal control over financial reporting during the three months ended March&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="ia5892dcce25547a19d63f064d49677ff_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part II -- Other Information&#160;</span></div><div style="text-align:center"><span><br/></span></div><div id="ia5892dcce25547a19d63f064d49677ff_82"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;Legal Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Securities Class Action Litigation.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against us and certain of our officers in the U.S. District Court for the Southern District of Texas, Houston Division.  Our motion to dismiss was granted and the action was dismissed with prejudice by the District Court on August 14, 2020.  The lead plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Fifth Circuit on September 11, 2020 and a brief in support of its appeal on December&#160;17, 2020.  We filed a response brief on February 18, 2021 and the lead plaintiffs filed a reply brief on March 11, 2021.  The lawsuit purports to be a class action brought on behalf of purchasers of our securities during the period from March 11, 2016 through July 29, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from our Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi Arbitration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  On October 16, 2020, we initiated arbitration proceedings against Sanofi seeking to recover damages for breach of contract relating to the Termination and Settlement Agreement and Mutual Releases with Sanofi, dated September 9, 2019.  In September 2020, Sanofi withheld approximately $23.2 million from the final $26 million payment due to us under the termination and settlement agreement, offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by us under the terms of the termination and settlement agreement.  We dispute that at least a significant portion of such costs are properly reimbursable by us under the terms of the termination and settlement agreement and assert that, in any event, Sanofi was not permitted to withhold any of such costs under the terms of the termination and settlement agreement.  We are seeking payment of up to $23.2 million in such disputed costs, together with late interest and attorneys&#8217; fees and costs.  Sanofi is seeking a declaratory judgment that we are liable for all disputed costs previously withheld and damages for any additional costs properly reimbursable under the terms of the termination and settlement agreement in excess of those previously withheld, together with late interest and attorneys&#8217; fees.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Normal Course Legal Proceedings.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are from time to time party to claims and legal proceedings that arise in the normal course of our business and that we believe will not have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or liquidity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ia5892dcce25547a19d63f064d49677ff_85"></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;Risk Factors</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following risks and uncertainties are important factors that could cause actual results or events to differ materially from those indicated by forward-looking statements.  The factors described below are not the only ones we face and additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our and our collaborators&#8217; ability to commercialize products.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We depend on our ability to gain alignment with certain regulatory authorities on our regulatory strategy for sotagliflozin in heart failure. If we fail to effectively gain such alignment, our business will suffer and our stock price will likely decline.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;The commercial success of any products that we or our collaborators may develop will depend upon the degree of market acceptance among physicians, patients, health care payers and the medical community.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;If we are unable to reestablish an effective sales force, marketing infrastructure and distribution capabilities, we will not be able to successfully commercialize any products that we or our collaborators may develop.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;If we are unable to maintain adequate coverage and reimbursement from third-party payers for any products that we or our collaborators may develop, our revenues and prospects for profitability will suffer.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We may not be able to manufacture products that we or our collaborators may develop in commercial quantities, which would impair our ability to commercialize such products.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We and our collaborators are subject to extensive and rigorous ongoing regulation relating to any products that we or our collaborators may develop.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may negatively affect our revenues and prospects for profitability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Our competitors may develop products that impair the value of any products that we or our collaborators may develop.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We face business disruption and related risks resulting from the outbreak of the novel coronavirus, or COVID-19, including delays in the enrollment of ongoing clinical trials and other operational impacts, each of which could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Risks Related to Our Capital Requirements and Financial Results</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We will need additional capital in the future and, if it is unavailable, we will be forced to delay, reduce or eliminate our research and development programs.  If additional capital is not available on reasonable terms, we will be forced to obtain funds, if at all, by entering into financing agreements on unattractive terms.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Our operating results have fluctuated and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We have indebtedness that may limit cash flow available to invest in the ongoing needs of our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We depend on our ability to establish a strategic collaboration for the commercialization of sotagliflozin in heart failure. If we are unable to establish such a collaboration, sotagliflozin may not be commercialized in heart failure, our business will suffer and our stock price will likely decline.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We depend on our ability to establish collaborations with pharmaceutical and biotechnology companies for the development and commercialization of our other drug candidates. If we are unable to establish such collaborations, or if pharmaceutical products are not successfully and timely developed and commercialized under such collaborations, our opportunities to generate revenues from our other drug candidates will be greatly reduced.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We rely on third parties to carry out our nonclinical studies and clinical trials, which may harm or delay our research and development efforts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We lack the capability to manufacture materials for nonclinical studies, clinical trials and rely on third parties to manufacture our drug candidates, which may harm or delay our research and development efforts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Intellectual Property</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our planned nonclinical and clinical development and commercialization activities.  We may not prevail in any such litigation or other dispute or be able to obtain required licenses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Data breaches and cyber-attacks could compromise our intellectual property or other sensitive information and cause significant damage to our business, reputational harm and financial loss.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Employees and Facilities</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;If we are unable to manage our growth, our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to operate and expand our operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Our facilities are located near coastal zones, and the occurrence of a hurricane or other disaster could damage our facilities and equipment, which could harm our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We have used hazardous chemicals and radioactive and biological substances in our business. Any claims relating to improper handling, storage or disposal of these substances could be time consuming and costly.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Our business has a substantial risk of product liability and we face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Common Stock</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Invus, L.P. and its affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Invus has additional rights under its stockholders&#8217; agreement relating to the membership of our board of directors, which provides Invus with substantial influence over significant corporate matters.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Our stock price may be extremely volatile.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We are subject to securities litigation, which is expensive and could divert management attention.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Future issuances or sales of our common stock, or the perception that such issuances or sales may occur, may depress our stock price.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of the risks and uncertainties that affect our business, see &#8220;Item&#160;1A. Risk Factors&#8221; included in our annual report on Form 10-K for the year ended December&#160;31, 2020 as filed with the Securities and Exchange Commission. </span></div><div><span><br/></span></div><div id="ia5892dcce25547a19d63f064d49677ff_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about our purchases of shares of our common stock during the three months ended March&#160;31, 2021:</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:40.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number of Shares that May Yet be Purchased Under the Plans or Programs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1-31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1-28, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372,040</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1-31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Represents shares retained by us in satisfaction of the tax withholding obligations of recipients of restricted stock units granted in February 2017, February 2018, February 2019 and February 2020 under our 2017 Equity Incentive Plan with respect to the vesting of such restricted stock units.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Represents the market price of our common stock on the date of vesting of such restricted stock units, calculated in accordance with the process for determination of fair market value under our 2017 Equity Incentive Plan.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3) &#160;&#160;&#160;&#160;In the future, we may grant additional equity securities under our 2017 Equity Incentive Plan for which the recipient's tax withholding obligations with respect to the grant or vesting of such securities may be satisfied by our retention of a portion of such securities.  Further, for any such equity securities which are subject to vesting conditions, the number of equity securities which we may retain in satisfaction of the recipient's tax withholding obligations may be dependent on the continued employment of such recipient or other performance-based conditions.  Accordingly, we cannot predict with any certainty either the total amount of equity securities or the approximate dollar value of such securities that we may purchase in future years.</span></div><div style="padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ia5892dcce25547a19d63f064d49677ff_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;Exhibits</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;text-indent:4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282221000029/exh31-secondamendedandrest.htm">Second Amended and Restated Certificate of Incorporation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K dated April 29, 2021 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;text-indent:4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282221000029/exh101-2017nonxemployeedir.htm">2017 Non-Employee Directors&#8217; Equity Incentive Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, as amended (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K dated April 29, 2021 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh311certificationofprinc.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh312certificationofprinc.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*32.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh321certificationofprinc.htm">Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension  Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ia5892dcce25547a19d63f064d49677ff_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lonnel Coats</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey L. Wade</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exh311certificationofprinc.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i12248f8b107d4eaa9bde9eab8866cdcc_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Lonnel Coats, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;6, 2021 </font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:46.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exh312certificationofprinc.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0d4c4ad4b2ef482eb62eda34a12c2761_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jeffrey L. Wade, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;6, 2021 </font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:51.023%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exh321certificationofprinc.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iab00acfbc8784d428cc36a26497f903a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Lonnel Coats, Principal Executive Officer of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221;), and Jeffrey L. Wade, Principal Financial Officer of Lexicon, each hereby certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Lexicon's Quarterly Report on Form 10-Q for the period ended March&#160;31, 2021, and to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Lexicon. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 6th day of May, 2021.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:56.432%"><tr><td style="width:1.0%"></td><td style="width:7.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:56.286%"><tr><td style="width:1.0%"></td><td style="width:8.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President, Corporate and Administrative</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Affairs and Chief Financial Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>lxrx-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4b8e7fc5-a67e-4e41-8672-ef3fbe451ee1,g:d40e2da2-7e73-4fe0-84fd-1f0cf7fd616c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParentheticals" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited">
        <link:definition>1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossParentheticals" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited">
        <link:definition>1006007 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNotes" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables">
        <link:definition>2303301 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails">
        <link:definition>2404401 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2">
        <link:definition>2406403 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails">
        <link:definition>2407404 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails">
        <link:definition>2408405 - Disclosure - Summary of Significant Accounting Policies Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsLevel1Notes" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes">
        <link:definition>2109102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestments" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments">
        <link:definition>2110103 - Disclosure - Cash and Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsTables" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables">
        <link:definition>2311302 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsDetails1" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1">
        <link:definition>2412406 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsDetails2" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2">
        <link:definition>2413407 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.lexpharma.com/role/FairValueMeasurements">
        <link:definition>2114104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables">
        <link:definition>2315303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1">
        <link:definition>2416408 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligations" roleURI="http://www.lexpharma.com/role/DebtObligations">
        <link:definition>2117105 - Disclosure - Debt Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsTables" roleURI="http://www.lexpharma.com/role/DebtObligationsTables">
        <link:definition>2318304 - Disclosure - Debt Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDetails" roleURI="http://www.lexpharma.com/role/DebtObligationsDetails">
        <link:definition>2419409 - Disclosure - Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies">
        <link:definition>2120106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2421410 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements">
        <link:definition>2122107 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTables" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables">
        <link:definition>2323305 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsDetails" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails">
        <link:definition>2424411 - Disclosure - Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalAgreements" roleURI="http://www.lexpharma.com/role/OtherCapitalAgreements">
        <link:definition>2125108 - Disclosure - Other Capital Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalAgreementsDetails" roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails">
        <link:definition>2426412 - Disclosure - Other Capital Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lxrx_SettlementPaymentFromTermination" abstract="false" name="SettlementPaymentFromTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Lxrx_sanofiInitialCashPayment" abstract="false" name="Lxrx_sanofiInitialCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" abstract="true" name="ConsolidatedStatementsOfStockholdersEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_FutureConvertibleDebtExchangeShares" abstract="false" name="FutureConvertibleDebtExchangeShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" abstract="false" name="MortgageDebtInterestRate_Base_Revere_LXRX" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_OtherCapitalAgreementsTextBlock" abstract="false" name="OtherCapitalAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lxrx_AccruedInterestOnConvertible" abstract="false" name="AccruedInterestOnConvertible" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_LiabilitiesAssumedByTerSera" abstract="false" name="LiabilitiesAssumedByTerSera" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_IpsenMilestonePaymentReceived" abstract="false" name="IpsenMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharePriceInJanuary2021ATMOffering" abstract="false" name="SharePriceInJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_GainOnSaleOfNonFinancialAssets" abstract="false" name="GainOnSaleOfNonFinancialAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" abstract="false" name="MortgageDebtInterestRateBasePlus_Revere_LXRX" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_ConsolidatedBalanceSheetsAbstract" abstract="true" name="ConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeSeptemberCashPortion" abstract="false" name="ConvertibleDebtExchangeSeptemberCashPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharePriceInNovember20ATMOffering" abstract="false" name="SharePriceInNovember20ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_Sellinggeneralandadministrativeexpenses" abstract="false" name="Sellinggeneralandadministrativeexpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeSeptemberSharePayment" abstract="false" name="ConvertibleDebtExchangeSeptemberSharePayment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_RecentAccountingPronouncementsAbstract" abstract="true" name="RecentAccountingPronouncementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesDomain" abstract="true" name="AccruedLiabilitiesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lxrx_ProceedsFromNov2020ATMOffering" abstract="false" name="ProceedsFromNov2020ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" abstract="false" name="StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvDebtInstrumentInterestRateStatedPercentage" abstract="false" name="ConvDebtInstrumentInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeRemainingNotes" abstract="false" name="ConvertibleDebtExchangeRemainingNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenRevenueRecognized" abstract="false" name="IpsenRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" abstract="false" name="ConvertibleDebtExchangeTotalPrincipalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesSoldInJanuary2021ATMOffering" abstract="false" name="SharesSoldInJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_AccruedResearchAndDevelopmentServicesCurrent" abstract="false" name="AccruedResearchAndDevelopmentServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Lxrx_Sanofiterminationcashpayment" abstract="false" name="Lxrx_Sanofiterminationcashpayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenTotalPayments" abstract="false" name="IpsenTotalPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesSoldInNov2020ATMOffering" abstract="false" name="SharesSoldInNov2020ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfOperationsAbstract" abstract="true" name="ConsolidatedStatementsOfOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_SanofiDisputedCosts" abstract="false" name="SanofiDisputedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenMaximumSalesMilestones" abstract="false" name="IpsenMaximumSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_FutureConvertibleDebtExchange" abstract="false" name="FutureConvertibleDebtExchange" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DebtObligationsAbstract" abstract="true" name="DebtObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ProceedsFromJanuary2021ATMOffering" abstract="false" name="ProceedsFromJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenMilestonePayment" abstract="false" name="IpsenMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesAxis" abstract="true" name="AccruedLiabilitiesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_FairValueMeasurementsAbstract" abstract="true" name="FairValueMeasurementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" abstract="false" name="Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_MortgageDebtBalloonPayment_LXRX" abstract="false" name="MortgageDebtBalloonPayment_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ATMOfferingTotal" abstract="false" name="ATMOfferingTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_AccruedCompensationAndBenefitsCurrent" abstract="false" name="AccruedCompensationAndBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" abstract="true" name="ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfCashFlowsAbstract" abstract="true" name="ConsolidatedStatementsOfCashFlowsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" abstract="false" name="IpsenRevenueAllocatedtoDevelopmentDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Netproductrevenue" abstract="false" name="Netproductrevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_LexiconIncrementalBorrowingRate" abstract="false" name="LexiconIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesLineItems" abstract="true" name="AccruedLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesTable" abstract="true" name="AccruedLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_SummaryOfSignificantAccountingPoliciesAbstract" abstract="true" name="SummaryOfSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_InitialRecognitionOfRightOfUseAsset" abstract="false" name="InitialRecognitionOfRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" abstract="true" name="CashAndCashEquivalentsAndInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchange" abstract="false" name="ConvertibleDebtExchange" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_PrincipalAmountOfConvertibleNotes" abstract="false" name="PrincipalAmountOfConvertibleNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_MortgageDebtInstrument_Revere_LXRX" abstract="false" name="MortgageDebtInstrument_Revere_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiRevenueRecognized" abstract="false" name="SanofiRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>lxrx-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4b8e7fc5-a67e-4e41-8672-ef3fbe451ee1,g:d40e2da2-7e73-4fe0-84fd-1f0cf7fd616c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="lxrx-20210331.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8eb4d459-1d35-4fd7-9c9b-68b651eb169b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5d6c0def-363f-4210-90bf-199e98604bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8eb4d459-1d35-4fd7-9c9b-68b651eb169b" xlink:to="loc_us-gaap_AssetsCurrent_5d6c0def-363f-4210-90bf-199e98604bc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9964417c-ab18-46e1-a494-76000a9b23c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8eb4d459-1d35-4fd7-9c9b-68b651eb169b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9964417c-ab18-46e1-a494-76000a9b23c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4fe88d3e-e276-40a1-b5bc-d7322e956dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8eb4d459-1d35-4fd7-9c9b-68b651eb169b" xlink:to="loc_us-gaap_Goodwill_4fe88d3e-e276-40a1-b5bc-d7322e956dc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5abc04d1-231b-4e0e-8aa7-c04cc3921181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8eb4d459-1d35-4fd7-9c9b-68b651eb169b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5abc04d1-231b-4e0e-8aa7-c04cc3921181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_53dbd56f-61f9-49b5-8707-9e407db20791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8eb4d459-1d35-4fd7-9c9b-68b651eb169b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_53dbd56f-61f9-49b5-8707-9e407db20791" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_20f8b00f-12c2-4002-b17e-319e4575e84c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_99239151-e141-401d-b03d-edcc6a8c1aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_20f8b00f-12c2-4002-b17e-319e4575e84c" xlink:to="loc_us-gaap_AccountsPayableCurrent_99239151-e141-401d-b03d-edcc6a8c1aa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0c82f6b4-dde0-4b88-b925-b56c322204c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_20f8b00f-12c2-4002-b17e-319e4575e84c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0c82f6b4-dde0-4b88-b925-b56c322204c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b245f436-5cdc-4dcb-a845-9a012c5232c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_20f8b00f-12c2-4002-b17e-319e4575e84c" xlink:to="loc_us-gaap_LongTermDebtCurrent_b245f436-5cdc-4dcb-a845-9a012c5232c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ee99da0e-35df-48a8-b24a-6d2f8b49432c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b178bcd7-8a58-4b2e-bc3f-f4cc50274fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ee99da0e-35df-48a8-b24a-6d2f8b49432c" xlink:to="loc_us-gaap_Liabilities_b178bcd7-8a58-4b2e-bc3f-f4cc50274fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a92f439c-beb8-4d00-8594-232584cadaa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ee99da0e-35df-48a8-b24a-6d2f8b49432c" xlink:to="loc_us-gaap_StockholdersEquity_a92f439c-beb8-4d00-8594-232584cadaa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fb95aef4-a320-4c08-9a58-38ddcb045fff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bc054885-87e9-4921-a0d4-243d9b541bf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fb95aef4-a320-4c08-9a58-38ddcb045fff" xlink:to="loc_us-gaap_LiabilitiesCurrent_bc054885-87e9-4921-a0d4-243d9b541bf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2fa1373c-a2ad-4eca-8dff-b704bbbaa18a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fb95aef4-a320-4c08-9a58-38ddcb045fff" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2fa1373c-a2ad-4eca-8dff-b704bbbaa18a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_47b7fc95-c9b6-4e73-b368-4ddded46c697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2cd9b118-c7d2-45f1-b6c7-048912bea635" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_47b7fc95-c9b6-4e73-b368-4ddded46c697" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2cd9b118-c7d2-45f1-b6c7-048912bea635" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_8332b9cd-cd28-4bad-9eb5-e85bb21cbde0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_47b7fc95-c9b6-4e73-b368-4ddded46c697" xlink:to="loc_us-gaap_ShortTermInvestments_8332b9cd-cd28-4bad-9eb5-e85bb21cbde0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bb1eb43a-bfd5-42ae-ad3d-4f8f99a51785" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_47b7fc95-c9b6-4e73-b368-4ddded46c697" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bb1eb43a-bfd5-42ae-ad3d-4f8f99a51785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9756dd43-34b0-4ea0-8d36-ccc2a75737d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_47b7fc95-c9b6-4e73-b368-4ddded46c697" xlink:to="loc_us-gaap_OtherAssetsCurrent_9756dd43-34b0-4ea0-8d36-ccc2a75737d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_822bf166-551b-4ca1-a4ea-666f2b2ece2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e0856ffd-9d91-4f6e-9768-6549489c3d00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_822bf166-551b-4ca1-a4ea-666f2b2ece2e" xlink:to="loc_us-gaap_PreferredStockValue_e0856ffd-9d91-4f6e-9768-6549489c3d00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0a5ee5e8-7e2c-4b9d-aa3b-19ee456bf33b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_822bf166-551b-4ca1-a4ea-666f2b2ece2e" xlink:to="loc_us-gaap_CommonStockValue_0a5ee5e8-7e2c-4b9d-aa3b-19ee456bf33b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e879e91a-2a18-48ff-857e-acc1fbfc2f36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_822bf166-551b-4ca1-a4ea-666f2b2ece2e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e879e91a-2a18-48ff-857e-acc1fbfc2f36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0ae97500-4ca9-4625-989f-b469b684fe8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_822bf166-551b-4ca1-a4ea-666f2b2ece2e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0ae97500-4ca9-4625-989f-b469b684fe8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_08b8abf1-1e72-455a-80bf-9fac3e498b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_822bf166-551b-4ca1-a4ea-666f2b2ece2e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_08b8abf1-1e72-455a-80bf-9fac3e498b89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_ff8d58fa-01fe-4696-a73e-54270fb88fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_822bf166-551b-4ca1-a4ea-666f2b2ece2e" xlink:to="loc_us-gaap_TreasuryStockValue_ff8d58fa-01fe-4696-a73e-54270fb88fd3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_788c33b0-df3a-4cb6-bea5-eeae27b821a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_e07ac0db-fee4-4f97-84db-2dbedc345fbc" xlink:href="lxrx-20210331.xsd#lxrx_Netproductrevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_788c33b0-df3a-4cb6-bea5-eeae27b821a4" xlink:to="loc_lxrx_Netproductrevenue_e07ac0db-fee4-4f97-84db-2dbedc345fbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d1dd8de3-7b66-44fc-82ea-f9797fed1aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_788c33b0-df3a-4cb6-bea5-eeae27b821a4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d1dd8de3-7b66-44fc-82ea-f9797fed1aa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_2d71ed5b-f76d-4841-8b22-a7019541bcb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_788c33b0-df3a-4cb6-bea5-eeae27b821a4" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_2d71ed5b-f76d-4841-8b22-a7019541bcb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7fcdaa90-cf0e-4a2e-8c27-8020a067e5d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7be47d4b-4418-466d-986f-aa1649145bf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7fcdaa90-cf0e-4a2e-8c27-8020a067e5d3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7be47d4b-4418-466d-986f-aa1649145bf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4be597df-902c-490a-a46d-13063bc973b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7fcdaa90-cf0e-4a2e-8c27-8020a067e5d3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4be597df-902c-490a-a46d-13063bc973b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_b7530a91-7eab-483b-abb1-5d9753b2409d" xlink:href="lxrx-20210331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7fcdaa90-cf0e-4a2e-8c27-8020a067e5d3" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_b7530a91-7eab-483b-abb1-5d9753b2409d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_54f11478-01e0-4ccd-8249-a0e121560f00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ab1e7c64-7952-420f-93b9-d7aeb80317f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_38a50ed1-2df4-4774-ba84-6dc12b84194d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ab1e7c64-7952-420f-93b9-d7aeb80317f0" xlink:to="loc_us-gaap_Revenues_38a50ed1-2df4-4774-ba84-6dc12b84194d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5e18d2fc-edbf-4198-a10d-2d0d39085079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ab1e7c64-7952-420f-93b9-d7aeb80317f0" xlink:to="loc_us-gaap_OperatingExpenses_5e18d2fc-edbf-4198-a10d-2d0d39085079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_dae77a1d-9b6f-45cb-a14b-1623c4f27ab4" xlink:href="lxrx-20210331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ab1e7c64-7952-420f-93b9-d7aeb80317f0" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_dae77a1d-9b6f-45cb-a14b-1623c4f27ab4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c6e96a3c-327b-4f84-8eea-a3a2ccb0e103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_83f18822-cfe9-42af-b3c3-33925398961d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c6e96a3c-327b-4f84-8eea-a3a2ccb0e103" xlink:to="loc_us-gaap_NetIncomeLoss_83f18822-cfe9-42af-b3c3-33925398961d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d609c5b1-ca5b-4caf-9f78-987a53573ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c6e96a3c-327b-4f84-8eea-a3a2ccb0e103" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d609c5b1-ca5b-4caf-9f78-987a53573ae3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedStatementsofComprehensiveLossParentheticals"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_cd510cf1-05cc-4361-bced-77bef33db87e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9ccb7542-684f-4368-b51e-91467bd7d599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_cd510cf1-05cc-4361-bced-77bef33db87e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9ccb7542-684f-4368-b51e-91467bd7d599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_48f8a351-e334-4d44-9838-e54dc1a43cac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_cd510cf1-05cc-4361-bced-77bef33db87e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_48f8a351-e334-4d44-9838-e54dc1a43cac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4a830be-9de0-42de-a558-16c98f635b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_cd510cf1-05cc-4361-bced-77bef33db87e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4a830be-9de0-42de-a558-16c98f635b2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7310a688-a2cf-4e58-844f-a4beb518df23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_70960615-ccdf-4f75-a632-b8fbb4ac5055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7310a688-a2cf-4e58-844f-a4beb518df23" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_70960615-ccdf-4f75-a632-b8fbb4ac5055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_8653bd6b-f81e-4073-9331-d89777e3f29c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7310a688-a2cf-4e58-844f-a4beb518df23" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_8653bd6b-f81e-4073-9331-d89777e3f29c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_f0b6f474-9d4d-40bc-ba77-fb89969a4387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7310a688-a2cf-4e58-844f-a4beb518df23" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_f0b6f474-9d4d-40bc-ba77-fb89969a4387" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed1fd350-a94d-4b65-91c3-fec80690ab09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3468ff8c-8da5-42d8-83f6-0827a915491d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed1fd350-a94d-4b65-91c3-fec80690ab09" xlink:to="loc_us-gaap_NetIncomeLoss_3468ff8c-8da5-42d8-83f6-0827a915491d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_594454fe-3efe-4708-bf47-56fda62274d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed1fd350-a94d-4b65-91c3-fec80690ab09" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_594454fe-3efe-4708-bf47-56fda62274d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b186edf2-6e11-4ccb-a7a5-94fe1ce91f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed1fd350-a94d-4b65-91c3-fec80690ab09" xlink:to="loc_us-gaap_ShareBasedCompensation_b186edf2-6e11-4ccb-a7a5-94fe1ce91f03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_6e7f4f3c-beaa-4759-94cb-c102218e0777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed1fd350-a94d-4b65-91c3-fec80690ab09" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_6e7f4f3c-beaa-4759-94cb-c102218e0777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_940b77b0-e7e2-4d2b-be52-a4068c676380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed1fd350-a94d-4b65-91c3-fec80690ab09" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_940b77b0-e7e2-4d2b-be52-a4068c676380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d99d9dfc-dbb4-4afd-bf26-52072458e623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed1fd350-a94d-4b65-91c3-fec80690ab09" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d99d9dfc-dbb4-4afd-bf26-52072458e623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7c35585f-3778-475f-8610-564ebfda59c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed1fd350-a94d-4b65-91c3-fec80690ab09" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7c35585f-3778-475f-8610-564ebfda59c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3a84e503-f31e-4d97-9901-542a89d8385f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed1fd350-a94d-4b65-91c3-fec80690ab09" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3a84e503-f31e-4d97-9901-542a89d8385f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3e82092f-0d61-494b-b49e-21b5c377f6a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed1fd350-a94d-4b65-91c3-fec80690ab09" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3e82092f-0d61-494b-b49e-21b5c377f6a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_04c9ecf3-6236-49dd-889f-d3f6984bfb63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed1fd350-a94d-4b65-91c3-fec80690ab09" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_04c9ecf3-6236-49dd-889f-d3f6984bfb63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_20473074-3a0b-455c-b1fa-bac59f9997b3" xlink:href="lxrx-20210331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed1fd350-a94d-4b65-91c3-fec80690ab09" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_20473074-3a0b-455c-b1fa-bac59f9997b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6f96ebc-4a4e-49c8-a9b0-6a8bcb116bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_db8edb32-b77a-4367-ada3-449ce7e6dbda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6f96ebc-4a4e-49c8-a9b0-6a8bcb116bcb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_db8edb32-b77a-4367-ada3-449ce7e6dbda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_34474bfb-698c-4a40-9912-110b1bbf803c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6f96ebc-4a4e-49c8-a9b0-6a8bcb116bcb" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_34474bfb-698c-4a40-9912-110b1bbf803c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7252b976-f1a1-4efd-bb2e-6b5a4320ed23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6f96ebc-4a4e-49c8-a9b0-6a8bcb116bcb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7252b976-f1a1-4efd-bb2e-6b5a4320ed23" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesNotes"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="simple" xlink:href="lxrx-20210331.xsd#RecentAccountingPronouncementsLevel1Notes"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CashandCashEquivalentsandInvestments"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CashandCashEquivalentsandInvestmentsDetails1"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CashandCashEquivalentsandInvestmentsDetails2"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20210331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20210331.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20210331.xsd#FairValueMeasurementsDetails1"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20210331.xsd#DebtObligations"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20210331.xsd#DebtObligationsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#DebtObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CommitmentsandContingenciesDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CollaborationandLicenseAgreements"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="simple" xlink:href="lxrx-20210331.xsd#OtherCapitalAgreements"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#OtherCapitalAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>lxrx-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4b8e7fc5-a67e-4e41-8672-ef3fbe451ee1,g:d40e2da2-7e73-4fe0-84fd-1f0cf7fd616c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="lxrx-20210331.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="extended" id="i3c6eca4b36794c0ea5adf8c4a5ac4c65_DocumentandEntityInformation"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended" id="i9336263ac1b242fa9bbf0632ceabc789_ConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0be42be1-c6fc-4027-bc61-c47a8c6f76a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0be42be1-c6fc-4027-bc61-c47a8c6f76a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a613f0c3-b518-4ac4-811b-6e23c4588173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0be42be1-c6fc-4027-bc61-c47a8c6f76a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a613f0c3-b518-4ac4-811b-6e23c4588173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_e31f456e-f16c-4933-b6a2-639789e9c2af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0be42be1-c6fc-4027-bc61-c47a8c6f76a5" xlink:to="loc_us-gaap_ShortTermInvestments_e31f456e-f16c-4933-b6a2-639789e9c2af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_193bb725-861c-45e2-9b51-45bff9bf4686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0be42be1-c6fc-4027-bc61-c47a8c6f76a5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_193bb725-861c-45e2-9b51-45bff9bf4686" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_86583279-44ef-46ba-9bb7-5b0f0872d59b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0be42be1-c6fc-4027-bc61-c47a8c6f76a5" xlink:to="loc_us-gaap_OtherAssetsCurrent_86583279-44ef-46ba-9bb7-5b0f0872d59b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3d32080b-f298-472d-bd41-176a252d8b95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0be42be1-c6fc-4027-bc61-c47a8c6f76a5" xlink:to="loc_us-gaap_AssetsCurrent_3d32080b-f298-472d-bd41-176a252d8b95" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3482d0ee-4414-4c84-a5e4-d5a38d5fc4ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3482d0ee-4414-4c84-a5e4-d5a38d5fc4ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_403cdc35-9ee7-4c8b-aebe-014e82ed104c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_Goodwill_403cdc35-9ee7-4c8b-aebe-014e82ed104c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1e400dbb-e536-4589-8cf5-17dbf7b8688a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1e400dbb-e536-4589-8cf5-17dbf7b8688a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0a9c54ab-666f-415d-95a7-a670f711f458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_Assets_0a9c54ab-666f-415d-95a7-a670f711f458" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_de9daa17-bbf9-40f5-9037-cff75e013b07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_de9daa17-bbf9-40f5-9037-cff75e013b07" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_05a0ccc6-cfcd-4540-bbbf-9470cb34a3af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de9daa17-bbf9-40f5-9037-cff75e013b07" xlink:to="loc_us-gaap_AccountsPayableCurrent_05a0ccc6-cfcd-4540-bbbf-9470cb34a3af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c034cc81-45e8-40b3-a9da-b29922e39ccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de9daa17-bbf9-40f5-9037-cff75e013b07" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c034cc81-45e8-40b3-a9da-b29922e39ccb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_0f621cd7-97fc-40e0-85b8-ed058809b6b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de9daa17-bbf9-40f5-9037-cff75e013b07" xlink:to="loc_us-gaap_LongTermDebtCurrent_0f621cd7-97fc-40e0-85b8-ed058809b6b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8ac3e82e-a965-4948-ab24-683973bf3951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de9daa17-bbf9-40f5-9037-cff75e013b07" xlink:to="loc_us-gaap_LiabilitiesCurrent_8ac3e82e-a965-4948-ab24-683973bf3951" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_91310787-baa0-4ef8-b9d9-019565a5430b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_91310787-baa0-4ef8-b9d9-019565a5430b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_440834ac-da20-453f-b0a9-9ed87a0cfbb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_Liabilities_440834ac-da20-453f-b0a9-9ed87a0cfbb0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7fae5841-f70a-45c8-99ae-5dcb5fdaa4da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7fae5841-f70a-45c8-99ae-5dcb5fdaa4da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9d765f89-099b-41ec-a9d5-7e4b1061a2a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:to="loc_us-gaap_PreferredStockValue_9d765f89-099b-41ec-a9d5-7e4b1061a2a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f96425bf-f42d-4ab4-b39c-d08293c0232b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:to="loc_us-gaap_CommonStockValue_f96425bf-f42d-4ab4-b39c-d08293c0232b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2b784c52-a6f1-4851-9826-2c40ab7761e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2b784c52-a6f1-4851-9826-2c40ab7761e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fb2a8c24-90aa-450c-b0c0-aef582d7bdc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fb2a8c24-90aa-450c-b0c0-aef582d7bdc3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_81254f13-09c0-47fd-8c20-6fc3299cc97d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_81254f13-09c0-47fd-8c20-6fc3299cc97d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_7033bfa5-f689-4a53-af61-2533cd17d85e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:to="loc_us-gaap_TreasuryStockValue_7033bfa5-f689-4a53-af61-2533cd17d85e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4aef4ed2-2aed-46c2-ae36-056ad5c6cc20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:to="loc_us-gaap_StockholdersEquity_4aef4ed2-2aed-46c2-ae36-056ad5c6cc20" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ace52603-f6d2-4084-a430-b3a8a54b8b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ace52603-f6d2-4084-a430-b3a8a54b8b4a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4f5894e8-c1c0-45f6-8e62-a26c60777b47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_StatementTable_4f5894e8-c1c0-45f6-8e62-a26c60777b47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_92d8374c-2c26-42e0-b921-17f39b161068" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4f5894e8-c1c0-45f6-8e62-a26c60777b47" xlink:to="loc_srt_StatementScenarioAxis_92d8374c-2c26-42e0-b921-17f39b161068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_92d8374c-2c26-42e0-b921-17f39b161068_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_92d8374c-2c26-42e0-b921-17f39b161068" xlink:to="loc_srt_ScenarioUnspecifiedDomain_92d8374c-2c26-42e0-b921-17f39b161068_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b46e8573-993b-4c9a-9acb-e5d1463414f0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_92d8374c-2c26-42e0-b921-17f39b161068" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b46e8573-993b-4c9a-9acb-e5d1463414f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ed8cf2de-5f97-4b64-8aeb-c279c99a5480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4f5894e8-c1c0-45f6-8e62-a26c60777b47" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ed8cf2de-5f97-4b64-8aeb-c279c99a5480" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ed8cf2de-5f97-4b64-8aeb-c279c99a5480_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ed8cf2de-5f97-4b64-8aeb-c279c99a5480" xlink:to="loc_us-gaap_ClassOfStockDomain_ed8cf2de-5f97-4b64-8aeb-c279c99a5480_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7c8a214f-4610-4b59-8308-c410acfd1e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ed8cf2de-5f97-4b64-8aeb-c279c99a5480" xlink:to="loc_us-gaap_ClassOfStockDomain_7c8a214f-4610-4b59-8308-c410acfd1e1a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended" id="ic7ebe52afc29440ca09f43bde62b0cc3_ConsolidatedBalanceSheetsParentheticals"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended" id="i384c665e4e7f4905bbf39c06926d1e28_ConsolidatedStatementsofComprehensiveLossUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8bd6943d-cee0-426b-9d52-ca1fcef3dcc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_RevenuesAbstract_8bd6943d-cee0-426b-9d52-ca1fcef3dcc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_3b0eff3f-65fb-461a-b70b-1f6d80b65a29" xlink:href="lxrx-20210331.xsd#lxrx_Netproductrevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_8bd6943d-cee0-426b-9d52-ca1fcef3dcc7" xlink:to="loc_lxrx_Netproductrevenue_3b0eff3f-65fb-461a-b70b-1f6d80b65a29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_479fe00d-e48d-4979-869b-9f5186bab2f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_8bd6943d-cee0-426b-9d52-ca1fcef3dcc7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_479fe00d-e48d-4979-869b-9f5186bab2f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_ab31a6de-6e02-48e1-b09d-01da3beeedba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_8bd6943d-cee0-426b-9d52-ca1fcef3dcc7" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_ab31a6de-6e02-48e1-b09d-01da3beeedba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_87ca707f-de97-4340-94dc-af799b9b180b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_8bd6943d-cee0-426b-9d52-ca1fcef3dcc7" xlink:to="loc_us-gaap_Revenues_87ca707f-de97-4340-94dc-af799b9b180b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ed7fe438-2803-40bc-a5a2-7e4a187b6b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ed7fe438-2803-40bc-a5a2-7e4a187b6b9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_85e7855a-02bf-4a84-8d9c-7bd0a86b26f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ed7fe438-2803-40bc-a5a2-7e4a187b6b9c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_85e7855a-02bf-4a84-8d9c-7bd0a86b26f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0ae31471-f3d0-405e-9f16-90770883499e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ed7fe438-2803-40bc-a5a2-7e4a187b6b9c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0ae31471-f3d0-405e-9f16-90770883499e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_5ead53d9-b227-4a54-ba63-367c9c471763" xlink:href="lxrx-20210331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ed7fe438-2803-40bc-a5a2-7e4a187b6b9c" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_5ead53d9-b227-4a54-ba63-367c9c471763" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f56579ab-f550-42e8-a068-e81c57aa0496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ed7fe438-2803-40bc-a5a2-7e4a187b6b9c" xlink:to="loc_us-gaap_OperatingExpenses_f56579ab-f550-42e8-a068-e81c57aa0496" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_2d448cf8-e074-4cf5-9c33-631ec11a1bb7" xlink:href="lxrx-20210331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_2d448cf8-e074-4cf5-9c33-631ec11a1bb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d182a9e8-1435-4a31-9975-3074292ad6e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_OperatingIncomeLoss_d182a9e8-1435-4a31-9975-3074292ad6e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f3527fb5-a296-4f75-8be5-757dca14550f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_InterestExpense_f3527fb5-a296-4f75-8be5-757dca14550f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_15f0ef2b-5d2c-4cf1-9c38-0140f44726af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_15f0ef2b-5d2c-4cf1-9c38-0140f44726af" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a34b928c-3f8e-49ba-9138-c78543ede714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_NetIncomeLoss_a34b928c-3f8e-49ba-9138-c78543ede714" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7741817e-367d-4423-8bb4-1765fa90cc5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_EarningsPerShareBasic_7741817e-367d-4423-8bb4-1765fa90cc5a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42679527-e32e-491c-8a0e-d6afe853f9d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42679527-e32e-491c-8a0e-d6afe853f9d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bf9807fc-586e-4741-943e-384854e20f70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bf9807fc-586e-4741-943e-384854e20f70" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_93969e79-a026-4800-af5d-eeb5ee350521" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_93969e79-a026-4800-af5d-eeb5ee350521" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_dd228c88-7913-449b-b8e4-9a8a803df85a" xlink:href="lxrx-20210331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_dd228c88-7913-449b-b8e4-9a8a803df85a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_0b1f9246-58e5-49b7-be58-7d11a839fac0" xlink:href="lxrx-20210331.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_0b1f9246-58e5-49b7-be58-7d11a839fac0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfRealEstate_1ce33a56-1859-4ff8-9aa5-f92d4bf4f1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_ImpairmentOfRealEstate_1ce33a56-1859-4ff8-9aa5-f92d4bf4f1f5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_f4013509-6d32-4ce1-a456-0e1e1cd52f68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_f4013509-6d32-4ce1-a456-0e1e1cd52f68" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c1580817-efc1-4e3e-a4cd-ca284064d5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_StatementTable_c1580817-efc1-4e3e-a4cd-ca284064d5ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6ce34c04-f63e-4f6c-afea-364395944862" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c1580817-efc1-4e3e-a4cd-ca284064d5ea" xlink:to="loc_srt_StatementScenarioAxis_6ce34c04-f63e-4f6c-afea-364395944862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6ce34c04-f63e-4f6c-afea-364395944862_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_6ce34c04-f63e-4f6c-afea-364395944862" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6ce34c04-f63e-4f6c-afea-364395944862_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1efc93f3-8588-4f3b-b389-942d76600cec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_6ce34c04-f63e-4f6c-afea-364395944862" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1efc93f3-8588-4f3b-b389-942d76600cec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedStatementsofComprehensiveLossParentheticals"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="extended" id="id7ca68dafc02467883ff74b285308fb6_ConsolidatedStatementsofComprehensiveLossParentheticals"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="i94d34e70b78d4b90b6826b91831bc259_ConsolidatedStatementsofCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33151b8a-a2e5-4211-83a3-4d95c7e349da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33151b8a-a2e5-4211-83a3-4d95c7e349da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_20feec6d-ce44-4a48-a42c-2aaeb5fe3035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33151b8a-a2e5-4211-83a3-4d95c7e349da" xlink:to="loc_us-gaap_NetIncomeLoss_20feec6d-ce44-4a48-a42c-2aaeb5fe3035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c040e294-b8bd-483e-bf0c-e19d0be058c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33151b8a-a2e5-4211-83a3-4d95c7e349da" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c040e294-b8bd-483e-bf0c-e19d0be058c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1991c19e-7b1c-437f-9cab-acbefa9b99df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c040e294-b8bd-483e-bf0c-e19d0be058c8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1991c19e-7b1c-437f-9cab-acbefa9b99df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7f3c85c4-62bc-4bbe-b2b9-737c42f93356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c040e294-b8bd-483e-bf0c-e19d0be058c8" xlink:to="loc_us-gaap_ShareBasedCompensation_7f3c85c4-62bc-4bbe-b2b9-737c42f93356" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d0f34a42-80df-495a-9ef5-8f602c63e3e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c040e294-b8bd-483e-bf0c-e19d0be058c8" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d0f34a42-80df-495a-9ef5-8f602c63e3e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_5fe251e4-60a5-4876-b2e8-856440551728" xlink:href="lxrx-20210331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c040e294-b8bd-483e-bf0c-e19d0be058c8" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_5fe251e4-60a5-4876-b2e8-856440551728" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_efb7da8c-1988-4324-af73-13024fce6e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c040e294-b8bd-483e-bf0c-e19d0be058c8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_efb7da8c-1988-4324-af73-13024fce6e5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b86cac22-3942-4437-90b7-faafe78c41c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_efb7da8c-1988-4324-af73-13024fce6e5a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b86cac22-3942-4437-90b7-faafe78c41c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b6edcaed-77ed-41f1-b5b2-05c151d6ad4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_efb7da8c-1988-4324-af73-13024fce6e5a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b6edcaed-77ed-41f1-b5b2-05c151d6ad4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f21c472c-7a0f-4167-82eb-d63e40495bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_efb7da8c-1988-4324-af73-13024fce6e5a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f21c472c-7a0f-4167-82eb-d63e40495bf4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_675bf495-dd38-433f-90bf-58b05e5a469c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_efb7da8c-1988-4324-af73-13024fce6e5a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_675bf495-dd38-433f-90bf-58b05e5a469c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3f77acfe-6ce6-41ec-b919-44ce9e891732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_efb7da8c-1988-4324-af73-13024fce6e5a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3f77acfe-6ce6-41ec-b919-44ce9e891732" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f17c4f00-cc65-41f8-81d0-b19d7e29a5aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33151b8a-a2e5-4211-83a3-4d95c7e349da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f17c4f00-cc65-41f8-81d0-b19d7e29a5aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7139beb8-d495-4260-9d87-018e8421ff41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7139beb8-d495-4260-9d87-018e8421ff41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7b80ea5a-4273-4693-b986-3059dd65e535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7139beb8-d495-4260-9d87-018e8421ff41" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7b80ea5a-4273-4693-b986-3059dd65e535" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_9812ed85-e62d-40fb-9a04-6faf1953b7fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7139beb8-d495-4260-9d87-018e8421ff41" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_9812ed85-e62d-40fb-9a04-6faf1953b7fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_e1ff1669-f20e-4c0d-abf0-f0b0bc95a177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7139beb8-d495-4260-9d87-018e8421ff41" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_e1ff1669-f20e-4c0d-abf0-f0b0bc95a177" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_e81b8360-50d8-4d59-84ec-ead35ef5ec08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7139beb8-d495-4260-9d87-018e8421ff41" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_e81b8360-50d8-4d59-84ec-ead35ef5ec08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16df8b3b-ee6e-4d6e-bd7a-e6196236842f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7139beb8-d495-4260-9d87-018e8421ff41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16df8b3b-ee6e-4d6e-bd7a-e6196236842f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_958196fd-1446-4c6e-b2d9-7ce6a5f78645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_958196fd-1446-4c6e-b2d9-7ce6a5f78645" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b509116f-a272-41f7-9b2f-5db8ccc4128e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_958196fd-1446-4c6e-b2d9-7ce6a5f78645" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b509116f-a272-41f7-9b2f-5db8ccc4128e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_db118e95-04d0-4198-9948-2d476255e0b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_958196fd-1446-4c6e-b2d9-7ce6a5f78645" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_db118e95-04d0-4198-9948-2d476255e0b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f3099734-6822-4e5c-bc8a-c69e1d616e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_958196fd-1446-4c6e-b2d9-7ce6a5f78645" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f3099734-6822-4e5c-bc8a-c69e1d616e76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_200adb01-a44b-49f7-8a1a-3b6bc43624c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_958196fd-1446-4c6e-b2d9-7ce6a5f78645" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_200adb01-a44b-49f7-8a1a-3b6bc43624c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_fb28cdd8-e707-41c1-b0d1-b8dbb5aa4eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_fb28cdd8-e707-41c1-b0d1-b8dbb5aa4eaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2e7d267f-85b2-45da-b242-79c0c20029f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2e7d267f-85b2-45da-b242-79c0c20029f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_37a04b6a-e51c-4f84-8256-b058a5553764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_07e8e74f-7588-4739-98b2-e2a27065bf64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_07e8e74f-7588-4739-98b2-e2a27065bf64" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_4fb6a770-3c09-448e-b652-dca3f72988ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_07e8e74f-7588-4739-98b2-e2a27065bf64" xlink:to="loc_us-gaap_InterestPaidNet_4fb6a770-3c09-448e-b652-dca3f72988ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InitialRecognitionOfRightOfUseAsset_f5cdb0d1-e055-4b08-bbc9-5054f4ef792e" xlink:href="lxrx-20210331.xsd#lxrx_InitialRecognitionOfRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_07e8e74f-7588-4739-98b2-e2a27065bf64" xlink:to="loc_lxrx_InitialRecognitionOfRightOfUseAsset_f5cdb0d1-e055-4b08-bbc9-5054f4ef792e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e344ddf6-e188-4cbb-9132-44a82efd84e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_07e8e74f-7588-4739-98b2-e2a27065bf64" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e344ddf6-e188-4cbb-9132-44a82efd84e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LiabilitiesAssumedByTerSera_a95844d0-3f89-4780-b44f-e032e7184152" xlink:href="lxrx-20210331.xsd#lxrx_LiabilitiesAssumedByTerSera"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_07e8e74f-7588-4739-98b2-e2a27065bf64" xlink:to="loc_lxrx_LiabilitiesAssumedByTerSera_a95844d0-3f89-4780-b44f-e032e7184152" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_096c825e-bf4d-46a7-94d4-ba879ada6d68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_07e8e74f-7588-4739-98b2-e2a27065bf64" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_096c825e-bf4d-46a7-94d4-ba879ada6d68" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8be5c9b7-d169-4ebd-878b-36b423d53ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:to="loc_us-gaap_StatementTable_8be5c9b7-d169-4ebd-878b-36b423d53ae0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_96801a08-8db2-454a-b469-c078c3147722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8be5c9b7-d169-4ebd-878b-36b423d53ae0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_96801a08-8db2-454a-b469-c078c3147722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_96801a08-8db2-454a-b469-c078c3147722_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_96801a08-8db2-454a-b469-c078c3147722" xlink:to="loc_us-gaap_EquityComponentDomain_96801a08-8db2-454a-b469-c078c3147722_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5344ecde-10f6-4ab1-8c89-20ce54be3c9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_96801a08-8db2-454a-b469-c078c3147722" xlink:to="loc_us-gaap_EquityComponentDomain_5344ecde-10f6-4ab1-8c89-20ce54be3c9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_25c21e28-071c-4b0f-bc4f-51009806ec75" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8be5c9b7-d169-4ebd-878b-36b423d53ae0" xlink:to="loc_srt_StatementScenarioAxis_25c21e28-071c-4b0f-bc4f-51009806ec75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_25c21e28-071c-4b0f-bc4f-51009806ec75_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_25c21e28-071c-4b0f-bc4f-51009806ec75" xlink:to="loc_srt_ScenarioUnspecifiedDomain_25c21e28-071c-4b0f-bc4f-51009806ec75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_03867e2b-7903-4570-ae29-e8170450d137" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_25c21e28-071c-4b0f-bc4f-51009806ec75" xlink:to="loc_srt_ScenarioUnspecifiedDomain_03867e2b-7903-4570-ae29-e8170450d137" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended" id="id5615b9b87a54a5189d05d315c712fb8_ConsolidatedStatementsofStockholdersEquityDeficitUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_756ec130-04d9-4f5b-9ec2-b988a1656a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_CommonStockSharesIssued_756ec130-04d9-4f5b-9ec2-b988a1656a19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4be86f9a-2599-4880-9b15-d9e942a5166e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4be86f9a-2599-4880-9b15-d9e942a5166e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_005733e1-5174-455f-a3ec-1396df180a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_005733e1-5174-455f-a3ec-1396df180a3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_de5839b0-5d4e-4dc6-a7e8-52249dec5529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_de5839b0-5d4e-4dc6-a7e8-52249dec5529" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1d364faa-bab4-4ed0-a1d6-c69699709f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1d364faa-bab4-4ed0-a1d6-c69699709f9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_52001f4f-a770-4fcf-81f8-3220705a874c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_52001f4f-a770-4fcf-81f8-3220705a874c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b2b12160-8164-44cc-8b64-989ba4d5d4fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_NetIncomeLoss_b2b12160-8164-44cc-8b64-989ba4d5d4fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_681bfd2c-ee4c-4341-aced-4ec74fcd80b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_681bfd2c-ee4c-4341-aced-4ec74fcd80b7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_30825ce3-4242-4759-8a38-27ddc6c315f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dca1b674-67a5-4b58-8e1f-9e74b2e43537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a2d5f0b8-d2ee-400b-8d53-1b002b19222d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a2d5f0b8-d2ee-400b-8d53-1b002b19222d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e495b4ed-4f1c-4c5c-9bb9-e4bb1da1c69b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e495b4ed-4f1c-4c5c-9bb9-e4bb1da1c69b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_08f31886-d63c-4e0b-a853-c5fa00a6d324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_StatementTable_08f31886-d63c-4e0b-a853-c5fa00a6d324" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_58c94de3-68a7-466f-98f1-59cf301dd0a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_08f31886-d63c-4e0b-a853-c5fa00a6d324" xlink:to="loc_srt_StatementScenarioAxis_58c94de3-68a7-466f-98f1-59cf301dd0a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_58c94de3-68a7-466f-98f1-59cf301dd0a2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_58c94de3-68a7-466f-98f1-59cf301dd0a2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_58c94de3-68a7-466f-98f1-59cf301dd0a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8c5f6260-ad89-445a-aac2-291b196b4a80" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_58c94de3-68a7-466f-98f1-59cf301dd0a2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8c5f6260-ad89-445a-aac2-291b196b4a80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_11a6b4f5-7ee8-4b7f-a4ae-d6793dd9da31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_08f31886-d63c-4e0b-a853-c5fa00a6d324" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_11a6b4f5-7ee8-4b7f-a4ae-d6793dd9da31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_11a6b4f5-7ee8-4b7f-a4ae-d6793dd9da31_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11a6b4f5-7ee8-4b7f-a4ae-d6793dd9da31" xlink:to="loc_us-gaap_EquityComponentDomain_11a6b4f5-7ee8-4b7f-a4ae-d6793dd9da31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1ecf9057-db8d-46a4-85c2-f28b701ea36e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11a6b4f5-7ee8-4b7f-a4ae-d6793dd9da31" xlink:to="loc_us-gaap_EquityComponentDomain_1ecf9057-db8d-46a4-85c2-f28b701ea36e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b7f65317-80e2-4ea1-aa10-b736d47076cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1ecf9057-db8d-46a4-85c2-f28b701ea36e" xlink:to="loc_us-gaap_CommonStockMember_b7f65317-80e2-4ea1-aa10-b736d47076cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6211aa41-3e08-4846-8f52-e7864cf7232a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1ecf9057-db8d-46a4-85c2-f28b701ea36e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6211aa41-3e08-4846-8f52-e7864cf7232a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e10fc494-1d20-495c-b2cb-300a0075d804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1ecf9057-db8d-46a4-85c2-f28b701ea36e" xlink:to="loc_us-gaap_RetainedEarningsMember_e10fc494-1d20-495c-b2cb-300a0075d804" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4513429d-d62f-45f6-8388-e180b23c3153" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1ecf9057-db8d-46a4-85c2-f28b701ea36e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4513429d-d62f-45f6-8388-e180b23c3153" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_8ce9048d-b88f-408a-abef-8372f1c23374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1ecf9057-db8d-46a4-85c2-f28b701ea36e" xlink:to="loc_us-gaap_TreasuryStockMember_8ce9048d-b88f-408a-abef-8372f1c23374" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_be61e5c0-5e58-45c7-8265-e4d51e4e13e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_08f31886-d63c-4e0b-a853-c5fa00a6d324" xlink:to="loc_us-gaap_StatementClassOfStockAxis_be61e5c0-5e58-45c7-8265-e4d51e4e13e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_be61e5c0-5e58-45c7-8265-e4d51e4e13e2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_be61e5c0-5e58-45c7-8265-e4d51e4e13e2" xlink:to="loc_us-gaap_ClassOfStockDomain_be61e5c0-5e58-45c7-8265-e4d51e4e13e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b533673b-f07c-43bb-a0ad-89af172f7dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_be61e5c0-5e58-45c7-8265-e4d51e4e13e2" xlink:to="loc_us-gaap_ClassOfStockDomain_b533673b-f07c-43bb-a0ad-89af172f7dc5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesNotes"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="extended" id="ic0f7ac6022c54574aa2f412da81cd96f_SummaryofSignificantAccountingPoliciesNotes"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i29690aaf701b40bca96a73d933f00d50_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="extended" id="i418e2def540b4a90af362163cf81fbcb_SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="extended" id="iaff142ff13794901958f96e6adfd3682_SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_6eabdbec-59e3-4b4d-af35-c1f438cc7b75" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_6eabdbec-59e3-4b4d-af35-c1f438cc7b75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_2835259e-c5d4-4b06-866e-02e982e54466" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_2835259e-c5d4-4b06-866e-02e982e54466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_9535aa14-9ceb-4990-b5d4-ab7a065f285e" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_9535aa14-9ceb-4990-b5d4-ab7a065f285e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_8469108d-69cc-4c29-b5fb-899a1178f88e" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_8469108d-69cc-4c29-b5fb-899a1178f88e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_b1cfc34f-a5ac-44ad-83df-c31d7a384a0c" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_b1cfc34f-a5ac-44ad-83df-c31d7a384a0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_f821b82c-1da7-467e-98d6-711250cdc99a" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_f821b82c-1da7-467e-98d6-711250cdc99a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_d57465c0-8f86-46e1-b096-7d492642f69b" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_d57465c0-8f86-46e1-b096-7d492642f69b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_e0530e59-7a8b-46df-896f-fd123c8f2b76" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_e0530e59-7a8b-46df-896f-fd123c8f2b76" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6b9c64c7-38c4-48ab-aa65-32a65c3a52c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:to="loc_us-gaap_PlanNameAxis_6b9c64c7-38c4-48ab-aa65-32a65c3a52c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6b9c64c7-38c4-48ab-aa65-32a65c3a52c9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6b9c64c7-38c4-48ab-aa65-32a65c3a52c9" xlink:to="loc_us-gaap_PlanNameDomain_6b9c64c7-38c4-48ab-aa65-32a65c3a52c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8ebe4b55-4113-4c96-b7f2-4499df4a312e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6b9c64c7-38c4-48ab-aa65-32a65c3a52c9" xlink:to="loc_us-gaap_PlanNameDomain_8ebe4b55-4113-4c96-b7f2-4499df4a312e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_edf94692-b5f0-4ef1-9968-b8aa4f7f5927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:to="loc_us-gaap_AwardDateAxis_edf94692-b5f0-4ef1-9968-b8aa4f7f5927" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_edf94692-b5f0-4ef1-9968-b8aa4f7f5927_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_edf94692-b5f0-4ef1-9968-b8aa4f7f5927" xlink:to="loc_us-gaap_AwardDateDomain_edf94692-b5f0-4ef1-9968-b8aa4f7f5927_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_289e809f-89f8-4275-afd5-70e025177830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_edf94692-b5f0-4ef1-9968-b8aa4f7f5927" xlink:to="loc_us-gaap_AwardDateDomain_289e809f-89f8-4275-afd5-70e025177830" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fb4b11c9-3a9f-429d-8e8a-437d45cf6950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:to="loc_us-gaap_AwardTypeAxis_fb4b11c9-3a9f-429d-8e8a-437d45cf6950" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb4b11c9-3a9f-429d-8e8a-437d45cf6950_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fb4b11c9-3a9f-429d-8e8a-437d45cf6950" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb4b11c9-3a9f-429d-8e8a-437d45cf6950_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a118bb23-127f-4660-af99-2055322f4278" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fb4b11c9-3a9f-429d-8e8a-437d45cf6950" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a118bb23-127f-4660-af99-2055322f4278" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_82659a04-454d-4747-8ffb-1fdcb389e54d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a118bb23-127f-4660-af99-2055322f4278" xlink:to="loc_us-gaap_StockOptionMember_82659a04-454d-4747-8ffb-1fdcb389e54d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_21bc7718-c485-4027-b1bc-267e156c412b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:to="loc_us-gaap_StatementClassOfStockAxis_21bc7718-c485-4027-b1bc-267e156c412b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_21bc7718-c485-4027-b1bc-267e156c412b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_21bc7718-c485-4027-b1bc-267e156c412b" xlink:to="loc_us-gaap_ClassOfStockDomain_21bc7718-c485-4027-b1bc-267e156c412b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c399335e-c50e-4e5b-bd8d-335c510f234c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_21bc7718-c485-4027-b1bc-267e156c412b" xlink:to="loc_us-gaap_ClassOfStockDomain_c399335e-c50e-4e5b-bd8d-335c510f234c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_391492bd-b308-4410-ae17-41a6a0b16364" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:to="loc_srt_RangeAxis_391492bd-b308-4410-ae17-41a6a0b16364" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_391492bd-b308-4410-ae17-41a6a0b16364_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_391492bd-b308-4410-ae17-41a6a0b16364" xlink:to="loc_srt_RangeMember_391492bd-b308-4410-ae17-41a6a0b16364_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_700399e9-31ea-4753-b061-11f2d21b8282" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_391492bd-b308-4410-ae17-41a6a0b16364" xlink:to="loc_srt_RangeMember_700399e9-31ea-4753-b061-11f2d21b8282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_fe751305-394d-44d9-befe-eaf789ecdb54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:to="loc_us-gaap_VestingAxis_fe751305-394d-44d9-befe-eaf789ecdb54" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_fe751305-394d-44d9-befe-eaf789ecdb54_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_fe751305-394d-44d9-befe-eaf789ecdb54" xlink:to="loc_us-gaap_VestingDomain_fe751305-394d-44d9-befe-eaf789ecdb54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_538de48f-89f6-4ec7-b161-f9fed5484b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_fe751305-394d-44d9-befe-eaf789ecdb54" xlink:to="loc_us-gaap_VestingDomain_538de48f-89f6-4ec7-b161-f9fed5484b67" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="extended" id="i8cea8862922a423dabf1874a7f701df4_SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ea376a7e-d375-46c1-bfea-14ad78ad2bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ea376a7e-d375-46c1-bfea-14ad78ad2bdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1fb29fc4-0fe6-4dff-9b4e-9a4f3440e1f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1fb29fc4-0fe6-4dff-9b4e-9a4f3440e1f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1ae8784f-bb82-4470-9573-ff6a58402721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1ae8784f-bb82-4470-9573-ff6a58402721" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ffe49759-4605-4bab-9fab-c84d3c094188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ffe49759-4605-4bab-9fab-c84d3c094188" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_01d0fdac-d05b-4daa-95e7-cbb15321d78a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_01d0fdac-d05b-4daa-95e7-cbb15321d78a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21aa852c-d9cf-406e-bc53-141c140b2f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21aa852c-d9cf-406e-bc53-141c140b2f0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4aa4eb2c-4b7e-47db-9156-a7902d0819fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4aa4eb2c-4b7e-47db-9156-a7902d0819fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_03ae59c4-68c0-49ab-aac7-c123e866ce95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_03ae59c4-68c0-49ab-aac7-c123e866ce95" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_36257ac1-b17b-4be2-ac1c-60e726370956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_36257ac1-b17b-4be2-ac1c-60e726370956" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7398c51d-4da1-4fe3-8bff-71745dcf126e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7398c51d-4da1-4fe3-8bff-71745dcf126e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_25a5ecd5-638f-484c-94b4-7e244f162ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_25a5ecd5-638f-484c-94b4-7e244f162ac5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_371f7e57-744d-4201-854d-33345102f584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_371f7e57-744d-4201-854d-33345102f584" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_55dc53a4-d3d1-4e3a-afd7-1cfff526b826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_55dc53a4-d3d1-4e3a-afd7-1cfff526b826" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bf49a7d1-05da-41c2-bb4a-dfc7556ca0c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bf49a7d1-05da-41c2-bb4a-dfc7556ca0c9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eba82b1c-9773-40e0-aa3d-db12bbe903ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eba82b1c-9773-40e0-aa3d-db12bbe903ea" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_404129da-44f5-485e-94e0-84b2eecad199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_404129da-44f5-485e-94e0-84b2eecad199" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_76472cdb-09c7-4340-890d-96216c493bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_76472cdb-09c7-4340-890d-96216c493bfa" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_764e7fe3-2b47-4c5c-972a-924a64670125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_764e7fe3-2b47-4c5c-972a-924a64670125" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d3d14f3f-96ee-4b9e-8367-d69782171627" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d3d14f3f-96ee-4b9e-8367-d69782171627" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_96cd8bcd-afe5-4345-9aa2-35b98059f5e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_96cd8bcd-afe5-4345-9aa2-35b98059f5e8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b0cf02ea-f29d-4011-b7a9-b55227bc375e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:to="loc_us-gaap_PlanNameAxis_b0cf02ea-f29d-4011-b7a9-b55227bc375e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b0cf02ea-f29d-4011-b7a9-b55227bc375e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b0cf02ea-f29d-4011-b7a9-b55227bc375e" xlink:to="loc_us-gaap_PlanNameDomain_b0cf02ea-f29d-4011-b7a9-b55227bc375e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_966174ad-e772-4610-9bc8-32c4d255f128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b0cf02ea-f29d-4011-b7a9-b55227bc375e" xlink:to="loc_us-gaap_PlanNameDomain_966174ad-e772-4610-9bc8-32c4d255f128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_73944a52-b952-4f98-a6ae-1d4c9fb3e4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:to="loc_us-gaap_AwardDateAxis_73944a52-b952-4f98-a6ae-1d4c9fb3e4c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_73944a52-b952-4f98-a6ae-1d4c9fb3e4c9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_73944a52-b952-4f98-a6ae-1d4c9fb3e4c9" xlink:to="loc_us-gaap_AwardDateDomain_73944a52-b952-4f98-a6ae-1d4c9fb3e4c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_9661f383-80d5-451f-9fe8-19b27ec7fa6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_73944a52-b952-4f98-a6ae-1d4c9fb3e4c9" xlink:to="loc_us-gaap_AwardDateDomain_9661f383-80d5-451f-9fe8-19b27ec7fa6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_374183e4-3d9b-451c-a0e5-6e52d3b078f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:to="loc_us-gaap_AwardTypeAxis_374183e4-3d9b-451c-a0e5-6e52d3b078f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374183e4-3d9b-451c-a0e5-6e52d3b078f5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_374183e4-3d9b-451c-a0e5-6e52d3b078f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_374183e4-3d9b-451c-a0e5-6e52d3b078f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26f79ff4-9198-4d49-a2f6-37209403502c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_374183e4-3d9b-451c-a0e5-6e52d3b078f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26f79ff4-9198-4d49-a2f6-37209403502c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_83b98a5d-8a02-4f31-8ffb-0b91d063db84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26f79ff4-9198-4d49-a2f6-37209403502c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_83b98a5d-8a02-4f31-8ffb-0b91d063db84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b3b3c1df-aeeb-4c9d-8d0b-9c96160245af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26f79ff4-9198-4d49-a2f6-37209403502c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b3b3c1df-aeeb-4c9d-8d0b-9c96160245af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_45d2c1d9-71c6-40cc-adbc-8edbee7f02ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_45d2c1d9-71c6-40cc-adbc-8edbee7f02ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_45d2c1d9-71c6-40cc-adbc-8edbee7f02ea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_45d2c1d9-71c6-40cc-adbc-8edbee7f02ea" xlink:to="loc_us-gaap_ClassOfStockDomain_45d2c1d9-71c6-40cc-adbc-8edbee7f02ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8c091b63-d638-4bfa-a032-a885d08039b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_45d2c1d9-71c6-40cc-adbc-8edbee7f02ea" xlink:to="loc_us-gaap_ClassOfStockDomain_8c091b63-d638-4bfa-a032-a885d08039b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_225893e5-839b-4665-9c2a-a47779678fec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:to="loc_srt_RangeAxis_225893e5-839b-4665-9c2a-a47779678fec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_225893e5-839b-4665-9c2a-a47779678fec_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_225893e5-839b-4665-9c2a-a47779678fec" xlink:to="loc_srt_RangeMember_225893e5-839b-4665-9c2a-a47779678fec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5e205fb8-d3d5-49cf-87a1-90736854dc92" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_225893e5-839b-4665-9c2a-a47779678fec" xlink:to="loc_srt_RangeMember_5e205fb8-d3d5-49cf-87a1-90736854dc92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_9a9fa1d2-cd5f-440d-8626-38d07f0ed964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:to="loc_us-gaap_VestingAxis_9a9fa1d2-cd5f-440d-8626-38d07f0ed964" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_9a9fa1d2-cd5f-440d-8626-38d07f0ed964_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_9a9fa1d2-cd5f-440d-8626-38d07f0ed964" xlink:to="loc_us-gaap_VestingDomain_9a9fa1d2-cd5f-440d-8626-38d07f0ed964_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_ca12aea5-afb2-4e60-a947-b9905f0b7fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_9a9fa1d2-cd5f-440d-8626-38d07f0ed964" xlink:to="loc_us-gaap_VestingDomain_ca12aea5-afb2-4e60-a947-b9905f0b7fc5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="extended" id="i5082a7f161b04474be1f8767983ee960_SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a924e78-1e82-4047-ac40-5286c7860512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32457e1b-59b5-4df8-8151-fc1d063d0e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a924e78-1e82-4047-ac40-5286c7860512" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32457e1b-59b5-4df8-8151-fc1d063d0e02" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_47a63ea9-7114-452e-b7d2-cbb92f4d483c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32457e1b-59b5-4df8-8151-fc1d063d0e02" xlink:to="loc_us-gaap_PlanNameAxis_47a63ea9-7114-452e-b7d2-cbb92f4d483c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_47a63ea9-7114-452e-b7d2-cbb92f4d483c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_47a63ea9-7114-452e-b7d2-cbb92f4d483c" xlink:to="loc_us-gaap_PlanNameDomain_47a63ea9-7114-452e-b7d2-cbb92f4d483c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7ff0e5f6-8ffb-46ad-b2ed-ad05a61d4993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_47a63ea9-7114-452e-b7d2-cbb92f4d483c" xlink:to="loc_us-gaap_PlanNameDomain_7ff0e5f6-8ffb-46ad-b2ed-ad05a61d4993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4d7678ea-2a84-4f04-8b52-f572d96fd2a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32457e1b-59b5-4df8-8151-fc1d063d0e02" xlink:to="loc_us-gaap_AwardTypeAxis_4d7678ea-2a84-4f04-8b52-f572d96fd2a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d7678ea-2a84-4f04-8b52-f572d96fd2a5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4d7678ea-2a84-4f04-8b52-f572d96fd2a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d7678ea-2a84-4f04-8b52-f572d96fd2a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdc6da2b-60b9-488d-b319-e5aa9301d19d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4d7678ea-2a84-4f04-8b52-f572d96fd2a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdc6da2b-60b9-488d-b319-e5aa9301d19d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ae50c4b2-3239-4142-82d3-519100d0ba5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32457e1b-59b5-4df8-8151-fc1d063d0e02" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ae50c4b2-3239-4142-82d3-519100d0ba5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ae50c4b2-3239-4142-82d3-519100d0ba5b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ae50c4b2-3239-4142-82d3-519100d0ba5b" xlink:to="loc_us-gaap_ClassOfStockDomain_ae50c4b2-3239-4142-82d3-519100d0ba5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2deff861-b85e-4bfe-b5d5-7f7b9df9e82d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ae50c4b2-3239-4142-82d3-519100d0ba5b" xlink:to="loc_us-gaap_ClassOfStockDomain_2deff861-b85e-4bfe-b5d5-7f7b9df9e82d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4853fe37-65df-4f5f-a9da-de1464a8e452" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32457e1b-59b5-4df8-8151-fc1d063d0e02" xlink:to="loc_srt_RangeAxis_4853fe37-65df-4f5f-a9da-de1464a8e452" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4853fe37-65df-4f5f-a9da-de1464a8e452_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4853fe37-65df-4f5f-a9da-de1464a8e452" xlink:to="loc_srt_RangeMember_4853fe37-65df-4f5f-a9da-de1464a8e452_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23233b25-0b94-45f5-abbb-c8298f1968ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4853fe37-65df-4f5f-a9da-de1464a8e452" xlink:to="loc_srt_RangeMember_23233b25-0b94-45f5-abbb-c8298f1968ae" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="extended" id="i694dd2c7fbef40b5b51210003a3a77fc_SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:href="lxrx-20210331.xsd#lxrx_AccruedLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_26c3011b-3932-4b9b-ae25-9ebdce85733a" xlink:href="lxrx-20210331.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:to="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_26c3011b-3932-4b9b-ae25-9ebdce85733a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent_983b7dec-dfe5-454a-b35e-31880ce91517" xlink:href="lxrx-20210331.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:to="loc_lxrx_AccruedCompensationAndBenefitsCurrent_983b7dec-dfe5-454a-b35e-31880ce91517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5f9334e-989f-466f-9ff9-b9e05be01db5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5f9334e-989f-466f-9ff9-b9e05be01db5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bed64af8-a275-4a66-8188-08bd7fb2846d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bed64af8-a275-4a66-8188-08bd7fb2846d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2c209c11-2efd-4530-9f4b-0b20be47ec93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2c209c11-2efd-4530-9f4b-0b20be47ec93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconIncrementalBorrowingRate_46bc9114-a649-48bf-accb-db4c2c50063e" xlink:href="lxrx-20210331.xsd#lxrx_LexiconIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:to="loc_lxrx_LexiconIncrementalBorrowingRate_46bc9114-a649-48bf-accb-db4c2c50063e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesTable_ac3d7276-7e68-48fa-b937-bc590af57768" xlink:href="lxrx-20210331.xsd#lxrx_AccruedLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:to="loc_lxrx_AccruedLiabilitiesTable_ac3d7276-7e68-48fa-b937-bc590af57768" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesAxis_9dcec159-e93b-46bb-9070-5c7c7faa4e99" xlink:href="lxrx-20210331.xsd#lxrx_AccruedLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lxrx_AccruedLiabilitiesTable_ac3d7276-7e68-48fa-b937-bc590af57768" xlink:to="loc_lxrx_AccruedLiabilitiesAxis_9dcec159-e93b-46bb-9070-5c7c7faa4e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain_9dcec159-e93b-46bb-9070-5c7c7faa4e99_default" xlink:href="lxrx-20210331.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lxrx_AccruedLiabilitiesAxis_9dcec159-e93b-46bb-9070-5c7c7faa4e99" xlink:to="loc_lxrx_AccruedLiabilitiesDomain_9dcec159-e93b-46bb-9070-5c7c7faa4e99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain_55bcde91-34d6-4a16-bf3a-f7f72fc4d798" xlink:href="lxrx-20210331.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lxrx_AccruedLiabilitiesAxis_9dcec159-e93b-46bb-9070-5c7c7faa4e99" xlink:to="loc_lxrx_AccruedLiabilitiesDomain_55bcde91-34d6-4a16-bf3a-f7f72fc4d798" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended" id="i73df3f422bba40718515a32581d58fe3_SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="simple" xlink:href="lxrx-20210331.xsd#RecentAccountingPronouncementsLevel1Notes"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="extended" id="i7ed50023481d459e953ec1ce1fb5f058_RecentAccountingPronouncementsLevel1Notes"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CashandCashEquivalentsandInvestments"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended" id="i64a12911a11c4b9c9f922584af99a8c5_CashandCashEquivalentsandInvestments"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended" id="ia2c9d01a707a459782ccb3d464e967d7_CashandCashEquivalentsandInvestmentsTables"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CashandCashEquivalentsandInvestmentsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="extended" id="ic1a6436301c546faaa1d53196d55513a_CashandCashEquivalentsandInvestmentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_876b8a30-32da-43b9-bb87-c1b38d1484df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2aa5233b-1a3a-4b81-9ba9-aeff34e6a4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_876b8a30-32da-43b9-bb87-c1b38d1484df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2aa5233b-1a3a-4b81-9ba9-aeff34e6a4a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5326e0a3-a9e2-473d-aebd-280ad56a2afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_876b8a30-32da-43b9-bb87-c1b38d1484df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5326e0a3-a9e2-473d-aebd-280ad56a2afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d4d28202-6e56-433d-a093-1fdfa5970438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_876b8a30-32da-43b9-bb87-c1b38d1484df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d4d28202-6e56-433d-a093-1fdfa5970438" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_2f374559-c81a-4a94-81d4-4c5705e20d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_876b8a30-32da-43b9-bb87-c1b38d1484df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_2f374559-c81a-4a94-81d4-4c5705e20d83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_fb4c15a4-c1f4-428d-93ed-b59f6a763d2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_876b8a30-32da-43b9-bb87-c1b38d1484df" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_fb4c15a4-c1f4-428d-93ed-b59f6a763d2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_19943ef0-052d-4bef-aba9-af6f815ce6fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_fb4c15a4-c1f4-428d-93ed-b59f6a763d2b" xlink:to="loc_us-gaap_InvestmentTypeAxis_19943ef0-052d-4bef-aba9-af6f815ce6fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_19943ef0-052d-4bef-aba9-af6f815ce6fe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_19943ef0-052d-4bef-aba9-af6f815ce6fe" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_19943ef0-052d-4bef-aba9-af6f815ce6fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0cd6a580-dc02-419d-b52f-7bf026500d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_19943ef0-052d-4bef-aba9-af6f815ce6fe" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0cd6a580-dc02-419d-b52f-7bf026500d3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_ad35c913-64c4-4ddf-844a-9c4117af2783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0cd6a580-dc02-419d-b52f-7bf026500d3f" xlink:to="loc_us-gaap_CashMember_ad35c913-64c4-4ddf-844a-9c4117af2783" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_73867372-3a86-43b4-b978-900142d0011c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0cd6a580-dc02-419d-b52f-7bf026500d3f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_73867372-3a86-43b4-b978-900142d0011c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_8d253773-1024-4ede-9551-40b353125ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0cd6a580-dc02-419d-b52f-7bf026500d3f" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_8d253773-1024-4ede-9551-40b353125ea8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_8480b439-bd1f-4a32-ac35-15023274b7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0cd6a580-dc02-419d-b52f-7bf026500d3f" xlink:to="loc_us-gaap_InvestmentsMember_8480b439-bd1f-4a32-ac35-15023274b7a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_23ceccc5-6068-47c6-8541-9621f53ab98e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0cd6a580-dc02-419d-b52f-7bf026500d3f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_23ceccc5-6068-47c6-8541-9621f53ab98e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CashandCashEquivalentsandInvestmentsDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="extended" id="i1e1979d187a54ae4851a4955236b7bdd_CashandCashEquivalentsandInvestmentsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_ad07f56e-8793-44de-8e2b-d30b2c1634b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_72e44cf9-2760-436e-a0f3-20c63083a16b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_ad07f56e-8793-44de-8e2b-d30b2c1634b8" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_72e44cf9-2760-436e-a0f3-20c63083a16b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_c485c461-e251-49bf-bee9-aa5bae66d9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_ad07f56e-8793-44de-8e2b-d30b2c1634b8" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_c485c461-e251-49bf-bee9-aa5bae66d9b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis_dbeea99e-988f-4e7f-8a56-3776dffff059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_c485c461-e251-49bf-bee9-aa5bae66d9b7" xlink:to="loc_us-gaap_TradingActivityByTypeAxis_dbeea99e-988f-4e7f-8a56-3776dffff059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_dbeea99e-988f-4e7f-8a56-3776dffff059_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_dbeea99e-988f-4e7f-8a56-3776dffff059" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_dbeea99e-988f-4e7f-8a56-3776dffff059_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_f31e4688-2056-46e6-a67e-551e7175e2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_dbeea99e-988f-4e7f-8a56-3776dffff059" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_f31e4688-2056-46e6-a67e-551e7175e2d6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20210331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended" id="i6bb479b1c45c44a09444ec42f797d959_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20210331.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i8db6a172481a4a4bb83f356cd3f8c968_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20210331.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="i5b2f7272fe224579893b8389914a8704_FairValueMeasurementsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e1629771-04ec-42da-82d5-c6d848837be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2c797b11-232c-42ae-ab47-6e5b170cab44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e1629771-04ec-42da-82d5-c6d848837be3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2c797b11-232c-42ae-ab47-6e5b170cab44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_ab4dab0e-7c81-4cb2-95a2-dc89a0299394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e1629771-04ec-42da-82d5-c6d848837be3" xlink:to="loc_us-gaap_AvailableForSaleSecurities_ab4dab0e-7c81-4cb2-95a2-dc89a0299394" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_519078d9-2655-4cdb-b6b6-575888af7758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e1629771-04ec-42da-82d5-c6d848837be3" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_519078d9-2655-4cdb-b6b6-575888af7758" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e405792d-4812-4520-bdc4-530e4a71977e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e1629771-04ec-42da-82d5-c6d848837be3" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e405792d-4812-4520-bdc4-530e4a71977e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cd11685d-7178-484e-8968-ba77ecbdad66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e405792d-4812-4520-bdc4-530e4a71977e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cd11685d-7178-484e-8968-ba77ecbdad66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd11685d-7178-484e-8968-ba77ecbdad66_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cd11685d-7178-484e-8968-ba77ecbdad66" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd11685d-7178-484e-8968-ba77ecbdad66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289c69ba-fae0-49fd-b62c-cca8f262c66f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cd11685d-7178-484e-8968-ba77ecbdad66" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289c69ba-fae0-49fd-b62c-cca8f262c66f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1e9d3460-c958-425d-a96b-98b06197a07a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289c69ba-fae0-49fd-b62c-cca8f262c66f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1e9d3460-c958-425d-a96b-98b06197a07a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7b455942-e4ac-483b-b831-cc12f374f819" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289c69ba-fae0-49fd-b62c-cca8f262c66f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7b455942-e4ac-483b-b831-cc12f374f819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fae430f5-350c-4ee1-b418-19fb6a880112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289c69ba-fae0-49fd-b62c-cca8f262c66f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fae430f5-350c-4ee1-b418-19fb6a880112" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20210331.xsd#DebtObligations"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended" id="ic577639837014105886b63ed6004cfc5_DebtObligations"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20210331.xsd#DebtObligationsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="extended" id="id14b2b5642b44f5f948066af51c2a587_DebtObligationsTables"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#DebtObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="extended" id="i4f22b38ea7044942a3e0d4f729d27cf3_DebtObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_81798fb3-df55-496a-8006-3c80f275df7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_81798fb3-df55-496a-8006-3c80f275df7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_afbf7d2f-53b6-4dcb-8d25-1589da229400" xlink:href="lxrx-20210331.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_afbf7d2f-53b6-4dcb-8d25-1589da229400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_adde6b66-0722-468f-a0a5-c98a347bc735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_adde6b66-0722-468f-a0a5-c98a347bc735" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_6bc335e5-17cd-4780-9338-d45697fdb814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_6bc335e5-17cd-4780-9338-d45697fdb814" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6787f82f-f85f-4d1f-baf2-2fb2e941a5d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6787f82f-f85f-4d1f-baf2-2fb2e941a5d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_729f991c-1642-4c65-bae3-338636293199" xlink:href="lxrx-20210331.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_729f991c-1642-4c65-bae3-338636293199" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_1509d17c-d57b-46d7-9759-6d694f3dd219" xlink:href="lxrx-20210331.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_1509d17c-d57b-46d7-9759-6d694f3dd219" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_15648968-339f-4ca9-8270-7dc03e5e7795" xlink:href="lxrx-20210331.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_15648968-339f-4ca9-8270-7dc03e5e7795" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX_93d3ab34-0643-4bfe-80d3-b8e752d9e956" xlink:href="lxrx-20210331.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_MortgageDebtBalloonPayment_LXRX_93d3ab34-0643-4bfe-80d3-b8e752d9e956" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6e2630db-acee-478c-960a-e62d594f513e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_us-gaap_CommonStockSharesIssued_6e2630db-acee-478c-960a-e62d594f513e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange_452e8c3e-33d8-4f32-8f29-ab277da4d212" xlink:href="lxrx-20210331.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_ConvertibleDebtExchange_452e8c3e-33d8-4f32-8f29-ab277da4d212" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedInterestOnConvertible_afa666f0-1a3e-429a-83eb-f281acf8609e" xlink:href="lxrx-20210331.xsd#lxrx_AccruedInterestOnConvertible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_AccruedInterestOnConvertible_afa666f0-1a3e-429a-83eb-f281acf8609e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_486be3e4-7788-4fad-9ef9-947831d0472b" xlink:href="lxrx-20210331.xsd#lxrx_ConvertibleDebtExchangeRemainingNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_486be3e4-7788-4fad-9ef9-947831d0472b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchangeShares_baca2651-2eab-407b-a28f-f6805ec67bde" xlink:href="lxrx-20210331.xsd#lxrx_FutureConvertibleDebtExchangeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_FutureConvertibleDebtExchangeShares_baca2651-2eab-407b-a28f-f6805ec67bde" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchange_90f94fa3-c268-453c-833c-21fb7d604865" xlink:href="lxrx-20210331.xsd#lxrx_FutureConvertibleDebtExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_FutureConvertibleDebtExchange_90f94fa3-c268-453c-833c-21fb7d604865" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes_605b73cf-e39c-4e87-b5ae-1a0ff9eb688e" xlink:href="lxrx-20210331.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_PrincipalAmountOfConvertibleNotes_605b73cf-e39c-4e87-b5ae-1a0ff9eb688e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_a68ffedb-edfe-42b5-969a-5671f7ce0fb5" xlink:href="lxrx-20210331.xsd#lxrx_ConvertibleDebtExchangeTotalPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_a68ffedb-edfe-42b5-969a-5671f7ce0fb5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_1194d957-2260-49b9-a594-c689f763088e" xlink:href="lxrx-20210331.xsd#lxrx_ConvertibleDebtExchangeSeptemberCashPortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_1194d957-2260-49b9-a594-c689f763088e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_00b078da-c520-4efc-af96-f23797ce474d" xlink:href="lxrx-20210331.xsd#lxrx_ConvertibleDebtExchangeSeptemberSharePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_00b078da-c520-4efc-af96-f23797ce474d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a39aef52-0fa7-40b4-a2f4-ef3e7cfe967b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_us-gaap_DebtInstrumentTable_a39aef52-0fa7-40b4-a2f4-ef3e7cfe967b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c7a0fa0a-296f-4f98-8bc8-5aac575d91b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a39aef52-0fa7-40b4-a2f4-ef3e7cfe967b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c7a0fa0a-296f-4f98-8bc8-5aac575d91b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c7a0fa0a-296f-4f98-8bc8-5aac575d91b3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c7a0fa0a-296f-4f98-8bc8-5aac575d91b3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c7a0fa0a-296f-4f98-8bc8-5aac575d91b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d02283cc-73e4-4ac2-8596-60d228701418" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c7a0fa0a-296f-4f98-8bc8-5aac575d91b3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d02283cc-73e4-4ac2-8596-60d228701418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4b200aeb-e77e-4b31-9ea7-68fd966606b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d02283cc-73e4-4ac2-8596-60d228701418" xlink:to="loc_us-gaap_SubsequentEventMember_4b200aeb-e77e-4b31-9ea7-68fd966606b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b49466a1-0586-4d69-8cf1-df1bdc39f305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a39aef52-0fa7-40b4-a2f4-ef3e7cfe967b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b49466a1-0586-4d69-8cf1-df1bdc39f305" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b49466a1-0586-4d69-8cf1-df1bdc39f305_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b49466a1-0586-4d69-8cf1-df1bdc39f305" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b49466a1-0586-4d69-8cf1-df1bdc39f305_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a8bcf168-4d43-46e0-880b-2bfd9db5d748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b49466a1-0586-4d69-8cf1-df1bdc39f305" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a8bcf168-4d43-46e0-880b-2bfd9db5d748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4498a1de-1e00-46f3-a110-9aeeccb53d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a39aef52-0fa7-40b4-a2f4-ef3e7cfe967b" xlink:to="loc_us-gaap_DebtInstrumentAxis_4498a1de-1e00-46f3-a110-9aeeccb53d99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4498a1de-1e00-46f3-a110-9aeeccb53d99_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4498a1de-1e00-46f3-a110-9aeeccb53d99" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4498a1de-1e00-46f3-a110-9aeeccb53d99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f308e327-4ccf-4761-8ca0-cbeec9d77038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4498a1de-1e00-46f3-a110-9aeeccb53d99" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f308e327-4ccf-4761-8ca0-cbeec9d77038" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended" id="i10ef839f19424dfb8295040010b72702_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i221fd6db9fa646238e8c3b84a0d18b5f_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_0103923d-ba46-420c-ae18-c2197c28ccec" xlink:href="lxrx-20210331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_0103923d-ba46-420c-ae18-c2197c28ccec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c1a80622-b85e-46e6-aa7a-c6b310d6eecc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c1a80622-b85e-46e6-aa7a-c6b310d6eecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c3ef5032-6e4e-4d17-b371-7f30bc25963d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c3ef5032-6e4e-4d17-b371-7f30bc25963d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c5e363a5-764e-47d1-8fe3-746291b2faf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c5e363a5-764e-47d1-8fe3-746291b2faf9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a56fd38e-a789-446a-80d4-50695233c250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a56fd38e-a789-446a-80d4-50695233c250" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_41f74d13-3c67-4d94-94b9-034b6c35304b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_41f74d13-3c67-4d94-94b9-034b6c35304b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_15bcb853-2ef9-4af4-b087-3a351fd78db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_15bcb853-2ef9-4af4-b087-3a351fd78db9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b09aa16b-bd26-42e2-aaca-ec43dee9ceea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b09aa16b-bd26-42e2-aaca-ec43dee9ceea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e11dff40-badc-446e-9eaa-ab464738862f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e11dff40-badc-446e-9eaa-ab464738862f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_65027e72-59ed-46aa-8d35-0b4ed6f5dd97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_OperatingLeaseLiability_65027e72-59ed-46aa-8d35-0b4ed6f5dd97" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount_65d87f2f-2f2b-4544-a249-8caa520a63cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_ShortTermLeaseCommitmentAmount_65d87f2f-2f2b-4544-a249-8caa520a63cd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_84f55920-fab6-4be8-b159-a6b58ab746b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_84f55920-fab6-4be8-b159-a6b58ab746b9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDisputedCosts_dab81d4e-1e1d-48aa-8b5a-6057b799328b" xlink:href="lxrx-20210331.xsd#lxrx_SanofiDisputedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_lxrx_SanofiDisputedCosts_dab81d4e-1e1d-48aa-8b5a-6057b799328b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_3c8d9c97-ec5e-48cc-a537-81a48b41fb1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_OtherCommitmentsTable_3c8d9c97-ec5e-48cc-a537-81a48b41fb1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_41e518db-a5d0-460b-a974-95e6dc15ab28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_3c8d9c97-ec5e-48cc-a537-81a48b41fb1c" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_41e518db-a5d0-460b-a974-95e6dc15ab28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_41e518db-a5d0-460b-a974-95e6dc15ab28_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_41e518db-a5d0-460b-a974-95e6dc15ab28" xlink:to="loc_us-gaap_ReceivableTypeDomain_41e518db-a5d0-460b-a974-95e6dc15ab28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_a39123b1-9de3-44bf-848f-569562b7afb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_41e518db-a5d0-460b-a974-95e6dc15ab28" xlink:to="loc_us-gaap_ReceivableTypeDomain_a39123b1-9de3-44bf-848f-569562b7afb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_0b285b3c-9f64-42d7-a639-31ebd964f618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_a39123b1-9de3-44bf-848f-569562b7afb6" xlink:to="loc_us-gaap_AccountsReceivableMember_0b285b3c-9f64-42d7-a639-31ebd964f618" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CollaborationandLicenseAgreements"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended" id="i6999f9d4a808456ead083ef69134bd5a_CollaborationandLicenseAgreements"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended" id="i254eaa29e7a349c7b25c01dfda8f0dc0_CollaborationandLicenseAgreementsTables"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended" id="i9e96ee548cc44881ac82a04147e0276f_CollaborationandLicenseAgreementsDetails"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="simple" xlink:href="lxrx-20210331.xsd#OtherCapitalAgreements"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="extended" id="i8a55d67ddc9340a099db5ff0a1769e68_OtherCapitalAgreements"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#OtherCapitalAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="extended" id="i0e1f386e2cf84b57a90d2791c916ea03_OtherCapitalAgreementsDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>lxrx-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4b8e7fc5-a67e-4e41-8672-ef3fbe451ee1,g:d40e2da2-7e73-4fe0-84fd-1f0cf7fd616c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_114be7e1-ff3b-4c4e-965f-b23ae3acde55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ecdcb3c4-c327-4d7f-bd56-1abc12a7e2de_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_fcf93ff7-aee3-4833-bedd-18914ab71e1c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_b71b6562-6bbe-484b-a7c9-83a16c954ab5_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange" xlink:href="lxrx-20210331.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchange" xlink:to="lab_lxrx_ConvertibleDebtExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5e5158a5-d974-4bd8-a13d-5596ed02a3f7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3e7d63d7-a13c-4258-ba99-2f1a1639aac0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_8716a0cd-1052-41c4-b3f7-f4cd6bc49a04_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_61aaf442-1e75-43f9-bebc-6696600cf20b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_7b88881f-8bf6-4a16-a742-cb332ad25970_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales (including finite-lived intangible asset amortization)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchangeShares_2bc65ac4-29bd-41e5-ac74-ba383264941e_terseLabel_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Convertible debt exchange shares</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchangeShares_label_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Convertible debt exchange shares</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchangeShares_documentation_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Convertible debt exchange shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchangeShares" xlink:href="lxrx-20210331.xsd#lxrx_FutureConvertibleDebtExchangeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FutureConvertibleDebtExchangeShares" xlink:to="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_6acd5a03-36fa-4daa-8964-6bd15537b601_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_9f9f9eaa-2639-4339-94fb-18b1e3f5d84c_terseLabel_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_d147fe79-cd67-4753-b38f-df1ad93b9bd7_negatedTerseLabel_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_label_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_documentation_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets" xlink:href="lxrx-20210331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_GainOnSaleOfNonFinancialAssets" xlink:to="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_132e541b-5b48-421d-a4e5-8d5e2e978267_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DebtObligationsAbstract_b154d9de-bd6b-4907-ad85-562fc7225715_terseLabel_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_label_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_documentation_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract" xlink:href="lxrx-20210331.xsd#lxrx_DebtObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DebtObligationsAbstract" xlink:to="lab_lxrx_DebtObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5cce5838-d9f8-45bc-ab44-a3248832a461_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_cae77df2-3f7a-4ede-a796-6d0edba2a342_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_aad8df7d-55af-4826-a44a-72a343d58317_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a8acce27-fe1c-4145-8d5f-9b0ea027e990_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_fd8a53e9-42b5-483a-b300-523c2f73b914_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0971f944-0e52-4af3-b998-a4477a95dcf3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02452754-d561-473b-a725-39626515a231_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LiabilitiesAssumedByTerSera_c255f254-95d7-4911-b97b-033b0b476e93_terseLabel_en-US" xlink:label="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by TerSera</link:label>
    <link:label id="lab_lxrx_LiabilitiesAssumedByTerSera_label_en-US" xlink:label="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by TerSera</link:label>
    <link:label id="lab_lxrx_LiabilitiesAssumedByTerSera_documentation_en-US" xlink:label="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by TerSera</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LiabilitiesAssumedByTerSera" xlink:href="lxrx-20210331.xsd#lxrx_LiabilitiesAssumedByTerSera"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LiabilitiesAssumedByTerSera" xlink:to="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4263aeb0-b376-4df7-873b-c6d675509f67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_12f88a9a-650c-4539-a72c-26bf7633aa3f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_507b31f2-8b30-4633-b35c-e127102e36fa_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b4247c15-d19e-4b72-9280-04bb8adca255_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_65da7d96-86e1-43a3-98da-855cb1a80402_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_68e56786-29e6-4c11-b8d1-b8f68da5f384_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0b769681-4b86-4740-a399-7f1f75822782_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1c167ea2-feb2-494e-a875-396f6ef03915_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b95e35d6-2a0e-469d-b5a3-5707c5b05838_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_1fc41c51-c583-49ed-a6aa-46378d02acfd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_2361aa0f-88a8-4acf-b657-e000c9ff638e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_063e1ae2-cc82-4f25-97a4-cb4713c31415_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_54613861-6c46-4ccf-a2a3-a40ce08bc973_terseLabel_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_label_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_documentation_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract" xlink:href="lxrx-20210331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FairValueMeasurementsAbstract" xlink:to="lab_lxrx_FairValueMeasurementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e159309c-cfca-4546-b711-b5106f335533_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_d3a03216-e78e-4fda-9613-249cd0d6dbd8_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c1c843fd-17ea-4a35-a8df-a4a7ef7bed55_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_47db5f60-6d5b-486d-b409-6cf97fddd455_terseLabel_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative, including stock-based compensation of $1,565, and $2,256, respectively</link:label>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_label_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_documentation_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses" xlink:href="lxrx-20210331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Sellinggeneralandadministrativeexpenses" xlink:to="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e7e79355-dc55-4d34-b42e-414cd8fbbd72_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_96a01cbb-b03e-4bd0-9495-19c23e13acef_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81b4629c-8046-407d-a5ae-c622989b1794_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_03b4cde4-68a4-4f96-99d3-c61785c337c7_terseLabel_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current</link:label>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_label_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current</link:label>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_documentation_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current - due within 1 year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:href="lxrx-20210331.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:to="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_fceb2b39-31a1-4090-b539-76e0cbaa6136_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_07bac125-28f8-4567-8cc8-95fa691bf213_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:href="lxrx-20210331.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_adcc426b-3e46-4c8e-ae2e-5aaaaf6c23be_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_03eb9412-3a97-46dc-85d5-07a6e62f61d0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_7aa87baa-0ca4-4dab-97f5-39d6851a47e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash and cash equivalents and investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_7cac1372-ab21-44b2-94f4-df5d92b983d8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4cba64f4-124a-4b2f-b41f-dc0567b9f8b9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cb6b01f1-0ede-43f0-b8e7-3fea3c94928c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b80b1dca-b16c-43e5-bf64-96c8b2465ee0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_72acf662-caa2-4fd3-b4e8-090a6d184610_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_f1be14eb-a332-4469-b54b-86eead18aebe_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_label_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones" xlink:href="lxrx-20210331.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumSalesMilestones" xlink:to="lab_lxrx_IpsenMaximumSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_46b89dbf-dae2-4b49-9958-e4dfcc839439_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchange_85cafb71-7f8c-4f29-9205-1172029812e6_terseLabel_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">future convertible debt exchange</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchange_label_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">future convertible debt exchange</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchange_documentation_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">future convertible debt exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchange" xlink:href="lxrx-20210331.xsd#lxrx_FutureConvertibleDebtExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FutureConvertibleDebtExchange" xlink:to="lab_lxrx_FutureConvertibleDebtExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_e19e7b49-3476-411a-a901-ce13064f1be6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_d0a71efa-97a6-4d18-ac68-d112a155ee8d_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:href="lxrx-20210331.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5e6cead3-44a4-48c5-8ea1-82187f958b9d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_84001a04-37f7-40e7-b42e-5e5ee8fd367e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesAxis_787ca553-c2e6-4cf2-b4e2-a06b00c60a8c_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Axis]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesAxis_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities [Axis]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesAxis_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesAxis" xlink:href="lxrx-20210331.xsd#lxrx_AccruedLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesAxis" xlink:to="lab_lxrx_AccruedLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5acfe715-f058-47b1-a766-21de23eca0cf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7e9d3b47-b166-43d4-9b9f-44cc0a2fdd0e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_97fe03dd-2ce7-413f-932e-5e2f67ef9f50_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - Total Principal Amount</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - Total Principal Amount</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - Total Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:href="lxrx-20210331.xsd#lxrx_ConvertibleDebtExchangeTotalPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:to="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_70580e80-183c-4cbe-815c-6c136f7c2ff2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_40bd8658-d4ea-497e-98e0-153799cd8225_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_69eaf96b-1155-41ac-937c-ef4a18e6017e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease Commitment, Amount</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:to="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_b4c912e2-c56d-4768-9330-1c26728f9a27_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_6f9ebc63-26b1-48ec-802e-abf07df8c397_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_47c80ae0-5b7d-43bc-be12-ff4dbe57a7ea_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d8ac7787-53f6-411c-884f-14abfaa8e343_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_29a6de6b-2560-4f4a-be82-87b3a05a0424_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_c086b6e8-d490-4ba8-b7f0-58990858d41e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4efef3a3-dad3-41fd-9f3b-40494567417a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_1065cfbb-6f5a-433f-a81d-869cc9b4199e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value; 5,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_87a7be59-32d2-41cd-a537-7cce7b192b43_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_ebc1c6c5-5767-457f-af67-a084dc70dcd7_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_8afbeb0f-a00a-495f-8045-67f37339c3a3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_9e066081-b4ad-4791-9086-51851e32cedc_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_92004faa-569d-4d45-b2d0-4ff6dd08c589_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ec01b77a-0996-4951-9f53-7866eebaee10_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_b9063cf6-4bfa-4fea-8240-742347eeefac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_73ea38f8-ae73-4ac3-936c-896f3f6261be_terseLabel_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_label_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_documentation_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:href="lxrx-20210331.xsd#lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesDomain_c65e6038-f35b-4299-a166-477510cfb330_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Domain]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesDomain_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Domain]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesDomain_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain" xlink:href="lxrx-20210331.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesDomain" xlink:to="lab_lxrx_AccruedLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_4d5525da-f50c-4dca-a7a4-5ce43d57f98d_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense included in research and development expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:href="lxrx-20210331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_721aad18-f7fa-40b2-88b3-e13e61348ea5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_aba4a38c-7515-43c0-839a-d981094989f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_253fe932-d9ab-48a6-8fa3-73e03f756bc9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_28d76adc-a26e-4bf4-8cb9-8f044e05c950_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_68097ee7-82ad-4d7c-ba70-fb62923585c4_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_077465f2-7284-43b5-9cd8-2c80937163ff_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b2f84983-8590-4075-9cfe-e6fc74815f88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_7a9766e7-19fe-4009-b239-a7d0b61dbf88_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_de3993c1-9989-40bd-9bbb-8dfdfb8f7d51_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e5448704-d9e0-43ff-a2b2-f832c72e77ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_1f92e4fa-715c-4bc5-94a4-7b9508e86d3a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_528a5388-e8fa-4d87-902e-38323e500d1d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_e4235f88-f763-47b3-9417-de5d0e35eb6e_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_label_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized" xlink:href="lxrx-20210331.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueRecognized" xlink:to="lab_lxrx_IpsenRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b8e434c6-d367-4c8d-ac81-6559a812488f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per common share, Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_e796ee2d-6e87-4dc8-9ba0-f4aa24bee570_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMilestonePayment_b9954aa1-827e-4df1-8aa9-9c520c786443_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePayment_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePayment_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePayment" xlink:href="lxrx-20210331.xsd#lxrx_IpsenMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePayment" xlink:to="lab_lxrx_IpsenMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b3310500-c01a-459f-a0be-7500b60b1496_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0deb7f97-bdea-4905-98ca-40e889739fdd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_fdda0cb2-5d4b-4f50-a66a-3937248f925a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_fd8c7e4c-0e79-4877-9816-3b0879f0ff58_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_a5f31768-abce-4e39-b9a4-aac48e0c6aea_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_e5fa5edc-f63a-4f46-bf6b-eefc62efad95_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_92e58a2c-34a5-471d-b9c1-a10769752e3c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_0da78f40-3ab7-4f04-9a66-ca09e8037ba4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e8887c26-2886-437d-94b1-78e050b4617a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3cce5834-89ad-4f64-aeeb-212120f1bc47_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_dfa780c9-ea92-4588-a876-5c52f4a6a0ac_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt borrowings, net of fees</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_5313e9ee-cd71-4aac-8e05-b23840d38f3b_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:href="lxrx-20210331.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_97a77a4a-ffc4-4a99-af53-4b7b421604e9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_8d53b3f7-a16f-4d52-9104-3bd4973b9181_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 225,000 shares authorized; 145,552 and 142,289 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c637538f-3279-4e4e-8345-941cf5c85bf2_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c23eec37-6665-4a3d-a5dc-e93f88689023_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e111cfca-35a2-4a24-bd83-c61b14aaeb3a_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_cf48163c-d1a0-4ef7-9624-69cc5edbea2f_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJanuary2021ATMOffering" xlink:href="lxrx-20210331.xsd#lxrx_SharePriceInJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInJanuary2021ATMOffering" xlink:to="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfRealEstate_db3f83df-c836-4c63-b36d-281870917cfa_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Real Estate</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfRealEstate_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfRealEstate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfRealEstate" xlink:to="lab_us-gaap_ImpairmentOfRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_1cc7bf7c-a282-4232-9282-1cfac3c3467d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_67d75002-c228-4c2b-9669-cd8f57d8ba21_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_b2baa092-4fb5-475d-b31b-82f1cf6756cf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc3d51cb-528e-440d-97cc-f93670ed0430_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5da939a8-7f0a-4653-b383-983718904c34_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_f355534f-352e-4379-927e-6043e15873e7_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_c702cced-bcde-4def-b46b-5e5f0063026c_terseLabel_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_label_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_documentation_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination" xlink:href="lxrx-20210331.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SettlementPaymentFromTermination" xlink:to="lab_lxrx_SettlementPaymentFromTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_06359310-363b-4b3e-8efb-0a72b95012da_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_6ba6fe3a-c05f-45a2-bd79-f6bd7f592684_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_a206ac70-5535-4c7b-ab93-733d2c55fc01_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e1c873fd-e271-450b-8641-ce693d415e58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_059c9203-18e0-4e1a-9334-d81fa53c20d6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingActivityByTypeDomain_6fd22c2b-0ae3-42a8-9ea6-b9be0ed32f93_terseLabel_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Domain]</link:label>
    <link:label id="lab_us-gaap_TradingActivityByTypeDomain_label_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingActivityByTypeDomain" xlink:to="lab_us-gaap_TradingActivityByTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_3027162d-1cbd-49cb-856a-883135241d5c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4eb09594-82ed-45b4-a1a5-770b49f76413_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3c246c4e-62f4-4753-b0de-6fce0914b6dc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f50bfb7f-2cc1-4db1-b08c-2c8eec09ae25_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_cb5c02c7-237c-40a1-b154-27c9e9b43084_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d057775f-c97b-4bba-9f46-de02a90ec41c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f14d1f80-d5ea-4a83-8c0e-ad5981c88250_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_fceb5b83-ddda-40b3-8625-0fd15601f3f7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_2af2b831-5572-4edf-97c7-7e228f7085e1_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:href="lxrx-20210331.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:to="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_d7893fcc-225c-49d2-9ded-42d37d16f45c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_2b02fad7-9c98-45b5-a057-43c8823d4814_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and other revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c320671e-3003-4d83-9703-912c4f7cd12e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c88207cc-2321-4110-abe3-ba6bcbf2b385_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_f23701af-ef0c-4a3b-831f-4c71ce2da0ce_terseLabel_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_label_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_documentation_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:href="lxrx-20210331.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:to="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b57fd00b-dff3-4356-8c5d-3df3acadca72_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f28c8dca-6ba7-4563-bf90-a24106e99387_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_bbdce26c-6dd7-4700-a5d0-b1232a94397c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_0613f12e-fbc2-4aa0-83a9-39ff33d1b634_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholder's equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_52b9525e-3e41-437e-b090-f499d05811f8_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:href="lxrx-20210331.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:to="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_c9343d72-77a6-445d-9790-8b4743a6ac3f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9c06801e-ac64-4c98-a61f-eee11a312c73_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0bc4c5aa-b95b-46d5-b685-66084c16fd92_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_056d4ba0-6684-4300-885e-1c5a67bfc028_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_6632959e-6741-4e47-8dd2-8665fd0bd01b_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:href="lxrx-20210331.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:to="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6b84955a-3d1e-4774-b2f2-a8346ad10772_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0718875d-5013-4f80-aa02-66a0fb1bf8e0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LexiconIncrementalBorrowingRate_df95ad79-049e-4432-865b-8e81b82d096a_terseLabel_en-US" xlink:label="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon incremental borrowing rate</link:label>
    <link:label id="lab_lxrx_LexiconIncrementalBorrowingRate_label_en-US" xlink:label="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon incremental borrowing rate</link:label>
    <link:label id="lab_lxrx_LexiconIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon incremental borrowing rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconIncrementalBorrowingRate" xlink:href="lxrx-20210331.xsd#lxrx_LexiconIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LexiconIncrementalBorrowingRate" xlink:to="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_007d2008-7567-46d9-853a-6158e35d8e12_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeRemainingNotes_f031e1f2-9af0-419a-8a56-49d21cc599f9_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange Remaining Notes</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeRemainingNotes_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange Remaining Notes</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeRemainingNotes_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange Remaining Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:href="lxrx-20210331.xsd#lxrx_ConvertibleDebtExchangeRemainingNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:to="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_57e7c262-6085-4562-a1bd-65a34dac3167_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenTotalPayments_544e64ef-7768-4fb9-b3a6-d9b370bd17dd_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalPayments_label_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalPayments_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPayments" xlink:href="lxrx-20210331.xsd#lxrx_IpsenTotalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalPayments" xlink:to="lab_lxrx_IpsenTotalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ccf2aa9a-209d-4f7e-bac1-c7aa9dc940a0_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_c66b74f8-f602-42b2-8d45-83c88bf64eaf_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September share payment</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September share payment</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September share payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:href="lxrx-20210331.xsd#lxrx_ConvertibleDebtExchangeSeptemberSharePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:to="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_620209a3-1216-4f02-a39f-ba63301a087f_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5df5532d-e1c7-4062-b841-65b85325eb6d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_330184f0-a592-4eb5-b22e-13b44db8990e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ac8627e4-4287-4d49-9863-f7f659bee478_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c9ce7b53-3793-4eff-8f73-ee8839d41384_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $5,851 and $5,815, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2c72bb15-d657-4fca-9b31-0b125054efe7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_21c54cf5-e58b-4ec1-95db-d6065cfb16b2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a0884e83-6f05-4b55-ab3a-f0fa892be8d0_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_31747398-dca0-482d-a101-acd4bf2de061_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_3bf89aba-2de1-4927-b590-bf3c5993fca0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfd8626b-0e63-4bdf-a69d-19f3e04412fe_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_22783296-7148-4078-935e-125f87889fed_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1e32b77e-ce67-4ba1-a7c3-aa98d31cc3d5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_b2c0d8de-723d-4a32-8390-b361407d7a02_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0e87e868-806e-4bed-8cd3-e5d23a4d8307_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91beeadc-4fa1-495e-af7c-6a6c5dba9880_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d84a6d63-bb95-4a49-a588-4e6335ad7cef_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f405ce0d-d61b-422f-ad0e-d146b72b2835_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4d355b46-aec8-45ef-b79d-4cdcc738e17e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_6194b747-0a6f-4522-ac0b-3cdfeb41950d_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4c3a52b3-314a-4f12-b879-9a1bb4b3620a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1ba4b4f3-3016-4a97-9204-ae612d2e9655_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_8e2698ef-2466-4269-b83e-a82b6df8c192_terseLabel_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements</link:label>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_label_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements [Text Block]</link:label>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_documentation_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock" xlink:href="lxrx-20210331.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OtherCapitalAgreementsTextBlock" xlink:to="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_e066bb66-3f00-4f64-af26-7b3809d3fcdc_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:href="lxrx-20210331.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_41d6d936-fcb2-47a5-a8f2-f8e939509b67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2e48ce95-5c90-48d9-905d-30de22f82efb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1bc4b224-ee3a-4921-ba17-d74b1ec7cc2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingActivityByTypeAxis_36806fa2-d790-419e-aa54-4abea36cbbab_terseLabel_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_TradingActivityByTypeAxis_label_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingActivityByTypeAxis" xlink:to="lab_us-gaap_TradingActivityByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_5e6ff697-8b8a-46c2-ac28-074b74421d0e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_cfaea45c-b32e-4a1c-ba3f-7797a832f35c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_7b45476e-a213-481f-9318-834490dfdc20_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_65242d18-3109-40a2-a71f-d7a5c2615fb7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a6578a6b-f136-4921-af97-1beb34c4bcef_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f5ea4aef-8705-4526-9132-d1c45aaaaad4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_2b14d4cb-f427-405e-9c96-4d7ae9f7c9a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_fdc95d8f-a709-4caa-939f-d856df976f92_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_3c9e9a1e-6223-4048-9594-2a6cd5db575f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_36531526-c82a-4708-b74e-4f6f4cd38e5f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_97d4c582-a1f6-471f-ba02-dcbe5e227b0a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f06cc8f5-85ec-4492-be54-b2fa1b8d3f29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_558d012a-0bcd-4f8a-a209-17046d928ee2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_40f08ee6-7198-4ffd-ad31-ca78116cb111_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7c08ff45-40df-4eec-af11-c2bfbd96812d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5df64738-f0c9-48d9-b38f-39f237b7e536_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4e5c05fd-2c08-435d-b937-9c412de7083a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_26c09c02-39d4-4fc1-905b-e8ef1611d2f7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_81c63d97-849c-4523-8862-e80a913e68d8_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_label_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_documentation_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:href="lxrx-20210331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:to="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f6c3ae8f-d50b-4ecc-b35f-67f54ac527e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_2e4319b5-28b4-4380-a6d9-ae38ecb87797_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_d49c1999-c000-493d-87df-cb2c2a64faeb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_861338e4-41b3-4760-a71b-f60a0242b9f6_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange- September cash portion</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange- September cash portion</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange- September cash portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:href="lxrx-20210331.xsd#lxrx_ConvertibleDebtExchangeSeptemberCashPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:to="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_19df9c4d-34ba-470b-b379-0b1247ebcb0a_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury Securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_10b5bbd9-0b86-4eef-b867-a25eb977907c_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:href="lxrx-20210331.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d5cf96a3-a890-478c-91bc-af2fe92b1b2e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_d7b3df33-ba9a-4ec3-858f-1d55fafc0188_terseLabel_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">principal amount of convertible notes</link:label>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_label_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">principal amount of convertible notes</link:label>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_documentation_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">principal amount of convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes" xlink:href="lxrx-20210331.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PrincipalAmountOfConvertibleNotes" xlink:to="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9feb6d52-b59b-4462-9fe7-7d6ffa9cd493_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f86f6aee-416b-470e-bf97-0eb43342843b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_65e0a75f-9d9a-4ff9-83c5-18fd4499ada9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_c49da10b-3047-4f6f-a6e8-eb89059b4efa_terseLabel_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_label_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_documentation_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:href="lxrx-20210331.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:to="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_a73ef64d-ca37-4313-b5c3-9c33ef97cb11_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_label_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInNov2020ATMOffering" xlink:href="lxrx-20210331.xsd#lxrx_SharesSoldInNov2020ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInNov2020ATMOffering" xlink:to="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_43b07e74-20a6-4e0f-a4c4-dfdc9f545d27_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:href="lxrx-20210331.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ffc8b04d-cbc2-40d5-b714-079256bd9a97_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization, property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesTable_812b41a6-98fc-403e-8244-68541045ccfe_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Table]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesTable_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities [Table]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesTable_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesTable" xlink:href="lxrx-20210331.xsd#lxrx_AccruedLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesTable" xlink:to="lab_lxrx_AccruedLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_dcfc86d6-5087-40f0-8603-f999524b1ab2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cd451be0-cd61-40fd-8488-f0cfadc3e54e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_581cf906-9ff5-4213-a394-040c9a248847_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_ee9c703e-9920-44c9-9fde-2e62f37997a9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_aa162e48-949a-426f-9a7b-0bdb4e516a24_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_c6207464-c266-47f3-9fc4-8499628edeae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ea99ed21-c9da-41e4-9a71-c89583185c3a_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1fbf5b2f-9407-4a7c-a075-f84a366f0642_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per common share, Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_90be4380-1640-4c44-b170-6b96b1229a12_terseLabel_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_label_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_documentation_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:href="lxrx-20210331.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:to="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_ef3f4ea0-493c-45e9-b430-28bf2487c119_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d10e12cd-7f8a-439b-8ab2-41871e660c51_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development, including stock-based compensation of $1,286 and $2,176, respectively</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1e742317-a134-4555-8354-ad6924222828_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_fe0fadca-bf7d-4151-be1a-23dbe2672070_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived" xlink:href="lxrx-20210331.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePaymentReceived" xlink:to="lab_lxrx_IpsenMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_481b5de7-9939-49d9-b9c3-3b0c2a5fbf29_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_010f5279-c29f-4824-8bf3-f87ad5437708_terseLabel_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:href="lxrx-20210331.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_9aac39a2-dd54-47ba-9928-eadc5830bd05_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1700b97b-dbc9-488c-b93d-a14325261b03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_28af34ef-4c64-43e2-bb2e-7a902baac5b6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_01627c37-66ae-4d2b-a603-29248659c19c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_83d54f1d-4371-4196-b813-9f3ddb72ae36_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_538e5ee7-3a40-4e5d-8c88-385d7a64271d_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_31a5433c-0c5c-4231-93f5-9c2fa9874cd2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4b436e5c-736d-47e7-97da-2522006a3c36_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_851c0eea-2b79-4f8d-b526-3772320f0582_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_aa439b70-de31-4c2f-a6b7-d05d7b3e215b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_28f5bad1-09f2-4970-aea1-6dcfee32374c_terseLabel_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_label_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_documentation_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:href="lxrx-20210331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:to="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e603f1a1-0965-447a-91bc-50a3ecbaa6f4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_7441d96d-fc59-418f-b1f3-94c0e2e64e01_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_36b849c8-4c4a-4095-9b25-3f579d5c0e11_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_4f5e2edd-2c19-41d7-8f49-f16e8727fd3a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cff3f5cb-bfce-4db9-95ad-ef82660d5bfe_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_fe8f2852-74cc-48b1-93f9-9104e241a01c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2dd3f060-a0c4-4728-aabf-bf66fbb56d47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_782e99ac-cdf4-4db4-b403-debe9462c47e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5e81c68c-6318-4bd9-9d53-2f6974968744_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_3cbcd0ad-f85d-48be-82fb-832ea113721e_terseLabel_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:href="lxrx-20210331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_InitialRecognitionOfRightOfUseAsset_8cf8fead-66fd-4eb8-beee-71c292140228_terseLabel_en-US" xlink:label="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right of use asset</link:label>
    <link:label id="lab_lxrx_InitialRecognitionOfRightOfUseAsset_label_en-US" xlink:label="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right of use asset</link:label>
    <link:label id="lab_lxrx_InitialRecognitionOfRightOfUseAsset_documentation_en-US" xlink:label="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right of use asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:href="lxrx-20210331.xsd#lxrx_InitialRecognitionOfRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:to="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_84782a06-f7fa-42a7-90f4-9e59f431d518_terseLabel_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:href="lxrx-20210331.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:to="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiDisputedCosts_a5ce67ee-46c7-44be-853a-5a8f3dad7d31_terseLabel_en-US" xlink:label="lab_lxrx_SanofiDisputedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Disputed Costs</link:label>
    <link:label id="lab_lxrx_SanofiDisputedCosts_label_en-US" xlink:label="lab_lxrx_SanofiDisputedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Disputed Costs</link:label>
    <link:label id="lab_lxrx_SanofiDisputedCosts_documentation_en-US" xlink:label="lab_lxrx_SanofiDisputedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Disputed Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDisputedCosts" xlink:href="lxrx-20210331.xsd#lxrx_SanofiDisputedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiDisputedCosts" xlink:to="lab_lxrx_SanofiDisputedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ac93f458-994e-4f76-8655-15100ba20137_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_9ed6f604-6f48-4cce-b816-c51297cd0a11_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_463afb29-0bad-4c87-93a8-1a40ff367fd9_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_label_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_documentation_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_sanofiInitialCashPayment" xlink:href="lxrx-20210331.xsd#lxrx_Lxrx_sanofiInitialCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_sanofiInitialCashPayment" xlink:to="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_8f268471-fd63-4335-b1f8-1b70ec3a4f66_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_aee4adab-3cc6-45ad-9a9c-254f01be1503_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4a7bcf9e-94e0-47c0-b7c9-1b8bbe5474e3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_a101b3a1-9cb0-4164-ad4f-280a8d2d331a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_4c93cdc7-ab59-45cd-911c-55005bc6196b_terseLabel_en-US" xlink:label="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of Asset and Liability for Lease of Acquiree</link:label>
    <link:label id="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of Asset and Liability for Lease of Acquiree [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:to="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c9fb3958-edcf-468e-828b-40da8338d204_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f6e3327d-23fa-411b-ac30-e921755c9a49_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_7f5d0cf1-62b6-4f8b-a459-8d27cb33e5c3_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_037b0ac5-dd8a-4812-a9e0-62fa1fe7bd5d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_60613478-0e8e-4f3e-ac0c-f2b79339c552_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_499c0ace-5db6-40aa-825f-421a7c557143_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_df8cc25e-8644-447a-b979-2405e2a10d00_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8f0051b3-11ab-4310-934f-72850a6fb494_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e0579dc4-21b7-4762-865f-f6b4774e3232_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_ce07135f-d9f3-42b6-864b-69b8a4c3c543_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_label_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering" xlink:href="lxrx-20210331.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInNovember20ATMOffering" xlink:to="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ATMOfferingTotal_f7bee590-a4bc-4bca-91c6-47e86b640ad7_terseLabel_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:label id="lab_lxrx_ATMOfferingTotal_label_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:label id="lab_lxrx_ATMOfferingTotal_documentation_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal" xlink:href="lxrx-20210331.xsd#lxrx_ATMOfferingTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ATMOfferingTotal" xlink:to="lab_lxrx_ATMOfferingTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_75682a8c-defa-40c4-a348-c4cf80cc38a9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Netproductrevenue_0fc797c0-4bb4-47c7-8ea0-b2e25f02ce21_terseLabel_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_lxrx_Netproductrevenue_label_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_lxrx_Netproductrevenue_documentation_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue" xlink:href="lxrx-20210331.xsd#lxrx_Netproductrevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Netproductrevenue" xlink:to="lab_lxrx_Netproductrevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_cd3df1e3-d2ae-42d6-8e66-ffadbc9e145a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_80e519d0-c8c5-4868-bc8c-1c5add0c2d3f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Inputs, Disclosure</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_27ef9f37-4c3f-4e1a-9602-e42d80730fe7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_1bb8bb96-b011-4662-bad1-6e90f6efa081_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedInterestOnConvertible_017d816d-3da6-4c5f-9c43-81f546700164_terseLabel_en-US" xlink:label="lab_lxrx_AccruedInterestOnConvertible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued interest on convertible</link:label>
    <link:label id="lab_lxrx_AccruedInterestOnConvertible_label_en-US" xlink:label="lab_lxrx_AccruedInterestOnConvertible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued interest on convertible</link:label>
    <link:label id="lab_lxrx_AccruedInterestOnConvertible_documentation_en-US" xlink:label="lab_lxrx_AccruedInterestOnConvertible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued interest on convertible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedInterestOnConvertible" xlink:href="lxrx-20210331.xsd#lxrx_AccruedInterestOnConvertible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedInterestOnConvertible" xlink:to="lab_lxrx_AccruedInterestOnConvertible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8347f0f6-cf0c-4709-9abc-b993aa9ebf06_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9a388d82-9487-4ff0-bbac-a3735507aa6d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_4f57cf17-5e5e-448e-be15-57ac5f51fc57_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_abfbcbd6-b125-4453-abd3-7ed199db5eed_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_label_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized" xlink:href="lxrx-20210331.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueRecognized" xlink:to="lab_lxrx_SanofiRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98ca3972-0cdc-4868-b371-cf8627cfdf94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80420bb4-4990-465a-a305-46f63e5a73e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_8e37ceae-7584-40f5-9531-6e42f8ffc910_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_ff4816af-02ae-40a5-a30f-512c91d6c104_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6c655a0f-02e8-4666-891c-8010fa6d683e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesLineItems_fee0fb68-f2c7-4458-b643-948bd9c63fb0_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesLineItems_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesLineItems_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesLineItems" xlink:href="lxrx-20210331.xsd#lxrx_AccruedLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems" xlink:to="lab_lxrx_AccruedLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_913c50b0-464c-4364-91bc-77aa33766946_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_577d409e-0d49-447e-aa5e-9970346b20f4_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering" xlink:href="lxrx-20210331.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromNov2020ATMOffering" xlink:to="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_00b89648-5165-4b43-9a59-dc0ecb45ea18_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e1ab343f-3174-4720-922f-a3d1a162d5f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_b55374e7-428b-43f6-bf77-eb5f8ed2eb09_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_8ba3e916-8c13-4ee1-87f0-0dc96ea85135_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_d464e328-87f8-4fe9-b266-a39240f672d3_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 1,165 and 793 shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_77fd8270-a68d-4036-92ae-a9c9fcb80e9f_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_478d0a14-e930-4c37-923f-8e95917be5d7_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:href="lxrx-20210331.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a40bcd26-e5df-448f-b8cb-dbff380be383_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_95c0b881-71c2-4d0f-a0e5-9c70dd135410_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:href="lxrx-20210331.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:to="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_5a50f376-d1a3-4d6c-93b0-c92f2b714ec3_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4911edc9-2c65-4ad9-8ca4-a888064076f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_557e4c20-1cbe-4e80-a1b7-da712d3b889c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_93e76639-d8ef-404f-97de-8cd5c7aef2bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>lxrx-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:4b8e7fc5-a67e-4e41-8672-ef3fbe451ee1,g:d40e2da2-7e73-4fe0-84fd-1f0cf7fd616c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="lxrx-20210331.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c12689fd-fd90-4415-936c-200356966fda" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_DocumentType_c12689fd-fd90-4415-936c-200356966fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7051d9f0-e5d8-4c51-8904-f68793bc0633" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7051d9f0-e5d8-4c51-8904-f68793bc0633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_f2e47b20-408b-4924-8db2-b07e11d8653c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_DocumentQuarterlyReport_f2e47b20-408b-4924-8db2-b07e11d8653c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_86b74add-9324-4493-bcd0-e0e183cf981c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_DocumentPeriodEndDate_86b74add-9324-4493-bcd0-e0e183cf981c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3bb99e90-577b-499a-8b85-7b5921e1e025" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_DocumentTransitionReport_3bb99e90-577b-499a-8b85-7b5921e1e025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c0d1b1dd-79ca-46de-98f5-80d46c3f028c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_AmendmentFlag_c0d1b1dd-79ca-46de-98f5-80d46c3f028c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5799eac1-906e-4daf-926c-bcf3e418ecf0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_DocumentFiscalYearFocus_5799eac1-906e-4daf-926c-bcf3e418ecf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_566dedcf-bb5f-4a37-b7b4-0855a38af1de" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_CurrentFiscalYearEndDate_566dedcf-bb5f-4a37-b7b4-0855a38af1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d1443c09-5706-4ad6-90f4-ecc0d12d1913" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntityFileNumber_d1443c09-5706-4ad6-90f4-ecc0d12d1913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d8bae693-0a1d-4d96-ac5d-857a1d0b5416" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntityRegistrantName_d8bae693-0a1d-4d96-ac5d-857a1d0b5416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3cc01497-830e-4540-a0b7-5e22abf0c0e9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntityCentralIndexKey_3cc01497-830e-4540-a0b7-5e22abf0c0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ddb37261-cb6f-4b49-af6d-eee7986a8837" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ddb37261-cb6f-4b49-af6d-eee7986a8837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fd9e17f3-96f0-4302-8bd9-786a352bc7a9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntityTaxIdentificationNumber_fd9e17f3-96f0-4302-8bd9-786a352bc7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2be66b22-efb0-4645-848d-1275f39c89b3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntityAddressAddressLine1_2be66b22-efb0-4645-848d-1275f39c89b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3d47cb95-4efe-4a79-ba37-137e900cfe77" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntityAddressCityOrTown_3d47cb95-4efe-4a79-ba37-137e900cfe77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_33f4ea9b-84e1-4f8f-b184-2f87f1c7e850" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntityAddressStateOrProvince_33f4ea9b-84e1-4f8f-b184-2f87f1c7e850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9b5962e8-614b-47ef-b774-1864982c7327" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntityAddressPostalZipCode_9b5962e8-614b-47ef-b774-1864982c7327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d2d5651e-0f05-4271-9510-6fc3d111df7e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_CityAreaCode_d2d5651e-0f05-4271-9510-6fc3d111df7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c362d344-7d9b-42d4-8b36-1a4c445dfc31" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_LocalPhoneNumber_c362d344-7d9b-42d4-8b36-1a4c445dfc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c43fe72b-1b36-43c9-b8e3-c65f8e6525d3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_Security12bTitle_c43fe72b-1b36-43c9-b8e3-c65f8e6525d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c7c99537-8837-432c-bd6d-60c75dda25f6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_TradingSymbol_c7c99537-8837-432c-bd6d-60c75dda25f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_35c47e78-f987-44d4-8a6f-3201c22d2943" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_SecurityExchangeName_35c47e78-f987-44d4-8a6f-3201c22d2943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a8dd08d2-2e5b-4ee3-91af-4bca35496600" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntityCurrentReportingStatus_a8dd08d2-2e5b-4ee3-91af-4bca35496600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d630085f-d565-48f0-93ee-a69ef0d14678" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntityInteractiveDataCurrent_d630085f-d565-48f0-93ee-a69ef0d14678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7beb935f-2bfa-4072-8f84-8c1658ab407f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntityFilerCategory_7beb935f-2bfa-4072-8f84-8c1658ab407f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f1060ffa-0782-429f-8389-4958ef41e532" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntitySmallBusiness_f1060ffa-0782-429f-8389-4958ef41e532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e1ccb39f-7c60-4c52-bb97-e5dd4952aebf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntityEmergingGrowthCompany_e1ccb39f-7c60-4c52-bb97-e5dd4952aebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e14dafdb-f036-4161-aae9-afd51784f785" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntityShellCompany_e14dafdb-f036-4161-aae9-afd51784f785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_70ff08ba-ffcb-4042-9452-b36fa85ebc56" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4c0f8478-ab3b-44dd-ab6a-cbb75547a5e5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_70ff08ba-ffcb-4042-9452-b36fa85ebc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_5980c45f-fae7-4264-958b-8badc32c6aa6" xlink:href="lxrx-20210331.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4f5894e8-c1c0-45f6-8e62-a26c60777b47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_5980c45f-fae7-4264-958b-8badc32c6aa6" xlink:to="loc_us-gaap_StatementTable_4f5894e8-c1c0-45f6-8e62-a26c60777b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_92d8374c-2c26-42e0-b921-17f39b161068" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4f5894e8-c1c0-45f6-8e62-a26c60777b47" xlink:to="loc_srt_StatementScenarioAxis_92d8374c-2c26-42e0-b921-17f39b161068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b46e8573-993b-4c9a-9acb-e5d1463414f0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_92d8374c-2c26-42e0-b921-17f39b161068" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b46e8573-993b-4c9a-9acb-e5d1463414f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ed8cf2de-5f97-4b64-8aeb-c279c99a5480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4f5894e8-c1c0-45f6-8e62-a26c60777b47" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ed8cf2de-5f97-4b64-8aeb-c279c99a5480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7c8a214f-4610-4b59-8308-c410acfd1e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ed8cf2de-5f97-4b64-8aeb-c279c99a5480" xlink:to="loc_us-gaap_ClassOfStockDomain_7c8a214f-4610-4b59-8308-c410acfd1e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4f5894e8-c1c0-45f6-8e62-a26c60777b47" xlink:to="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0be42be1-c6fc-4027-bc61-c47a8c6f76a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0be42be1-c6fc-4027-bc61-c47a8c6f76a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a613f0c3-b518-4ac4-811b-6e23c4588173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0be42be1-c6fc-4027-bc61-c47a8c6f76a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a613f0c3-b518-4ac4-811b-6e23c4588173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_e31f456e-f16c-4933-b6a2-639789e9c2af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0be42be1-c6fc-4027-bc61-c47a8c6f76a5" xlink:to="loc_us-gaap_ShortTermInvestments_e31f456e-f16c-4933-b6a2-639789e9c2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_193bb725-861c-45e2-9b51-45bff9bf4686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0be42be1-c6fc-4027-bc61-c47a8c6f76a5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_193bb725-861c-45e2-9b51-45bff9bf4686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_86583279-44ef-46ba-9bb7-5b0f0872d59b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0be42be1-c6fc-4027-bc61-c47a8c6f76a5" xlink:to="loc_us-gaap_OtherAssetsCurrent_86583279-44ef-46ba-9bb7-5b0f0872d59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3d32080b-f298-472d-bd41-176a252d8b95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0be42be1-c6fc-4027-bc61-c47a8c6f76a5" xlink:to="loc_us-gaap_AssetsCurrent_3d32080b-f298-472d-bd41-176a252d8b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3482d0ee-4414-4c84-a5e4-d5a38d5fc4ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3482d0ee-4414-4c84-a5e4-d5a38d5fc4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_403cdc35-9ee7-4c8b-aebe-014e82ed104c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_Goodwill_403cdc35-9ee7-4c8b-aebe-014e82ed104c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1e400dbb-e536-4589-8cf5-17dbf7b8688a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1e400dbb-e536-4589-8cf5-17dbf7b8688a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0a9c54ab-666f-415d-95a7-a670f711f458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_Assets_0a9c54ab-666f-415d-95a7-a670f711f458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_de9daa17-bbf9-40f5-9037-cff75e013b07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_de9daa17-bbf9-40f5-9037-cff75e013b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_05a0ccc6-cfcd-4540-bbbf-9470cb34a3af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de9daa17-bbf9-40f5-9037-cff75e013b07" xlink:to="loc_us-gaap_AccountsPayableCurrent_05a0ccc6-cfcd-4540-bbbf-9470cb34a3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c034cc81-45e8-40b3-a9da-b29922e39ccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de9daa17-bbf9-40f5-9037-cff75e013b07" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c034cc81-45e8-40b3-a9da-b29922e39ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_0f621cd7-97fc-40e0-85b8-ed058809b6b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de9daa17-bbf9-40f5-9037-cff75e013b07" xlink:to="loc_us-gaap_LongTermDebtCurrent_0f621cd7-97fc-40e0-85b8-ed058809b6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8ac3e82e-a965-4948-ab24-683973bf3951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de9daa17-bbf9-40f5-9037-cff75e013b07" xlink:to="loc_us-gaap_LiabilitiesCurrent_8ac3e82e-a965-4948-ab24-683973bf3951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_91310787-baa0-4ef8-b9d9-019565a5430b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_91310787-baa0-4ef8-b9d9-019565a5430b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_440834ac-da20-453f-b0a9-9ed87a0cfbb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_Liabilities_440834ac-da20-453f-b0a9-9ed87a0cfbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7fae5841-f70a-45c8-99ae-5dcb5fdaa4da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7fae5841-f70a-45c8-99ae-5dcb5fdaa4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9d765f89-099b-41ec-a9d5-7e4b1061a2a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:to="loc_us-gaap_PreferredStockValue_9d765f89-099b-41ec-a9d5-7e4b1061a2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f96425bf-f42d-4ab4-b39c-d08293c0232b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:to="loc_us-gaap_CommonStockValue_f96425bf-f42d-4ab4-b39c-d08293c0232b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2b784c52-a6f1-4851-9826-2c40ab7761e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2b784c52-a6f1-4851-9826-2c40ab7761e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fb2a8c24-90aa-450c-b0c0-aef582d7bdc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fb2a8c24-90aa-450c-b0c0-aef582d7bdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_81254f13-09c0-47fd-8c20-6fc3299cc97d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_81254f13-09c0-47fd-8c20-6fc3299cc97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_7033bfa5-f689-4a53-af61-2533cd17d85e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:to="loc_us-gaap_TreasuryStockValue_7033bfa5-f689-4a53-af61-2533cd17d85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4aef4ed2-2aed-46c2-ae36-056ad5c6cc20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8af90d74-2960-4e06-830c-9eda2ebb513b" xlink:to="loc_us-gaap_StockholdersEquity_4aef4ed2-2aed-46c2-ae36-056ad5c6cc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ace52603-f6d2-4084-a430-b3a8a54b8b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a8795825-fc86-469a-bed1-31649a264b5f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ace52603-f6d2-4084-a430-b3a8a54b8b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_446c7fa9-e4c1-44d2-b04e-8852f6b230e5" xlink:href="lxrx-20210331.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_68ff45e3-0593-48b4-863d-e283a4a1f623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_446c7fa9-e4c1-44d2-b04e-8852f6b230e5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_68ff45e3-0593-48b4-863d-e283a4a1f623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a1333efc-2309-4aba-976e-3da34a805006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_446c7fa9-e4c1-44d2-b04e-8852f6b230e5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a1333efc-2309-4aba-976e-3da34a805006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ae986ed8-78d6-44aa-936a-72c6426f1650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_446c7fa9-e4c1-44d2-b04e-8852f6b230e5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ae986ed8-78d6-44aa-936a-72c6426f1650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_a1b20516-bbf9-4292-bbe9-c3cd3efa63e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_446c7fa9-e4c1-44d2-b04e-8852f6b230e5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_a1b20516-bbf9-4292-bbe9-c3cd3efa63e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ae0235ae-2e3c-4c88-80a6-dd8aefe38c61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_446c7fa9-e4c1-44d2-b04e-8852f6b230e5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ae0235ae-2e3c-4c88-80a6-dd8aefe38c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b22ce1e7-0356-4652-a9d9-bfb44f90e544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_446c7fa9-e4c1-44d2-b04e-8852f6b230e5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b22ce1e7-0356-4652-a9d9-bfb44f90e544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_41947c50-c794-4388-b237-09238872524f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_446c7fa9-e4c1-44d2-b04e-8852f6b230e5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_41947c50-c794-4388-b237-09238872524f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1d3d326d-93bc-4843-aa0d-01e3fdcb4a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_446c7fa9-e4c1-44d2-b04e-8852f6b230e5" xlink:to="loc_us-gaap_CommonStockSharesIssued_1d3d326d-93bc-4843-aa0d-01e3fdcb4a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_656e84de-8371-4a66-9c69-106d19b2e29b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_446c7fa9-e4c1-44d2-b04e-8852f6b230e5" xlink:to="loc_us-gaap_TreasuryStockShares_656e84de-8371-4a66-9c69-106d19b2e29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_dbfb3de5-4ac5-4969-9f0c-a597593770c3" xlink:href="lxrx-20210331.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c1580817-efc1-4e3e-a4cd-ca284064d5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_dbfb3de5-4ac5-4969-9f0c-a597593770c3" xlink:to="loc_us-gaap_StatementTable_c1580817-efc1-4e3e-a4cd-ca284064d5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6ce34c04-f63e-4f6c-afea-364395944862" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c1580817-efc1-4e3e-a4cd-ca284064d5ea" xlink:to="loc_srt_StatementScenarioAxis_6ce34c04-f63e-4f6c-afea-364395944862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1efc93f3-8588-4f3b-b389-942d76600cec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_6ce34c04-f63e-4f6c-afea-364395944862" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1efc93f3-8588-4f3b-b389-942d76600cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c1580817-efc1-4e3e-a4cd-ca284064d5ea" xlink:to="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8bd6943d-cee0-426b-9d52-ca1fcef3dcc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_RevenuesAbstract_8bd6943d-cee0-426b-9d52-ca1fcef3dcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_3b0eff3f-65fb-461a-b70b-1f6d80b65a29" xlink:href="lxrx-20210331.xsd#lxrx_Netproductrevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8bd6943d-cee0-426b-9d52-ca1fcef3dcc7" xlink:to="loc_lxrx_Netproductrevenue_3b0eff3f-65fb-461a-b70b-1f6d80b65a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_479fe00d-e48d-4979-869b-9f5186bab2f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8bd6943d-cee0-426b-9d52-ca1fcef3dcc7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_479fe00d-e48d-4979-869b-9f5186bab2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_ab31a6de-6e02-48e1-b09d-01da3beeedba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8bd6943d-cee0-426b-9d52-ca1fcef3dcc7" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_ab31a6de-6e02-48e1-b09d-01da3beeedba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_87ca707f-de97-4340-94dc-af799b9b180b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8bd6943d-cee0-426b-9d52-ca1fcef3dcc7" xlink:to="loc_us-gaap_Revenues_87ca707f-de97-4340-94dc-af799b9b180b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ed7fe438-2803-40bc-a5a2-7e4a187b6b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ed7fe438-2803-40bc-a5a2-7e4a187b6b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_85e7855a-02bf-4a84-8d9c-7bd0a86b26f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ed7fe438-2803-40bc-a5a2-7e4a187b6b9c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_85e7855a-02bf-4a84-8d9c-7bd0a86b26f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0ae31471-f3d0-405e-9f16-90770883499e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ed7fe438-2803-40bc-a5a2-7e4a187b6b9c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0ae31471-f3d0-405e-9f16-90770883499e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_5ead53d9-b227-4a54-ba63-367c9c471763" xlink:href="lxrx-20210331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ed7fe438-2803-40bc-a5a2-7e4a187b6b9c" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_5ead53d9-b227-4a54-ba63-367c9c471763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f56579ab-f550-42e8-a068-e81c57aa0496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ed7fe438-2803-40bc-a5a2-7e4a187b6b9c" xlink:to="loc_us-gaap_OperatingExpenses_f56579ab-f550-42e8-a068-e81c57aa0496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_2d448cf8-e074-4cf5-9c33-631ec11a1bb7" xlink:href="lxrx-20210331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_2d448cf8-e074-4cf5-9c33-631ec11a1bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d182a9e8-1435-4a31-9975-3074292ad6e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_OperatingIncomeLoss_d182a9e8-1435-4a31-9975-3074292ad6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f3527fb5-a296-4f75-8be5-757dca14550f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_InterestExpense_f3527fb5-a296-4f75-8be5-757dca14550f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_15f0ef2b-5d2c-4cf1-9c38-0140f44726af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_15f0ef2b-5d2c-4cf1-9c38-0140f44726af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a34b928c-3f8e-49ba-9138-c78543ede714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_NetIncomeLoss_a34b928c-3f8e-49ba-9138-c78543ede714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7741817e-367d-4423-8bb4-1765fa90cc5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_EarningsPerShareBasic_7741817e-367d-4423-8bb4-1765fa90cc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42679527-e32e-491c-8a0e-d6afe853f9d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42679527-e32e-491c-8a0e-d6afe853f9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bf9807fc-586e-4741-943e-384854e20f70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bf9807fc-586e-4741-943e-384854e20f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_93969e79-a026-4800-af5d-eeb5ee350521" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_93969e79-a026-4800-af5d-eeb5ee350521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_dd228c88-7913-449b-b8e4-9a8a803df85a" xlink:href="lxrx-20210331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_dd228c88-7913-449b-b8e4-9a8a803df85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_0b1f9246-58e5-49b7-be58-7d11a839fac0" xlink:href="lxrx-20210331.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_0b1f9246-58e5-49b7-be58-7d11a839fac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfRealEstate_1ce33a56-1859-4ff8-9aa5-f92d4bf4f1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_ImpairmentOfRealEstate_1ce33a56-1859-4ff8-9aa5-f92d4bf4f1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_f4013509-6d32-4ce1-a456-0e1e1cd52f68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dee9971-4b2c-4937-96d8-cc1ebd2f4025" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_f4013509-6d32-4ce1-a456-0e1e1cd52f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedStatementsofComprehensiveLossParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_fe2354c5-c283-46cf-bc5b-072f05430487" xlink:href="lxrx-20210331.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_7457d7a7-f8b1-4608-be79-e5be971692ab" xlink:href="lxrx-20210331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_fe2354c5-c283-46cf-bc5b-072f05430487" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_7457d7a7-f8b1-4608-be79-e5be971692ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_1b8f8975-89c3-4094-95ca-7141a4e5d311" xlink:href="lxrx-20210331.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_fe2354c5-c283-46cf-bc5b-072f05430487" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_1b8f8975-89c3-4094-95ca-7141a4e5d311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_e7c1078e-82d8-4a53-9d5c-34d400b53372" xlink:href="lxrx-20210331.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8be5c9b7-d169-4ebd-878b-36b423d53ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_e7c1078e-82d8-4a53-9d5c-34d400b53372" xlink:to="loc_us-gaap_StatementTable_8be5c9b7-d169-4ebd-878b-36b423d53ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_96801a08-8db2-454a-b469-c078c3147722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8be5c9b7-d169-4ebd-878b-36b423d53ae0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_96801a08-8db2-454a-b469-c078c3147722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5344ecde-10f6-4ab1-8c89-20ce54be3c9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_96801a08-8db2-454a-b469-c078c3147722" xlink:to="loc_us-gaap_EquityComponentDomain_5344ecde-10f6-4ab1-8c89-20ce54be3c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_25c21e28-071c-4b0f-bc4f-51009806ec75" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8be5c9b7-d169-4ebd-878b-36b423d53ae0" xlink:to="loc_srt_StatementScenarioAxis_25c21e28-071c-4b0f-bc4f-51009806ec75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_03867e2b-7903-4570-ae29-e8170450d137" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_25c21e28-071c-4b0f-bc4f-51009806ec75" xlink:to="loc_srt_ScenarioUnspecifiedDomain_03867e2b-7903-4570-ae29-e8170450d137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8be5c9b7-d169-4ebd-878b-36b423d53ae0" xlink:to="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33151b8a-a2e5-4211-83a3-4d95c7e349da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33151b8a-a2e5-4211-83a3-4d95c7e349da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_20feec6d-ce44-4a48-a42c-2aaeb5fe3035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33151b8a-a2e5-4211-83a3-4d95c7e349da" xlink:to="loc_us-gaap_NetIncomeLoss_20feec6d-ce44-4a48-a42c-2aaeb5fe3035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c040e294-b8bd-483e-bf0c-e19d0be058c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33151b8a-a2e5-4211-83a3-4d95c7e349da" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c040e294-b8bd-483e-bf0c-e19d0be058c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1991c19e-7b1c-437f-9cab-acbefa9b99df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c040e294-b8bd-483e-bf0c-e19d0be058c8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1991c19e-7b1c-437f-9cab-acbefa9b99df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7f3c85c4-62bc-4bbe-b2b9-737c42f93356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c040e294-b8bd-483e-bf0c-e19d0be058c8" xlink:to="loc_us-gaap_ShareBasedCompensation_7f3c85c4-62bc-4bbe-b2b9-737c42f93356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d0f34a42-80df-495a-9ef5-8f602c63e3e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c040e294-b8bd-483e-bf0c-e19d0be058c8" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d0f34a42-80df-495a-9ef5-8f602c63e3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_5fe251e4-60a5-4876-b2e8-856440551728" xlink:href="lxrx-20210331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c040e294-b8bd-483e-bf0c-e19d0be058c8" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_5fe251e4-60a5-4876-b2e8-856440551728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_efb7da8c-1988-4324-af73-13024fce6e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c040e294-b8bd-483e-bf0c-e19d0be058c8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_efb7da8c-1988-4324-af73-13024fce6e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b86cac22-3942-4437-90b7-faafe78c41c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_efb7da8c-1988-4324-af73-13024fce6e5a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b86cac22-3942-4437-90b7-faafe78c41c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b6edcaed-77ed-41f1-b5b2-05c151d6ad4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_efb7da8c-1988-4324-af73-13024fce6e5a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b6edcaed-77ed-41f1-b5b2-05c151d6ad4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f21c472c-7a0f-4167-82eb-d63e40495bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_efb7da8c-1988-4324-af73-13024fce6e5a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f21c472c-7a0f-4167-82eb-d63e40495bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_675bf495-dd38-433f-90bf-58b05e5a469c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_efb7da8c-1988-4324-af73-13024fce6e5a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_675bf495-dd38-433f-90bf-58b05e5a469c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3f77acfe-6ce6-41ec-b919-44ce9e891732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_efb7da8c-1988-4324-af73-13024fce6e5a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3f77acfe-6ce6-41ec-b919-44ce9e891732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f17c4f00-cc65-41f8-81d0-b19d7e29a5aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33151b8a-a2e5-4211-83a3-4d95c7e349da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f17c4f00-cc65-41f8-81d0-b19d7e29a5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7139beb8-d495-4260-9d87-018e8421ff41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7139beb8-d495-4260-9d87-018e8421ff41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7b80ea5a-4273-4693-b986-3059dd65e535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7139beb8-d495-4260-9d87-018e8421ff41" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7b80ea5a-4273-4693-b986-3059dd65e535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_9812ed85-e62d-40fb-9a04-6faf1953b7fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7139beb8-d495-4260-9d87-018e8421ff41" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_9812ed85-e62d-40fb-9a04-6faf1953b7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_e1ff1669-f20e-4c0d-abf0-f0b0bc95a177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7139beb8-d495-4260-9d87-018e8421ff41" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_e1ff1669-f20e-4c0d-abf0-f0b0bc95a177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_e81b8360-50d8-4d59-84ec-ead35ef5ec08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7139beb8-d495-4260-9d87-018e8421ff41" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_e81b8360-50d8-4d59-84ec-ead35ef5ec08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16df8b3b-ee6e-4d6e-bd7a-e6196236842f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7139beb8-d495-4260-9d87-018e8421ff41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16df8b3b-ee6e-4d6e-bd7a-e6196236842f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_958196fd-1446-4c6e-b2d9-7ce6a5f78645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_958196fd-1446-4c6e-b2d9-7ce6a5f78645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b509116f-a272-41f7-9b2f-5db8ccc4128e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_958196fd-1446-4c6e-b2d9-7ce6a5f78645" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b509116f-a272-41f7-9b2f-5db8ccc4128e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_db118e95-04d0-4198-9948-2d476255e0b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_958196fd-1446-4c6e-b2d9-7ce6a5f78645" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_db118e95-04d0-4198-9948-2d476255e0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f3099734-6822-4e5c-bc8a-c69e1d616e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_958196fd-1446-4c6e-b2d9-7ce6a5f78645" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f3099734-6822-4e5c-bc8a-c69e1d616e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_200adb01-a44b-49f7-8a1a-3b6bc43624c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_958196fd-1446-4c6e-b2d9-7ce6a5f78645" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_200adb01-a44b-49f7-8a1a-3b6bc43624c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_fb28cdd8-e707-41c1-b0d1-b8dbb5aa4eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_fb28cdd8-e707-41c1-b0d1-b8dbb5aa4eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2e7d267f-85b2-45da-b242-79c0c20029f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2e7d267f-85b2-45da-b242-79c0c20029f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_37a04b6a-e51c-4f84-8256-b058a5553764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_37a04b6a-e51c-4f84-8256-b058a5553764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_07e8e74f-7588-4739-98b2-e2a27065bf64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_88b1cd37-760d-4583-8fbe-438a33965583" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_07e8e74f-7588-4739-98b2-e2a27065bf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_4fb6a770-3c09-448e-b652-dca3f72988ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_07e8e74f-7588-4739-98b2-e2a27065bf64" xlink:to="loc_us-gaap_InterestPaidNet_4fb6a770-3c09-448e-b652-dca3f72988ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InitialRecognitionOfRightOfUseAsset_f5cdb0d1-e055-4b08-bbc9-5054f4ef792e" xlink:href="lxrx-20210331.xsd#lxrx_InitialRecognitionOfRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_07e8e74f-7588-4739-98b2-e2a27065bf64" xlink:to="loc_lxrx_InitialRecognitionOfRightOfUseAsset_f5cdb0d1-e055-4b08-bbc9-5054f4ef792e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e344ddf6-e188-4cbb-9132-44a82efd84e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_07e8e74f-7588-4739-98b2-e2a27065bf64" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e344ddf6-e188-4cbb-9132-44a82efd84e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LiabilitiesAssumedByTerSera_a95844d0-3f89-4780-b44f-e032e7184152" xlink:href="lxrx-20210331.xsd#lxrx_LiabilitiesAssumedByTerSera"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_07e8e74f-7588-4739-98b2-e2a27065bf64" xlink:to="loc_lxrx_LiabilitiesAssumedByTerSera_a95844d0-3f89-4780-b44f-e032e7184152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_096c825e-bf4d-46a7-94d4-ba879ada6d68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_07e8e74f-7588-4739-98b2-e2a27065bf64" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_096c825e-bf4d-46a7-94d4-ba879ada6d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="lxrx-20210331.xsd#ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_990f9c19-781a-4e6e-9843-b8345eaa7561" xlink:href="lxrx-20210331.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_08f31886-d63c-4e0b-a853-c5fa00a6d324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_990f9c19-781a-4e6e-9843-b8345eaa7561" xlink:to="loc_us-gaap_StatementTable_08f31886-d63c-4e0b-a853-c5fa00a6d324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_58c94de3-68a7-466f-98f1-59cf301dd0a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_08f31886-d63c-4e0b-a853-c5fa00a6d324" xlink:to="loc_srt_StatementScenarioAxis_58c94de3-68a7-466f-98f1-59cf301dd0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8c5f6260-ad89-445a-aac2-291b196b4a80" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_58c94de3-68a7-466f-98f1-59cf301dd0a2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8c5f6260-ad89-445a-aac2-291b196b4a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_11a6b4f5-7ee8-4b7f-a4ae-d6793dd9da31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_08f31886-d63c-4e0b-a853-c5fa00a6d324" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_11a6b4f5-7ee8-4b7f-a4ae-d6793dd9da31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1ecf9057-db8d-46a4-85c2-f28b701ea36e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11a6b4f5-7ee8-4b7f-a4ae-d6793dd9da31" xlink:to="loc_us-gaap_EquityComponentDomain_1ecf9057-db8d-46a4-85c2-f28b701ea36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b7f65317-80e2-4ea1-aa10-b736d47076cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1ecf9057-db8d-46a4-85c2-f28b701ea36e" xlink:to="loc_us-gaap_CommonStockMember_b7f65317-80e2-4ea1-aa10-b736d47076cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6211aa41-3e08-4846-8f52-e7864cf7232a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1ecf9057-db8d-46a4-85c2-f28b701ea36e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6211aa41-3e08-4846-8f52-e7864cf7232a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e10fc494-1d20-495c-b2cb-300a0075d804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1ecf9057-db8d-46a4-85c2-f28b701ea36e" xlink:to="loc_us-gaap_RetainedEarningsMember_e10fc494-1d20-495c-b2cb-300a0075d804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4513429d-d62f-45f6-8388-e180b23c3153" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1ecf9057-db8d-46a4-85c2-f28b701ea36e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4513429d-d62f-45f6-8388-e180b23c3153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_8ce9048d-b88f-408a-abef-8372f1c23374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1ecf9057-db8d-46a4-85c2-f28b701ea36e" xlink:to="loc_us-gaap_TreasuryStockMember_8ce9048d-b88f-408a-abef-8372f1c23374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_be61e5c0-5e58-45c7-8265-e4d51e4e13e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_08f31886-d63c-4e0b-a853-c5fa00a6d324" xlink:to="loc_us-gaap_StatementClassOfStockAxis_be61e5c0-5e58-45c7-8265-e4d51e4e13e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b533673b-f07c-43bb-a0ad-89af172f7dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_be61e5c0-5e58-45c7-8265-e4d51e4e13e2" xlink:to="loc_us-gaap_ClassOfStockDomain_b533673b-f07c-43bb-a0ad-89af172f7dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_08f31886-d63c-4e0b-a853-c5fa00a6d324" xlink:to="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_756ec130-04d9-4f5b-9ec2-b988a1656a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_CommonStockSharesIssued_756ec130-04d9-4f5b-9ec2-b988a1656a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4be86f9a-2599-4880-9b15-d9e942a5166e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4be86f9a-2599-4880-9b15-d9e942a5166e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_005733e1-5174-455f-a3ec-1396df180a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_005733e1-5174-455f-a3ec-1396df180a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_de5839b0-5d4e-4dc6-a7e8-52249dec5529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_de5839b0-5d4e-4dc6-a7e8-52249dec5529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1d364faa-bab4-4ed0-a1d6-c69699709f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1d364faa-bab4-4ed0-a1d6-c69699709f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_52001f4f-a770-4fcf-81f8-3220705a874c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_52001f4f-a770-4fcf-81f8-3220705a874c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b2b12160-8164-44cc-8b64-989ba4d5d4fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_NetIncomeLoss_b2b12160-8164-44cc-8b64-989ba4d5d4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_681bfd2c-ee4c-4341-aced-4ec74fcd80b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_681bfd2c-ee4c-4341-aced-4ec74fcd80b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_30825ce3-4242-4759-8a38-27ddc6c315f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_CommonStockSharesIssued_30825ce3-4242-4759-8a38-27ddc6c315f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dca1b674-67a5-4b58-8e1f-9e74b2e43537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dca1b674-67a5-4b58-8e1f-9e74b2e43537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a2d5f0b8-d2ee-400b-8d53-1b002b19222d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a2d5f0b8-d2ee-400b-8d53-1b002b19222d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e495b4ed-4f1c-4c5c-9bb9-e4bb1da1c69b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7126532e-1206-4c8b-a891-6430d0cd0a68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e495b4ed-4f1c-4c5c-9bb9-e4bb1da1c69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesNotes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_6166f615-9ec4-494e-888e-232c3b759d3c" xlink:href="lxrx-20210331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8591e559-b63d-4c22-9c37-4da4286f5fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_6166f615-9ec4-494e-888e-232c3b759d3c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8591e559-b63d-4c22-9c37-4da4286f5fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_8774619b-db17-431c-b7ce-d2066e345fb8" xlink:href="lxrx-20210331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_2d8d0a24-2096-4094-88a3-7686264afd53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_8774619b-db17-431c-b7ce-d2066e345fb8" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_2d8d0a24-2096-4094-88a3-7686264afd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f688b3e0-d02a-48eb-9ed1-e774b799d24e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_8774619b-db17-431c-b7ce-d2066e345fb8" xlink:to="loc_us-gaap_UseOfEstimates_f688b3e0-d02a-48eb-9ed1-e774b799d24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_516705cf-b8dc-42eb-bae8-46bb165018f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_8774619b-db17-431c-b7ce-d2066e345fb8" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_516705cf-b8dc-42eb-bae8-46bb165018f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_bcd6d91a-cf89-47f8-bdfa-e50fa2104518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_8774619b-db17-431c-b7ce-d2066e345fb8" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_bcd6d91a-cf89-47f8-bdfa-e50fa2104518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_c1d59639-b419-40af-8d89-0dbe8219d335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_8774619b-db17-431c-b7ce-d2066e345fb8" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_c1d59639-b419-40af-8d89-0dbe8219d335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e802cf9b-5b4f-4a43-b698-de5179a3387c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_8774619b-db17-431c-b7ce-d2066e345fb8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e802cf9b-5b4f-4a43-b698-de5179a3387c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_70ff1f55-245e-4c08-a6eb-1d4ac7e18844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_8774619b-db17-431c-b7ce-d2066e345fb8" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_70ff1f55-245e-4c08-a6eb-1d4ac7e18844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_f76e9d6b-7e63-431a-871d-4e5e33daebfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_8774619b-db17-431c-b7ce-d2066e345fb8" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_f76e9d6b-7e63-431a-871d-4e5e33daebfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_94b2e424-0f4b-42f8-aa15-3fdb489a03ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_8774619b-db17-431c-b7ce-d2066e345fb8" xlink:to="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_94b2e424-0f4b-42f8-aa15-3fdb489a03ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_c7ccb0c9-ad7d-4a5c-bf58-b90d5e9ef24f" xlink:href="lxrx-20210331.xsd#lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d5b648cd-09cd-417c-a5a0-4d64a59a5d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_c7ccb0c9-ad7d-4a5c-bf58-b90d5e9ef24f" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d5b648cd-09cd-417c-a5a0-4d64a59a5d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7b402d47-1287-4619-9132-12d7cd8307e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_c7ccb0c9-ad7d-4a5c-bf58-b90d5e9ef24f" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7b402d47-1287-4619-9132-12d7cd8307e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e633f1bd-7cb1-402a-802c-7345f95034de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_c7ccb0c9-ad7d-4a5c-bf58-b90d5e9ef24f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e633f1bd-7cb1-402a-802c-7345f95034de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_15c2a19f-83d0-4414-853e-e0f9eda8fd86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_c7ccb0c9-ad7d-4a5c-bf58-b90d5e9ef24f" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_15c2a19f-83d0-4414-853e-e0f9eda8fd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_e36b2891-e5b8-4e65-9ddd-8ce3a08a4703" xlink:href="lxrx-20210331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_e36b2891-e5b8-4e65-9ddd-8ce3a08a4703" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6b9c64c7-38c4-48ab-aa65-32a65c3a52c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:to="loc_us-gaap_PlanNameAxis_6b9c64c7-38c4-48ab-aa65-32a65c3a52c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8ebe4b55-4113-4c96-b7f2-4499df4a312e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6b9c64c7-38c4-48ab-aa65-32a65c3a52c9" xlink:to="loc_us-gaap_PlanNameDomain_8ebe4b55-4113-4c96-b7f2-4499df4a312e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_edf94692-b5f0-4ef1-9968-b8aa4f7f5927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:to="loc_us-gaap_AwardDateAxis_edf94692-b5f0-4ef1-9968-b8aa4f7f5927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_289e809f-89f8-4275-afd5-70e025177830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_edf94692-b5f0-4ef1-9968-b8aa4f7f5927" xlink:to="loc_us-gaap_AwardDateDomain_289e809f-89f8-4275-afd5-70e025177830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fb4b11c9-3a9f-429d-8e8a-437d45cf6950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:to="loc_us-gaap_AwardTypeAxis_fb4b11c9-3a9f-429d-8e8a-437d45cf6950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a118bb23-127f-4660-af99-2055322f4278" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fb4b11c9-3a9f-429d-8e8a-437d45cf6950" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a118bb23-127f-4660-af99-2055322f4278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_82659a04-454d-4747-8ffb-1fdcb389e54d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a118bb23-127f-4660-af99-2055322f4278" xlink:to="loc_us-gaap_StockOptionMember_82659a04-454d-4747-8ffb-1fdcb389e54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_21bc7718-c485-4027-b1bc-267e156c412b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:to="loc_us-gaap_StatementClassOfStockAxis_21bc7718-c485-4027-b1bc-267e156c412b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c399335e-c50e-4e5b-bd8d-335c510f234c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_21bc7718-c485-4027-b1bc-267e156c412b" xlink:to="loc_us-gaap_ClassOfStockDomain_c399335e-c50e-4e5b-bd8d-335c510f234c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_391492bd-b308-4410-ae17-41a6a0b16364" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:to="loc_srt_RangeAxis_391492bd-b308-4410-ae17-41a6a0b16364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_700399e9-31ea-4753-b061-11f2d21b8282" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_391492bd-b308-4410-ae17-41a6a0b16364" xlink:to="loc_srt_RangeMember_700399e9-31ea-4753-b061-11f2d21b8282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_fe751305-394d-44d9-befe-eaf789ecdb54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:to="loc_us-gaap_VestingAxis_fe751305-394d-44d9-befe-eaf789ecdb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_538de48f-89f6-4ec7-b161-f9fed5484b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_fe751305-394d-44d9-befe-eaf789ecdb54" xlink:to="loc_us-gaap_VestingDomain_538de48f-89f6-4ec7-b161-f9fed5484b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d1422f2-2c95-4221-99e2-3f57cbdbbaed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_6eabdbec-59e3-4b4d-af35-c1f438cc7b75" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_6eabdbec-59e3-4b4d-af35-c1f438cc7b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_2835259e-c5d4-4b06-866e-02e982e54466" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_2835259e-c5d4-4b06-866e-02e982e54466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_9535aa14-9ceb-4990-b5d4-ab7a065f285e" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_9535aa14-9ceb-4990-b5d4-ab7a065f285e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_8469108d-69cc-4c29-b5fb-899a1178f88e" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_8469108d-69cc-4c29-b5fb-899a1178f88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_b1cfc34f-a5ac-44ad-83df-c31d7a384a0c" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_b1cfc34f-a5ac-44ad-83df-c31d7a384a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_f821b82c-1da7-467e-98d6-711250cdc99a" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_f821b82c-1da7-467e-98d6-711250cdc99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_d57465c0-8f86-46e1-b096-7d492642f69b" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_d57465c0-8f86-46e1-b096-7d492642f69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_e0530e59-7a8b-46df-896f-fd123c8f2b76" xlink:href="lxrx-20210331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdd54738-9ad8-4887-96a8-aab0fa1453c5" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_e0530e59-7a8b-46df-896f-fd123c8f2b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_760489b7-b7c9-4d98-8c30-6db9c6a46512" xlink:href="lxrx-20210331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_760489b7-b7c9-4d98-8c30-6db9c6a46512" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b0cf02ea-f29d-4011-b7a9-b55227bc375e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:to="loc_us-gaap_PlanNameAxis_b0cf02ea-f29d-4011-b7a9-b55227bc375e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_966174ad-e772-4610-9bc8-32c4d255f128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b0cf02ea-f29d-4011-b7a9-b55227bc375e" xlink:to="loc_us-gaap_PlanNameDomain_966174ad-e772-4610-9bc8-32c4d255f128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_73944a52-b952-4f98-a6ae-1d4c9fb3e4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:to="loc_us-gaap_AwardDateAxis_73944a52-b952-4f98-a6ae-1d4c9fb3e4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_9661f383-80d5-451f-9fe8-19b27ec7fa6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_73944a52-b952-4f98-a6ae-1d4c9fb3e4c9" xlink:to="loc_us-gaap_AwardDateDomain_9661f383-80d5-451f-9fe8-19b27ec7fa6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_374183e4-3d9b-451c-a0e5-6e52d3b078f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:to="loc_us-gaap_AwardTypeAxis_374183e4-3d9b-451c-a0e5-6e52d3b078f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26f79ff4-9198-4d49-a2f6-37209403502c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_374183e4-3d9b-451c-a0e5-6e52d3b078f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26f79ff4-9198-4d49-a2f6-37209403502c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_83b98a5d-8a02-4f31-8ffb-0b91d063db84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26f79ff4-9198-4d49-a2f6-37209403502c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_83b98a5d-8a02-4f31-8ffb-0b91d063db84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b3b3c1df-aeeb-4c9d-8d0b-9c96160245af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26f79ff4-9198-4d49-a2f6-37209403502c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b3b3c1df-aeeb-4c9d-8d0b-9c96160245af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_45d2c1d9-71c6-40cc-adbc-8edbee7f02ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_45d2c1d9-71c6-40cc-adbc-8edbee7f02ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8c091b63-d638-4bfa-a032-a885d08039b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_45d2c1d9-71c6-40cc-adbc-8edbee7f02ea" xlink:to="loc_us-gaap_ClassOfStockDomain_8c091b63-d638-4bfa-a032-a885d08039b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_225893e5-839b-4665-9c2a-a47779678fec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:to="loc_srt_RangeAxis_225893e5-839b-4665-9c2a-a47779678fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5e205fb8-d3d5-49cf-87a1-90736854dc92" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_225893e5-839b-4665-9c2a-a47779678fec" xlink:to="loc_srt_RangeMember_5e205fb8-d3d5-49cf-87a1-90736854dc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_9a9fa1d2-cd5f-440d-8626-38d07f0ed964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:to="loc_us-gaap_VestingAxis_9a9fa1d2-cd5f-440d-8626-38d07f0ed964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_ca12aea5-afb2-4e60-a947-b9905f0b7fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_9a9fa1d2-cd5f-440d-8626-38d07f0ed964" xlink:to="loc_us-gaap_VestingDomain_ca12aea5-afb2-4e60-a947-b9905f0b7fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4494429e-0a2d-4667-9079-38b8f957390f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ea376a7e-d375-46c1-bfea-14ad78ad2bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ea376a7e-d375-46c1-bfea-14ad78ad2bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1fb29fc4-0fe6-4dff-9b4e-9a4f3440e1f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1fb29fc4-0fe6-4dff-9b4e-9a4f3440e1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1ae8784f-bb82-4470-9573-ff6a58402721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1ae8784f-bb82-4470-9573-ff6a58402721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ffe49759-4605-4bab-9fab-c84d3c094188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ffe49759-4605-4bab-9fab-c84d3c094188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_01d0fdac-d05b-4daa-95e7-cbb15321d78a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_01d0fdac-d05b-4daa-95e7-cbb15321d78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21aa852c-d9cf-406e-bc53-141c140b2f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21aa852c-d9cf-406e-bc53-141c140b2f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4aa4eb2c-4b7e-47db-9156-a7902d0819fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4aa4eb2c-4b7e-47db-9156-a7902d0819fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_03ae59c4-68c0-49ab-aac7-c123e866ce95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_03ae59c4-68c0-49ab-aac7-c123e866ce95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_36257ac1-b17b-4be2-ac1c-60e726370956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_36257ac1-b17b-4be2-ac1c-60e726370956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7398c51d-4da1-4fe3-8bff-71745dcf126e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7398c51d-4da1-4fe3-8bff-71745dcf126e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_25a5ecd5-638f-484c-94b4-7e244f162ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_25a5ecd5-638f-484c-94b4-7e244f162ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_371f7e57-744d-4201-854d-33345102f584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_371f7e57-744d-4201-854d-33345102f584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_55dc53a4-d3d1-4e3a-afd7-1cfff526b826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_55dc53a4-d3d1-4e3a-afd7-1cfff526b826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bf49a7d1-05da-41c2-bb4a-dfc7556ca0c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bf49a7d1-05da-41c2-bb4a-dfc7556ca0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eba82b1c-9773-40e0-aa3d-db12bbe903ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eba82b1c-9773-40e0-aa3d-db12bbe903ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_404129da-44f5-485e-94e0-84b2eecad199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_404129da-44f5-485e-94e0-84b2eecad199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_76472cdb-09c7-4340-890d-96216c493bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_76472cdb-09c7-4340-890d-96216c493bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_764e7fe3-2b47-4c5c-972a-924a64670125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_764e7fe3-2b47-4c5c-972a-924a64670125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d3d14f3f-96ee-4b9e-8367-d69782171627" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d3d14f3f-96ee-4b9e-8367-d69782171627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_96cd8bcd-afe5-4345-9aa2-35b98059f5e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d45af144-2b56-4473-8fe2-7e4a8aac7a8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_96cd8bcd-afe5-4345-9aa2-35b98059f5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_0a257333-4ec3-465f-be91-18ef5c7c53d8" xlink:href="lxrx-20210331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32457e1b-59b5-4df8-8151-fc1d063d0e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_0a257333-4ec3-465f-be91-18ef5c7c53d8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32457e1b-59b5-4df8-8151-fc1d063d0e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_47a63ea9-7114-452e-b7d2-cbb92f4d483c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32457e1b-59b5-4df8-8151-fc1d063d0e02" xlink:to="loc_us-gaap_PlanNameAxis_47a63ea9-7114-452e-b7d2-cbb92f4d483c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7ff0e5f6-8ffb-46ad-b2ed-ad05a61d4993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_47a63ea9-7114-452e-b7d2-cbb92f4d483c" xlink:to="loc_us-gaap_PlanNameDomain_7ff0e5f6-8ffb-46ad-b2ed-ad05a61d4993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4d7678ea-2a84-4f04-8b52-f572d96fd2a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32457e1b-59b5-4df8-8151-fc1d063d0e02" xlink:to="loc_us-gaap_AwardTypeAxis_4d7678ea-2a84-4f04-8b52-f572d96fd2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdc6da2b-60b9-488d-b319-e5aa9301d19d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4d7678ea-2a84-4f04-8b52-f572d96fd2a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdc6da2b-60b9-488d-b319-e5aa9301d19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ae50c4b2-3239-4142-82d3-519100d0ba5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32457e1b-59b5-4df8-8151-fc1d063d0e02" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ae50c4b2-3239-4142-82d3-519100d0ba5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2deff861-b85e-4bfe-b5d5-7f7b9df9e82d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ae50c4b2-3239-4142-82d3-519100d0ba5b" xlink:to="loc_us-gaap_ClassOfStockDomain_2deff861-b85e-4bfe-b5d5-7f7b9df9e82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4853fe37-65df-4f5f-a9da-de1464a8e452" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32457e1b-59b5-4df8-8151-fc1d063d0e02" xlink:to="loc_srt_RangeAxis_4853fe37-65df-4f5f-a9da-de1464a8e452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23233b25-0b94-45f5-abbb-c8298f1968ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4853fe37-65df-4f5f-a9da-de1464a8e452" xlink:to="loc_srt_RangeMember_23233b25-0b94-45f5-abbb-c8298f1968ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a924e78-1e82-4047-ac40-5286c7860512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32457e1b-59b5-4df8-8151-fc1d063d0e02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a924e78-1e82-4047-ac40-5286c7860512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fe939cf4-9692-461c-81f7-8e396b25cfdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesTable_ac3d7276-7e68-48fa-b937-bc590af57768" xlink:href="lxrx-20210331.xsd#lxrx_AccruedLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fe939cf4-9692-461c-81f7-8e396b25cfdd" xlink:to="loc_lxrx_AccruedLiabilitiesTable_ac3d7276-7e68-48fa-b937-bc590af57768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesAxis_9dcec159-e93b-46bb-9070-5c7c7faa4e99" xlink:href="lxrx-20210331.xsd#lxrx_AccruedLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesTable_ac3d7276-7e68-48fa-b937-bc590af57768" xlink:to="loc_lxrx_AccruedLiabilitiesAxis_9dcec159-e93b-46bb-9070-5c7c7faa4e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain_55bcde91-34d6-4a16-bf3a-f7f72fc4d798" xlink:href="lxrx-20210331.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesAxis_9dcec159-e93b-46bb-9070-5c7c7faa4e99" xlink:to="loc_lxrx_AccruedLiabilitiesDomain_55bcde91-34d6-4a16-bf3a-f7f72fc4d798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:href="lxrx-20210331.xsd#lxrx_AccruedLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesTable_ac3d7276-7e68-48fa-b937-bc590af57768" xlink:to="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_26c3011b-3932-4b9b-ae25-9ebdce85733a" xlink:href="lxrx-20210331.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:to="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_26c3011b-3932-4b9b-ae25-9ebdce85733a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent_983b7dec-dfe5-454a-b35e-31880ce91517" xlink:href="lxrx-20210331.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:to="loc_lxrx_AccruedCompensationAndBenefitsCurrent_983b7dec-dfe5-454a-b35e-31880ce91517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5f9334e-989f-466f-9ff9-b9e05be01db5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5f9334e-989f-466f-9ff9-b9e05be01db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bed64af8-a275-4a66-8188-08bd7fb2846d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bed64af8-a275-4a66-8188-08bd7fb2846d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2c209c11-2efd-4530-9f4b-0b20be47ec93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2c209c11-2efd-4530-9f4b-0b20be47ec93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconIncrementalBorrowingRate_46bc9114-a649-48bf-accb-db4c2c50063e" xlink:href="lxrx-20210331.xsd#lxrx_LexiconIncrementalBorrowingRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_ced369a0-763b-43a4-84f9-25ecf567b680" xlink:to="loc_lxrx_LexiconIncrementalBorrowingRate_46bc9114-a649-48bf-accb-db4c2c50063e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e71b9da5-44e0-454f-b98b-b81d4af8d31f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_05581532-0614-4c28-947d-68038c3c9dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e71b9da5-44e0-454f-b98b-b81d4af8d31f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_05581532-0614-4c28-947d-68038c3c9dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b3268a38-a7fa-4d3b-aa88-b91557843ba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e71b9da5-44e0-454f-b98b-b81d4af8d31f" xlink:to="loc_us-gaap_AssetImpairmentCharges_b3268a38-a7fa-4d3b-aa88-b91557843ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="simple" xlink:href="lxrx-20210331.xsd#RecentAccountingPronouncementsLevel1Notes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_ba3dca82-f8d8-4df8-ae99-15234ea02850" xlink:href="lxrx-20210331.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d38afdcf-88f8-409f-abc6-10b79adec7bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_ba3dca82-f8d8-4df8-ae99-15234ea02850" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d38afdcf-88f8-409f-abc6-10b79adec7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CashandCashEquivalentsandInvestments"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_1a968c25-f05d-4925-9592-e9199d4b78a8" xlink:href="lxrx-20210331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_b1c8f88d-ac85-497f-bc0c-013d764ee6fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_1a968c25-f05d-4925-9592-e9199d4b78a8" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_b1c8f88d-ac85-497f-bc0c-013d764ee6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_ad7a3526-954a-4dac-9a5b-c86227cc6667" xlink:href="lxrx-20210331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_e0ced0ec-0095-404b-a9bb-29577fac5968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_ad7a3526-954a-4dac-9a5b-c86227cc6667" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_e0ced0ec-0095-404b-a9bb-29577fac5968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CashandCashEquivalentsandInvestmentsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_7ae6864a-ebbd-469d-8057-97433b3a6cd7" xlink:href="lxrx-20210331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_fb4c15a4-c1f4-428d-93ed-b59f6a763d2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_7ae6864a-ebbd-469d-8057-97433b3a6cd7" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_fb4c15a4-c1f4-428d-93ed-b59f6a763d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_19943ef0-052d-4bef-aba9-af6f815ce6fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_fb4c15a4-c1f4-428d-93ed-b59f6a763d2b" xlink:to="loc_us-gaap_InvestmentTypeAxis_19943ef0-052d-4bef-aba9-af6f815ce6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0cd6a580-dc02-419d-b52f-7bf026500d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_19943ef0-052d-4bef-aba9-af6f815ce6fe" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0cd6a580-dc02-419d-b52f-7bf026500d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_ad35c913-64c4-4ddf-844a-9c4117af2783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0cd6a580-dc02-419d-b52f-7bf026500d3f" xlink:to="loc_us-gaap_CashMember_ad35c913-64c4-4ddf-844a-9c4117af2783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_73867372-3a86-43b4-b978-900142d0011c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0cd6a580-dc02-419d-b52f-7bf026500d3f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_73867372-3a86-43b4-b978-900142d0011c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_8d253773-1024-4ede-9551-40b353125ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0cd6a580-dc02-419d-b52f-7bf026500d3f" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_8d253773-1024-4ede-9551-40b353125ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_8480b439-bd1f-4a32-ac35-15023274b7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0cd6a580-dc02-419d-b52f-7bf026500d3f" xlink:to="loc_us-gaap_InvestmentsMember_8480b439-bd1f-4a32-ac35-15023274b7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_23ceccc5-6068-47c6-8541-9621f53ab98e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0cd6a580-dc02-419d-b52f-7bf026500d3f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_23ceccc5-6068-47c6-8541-9621f53ab98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_876b8a30-32da-43b9-bb87-c1b38d1484df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_fb4c15a4-c1f4-428d-93ed-b59f6a763d2b" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_876b8a30-32da-43b9-bb87-c1b38d1484df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2aa5233b-1a3a-4b81-9ba9-aeff34e6a4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_876b8a30-32da-43b9-bb87-c1b38d1484df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2aa5233b-1a3a-4b81-9ba9-aeff34e6a4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5326e0a3-a9e2-473d-aebd-280ad56a2afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_876b8a30-32da-43b9-bb87-c1b38d1484df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5326e0a3-a9e2-473d-aebd-280ad56a2afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d4d28202-6e56-433d-a093-1fdfa5970438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_876b8a30-32da-43b9-bb87-c1b38d1484df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d4d28202-6e56-433d-a093-1fdfa5970438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_2f374559-c81a-4a94-81d4-4c5705e20d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_876b8a30-32da-43b9-bb87-c1b38d1484df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_2f374559-c81a-4a94-81d4-4c5705e20d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CashandCashEquivalentsandInvestmentsDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_b985ebeb-9f11-46ec-b215-12d858634762" xlink:href="lxrx-20210331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_c485c461-e251-49bf-bee9-aa5bae66d9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_b985ebeb-9f11-46ec-b215-12d858634762" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_c485c461-e251-49bf-bee9-aa5bae66d9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis_dbeea99e-988f-4e7f-8a56-3776dffff059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_c485c461-e251-49bf-bee9-aa5bae66d9b7" xlink:to="loc_us-gaap_TradingActivityByTypeAxis_dbeea99e-988f-4e7f-8a56-3776dffff059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_f31e4688-2056-46e6-a67e-551e7175e2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_dbeea99e-988f-4e7f-8a56-3776dffff059" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_f31e4688-2056-46e6-a67e-551e7175e2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_ad07f56e-8793-44de-8e2b-d30b2c1634b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_c485c461-e251-49bf-bee9-aa5bae66d9b7" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_ad07f56e-8793-44de-8e2b-d30b2c1634b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_72e44cf9-2760-436e-a0f3-20c63083a16b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_ad07f56e-8793-44de-8e2b-d30b2c1634b8" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_72e44cf9-2760-436e-a0f3-20c63083a16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20210331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_7d486431-ff86-4691-b096-521d49aeb0a7" xlink:href="lxrx-20210331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_6fd7805c-545b-4641-a947-9dc910734e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_7d486431-ff86-4691-b096-521d49aeb0a7" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_6fd7805c-545b-4641-a947-9dc910734e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20210331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_d798123c-048f-4100-9c6f-ad0b227d4f58" xlink:href="lxrx-20210331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_ef896bfe-b215-42f3-93d3-f66bc199e15d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_d798123c-048f-4100-9c6f-ad0b227d4f58" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_ef896bfe-b215-42f3-93d3-f66bc199e15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20210331.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_d12397fd-177d-40c4-a5b7-f9edacb21699" xlink:href="lxrx-20210331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e405792d-4812-4520-bdc4-530e4a71977e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_d12397fd-177d-40c4-a5b7-f9edacb21699" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e405792d-4812-4520-bdc4-530e4a71977e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cd11685d-7178-484e-8968-ba77ecbdad66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e405792d-4812-4520-bdc4-530e4a71977e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cd11685d-7178-484e-8968-ba77ecbdad66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289c69ba-fae0-49fd-b62c-cca8f262c66f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cd11685d-7178-484e-8968-ba77ecbdad66" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289c69ba-fae0-49fd-b62c-cca8f262c66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1e9d3460-c958-425d-a96b-98b06197a07a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289c69ba-fae0-49fd-b62c-cca8f262c66f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1e9d3460-c958-425d-a96b-98b06197a07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7b455942-e4ac-483b-b831-cc12f374f819" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289c69ba-fae0-49fd-b62c-cca8f262c66f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7b455942-e4ac-483b-b831-cc12f374f819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fae430f5-350c-4ee1-b418-19fb6a880112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_289c69ba-fae0-49fd-b62c-cca8f262c66f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fae430f5-350c-4ee1-b418-19fb6a880112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e1629771-04ec-42da-82d5-c6d848837be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e405792d-4812-4520-bdc4-530e4a71977e" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e1629771-04ec-42da-82d5-c6d848837be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2c797b11-232c-42ae-ab47-6e5b170cab44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e1629771-04ec-42da-82d5-c6d848837be3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2c797b11-232c-42ae-ab47-6e5b170cab44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_ab4dab0e-7c81-4cb2-95a2-dc89a0299394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e1629771-04ec-42da-82d5-c6d848837be3" xlink:to="loc_us-gaap_AvailableForSaleSecurities_ab4dab0e-7c81-4cb2-95a2-dc89a0299394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_519078d9-2655-4cdb-b6b6-575888af7758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e1629771-04ec-42da-82d5-c6d848837be3" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_519078d9-2655-4cdb-b6b6-575888af7758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20210331.xsd#DebtObligations"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_e9b5cd98-58f7-49c3-ae4a-038f4f3ea705" xlink:href="lxrx-20210331.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_68df47f8-ff75-42ca-8139-c84ea2b9455f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_e9b5cd98-58f7-49c3-ae4a-038f4f3ea705" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_68df47f8-ff75-42ca-8139-c84ea2b9455f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20210331.xsd#DebtObligationsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#DebtObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_be47a281-efb6-479d-b299-6fd4d6a428fa" xlink:href="lxrx-20210331.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a39aef52-0fa7-40b4-a2f4-ef3e7cfe967b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_be47a281-efb6-479d-b299-6fd4d6a428fa" xlink:to="loc_us-gaap_DebtInstrumentTable_a39aef52-0fa7-40b4-a2f4-ef3e7cfe967b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c7a0fa0a-296f-4f98-8bc8-5aac575d91b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a39aef52-0fa7-40b4-a2f4-ef3e7cfe967b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c7a0fa0a-296f-4f98-8bc8-5aac575d91b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d02283cc-73e4-4ac2-8596-60d228701418" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c7a0fa0a-296f-4f98-8bc8-5aac575d91b3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d02283cc-73e4-4ac2-8596-60d228701418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4b200aeb-e77e-4b31-9ea7-68fd966606b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d02283cc-73e4-4ac2-8596-60d228701418" xlink:to="loc_us-gaap_SubsequentEventMember_4b200aeb-e77e-4b31-9ea7-68fd966606b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b49466a1-0586-4d69-8cf1-df1bdc39f305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a39aef52-0fa7-40b4-a2f4-ef3e7cfe967b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b49466a1-0586-4d69-8cf1-df1bdc39f305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a8bcf168-4d43-46e0-880b-2bfd9db5d748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b49466a1-0586-4d69-8cf1-df1bdc39f305" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a8bcf168-4d43-46e0-880b-2bfd9db5d748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4498a1de-1e00-46f3-a110-9aeeccb53d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a39aef52-0fa7-40b4-a2f4-ef3e7cfe967b" xlink:to="loc_us-gaap_DebtInstrumentAxis_4498a1de-1e00-46f3-a110-9aeeccb53d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f308e327-4ccf-4761-8ca0-cbeec9d77038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4498a1de-1e00-46f3-a110-9aeeccb53d99" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f308e327-4ccf-4761-8ca0-cbeec9d77038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a39aef52-0fa7-40b4-a2f4-ef3e7cfe967b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_81798fb3-df55-496a-8006-3c80f275df7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_81798fb3-df55-496a-8006-3c80f275df7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_afbf7d2f-53b6-4dcb-8d25-1589da229400" xlink:href="lxrx-20210331.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_afbf7d2f-53b6-4dcb-8d25-1589da229400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_adde6b66-0722-468f-a0a5-c98a347bc735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_adde6b66-0722-468f-a0a5-c98a347bc735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_6bc335e5-17cd-4780-9338-d45697fdb814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_6bc335e5-17cd-4780-9338-d45697fdb814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6787f82f-f85f-4d1f-baf2-2fb2e941a5d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6787f82f-f85f-4d1f-baf2-2fb2e941a5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_729f991c-1642-4c65-bae3-338636293199" xlink:href="lxrx-20210331.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_729f991c-1642-4c65-bae3-338636293199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_1509d17c-d57b-46d7-9759-6d694f3dd219" xlink:href="lxrx-20210331.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_1509d17c-d57b-46d7-9759-6d694f3dd219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_15648968-339f-4ca9-8270-7dc03e5e7795" xlink:href="lxrx-20210331.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_15648968-339f-4ca9-8270-7dc03e5e7795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX_93d3ab34-0643-4bfe-80d3-b8e752d9e956" xlink:href="lxrx-20210331.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_MortgageDebtBalloonPayment_LXRX_93d3ab34-0643-4bfe-80d3-b8e752d9e956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6e2630db-acee-478c-960a-e62d594f513e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_us-gaap_CommonStockSharesIssued_6e2630db-acee-478c-960a-e62d594f513e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange_452e8c3e-33d8-4f32-8f29-ab277da4d212" xlink:href="lxrx-20210331.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_ConvertibleDebtExchange_452e8c3e-33d8-4f32-8f29-ab277da4d212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedInterestOnConvertible_afa666f0-1a3e-429a-83eb-f281acf8609e" xlink:href="lxrx-20210331.xsd#lxrx_AccruedInterestOnConvertible"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_AccruedInterestOnConvertible_afa666f0-1a3e-429a-83eb-f281acf8609e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_486be3e4-7788-4fad-9ef9-947831d0472b" xlink:href="lxrx-20210331.xsd#lxrx_ConvertibleDebtExchangeRemainingNotes"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_486be3e4-7788-4fad-9ef9-947831d0472b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchangeShares_baca2651-2eab-407b-a28f-f6805ec67bde" xlink:href="lxrx-20210331.xsd#lxrx_FutureConvertibleDebtExchangeShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_FutureConvertibleDebtExchangeShares_baca2651-2eab-407b-a28f-f6805ec67bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchange_90f94fa3-c268-453c-833c-21fb7d604865" xlink:href="lxrx-20210331.xsd#lxrx_FutureConvertibleDebtExchange"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_FutureConvertibleDebtExchange_90f94fa3-c268-453c-833c-21fb7d604865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes_605b73cf-e39c-4e87-b5ae-1a0ff9eb688e" xlink:href="lxrx-20210331.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_PrincipalAmountOfConvertibleNotes_605b73cf-e39c-4e87-b5ae-1a0ff9eb688e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_a68ffedb-edfe-42b5-969a-5671f7ce0fb5" xlink:href="lxrx-20210331.xsd#lxrx_ConvertibleDebtExchangeTotalPrincipalAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_a68ffedb-edfe-42b5-969a-5671f7ce0fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_1194d957-2260-49b9-a594-c689f763088e" xlink:href="lxrx-20210331.xsd#lxrx_ConvertibleDebtExchangeSeptemberCashPortion"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_1194d957-2260-49b9-a594-c689f763088e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_00b078da-c520-4efc-af96-f23797ce474d" xlink:href="lxrx-20210331.xsd#lxrx_ConvertibleDebtExchangeSeptemberSharePayment"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_768aa5d7-4136-4120-8e71-7d6097ad878c" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_00b078da-c520-4efc-af96-f23797ce474d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d0762a29-a5e3-4d1b-84fe-831ce1cd5c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0416fdb3-6298-47bc-8249-6d7d2e5d7315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d0762a29-a5e3-4d1b-84fe-831ce1cd5c53" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0416fdb3-6298-47bc-8249-6d7d2e5d7315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a34d977-e0ac-4956-b75d-630a7e15c8e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_d0cc948d-0d71-4b3f-aa4e-bcd48ccd0e3f" xlink:href="lxrx-20210331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a34d977-e0ac-4956-b75d-630a7e15c8e9" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_d0cc948d-0d71-4b3f-aa4e-bcd48ccd0e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_3c8d9c97-ec5e-48cc-a537-81a48b41fb1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a34d977-e0ac-4956-b75d-630a7e15c8e9" xlink:to="loc_us-gaap_OtherCommitmentsTable_3c8d9c97-ec5e-48cc-a537-81a48b41fb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_41e518db-a5d0-460b-a974-95e6dc15ab28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_3c8d9c97-ec5e-48cc-a537-81a48b41fb1c" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_41e518db-a5d0-460b-a974-95e6dc15ab28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_a39123b1-9de3-44bf-848f-569562b7afb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_41e518db-a5d0-460b-a974-95e6dc15ab28" xlink:to="loc_us-gaap_ReceivableTypeDomain_a39123b1-9de3-44bf-848f-569562b7afb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_0b285b3c-9f64-42d7-a639-31ebd964f618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_a39123b1-9de3-44bf-848f-569562b7afb6" xlink:to="loc_us-gaap_AccountsReceivableMember_0b285b3c-9f64-42d7-a639-31ebd964f618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_3c8d9c97-ec5e-48cc-a537-81a48b41fb1c" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_0103923d-ba46-420c-ae18-c2197c28ccec" xlink:href="lxrx-20210331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_0103923d-ba46-420c-ae18-c2197c28ccec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c1a80622-b85e-46e6-aa7a-c6b310d6eecc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c1a80622-b85e-46e6-aa7a-c6b310d6eecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c3ef5032-6e4e-4d17-b371-7f30bc25963d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c3ef5032-6e4e-4d17-b371-7f30bc25963d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c5e363a5-764e-47d1-8fe3-746291b2faf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c5e363a5-764e-47d1-8fe3-746291b2faf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a56fd38e-a789-446a-80d4-50695233c250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a56fd38e-a789-446a-80d4-50695233c250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_41f74d13-3c67-4d94-94b9-034b6c35304b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_41f74d13-3c67-4d94-94b9-034b6c35304b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_15bcb853-2ef9-4af4-b087-3a351fd78db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_15bcb853-2ef9-4af4-b087-3a351fd78db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b09aa16b-bd26-42e2-aaca-ec43dee9ceea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b09aa16b-bd26-42e2-aaca-ec43dee9ceea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e11dff40-badc-446e-9eaa-ab464738862f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e11dff40-badc-446e-9eaa-ab464738862f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_65027e72-59ed-46aa-8d35-0b4ed6f5dd97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_OperatingLeaseLiability_65027e72-59ed-46aa-8d35-0b4ed6f5dd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount_65d87f2f-2f2b-4544-a249-8caa520a63cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_ShortTermLeaseCommitmentAmount_65d87f2f-2f2b-4544-a249-8caa520a63cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_84f55920-fab6-4be8-b159-a6b58ab746b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_84f55920-fab6-4be8-b159-a6b58ab746b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDisputedCosts_dab81d4e-1e1d-48aa-8b5a-6057b799328b" xlink:href="lxrx-20210331.xsd#lxrx_SanofiDisputedCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_376b5175-aa4e-40d5-b3c0-02a2c1d75149" xlink:to="loc_lxrx_SanofiDisputedCosts_dab81d4e-1e1d-48aa-8b5a-6057b799328b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_37b26814-37b3-4dc0-bcec-2ed961dba133" xlink:href="lxrx-20210331.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_45c56225-81b5-49e0-80f3-448851ce51a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_37b26814-37b3-4dc0-bcec-2ed961dba133" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_45c56225-81b5-49e0-80f3-448851ce51a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1291fc92-c2b4-4724-a618-080c5170224d" xlink:href="lxrx-20210331.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_d9d9ba77-5b95-4534-916e-f858d91cab60" xlink:href="lxrx-20210331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1291fc92-c2b4-4724-a618-080c5170224d" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_d9d9ba77-5b95-4534-916e-f858d91cab60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized_2b0119ac-ecac-4523-90be-8404137e4d62" xlink:href="lxrx-20210331.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1291fc92-c2b4-4724-a618-080c5170224d" xlink:to="loc_lxrx_SanofiRevenueRecognized_2b0119ac-ecac-4523-90be-8404137e4d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPayments_422c9230-1f04-4722-8090-474d089168b6" xlink:href="lxrx-20210331.xsd#lxrx_IpsenTotalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1291fc92-c2b4-4724-a618-080c5170224d" xlink:to="loc_lxrx_IpsenTotalPayments_422c9230-1f04-4722-8090-474d089168b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones_e00f6131-c2ce-41a5-9d49-09093c37547f" xlink:href="lxrx-20210331.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1291fc92-c2b4-4724-a618-080c5170224d" xlink:to="loc_lxrx_IpsenMaximumSalesMilestones_e00f6131-c2ce-41a5-9d49-09093c37547f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePayment_f4ee5f50-fee0-477c-a985-7ebc8365385a" xlink:href="lxrx-20210331.xsd#lxrx_IpsenMilestonePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1291fc92-c2b4-4724-a618-080c5170224d" xlink:to="loc_lxrx_IpsenMilestonePayment_f4ee5f50-fee0-477c-a985-7ebc8365385a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived_0ea8e72f-2567-414c-bea1-38d531b86a0c" xlink:href="lxrx-20210331.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1291fc92-c2b4-4724-a618-080c5170224d" xlink:to="loc_lxrx_IpsenMilestonePaymentReceived_0ea8e72f-2567-414c-bea1-38d531b86a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_3aeab7a5-9bd4-4777-838a-8b21f811b491" xlink:href="lxrx-20210331.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1291fc92-c2b4-4724-a618-080c5170224d" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_3aeab7a5-9bd4-4777-838a-8b21f811b491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized_68cf54c0-5f02-47af-935a-e83224ec7aee" xlink:href="lxrx-20210331.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1291fc92-c2b4-4724-a618-080c5170224d" xlink:to="loc_lxrx_IpsenRevenueRecognized_68cf54c0-5f02-47af-935a-e83224ec7aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_sanofiInitialCashPayment_7caee15a-f99d-4d17-9ebd-5533c8d5799b" xlink:href="lxrx-20210331.xsd#lxrx_Lxrx_sanofiInitialCashPayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1291fc92-c2b4-4724-a618-080c5170224d" xlink:to="loc_lxrx_Lxrx_sanofiInitialCashPayment_7caee15a-f99d-4d17-9ebd-5533c8d5799b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination_a2a3a80c-f3df-407b-aebb-b5f56ea4b6c0" xlink:href="lxrx-20210331.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1291fc92-c2b4-4724-a618-080c5170224d" xlink:to="loc_lxrx_SettlementPaymentFromTermination_a2a3a80c-f3df-407b-aebb-b5f56ea4b6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="simple" xlink:href="lxrx-20210331.xsd#OtherCapitalAgreements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f83baf41-c513-4157-a3ab-f17c82fabca5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock_c02c8ccb-1560-4c2f-94a1-5a8a8e90d785" xlink:href="lxrx-20210331.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f83baf41-c513-4157-a3ab-f17c82fabca5" xlink:to="loc_lxrx_OtherCapitalAgreementsTextBlock_c02c8ccb-1560-4c2f-94a1-5a8a8e90d785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20210331.xsd#OtherCapitalAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a5c09e61-3507-4e71-8dbe-7f46b1926f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal_f4d1c8e8-63de-47ce-b0ed-8cf3bb7162ce" xlink:href="lxrx-20210331.xsd#lxrx_ATMOfferingTotal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a5c09e61-3507-4e71-8dbe-7f46b1926f58" xlink:to="loc_lxrx_ATMOfferingTotal_f4d1c8e8-63de-47ce-b0ed-8cf3bb7162ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInNov2020ATMOffering_7a07ec8e-0310-4949-912a-eba8298d7a01" xlink:href="lxrx-20210331.xsd#lxrx_SharesSoldInNov2020ATMOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a5c09e61-3507-4e71-8dbe-7f46b1926f58" xlink:to="loc_lxrx_SharesSoldInNov2020ATMOffering_7a07ec8e-0310-4949-912a-eba8298d7a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering_eb0705a8-ed9a-42e1-9d5a-3ef541243aa0" xlink:href="lxrx-20210331.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a5c09e61-3507-4e71-8dbe-7f46b1926f58" xlink:to="loc_lxrx_SharePriceInNovember20ATMOffering_eb0705a8-ed9a-42e1-9d5a-3ef541243aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering_4ded0fe6-37bb-4df0-bd22-0646ecdf4dfe" xlink:href="lxrx-20210331.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a5c09e61-3507-4e71-8dbe-7f46b1926f58" xlink:to="loc_lxrx_ProceedsFromNov2020ATMOffering_4ded0fe6-37bb-4df0-bd22-0646ecdf4dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering_4c02c4f4-06ec-47bd-875d-6a9cd655cbf3" xlink:href="lxrx-20210331.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a5c09e61-3507-4e71-8dbe-7f46b1926f58" xlink:to="loc_lxrx_SharesSoldInJanuary2021ATMOffering_4c02c4f4-06ec-47bd-875d-6a9cd655cbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJanuary2021ATMOffering_2eb32520-0263-4d5d-80cc-d475a73d1325" xlink:href="lxrx-20210331.xsd#lxrx_SharePriceInJanuary2021ATMOffering"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a5c09e61-3507-4e71-8dbe-7f46b1926f58" xlink:to="loc_lxrx_SharePriceInJanuary2021ATMOffering_2eb32520-0263-4d5d-80cc-d475a73d1325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering_ca24e1c7-e633-4550-8793-89306f899d64" xlink:href="lxrx-20210331.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a5c09e61-3507-4e71-8dbe-7f46b1926f58" xlink:to="loc_lxrx_ProceedsFromJanuary2021ATMOffering_ca24e1c7-e633-4550-8793-89306f899d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>lxrx-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lxrx="http://www.lexpharma.com/20210331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lxrx-20210331.xsd" xlink:type="simple"/>
    <context id="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3242745ce2a44d3f9f9445dc84df1632_I20210504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2dca67dbb6624abeb8141b5923482d81_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i50ee913592ef4520b5d81d6e189446e8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8fdc7cf67e874d559ff410b0ab012041_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3e58e312dc3047689801cba0f72629d5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5f0724b0fae84864825b9dc62f678c5b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a606756c32f497285a9518996aac3b4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7d3a9feed1574e7ab2f1969416fef122_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie90037db436a4b29a12d6bbac4f4cca8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i375cc32ca2c34f1e9336833c1ed0ea7f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i078b6b9a2fc943a09745dbb2ce3a271f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i80bed1b60e694ddf8bec5653c1a55108_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia36b6c47696646d39cb6d3753f25f8fc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2d2a1d2958c44883b7cb551a566117ba_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i071c8ec8b6154a1e922ede9df8277cc5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6becb50947fe41d7a703d27c05c60d23_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9bb8568447be4c9fbfc10b295ff7b33a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if27faa5c3eef4da8a2be4870c962c535_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i24e6c722889a4e529025d61dbe7edbca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42dd529b05c74e7cb35485cf486d3ef7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie1cdf94e04d943c08450a611bfc2b63f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa953ef8800f442aa472c4b20bef4764_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic60d7c15b6e143cdb8e7f57bad14a09a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04674a820fd84a47af510792ed23d319_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8da06dd15088483d9ddeaea504d86cd7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1df52d1685b845e99310b7cf678d9bc1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i191cef183ce042d78110d9e5f705083b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i75076d7889ad4eb8b803991721300015_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie96e698d44f741e8b15ba8a973f9aaaa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5e98480c8ab24073a57917c703b340ca_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7f7ed8cd8f7b42aeb8bcb7b11be2be35_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9b5277bb1cee46b0a0e275f43ab30ecd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i05e826ffe0344bbbb51ccbc13eaa4d00_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i146253cab0294e3eae00a7148487429e_I20210301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="icef415129a23469b9ec147c98cb56572_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7680cb4d42ed478997941e9bf13624ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c017c3c99f6498daff3ecf3edf83a48_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia6aa61cc7aaf43e6bbc474b8505cc3d4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i05f812c6327541b6b09fdc249c90d7f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5f92e864c7242d5879f8636e1617415_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4c83f6001ecc4b738df4e9c1c3f4412f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5f6b3dae24ed4be1a4420f2bc0f76d2f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0c1c834ecce44f16b35b81cf92f8af4c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i291ed1f6abf04110bd6f3f96dfaf9687_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4f3856fc70db4f0eb8819a27978a3fb5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i25913c0c6d894c7284fdf1a62f452c6a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i128725cdccf34310af9e7048fc57e23a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iafe798e7d357475783018b7f99e88eef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idce92942910c43e4903e00d0f785c79f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i538c6f098f45484a9093e4c6f76257da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f07d12ec62145c8975b2c25813bcab8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie788a1a6bb1842ee842bbab7098f63f2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id00ac6a719fe4e628278d8c2ce3383db_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i01fc13da04a74ba9a24a1954fe5e09d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4e16817a1f8b455fa37d4b4d3496642d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia420366f6ef2477b888780f5aa7343c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2fc5a7556d44214b71b2e8a010774b2_D20141101-20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="icb9c8c0f84be4d2bb3ae691e86ab0e8b_I20141120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2014-11-20</instant>
        </period>
    </context>
    <context id="i1e1514570bdc407c8e2a1b9524eab9cc_I20200928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-09-28</instant>
        </period>
    </context>
    <context id="i683e05dc441240d9a2492d0fd1aa4361_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i75c9ca72d87c4541bcbf8632f671f7ae_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id0d9a71689364f11b5b23e80ebdf0b0e_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i404c6b80bc36405880a95d223586358a_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2747cad63b6941889a2232ada4034c1e_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0953aa39e2f84e829c3acc2d7f88a6a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9cf39493d3443c4a790590a54c215b8_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80L2ZyYWc6NzM2MzM2NDE4MzZhNGE4NTkzNGViNDA3YjE4ZDhmMjMvdGFibGU6ODI2Zjg2ZGQzOWFiNGVhYzg5Mzg1MGQwYTdmZWVjNzIvdGFibGVyYW5nZTo4MjZmODZkZDM5YWI0ZWFjODkzODUwZDBhN2ZlZWM3Ml81LTQtMS0xLTA_923330d7-ac62-4c93-bd24-3f9a44fc5eeb">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80L2ZyYWc6NzM2MzM2NDE4MzZhNGE4NTkzNGViNDA3YjE4ZDhmMjMvdGFibGU6ODI2Zjg2ZGQzOWFiNGVhYzg5Mzg1MGQwYTdmZWVjNzIvdGFibGVyYW5nZTo4MjZmODZkZDM5YWI0ZWFjODkzODUwZDBhN2ZlZWM3Ml85LTQtMS0xLTA_a15f740d-6d35-422d-8c43-f949e5475742">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80L2ZyYWc6NzM2MzM2NDE4MzZhNGE4NTkzNGViNDA3YjE4ZDhmMjMvdGFibGU6ODI2Zjg2ZGQzOWFiNGVhYzg5Mzg1MGQwYTdmZWVjNzIvdGFibGVyYW5nZTo4MjZmODZkZDM5YWI0ZWFjODkzODUwZDBhN2ZlZWM3Ml8xMC00LTEtMS0w_69b4247d-3684-43d6-8615-452801e8eed6">2021</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80L2ZyYWc6NzM2MzM2NDE4MzZhNGE4NTkzNGViNDA3YjE4ZDhmMjMvdGFibGU6ODI2Zjg2ZGQzOWFiNGVhYzg5Mzg1MGQwYTdmZWVjNzIvdGFibGVyYW5nZTo4MjZmODZkZDM5YWI0ZWFjODkzODUwZDBhN2ZlZWM3Ml8xMS00LTEtMS0w_ce16ed66-6d19-4d79-80a7-70d84d7dfb74">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80L2ZyYWc6NzM2MzM2NDE4MzZhNGE4NTkzNGViNDA3YjE4ZDhmMjMvdGFibGU6ODI2Zjg2ZGQzOWFiNGVhYzg5Mzg1MGQwYTdmZWVjNzIvdGFibGVyYW5nZTo4MjZmODZkZDM5YWI0ZWFjODkzODUwZDBhN2ZlZWM3Ml8xNC00LTEtMS0w_cd7d56f8-5a85-403b-9146-190c708a36e8">0001062822</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF84Mg_4bae2902-df9e-4bbd-8e14-85e91870a1c6">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6NDJiYTUyOGZiZmY1NDExMWIxMDdhMzkzZTY4NDRjZTUvdGFibGVyYW5nZTo0MmJhNTI4ZmJmZjU0MTExYjEwN2EzOTNlNjg0NGNlNV8wLTAtMS0xLTA_4adab47c-8a1e-4a0e-a2c5-664bfe934051">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8xNjk_50c4b3c6-3c5c-4c6f-ba55-52d085a5289f">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6NTAxYjJiYTNlNDE5NDNmYWFjMzViM2YzODFlMmZhMjQvdGFibGVyYW5nZTo1MDFiMmJhM2U0MTk0M2ZhYWMzNWIzZjM4MWUyZmEyNF8wLTAtMS0xLTA_eb65dec4-1c9c-4c8d-ae95-07bcba855d92">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8yNjU_a229aa0a-dc04-43b9-a6db-bf617cae4c23">000-30111</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8yNjg_b63efd61-a380-4717-9e7c-1f213cdf7f98">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6N2YwNmEwNDYzMDhkNDUxMWI5ZDRhOWY3YzViMDIzZWMvdGFibGVyYW5nZTo3ZjA2YTA0NjMwOGQ0NTExYjlkNGE5ZjdjNWIwMjNlY18wLTAtMS0xLTA_6a361704-c5c5-4bbc-802e-1962f2d4011a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6N2YwNmEwNDYzMDhkNDUxMWI5ZDRhOWY3YzViMDIzZWMvdGFibGVyYW5nZTo3ZjA2YTA0NjMwOGQ0NTExYjlkNGE5ZjdjNWIwMjNlY18wLTEtMS0xLTA_877fd0f4-1a5b-4cd4-84f1-f79798d0ab7d">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8zMjg_d3aff391-8d67-41d3-b670-8f4923142808">8800 Technology Forest Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8zMzE_9b48c604-0e5d-43db-b858-408e9588ef88">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8zMzU_4dc0b39b-7b3e-43b9-8ed7-6bfd3ceae015">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8zMzg_44269fa5-5769-43ea-8476-2be2ea3fa2eb">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8zOTY_e0151a89-a4ce-4689-8314-15cbd462c451">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF80MDA_baf1b776-db8a-4539-b3c5-1836ddca4fe8">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6OWUxNzljOGI0OGVhNDZmN2ExYWRmMDM0YThhY2E5YjkvdGFibGVyYW5nZTo5ZTE3OWM4YjQ4ZWE0NmY3YTFhZGYwMzRhOGFjYTliOV8xLTAtMS0xLTA_9879a8ac-92c3-417f-b1d1-b878b3d57c4a">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6OWUxNzljOGI0OGVhNDZmN2ExYWRmMDM0YThhY2E5YjkvdGFibGVyYW5nZTo5ZTE3OWM4YjQ4ZWE0NmY3YTFhZGYwMzRhOGFjYTliOV8xLTEtMS0xLTA_2f8d1bea-bff6-4ad0-b3be-4a9673aec282">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6OWUxNzljOGI0OGVhNDZmN2ExYWRmMDM0YThhY2E5YjkvdGFibGVyYW5nZTo5ZTE3OWM4YjQ4ZWE0NmY3YTFhZGYwMzRhOGFjYTliOV8xLTItMS0xLTA_573ddee1-fa41-45a9-b09f-2f7291cbd7c6">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6MzcwYWY2ZmE3YTQyNDA0NTk2OTgwMDYwZGI0NTU2YTYvdGFibGVyYW5nZTozNzBhZjZmYTdhNDI0MDQ1OTY5ODAwNjBkYjQ1NTZhNl8wLTAtMS0xLTA_71db5b12-3489-499f-b0f9-8a2dd0d659e3">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6MDg1NTk2YmFjMmFhNDZkNTllMDhkM2NjYjFiNjZhYjUvdGFibGVyYW5nZTowODU1OTZiYWMyYWE0NmQ1OWUwOGQzY2NiMWI2NmFiNV8wLTAtMS0xLTA_93cadab2-c912-4b0c-a2e9-5b513bd26817">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8xNTY1_c53f3374-b8ab-4153-979a-76b7ac41fe8c">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8yMTY4_c955e644-5a68-4261-8f4e-e9fb11eab0f6">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8xNjg0_5754cfd2-c5e4-4c61-b604-06d2d87a3c76">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGFibGU6MTYzMTkwMjMwMWJlNDg2MzlkNTQ2OTYxN2FjZGMzYzQvdGFibGVyYW5nZToxNjMxOTAyMzAxYmU0ODYzOWQ1NDY5NjE3YWNkYzNjNF8wLTEtMS0xLTA_5c7de822-17af-40d5-894e-e1fae5746150">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i3242745ce2a44d3f9f9445dc84df1632_I20210504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xL2ZyYWc6ODVjMDkzNTlmNTI0NGQxOGFmMzEzNGYyN2ZmYzFjMjAvdGV4dHJlZ2lvbjo4NWMwOTM1OWY1MjQ0ZDE4YWYzMTM0ZjI3ZmZjMWMyMF8yMDc3_77f7a174-2b87-4bc5-aed3-cf56d964d218"
      unitRef="shares">144387799</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfNC0yLTEtMS0w_08d5eb59-bfdd-4617-8235-a31e76c7b777"
      unitRef="usd">97652000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfNC00LTEtMS0w_b3ec9cbc-be3e-4148-925c-ae92543e786e"
      unitRef="usd">126263000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfNS0yLTEtMS0w_74ad00ce-aa16-418c-871a-3005356f3590"
      unitRef="usd">43709000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfNS00LTEtMS0w_a9311b17-8dd7-4bb2-a605-171569fdbef2"
      unitRef="usd">26012000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfNi0yLTEtMS0w_1a7a81b5-2997-4719-b9eb-72a9bf93c642"
      unitRef="usd">101000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfNi00LTEtMS0w_9ffec7f4-5ded-42ba-b97a-b1f6320a4f50"
      unitRef="usd">395000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfOS0yLTEtMS0w_a04619bf-06c3-498d-8eed-bbabcf974027"
      unitRef="usd">3954000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfOS00LTEtMS0w_dde114ca-713c-4e35-b9b2-12b8ebced6f6"
      unitRef="usd">5049000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTAtMi0xLTEtMA_8dee9dbe-682f-496f-8905-e2ef93d91863"
      unitRef="usd">145416000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTAtNC0xLTEtMA_d4fad955-5686-4854-8d94-36fccd9cd171"
      unitRef="usd">157719000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjJkMWJlY2ZhN2ZiODQ1YzM4NGE5ODUyNDE0Mzg0Y2FlXzgw_29602ea2-7b5b-443e-8eb8-4277f2394159"
      unitRef="usd">5851000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjJkMWJlY2ZhN2ZiODQ1YzM4NGE5ODUyNDE0Mzg0Y2FlXzg3_15f08e4b-0f5c-4f35-b352-a1c4468aefa8"
      unitRef="usd">5815000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTEtMi0xLTEtMA_7b798cc3-81e5-4eba-8d6a-f172af96b195"
      unitRef="usd">296000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTEtNC0xLTEtMA_c7f45f38-216f-4bca-a206-8e4b8e546ca2"
      unitRef="usd">295000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTItMi0xLTEtMA_d4f05cdb-8159-4734-a752-99cc393c4e8c"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTItNC0xLTEtMA_13130e57-add3-4ea7-ad1e-98ddea337d7c"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTQtMi0xLTEtMA_26e12403-5e23-46b3-bbf7-0d6b985bb984"
      unitRef="usd">3005000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTQtNC0xLTEtMA_d13a924a-328c-493d-97e8-47af811eb77b"
      unitRef="usd">1231000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTUtMi0xLTEtMA_d7e96e15-fd89-458e-bea3-c0ea00db4883"
      unitRef="usd">193260000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTUtNC0xLTEtMA_2bf8c93a-c302-423e-90a5-684429715f1e"
      unitRef="usd">203788000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTgtMi0xLTEtMA_fa991ec4-ac25-46a6-86cc-bd15dcbf6bee"
      unitRef="usd">4926000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTgtNC0xLTEtMA_460a8cb1-f6ba-441a-a0aa-2141df4c3202"
      unitRef="usd">5469000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTktMi0xLTEtMA_b684be0d-2236-4a4a-89c9-2cf8572d3b99"
      unitRef="usd">22409000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMTktNC0xLTEtMA_25c6800f-5ac5-4346-b030-93b39a9258ca"
      unitRef="usd">29691000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjEtMi0xLTEtMA_08bb348d-1457-4a36-a09e-d9ccbced58b3"
      unitRef="usd">11660000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjEtNC0xLTEtMA_96f948ac-a8b8-4c3a-8c55-1accb4a95ab8"
      unitRef="usd">11646000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjItMi0xLTEtMA_8296ee2f-78c2-4c51-b194-7d5093c3c8f1"
      unitRef="usd">38995000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjItNC0xLTEtMA_bc2dca65-4000-4207-84f2-b11dcc7221d3"
      unitRef="usd">46806000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjYtMi0xLTEtMA_15f53dde-2625-4c5d-b7e2-4ce7ed857a36"
      unitRef="usd">1718000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjYtNC0xLTEtMA_10f3ffc0-6570-4f6a-bc2b-163244f8b2c0"
      unitRef="usd">611000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjctMi0xLTEtMA_da59a6ea-8bd4-49a8-97b4-b2d7c3bd68fd"
      unitRef="usd">40713000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjctNC0xLTEtMA_8c841fa0-77b0-4313-bb96-c88d949b17a9"
      unitRef="usd">47417000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjgtMi0xLTEtMA_20108018-e957-4991-957a-1ced17d50f68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMjgtNC0xLTEtMA_e58715f8-a323-403e-beee-2df88620b07d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzIy_0370998e-e6dd-47bc-9542-fa635a2ab1d6"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzIy_1025b6ce-6e4d-4c56-b682-40564d214f30"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzM2_27c547a3-b40d-41ee-84d8-8e2e5af0621d"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzM2_7000c803-2f22-4b2a-8fa1-9ddb93f5f6c1"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzU4_09dd3672-717a-47d4-9ea4-6c082e3aa3ae"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzU4_66b5e28a-0eec-4ca7-8abf-a0765c80cd4b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzU4_d490778c-de6d-4091-9960-aac1b6af6027"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjdkYzlmMWM4NGFmMDQ2NDJhY2JhNmYyNjYyNWUwOGNlXzU4_f37de82c-35e6-46ea-a9d9-12ff7f94f338"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtMi0xLTEtMA_1c38bb46-417d-4ef3-8ef2-753fb13e9933"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzAtNC0xLTEtMA_240f8354-0510-4341-85ec-a304d37c9067"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjIzMTQwNjhmNGM4MjQ2MTA5ODYxYzAyYjVhOWFhN2UwXzE4_1dd4b6a6-3eed-423e-b96b-e81052db9878"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjIzMTQwNjhmNGM4MjQ2MTA5ODYxYzAyYjVhOWFhN2UwXzE4_4ea943d7-a763-4a78-8498-a150fd821f43"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjIzMTQwNjhmNGM4MjQ2MTA5ODYxYzAyYjVhOWFhN2UwXzMy_93428110-e8ef-4fba-b40a-5801e8de58d2"
      unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjIzMTQwNjhmNGM4MjQ2MTA5ODYxYzAyYjVhOWFhN2UwXzMy_f466b945-3893-4749-ab3f-154f0380d6fb"
      unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjIzMTQwNjhmNGM4MjQ2MTA5ODYxYzAyYjVhOWFhN2UwXzU0_fd99beba-0703-4def-b5dd-7e72db11a338"
      unitRef="shares">145552000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjIzMTQwNjhmNGM4MjQ2MTA5ODYxYzAyYjVhOWFhN2UwXzYx_269d65f2-4635-421c-979f-99c8319a3897"
      unitRef="shares">142289000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtMi0xLTEtMA_f80c01cb-f20c-4303-92f8-caade9c7b33e"
      unitRef="usd">145000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzEtNC0xLTEtMA_03596f25-3f23-4f3e-9de1-bec2e19344dd"
      unitRef="usd">142000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzItMi0xLTEtMA_fca44f2b-771b-47de-b645-a87e7b135088"
      unitRef="usd">1580891000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzItNC0xLTEtMA_3197a247-de26-4905-9a90-eedeb9a7b86a"
      unitRef="usd">1561096000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzMtMi0xLTEtMA_4d42f7c3-2fde-4ed9-bb3f-e0312abfe69d"
      unitRef="usd">-1420976000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzMtNC0xLTEtMA_2b321af1-1c85-46f5-b619-679d265768ec"
      unitRef="usd">-1400018000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzQtMi0xLTEtMA_c05a69bf-4b02-46ac-bab6-e738d73b5f97"
      unitRef="usd">5000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzQtNC0xLTEtMA_d58ac012-a4aa-4c05-aa9d-63c36afec39e"
      unitRef="usd">-6000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockShares
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjhlNzc1OTM4YjY1MTQyM2JhM2Q3OGY2YzAyMjhmNTYyXzI5_eebdaf2b-cb68-4711-9ecc-6f9620169255"
      unitRef="shares">1165000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjhlNzc1OTM4YjY1MTQyM2JhM2Q3OGY2YzAyMjhmNTYyXzM2_7507b07b-6dd7-4059-8425-1dc4ef68dfc3"
      unitRef="shares">793000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzUtMi0xLTEtMA_e8bb6ae5-5ef9-4448-99b1-28153e5412fb"
      unitRef="usd">7518000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzUtNC0xLTEtMA_34b4f2fc-e055-4549-9445-141129337f76"
      unitRef="usd">4843000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzYtMi0xLTEtMA_06c9e642-21ea-4356-a2cc-91ef21ffca17"
      unitRef="usd">152547000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzYtNC0xLTEtMA_58bb9e69-3db5-4541-84d9-bab7ed24deae"
      unitRef="usd">156371000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzctMi0xLTEtMA_48f660fa-82bd-415e-9be0-f6827c6ebd5c"
      unitRef="usd">193260000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8xOS9mcmFnOmIzOTdlY2U4MmExNTQ0MDk5MzQ4MDUwOTlhMjljZGRhL3RhYmxlOmRjZTgwYzQ5NDY4NjQ5NjRhM2JkMzkwOTY5N2Q2NGFmL3RhYmxlcmFuZ2U6ZGNlODBjNDk0Njg2NDk2NGEzYmQzOTA5Njk3ZDY0YWZfMzctNC0xLTEtMA_341e3acc-bf02-4ec8-bbc5-08ea9e2ddcaf"
      unitRef="usd">203788000</us-gaap:LiabilitiesAndStockholdersEquity>
    <lxrx:Netproductrevenue
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMy0yLTEtMS0w_1efa03b6-46aa-4865-8071-e12eb9e99d7d"
      unitRef="usd">0</lxrx:Netproductrevenue>
    <lxrx:Netproductrevenue
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMy00LTEtMS0w_77d36e20-9917-4078-bd9a-c258e054956f"
      unitRef="usd">7877000</lxrx:Netproductrevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfNC0yLTEtMS0w_25a81b82-3ed5-46b7-b2fb-987665d59ccb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfNC00LTEtMS0w_6c8be643-5feb-462c-b674-3ea6cef2b461"
      unitRef="usd">8000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfNS0yLTEtMS0w_6b7347cb-85f2-4c65-a816-b04e4ad39c3d"
      unitRef="usd">27000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfNS00LTEtMS0w_bf0f37fa-29f6-4025-a26e-79caa34dd369"
      unitRef="usd">114000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:Revenues
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfNi0yLTEtMS0w_c7fb513d-84f8-4075-8e23-ac79bb3197c6"
      unitRef="usd">27000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfNi00LTEtMS0w_44eaaac0-d65a-4fa3-a45e-d00d236032ee"
      unitRef="usd">7999000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfOC0yLTEtMS0w_e2d6c4bd-b7b7-4410-b052-fb8c26bd5428"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfOC00LTEtMS0w_c3cf7196-b384-4e81-9438-9f52778085be"
      unitRef="usd">568000</us-gaap:CostOfGoodsAndServicesSold>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfOS0wLTEtMS0wL3RleHRyZWdpb246MmM5ZTgwZDhkMDllNGM0ZGJhNWVkNmMxZmEwOGU1NTdfNjg_c65d5f34-f27b-4adb-aff6-393c389fda97"
      unitRef="usd">1286000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfOS0wLTEtMS0wL3RleHRyZWdpb246MmM5ZTgwZDhkMDllNGM0ZGJhNWVkNmMxZmEwOGU1NTdfNzI_ae02a8ab-0919-4dc0-9ab4-65c80940710b"
      unitRef="usd">2176000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfOS0yLTEtMS0w_0e9a780a-00a7-44f2-a482-617f6255db25"
      unitRef="usd">12609000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfOS00LTEtMS0w_e9fe8935-d362-4d20-af53-14214ea6b513"
      unitRef="usd">55181000</us-gaap:ResearchAndDevelopmentExpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRhZGQwZjI0NDQzMTQ2YWQ4MGUxN2E4ZTA3MmNjZjEzXzc5_731b8fad-39c7-4884-adcb-9c7b931578a1"
      unitRef="usd">1565000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjRhZGQwZjI0NDQzMTQ2YWQ4MGUxN2E4ZTA3MmNjZjEzXzgz_f2f68caa-043a-44a2-9687-dd61e047a879"
      unitRef="usd">2256000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTEtMi0xLTEtMA_e17f92b4-a855-4cf7-949b-1618913dde94"
      unitRef="usd">8257000</lxrx:Sellinggeneralandadministrativeexpenses>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTEtNC0xLTEtMA_4cd1c9a5-8771-4096-8057-432333b97a1a"
      unitRef="usd">14688000</lxrx:Sellinggeneralandadministrativeexpenses>
    <us-gaap:OperatingExpenses
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTUtMi0xLTEtMA_01dbad8f-12ae-4a55-8941-8863f1115b4f"
      unitRef="usd">20866000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTUtNC0xLTEtMA_2fbe7c1d-1ac9-49bb-be35-f7cf47310ad1"
      unitRef="usd">70437000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTgtMi0xLTEtMA_35c8b1af-851b-491e-ba0c-219ef972c14a"
      unitRef="usd">-20839000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMTgtNC0xLTEtMA_8d0afa19-d03c-440a-8634-aca4b2ab3899"
      unitRef="usd">-62438000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjEtMi0xLTEtMA_c83350e7-2790-41d9-823e-39cc0358d51c"
      unitRef="usd">167000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjEtNC0xLTEtMA_78bb3273-9fdb-494e-817a-076c543c1099"
      unitRef="usd">5131000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjItMi0xLTEtMA_e71b2870-cd10-4ae2-9d1b-df130a8fcbfc"
      unitRef="usd">48000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjItNC0xLTEtMA_a5479848-5b25-46f1-840f-a3e389fbdc09"
      unitRef="usd">958000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjUtMi0xLTEtMA_6d594d9f-4e5e-4149-82b8-e53f9e12ad55"
      unitRef="usd">-20958000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjUtNC0xLTEtMA_0d128135-b711-455d-8ab0-8619ce6b3a80"
      unitRef="usd">-66611000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjYtMi0xLTEtMA_32707c9a-d77d-4248-b769-7d3159c5ed22"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjYtNC0xLTEtMA_8a962d17-f9ac-4eae-a780-89a296620d6c"
      unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjktMi0xLTEtMA_1e880718-0c2e-4e6b-af59-d0b8ea9881d7"
      unitRef="shares">143379000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMjktNC0xLTEtMA_bc6ca58a-6a2f-4a0b-b1ca-03f6134ea117"
      unitRef="shares">106536000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMzMtMi0xLTEtMA_fcb63a8c-4ef8-4ae1-8f65-127cf30ee165"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMzMtNC0xLTEtMA_8cf711c2-0c94-4d28-99c6-6b6d67f6c266"
      unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMzQtMi0xLTEtMA_8021340a-6d9a-4946-9236-5b121640b800"
      unitRef="usd">-20947000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yMi9mcmFnOjNiMTQwYzU4OTAwODRhZmZiYTdiNWQ3ZjFiYjBmYTlhL3RhYmxlOjFjODY5MDBkNDhlNjQ5NWNiM2M0MjljNDhkZTcwMGNhL3RhYmxlcmFuZ2U6MWM4NjkwMGQ0OGU2NDk1Y2IzYzQyOWM0OGRlNzAwY2FfMzQtNC0xLTEtMA_29566e7c-1903-42fc-a58f-b5825cb48ed1"
      unitRef="usd">-65835000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2dca67dbb6624abeb8141b5923482d81_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMi0yLTEtMS0w_3510fa78-bc1f-48ef-9724-69f51dc998b3"
      unitRef="shares">106679000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2dca67dbb6624abeb8141b5923482d81_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMi00LTEtMS0w_89dabbac-8f96-47de-85e9-15042e617ba8"
      unitRef="usd">106000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50ee913592ef4520b5d81d6e189446e8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMi02LTEtMS0w_49b0ad34-3b8c-45de-858e-2087cb554512"
      unitRef="usd">1462172000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8fdc7cf67e874d559ff410b0ab012041_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMi04LTEtMS0w_9df72f6e-35d8-4cf8-a583-a124c4bafee3"
      unitRef="usd">-1341444000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e58e312dc3047689801cba0f72629d5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMi0xMC0xLTEtMA_fca86db9-ab33-409d-b755-8a9bb5c401d2"
      unitRef="usd">84000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f0724b0fae84864825b9dc62f678c5b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMi0xMi0xLTEtMA_4954d27f-aafb-47d9-9d07-4c78c6f1153c"
      unitRef="usd">-3817000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a606756c32f497285a9518996aac3b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMi0xNC0xLTEtMA_41689130-9096-4f6e-bde4-9d96f8fbe75e"
      unitRef="usd">117101000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7d3a9feed1574e7ab2f1969416fef122_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNS00LTEtMS0w_70b0f88b-20ef-4fdd-b423-ae2645dfc05e"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie90037db436a4b29a12d6bbac4f4cca8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNS02LTEtMS0w_6bda058c-f40c-402d-8032-b0ba2aaf39a5"
      unitRef="usd">4432000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i375cc32ca2c34f1e9336833c1ed0ea7f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNS04LTEtMS0w_fb3c3a6f-1139-45cd-ad6e-73a22e381814"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i078b6b9a2fc943a09745dbb2ce3a271f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNS0xMC0xLTEtMA_d8a29d4b-1538-407a-99a8-c2b5057c302a"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i80bed1b60e694ddf8bec5653c1a55108_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNS0xMi0xLTEtMA_5072857d-6866-4295-b99e-f2f2743170e7"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNS0xNC0xLTEtMA_759fb30a-dad7-4ad3-a594-84725a26c1cd"
      unitRef="usd">4432000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i7d3a9feed1574e7ab2f1969416fef122_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNi0yLTEtMS0w_0d2c59c4-0f5f-4480-9346-67df1e458016"
      unitRef="shares">1032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7d3a9feed1574e7ab2f1969416fef122_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNi00LTEtMS0w_fa9eacb8-f987-47c3-a35c-a496205e2001"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie90037db436a4b29a12d6bbac4f4cca8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNi02LTEtMS0w_6bdae9f4-e476-4b91-86ee-daddb3c11c34"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i375cc32ca2c34f1e9336833c1ed0ea7f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNi04LTEtMS0w_ec4a6ccc-e849-4e15-8270-8f6adacaecd9"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i078b6b9a2fc943a09745dbb2ce3a271f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNi0xMC0xLTEtMA_64667a31-bf7e-43fd-9268-b25d953722d8"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i80bed1b60e694ddf8bec5653c1a55108_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNi0xMi0xLTEtMA_45079f05-665a-4b24-844c-aeacf496912b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfNi0xNC0xLTEtMA_c7ae40d7-7d0e-4429-b6c1-2d60bf180159"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7d3a9feed1574e7ab2f1969416fef122_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOC00LTEtMS0w_1f24e5d5-04ed-4d99-8623-9900e58184e4"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie90037db436a4b29a12d6bbac4f4cca8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOC02LTEtMS0w_1d01378c-7535-4f0f-a287-96cbdaa79141"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i375cc32ca2c34f1e9336833c1ed0ea7f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOC04LTEtMS0w_7e3a77cd-aba6-46c2-8e2c-4f86507272cd"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i078b6b9a2fc943a09745dbb2ce3a271f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOC0xMC0xLTEtMA_6f7a253e-48b3-428e-b101-011c78194d10"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i80bed1b60e694ddf8bec5653c1a55108_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOC0xMi0xLTEtMA_bb277ec7-d752-4c32-a16d-99a486bf671a"
      unitRef="usd">923000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOC0xNC0xLTEtMA_00206502-ab4f-4c81-978f-c2527a189e7a"
      unitRef="usd">923000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="i7d3a9feed1574e7ab2f1969416fef122_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOS00LTEtMS0w_39cff951-992b-4e27-a952-779230289639"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie90037db436a4b29a12d6bbac4f4cca8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOS02LTEtMS0w_8a36bc10-cd16-4596-a6e7-921f0868e146"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i375cc32ca2c34f1e9336833c1ed0ea7f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOS04LTEtMS0w_cdcf25b9-c2d2-4e80-86f8-a8797bf78f5c"
      unitRef="usd">-66611000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i078b6b9a2fc943a09745dbb2ce3a271f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOS0xMC0xLTEtMA_3072b429-cc46-4504-887a-6910c9f783e7"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i80bed1b60e694ddf8bec5653c1a55108_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOS0xMi0xLTEtMA_bcd7f505-541d-43ec-b255-c6c1a62240cc"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i375cc32ca2c34f1e9336833c1ed0ea7f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfOS0xNC0xLTEtMA_9eaed459-5e90-4e0f-a1a7-779378f0cead"
      unitRef="usd">-66611000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7d3a9feed1574e7ab2f1969416fef122_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTAtNC0xLTEtMA_45ea9789-55a0-4fd0-835f-3a01dc195f4c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie90037db436a4b29a12d6bbac4f4cca8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTAtNi0xLTEtMA_b4ad5dec-d13d-41be-91f1-5cb06a92286b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i375cc32ca2c34f1e9336833c1ed0ea7f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTAtOC0xLTEtMA_55c4a7d5-4a1d-48f9-9e55-18b9025a9893"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i078b6b9a2fc943a09745dbb2ce3a271f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTAtMTAtMS0xLTA_dfcefd53-515d-4f3c-9bdf-fd00510ae83d"
      unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i80bed1b60e694ddf8bec5653c1a55108_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTAtMTItMS0xLTA_25e65839-39bf-48c5-8a97-e042ca610054"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTAtMTQtMS0xLTA_71aed17b-85f6-43ef-bae6-d91e12f0f186"
      unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia36b6c47696646d39cb6d3753f25f8fc_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTItMi0xLTEtMA_85381979-e123-40bd-b5be-3d60889a0414"
      unitRef="shares">107711000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia36b6c47696646d39cb6d3753f25f8fc_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTItNC0xLTEtMA_5807a132-f350-4fed-8c1d-2d444cbeabba"
      unitRef="usd">108000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d2a1d2958c44883b7cb551a566117ba_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTItNi0xLTEtMA_853c3228-31d6-4568-b7e5-1c9bbdd08d96"
      unitRef="usd">1466604000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i071c8ec8b6154a1e922ede9df8277cc5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTItOC0xLTEtMA_4e634686-5755-409e-8e1f-6447ef6dcef0"
      unitRef="usd">-1408055000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6becb50947fe41d7a703d27c05c60d23_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTItMTAtMS0xLTA_560c7f6a-f671-4e51-a84f-8d646e5cc2c2"
      unitRef="usd">860000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9bb8568447be4c9fbfc10b295ff7b33a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTItMTItMS0xLTA_d5aad611-fd07-465a-8ace-d38dffa48a91"
      unitRef="usd">-4740000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if27faa5c3eef4da8a2be4870c962c535_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOjFhZWQwOTEzYjFlMzQxYWI4YzRiOWQxZWVhZGI2MWEwL3RhYmxlcmFuZ2U6MWFlZDA5MTNiMWUzNDFhYjhjNGI5ZDFlZWFkYjYxYTBfMTItMTQtMS0xLTA_96e0c860-4005-4b00-9bcd-24347db0d70f"
      unitRef="usd">54777000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i24e6c722889a4e529025d61dbe7edbca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMi0yLTEtMS0w_56a9eeaf-1d1d-498f-9ec3-fa8e1f607ba2"
      unitRef="shares">142289000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i24e6c722889a4e529025d61dbe7edbca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMi00LTEtMS0w_90e5d74c-65a7-43b6-b64b-cb1e7bd768cd"
      unitRef="usd">142000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42dd529b05c74e7cb35485cf486d3ef7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMi02LTEtMS0w_4ceb9b97-eb4a-4ed5-8ae5-b48412207dc0"
      unitRef="usd">1561096000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie1cdf94e04d943c08450a611bfc2b63f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMi04LTEtMS0w_7dae1c02-231d-4624-b608-5db02431dfa9"
      unitRef="usd">-1400018000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa953ef8800f442aa472c4b20bef4764_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMi0xMC0xLTEtMA_f244afd5-b640-46e7-be24-10df3d1616d2"
      unitRef="usd">-6000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic60d7c15b6e143cdb8e7f57bad14a09a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMi0xMi0xLTEtMA_4e6046c1-ae4d-4dc8-acbe-297dd979f4ca"
      unitRef="usd">-4843000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMi0xNC0xLTEtMA_58b088fb-8631-4afd-8411-99a630fcfe59"
      unitRef="usd">156371000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNC00LTEtMS0w_21d9be28-6a03-4d44-8b67-58c95d7dfc56"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8da06dd15088483d9ddeaea504d86cd7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNC02LTEtMS0w_2210fb6f-6126-4535-a103-e8f5ee59b662"
      unitRef="usd">2851000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1df52d1685b845e99310b7cf678d9bc1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNC04LTEtMS0w_fb1f1d09-ab1e-4360-b6da-6d34d187c46a"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i191cef183ce042d78110d9e5f705083b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNC0xMC0xLTEtMA_6577aa73-c7db-4acc-a769-e647de7a1f04"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i75076d7889ad4eb8b803991721300015_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNC0xMi0xLTEtMA_b0e44cd6-06ce-427c-9643-815ef314ab7f"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNC0xNC0xLTEtMA_dac14415-17ea-48d0-8e21-e5d1818a3c63"
      unitRef="usd">2851000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNS0yLTEtMS0w_dc1c4edc-dd3d-4c7f-8ead-c02db1718e1b"
      unitRef="shares">1263000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNS00LTEtMS0w_141f634d-976a-4fae-be1f-95ad26338209"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8da06dd15088483d9ddeaea504d86cd7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNS02LTEtMS0w_73e19cbe-ef6c-47bc-a13d-b20a16aba558"
      unitRef="usd">547000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1df52d1685b845e99310b7cf678d9bc1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNS04LTEtMS0w_d6637cdd-cca5-4e28-bf9d-e39e915b166f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i191cef183ce042d78110d9e5f705083b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNS0xMC0xLTEtMA_68d8b8a1-2d0f-48f3-bddd-d8ad7ae41eb7"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i75076d7889ad4eb8b803991721300015_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNS0xMi0xLTEtMA_26e287e5-f50a-4d8f-8c25-5e687a7b1fee"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNS0xNC0xLTEtMA_a56bfe5c-589f-406e-a845-11d28acc051a"
      unitRef="usd">548000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNi0yLTEtMS04NzM_1f215336-14d7-42c9-8e89-1fa27b6ea600"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNi00LTEtMS04NzM_ae3f61c2-9f4a-40d9-9dff-b60f3c8ae2dc"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8da06dd15088483d9ddeaea504d86cd7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNi02LTEtMS00ODM_60cb0c2e-1369-43c3-bbe7-5101e26cdcb8"
      unitRef="usd">16397000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1df52d1685b845e99310b7cf678d9bc1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNi04LTEtMS00ODM_392db1a5-34c0-4d0e-a550-2eb39b566ed0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i191cef183ce042d78110d9e5f705083b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNi0xMC0xLTEtODcz_ffbe92e3-5cf5-435d-9fbe-664564942ef4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i75076d7889ad4eb8b803991721300015_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNi0xMi0xLTEtODcz_f7bd66d0-9d07-4a58-914d-17def16a3c43"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNi0xNC0xLTEtODcz_5aea6eea-d26c-4b30-b160-8be5df733ee3"
      unitRef="usd">16399000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNy00LTEtMS0w_fadf0106-030a-4ba2-ad88-af2497a117a8"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8da06dd15088483d9ddeaea504d86cd7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNy02LTEtMS0w_c09ffe01-cd98-4d97-970d-d83e777eaf54"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1df52d1685b845e99310b7cf678d9bc1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNy04LTEtMS0w_c7ea2913-baa5-4da2-a989-ef8046dc3926"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i191cef183ce042d78110d9e5f705083b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNy0xMC0xLTEtMA_f12f4657-14f4-41f6-ab68-0b3d0d759db9"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i75076d7889ad4eb8b803991721300015_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNy0xMi0xLTEtMA_ebb105b8-7800-4c36-8de4-26108231a8fa"
      unitRef="usd">2675000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfNy0xNC0xLTEtMA_7f186c15-0a22-4513-a9dd-1777b1e70c59"
      unitRef="usd">2675000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfOC00LTEtMS0w_d07482ee-a190-46e9-889a-e99517fa6d06"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8da06dd15088483d9ddeaea504d86cd7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfOC02LTEtMS0w_48d1bfb0-c85e-48df-ba85-5d02c922f4d2"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1df52d1685b845e99310b7cf678d9bc1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfOC04LTEtMS0w_becfa2a9-df4f-4397-9c82-46fd8d2db249"
      unitRef="usd">-20958000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i191cef183ce042d78110d9e5f705083b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfOC0xMC0xLTEtMA_98a6200c-d155-4859-bab0-e581336f58f8"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i75076d7889ad4eb8b803991721300015_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfOC0xMi0xLTEtMA_a937b469-db13-41cf-8d7e-d138c79266e5"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfOC0xNC0xLTEtMA_e549cbc9-251b-44b9-af84-dc7e47676c19"
      unitRef="usd">-20958000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i04674a820fd84a47af510792ed23d319_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTAtNC0xLTEtMA_af0deac5-eab4-4be2-88b5-0daa8c3f827a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8da06dd15088483d9ddeaea504d86cd7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTAtNi0xLTEtMA_2a87c840-4506-4262-8e0a-3906b4823a4b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1df52d1685b845e99310b7cf678d9bc1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTAtOC0xLTEtMA_2e4e767c-2043-43ae-b0f7-92fefe7e615b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i191cef183ce042d78110d9e5f705083b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTAtMTAtMS0xLTA_6724cd0b-b6ac-4c05-b701-24a1d3f102c2"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i75076d7889ad4eb8b803991721300015_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTAtMTItMS0xLTA_1566661c-6a09-4e03-9858-f2c5ce4ac272"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTAtMTQtMS0xLTA_40de6a7b-57d2-478d-9876-54030103aa0c"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie96e698d44f741e8b15ba8a973f9aaaa_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTEtMi0xLTEtMA_0c3ef585-2092-4cac-b718-eeca7dbfd537"
      unitRef="shares">145552000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie96e698d44f741e8b15ba8a973f9aaaa_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTEtNC0xLTEtMA_773af53e-a88f-4791-9d36-b80e5ae3b751"
      unitRef="usd">145000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e98480c8ab24073a57917c703b340ca_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTEtNi0xLTEtMA_0d3efc8a-a2a8-4879-92d0-4b3ae533a91e"
      unitRef="usd">1580891000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f7ed8cd8f7b42aeb8bcb7b11be2be35_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTEtOC0xLTEtMA_c7a7c750-eeeb-40eb-9e05-0fe9eb6798d8"
      unitRef="usd">-1420976000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b5277bb1cee46b0a0e275f43ab30ecd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTEtMTAtMS0xLTA_f2a42e9f-a7e1-480b-ae33-d273c9d2a742"
      unitRef="usd">5000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i05e826ffe0344bbbb51ccbc13eaa4d00_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTEtMTItMS0xLTA_e33a848d-42f7-4e75-9548-77965dbfac6b"
      unitRef="usd">-7518000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yNS9mcmFnOjgwNTM2OThkNWY2YzQ0YzM4YWUwZWEyNTZkMmY4NmY1L3RhYmxlOmVjMjRmYzE1NzkwNDQ5NTQ5YzQwYTA4NDU4MjE2YTk0L3RhYmxlcmFuZ2U6ZWMyNGZjMTU3OTA0NDk1NDljNDBhMDg0NTgyMTZhOTRfMTEtMTQtMS0xLTA_7661c05f-ff4d-43d2-8298-7417cbe830ad"
      unitRef="usd">152547000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMy0yLTEtMS0w_77d55a2b-aac8-4b07-b01b-dd8a2164d1d3"
      unitRef="usd">-20958000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMy00LTEtMS0w_4ed99a7d-cfca-437b-a749-f7b1ea03fadc"
      unitRef="usd">-66611000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNS0yLTEtMS0w_d02949bb-5e7d-4dde-b7ad-2aed3cfd31bf"
      unitRef="usd">37000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNS00LTEtMS0w_5417936a-1bc8-48b6-88fa-fd77a5852662"
      unitRef="usd">906000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNy0yLTEtMS0w_1e9d1aa0-da14-442e-901b-b48ff7cb8b61"
      unitRef="usd">2851000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNy00LTEtMS0w_feb07f90-3207-4b6b-9b8d-f1361399b315"
      unitRef="usd">4432000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfOC0yLTEtMS0w_f947ed0c-ee40-4920-888b-b42e7c378789"
      unitRef="usd">14000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfOC00LTEtMS0w_e833e18d-4d0b-4b54-82e8-1acc94da51bb"
      unitRef="usd">362000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTUtMi0xLTEtMA_199b4ef6-603a-47c3-97e6-fd993149e155"
      unitRef="usd">-294000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTUtNC0xLTEtMA_f9bf289f-6bac-4540-a57a-79bfee59683f"
      unitRef="usd">-26397000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTYtMi0xLTEtMA_6c5b783e-e80c-4dec-a1d0-fdcc51ca95a4"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTYtNC0xLTEtMA_76ffce89-8e31-4b24-8c30-9d5af67217f5"
      unitRef="usd">-96000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTctMi0xLTEtMA_e85b7c16-0822-4488-9fcb-b88c6b911e61"
      unitRef="usd">-1095000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTctNC0xLTEtMA_fad8f1cf-aab6-4a10-9fa4-8a4d23ad6862"
      unitRef="usd">2875000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTgtMi0xLTEtMA_6984e332-049c-479d-8947-7c889108527a"
      unitRef="usd">74000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTgtNC0xLTEtMA_ee96d9b2-cde5-4026-ac40-3fab0b88bf2b"
      unitRef="usd">-102000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTktMi0xLTEtMA_5903e4a5-f85e-47d5-9071-19942b7e1943"
      unitRef="usd">-8418000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMTktNC0xLTEtMA_acbb131f-cb97-42dd-a05b-e72960523bb4"
      unitRef="usd">15137000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjEtMi0xLTEtMA_dfd423fb-9ad2-41d8-b6b8-5c4d90373b69"
      unitRef="usd">-25159000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjEtNC0xLTEtMA_25bc5c13-5e57-405a-9a97-52d1ce59a63b"
      unitRef="usd">-22054000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjMtMi0xLTEtMA_4440d3c9-060a-4fdc-872c-7937501694f2"
      unitRef="usd">38000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjMtNC0xLTEtMA_c36884d3-edc9-4d53-8f6c-b82bf2f7bff7"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjYtMi0xLTEtMA_f420d9c6-aff7-4052-bdda-290d257bc649"
      unitRef="usd">21686000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjYtNC0xLTEtMA_fa985efd-9ee3-42be-ac8b-420e67e00f11"
      unitRef="usd">33222000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjctMi0xLTEtMA_37f725d1-e79a-4301-918d-014ca25e3b6c"
      unitRef="usd">4000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjctNC0xLTEtMA_721e28d7-4ac1-4fe7-94e3-ec9b2ab001fe"
      unitRef="usd">76000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjgtMi0xLTEtMA_82cda8c8-362d-45d5-82c7-2ea541bd630e"
      unitRef="usd">-17724000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMjgtNC0xLTEtMA_1d9b1472-c1be-4eb0-ab6b-f81b8804febf"
      unitRef="usd">42778000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzAtMi0xLTEtMA_ec355bb6-351b-4d53-980c-75b1fd4c657e"
      unitRef="usd">16947000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzAtNC0xLTEtMA_0121481b-6e54-4bcf-b349-1199b7a1b331"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzEtMi0xLTEtMA_e9e371d2-c404-4799-bd3d-35c40a504e00"
      unitRef="usd">2675000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzEtNC0xLTEtMA_67f1d687-f9b2-46e4-bf9e-53a953af2a6e"
      unitRef="usd">923000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzMtMi0xLTEtMA_1009f2a3-bd03-4769-a97a-2a55c857d988"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzMtNC0xLTEtMA_a06348bf-2e5a-4a85-afef-04c0ad15aedd"
      unitRef="usd">321000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzUtMi0xLTEtMA_b9f4034d-36e2-4e4e-bba9-3abf6b4d8dc0"
      unitRef="usd">14272000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzUtNC0xLTEtMA_f2dc4c89-47eb-463f-918e-36e3d3a22d24"
      unitRef="usd">-1244000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzYtMi0xLTEtMA_5631ced3-410f-4485-8f83-5458b630dc2a"
      unitRef="usd">-28611000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzYtNC0xLTEtMA_6a803017-06e5-482e-a30d-2b8957c1d87c"
      unitRef="usd">19480000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzctMi0xLTEtMA_de958b54-ac61-4faa-8f7f-707765f6240e"
      unitRef="usd">126263000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0a606756c32f497285a9518996aac3b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzctNC0xLTEtMA_2c1f0f87-9afb-49dc-bd97-e74fc4d812b6"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzgtMi0xLTEtMA_27186214-4df0-498c-86b9-bdd3ea475363"
      unitRef="usd">97652000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if27faa5c3eef4da8a2be4870c962c535_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfMzgtNC0xLTEtMA_85685d89-dbec-4518-8e32-0bb3133b94c9"
      unitRef="usd">55592000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNDEtMi0xLTEtMA_cd9c94f6-9952-45b4-9097-40471b27a97a"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNDEtNC0xLTEtMA_cf79decb-2683-4623-86ad-0aa107231fcc"
      unitRef="usd">3658000</us-gaap:InterestPaidNet>
    <lxrx:InitialRecognitionOfRightOfUseAsset
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNDQtMi0xLTEtMTA4Nw_2df17db4-4ad1-4801-b9fe-7d2c6068866a"
      unitRef="usd">1700000</lxrx:InitialRecognitionOfRightOfUseAsset>
    <lxrx:InitialRecognitionOfRightOfUseAsset
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8yOC9mcmFnOjZkMmYzMTQ0MjQ2YTQzZjhiMTk4YTk3YzJiOGVlNmI4L3RhYmxlOmQyZTMwMDc0ZjQwODQ1OGQ4NTBhZTQ0NTJmNGQxZWQ5L3RhYmxlcmFuZ2U6ZDJlMzAwNzRmNDA4NDU4ZDg1MGFlNDQ1MmY0ZDFlZDlfNDQtNC0xLTEtMTA4Nw_06be9bf8-b425-4bf3-922c-8aeead784ffc"
      unitRef="usd">0</lxrx:InitialRecognitionOfRightOfUseAsset>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3ODc_5f63575a-d92d-4930-be82-dba003f73cf1">Summary of Significant Accounting Policies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#x201c;Lexicon&#x201d; or the &#x201c;Company&#x201d;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month period ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further information, refer to the financial statements and footnotes thereto included in Lexicon&#x2019;s annual report on Form 10-K for the year ended December&#160;31, 2020, as filed with the SEC.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2021, short-term investments consisted of U.S. treasury bills and corporate debt securities.  As of December&#160;31, 2020, short-term investments consisted of corporate debt securities.  The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued liabilities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.163%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future minimum lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon uses its incremental borrowing rate of 9% at the commencement date in determining the present value of future payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Company&#x2019;s sale of XERMELO and related assets to TerSera in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (&#x201c;Ipsen&#x201d;).  Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#x2019;s net product revenues reflected the Company&#x2019;s best estimates of the amounts of consideration to which it was entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs were considered a fulfillment activity when control transferred to the Company&#x2019;s customers and such costs were included in cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements in which a license to the Company&#x2019;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of Sales: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Product shipping and handling costs were included in cost of sales. Cost of sales also included the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#x2019;s estimates of the clinical study costs and costs to transition activities from Sanofi for the development of sotagliflozin for type 2 diabetes and heart failure, as well as the wind down of those activities, were based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that conducted and managed the clinical studies on its behalf.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.&#160;&#160;The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the three months ended March&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock option activity under Lexicon&#x2019;s stock-based compensation plans for the three months ended March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021, Lexicon also granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three annual installments.  The following is a summary of restricted stock units activity under Lexicon&#x2019;s stock-based compensation plans for the three months ended March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NDk_842e5b59-8b0c-43eb-9d7f-12edd7ece63f">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NTE_7e53a8dd-f741-4046-ac02-206a298a7e33">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3ODQ_f686a76d-6f7c-473e-b689-b05b8d4d1ee3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2021, short-term investments consisted of U.S. treasury bills and corporate debt securities.  As of December&#160;31, 2020, short-term investments consisted of corporate debt securities.  The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NzE_3b5af74b-79f3-4e41-b221-4c4aff73c27d">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued liabilities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.163%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <lxrx:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfMy0yLTEtMS0w_cd6fd074-4638-437d-b7f4-88b96040a71c"
      unitRef="usd">16505000</lxrx:AccruedResearchAndDevelopmentServicesCurrent>
    <lxrx:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfMy00LTEtMS0w_4cdfad4b-15da-49de-bc89-f4448ea739dd"
      unitRef="usd">21962000</lxrx:AccruedResearchAndDevelopmentServicesCurrent>
    <lxrx:AccruedCompensationAndBenefitsCurrent
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNC0yLTEtMS0w_e6550163-c593-4b71-a053-7521c6f72391"
      unitRef="usd">3552000</lxrx:AccruedCompensationAndBenefitsCurrent>
    <lxrx:AccruedCompensationAndBenefitsCurrent
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNC00LTEtMS0w_51fe39dd-f1b0-476a-966a-6653f246371d"
      unitRef="usd">6200000</lxrx:AccruedCompensationAndBenefitsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNS0yLTEtMS0w_125dc410-59da-47f3-802d-3e2d689ad7a9"
      unitRef="usd">-1026000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNS00LTEtMS0w_4989664a-cdb5-4649-84b8-2685c9d455b1"
      unitRef="usd">553000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNi0yLTEtMS0w_e778b1e8-db7b-4bc4-b6f1-f392c836e7f2"
      unitRef="usd">1326000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNi00LTEtMS0w_73d8debe-1bee-4474-a0c6-158e3e76c625"
      unitRef="usd">976000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNy0yLTEtMS0w_828146f3-851e-4326-826f-31e9e2b68a02"
      unitRef="usd">22409000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjA2YjBkNjAxYmI1ZDRhMTc4ZThlMTlhMDFiNmQzNjQ4L3RhYmxlcmFuZ2U6MDZiMGQ2MDFiYjVkNGExNzhlOGUxOWEwMWI2ZDM2NDhfNy00LTEtMS0w_7ede1d17-5b5b-4fb5-ae82-b19deb44bfdc"
      unitRef="usd">29691000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMjE5OTAyMzI3NjM5MQ_a9b8c02b-307f-4e91-9cb3-bd991958d5ca">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less.&lt;/span&gt;Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future minimum lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon uses its incremental borrowing rate of 9% at the commencement date in determining the present value of future payments.</us-gaap:RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock>
    <lxrx:LexiconIncrementalBorrowingRate
      contextRef="i146253cab0294e3eae00a7148487429e_I20210301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfOTM0NTg0ODg1NjkzNg_b62cf118-1ef9-43ac-bb67-369ff24e9ff0"
      unitRef="number">9</lxrx:LexiconIncrementalBorrowingRate>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NTI_997261c2-db83-48ac-b3d4-1e25ffb17be9">&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Company&#x2019;s sale of XERMELO and related assets to TerSera in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (&#x201c;Ipsen&#x201d;).  Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#x2019;s net product revenues reflected the Company&#x2019;s best estimates of the amounts of consideration to which it was entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs were considered a fulfillment activity when control transferred to the Company&#x2019;s customers and such costs were included in cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements in which a license to the Company&#x2019;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfOTM0NTg0ODg1NjkzNA_8e4a78d5-def5-47f3-b270-f15e86cfa47b">Cost of Sales:  Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Product shipping and handling costs were included in cost of sales. Cost of sales also included the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3ODk_035379d7-d226-47d8-ba7b-fd2b601045db">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#x2019;s estimates of the clinical study costs and costs to transition activities from Sanofi for the development of sotagliflozin for type 2 diabetes and heart failure, as well as the wind down of those activities, were based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that conducted and managed the clinical studies on its behalf.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3OTQ_ad96da6e-a32a-4215-bd56-8846b39fe327">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NDY_fb9c43a1-0e87-4472-a946-7afa4e876ac8">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMi0yLTEtMS0w_479e90b0-9e6e-467f-b5f0-6ff92bddc42d"
      unitRef="number">1.05</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMi00LTEtMS0w_51e17655-5b64-41a8-8af8-eea12042c615"
      unitRef="number">0.004</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMi02LTEtMS0w_1d83277c-2565-49f1-8893-1bb725961341">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMi04LTEtMS0w_323a6328-ec37-45f9-9822-a182f6d92ff9"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMy0yLTEtMS0w_658afecd-5880-43fc-b51b-938e240b2172"
      unitRef="number">0.90</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMy00LTEtMS0w_428b4132-4551-4896-812d-b940d9bf07fc"
      unitRef="number">0.010</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMy02LTEtMS0w_db1b7da6-bad4-407e-8f3b-a3c14e40bb41">P7Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="icef415129a23469b9ec147c98cb56572_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfMy04LTEtMS0w_01b120ac-085e-435c-a8c2-67aed3798b38"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNS0yLTEtMS0w_5793820d-340a-45c2-a637-84ff3b3272a1"
      unitRef="number">0.89</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNS00LTEtMS0w_1720ce9a-9949-4b82-8575-e7819a42bf91"
      unitRef="number">0.013</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNS02LTEtMS0w_4e946007-b82b-4974-8e47-1ccdb2c893a5">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNS04LTEtMS0w_471c1112-160b-422a-b872-c9ce45b9e1cb"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNi0yLTEtMS0w_9a266d34-1b70-4340-9e30-5b1a357da3c8"
      unitRef="number">0.77</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNi00LTEtMS0w_91692582-fc78-4251-972e-ef5fb6b80daa"
      unitRef="number">0.014</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNi02LTEtMS0w_6cbc053f-3924-4275-b2c8-650051de3d2d">P8Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="i2be5214e91e9420bbdb89fcf0d52072f_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjQxMjUzZTRiMDJlOTQ0ZDg4YmRkN2RiYTA3OWZlMjc2L3RhYmxlcmFuZ2U6NDEyNTNlNGIwMmU5NDRkODhiZGQ3ZGJhMDc5ZmUyNzZfNi04LTEtMS0w_7836d272-28e0-4bf1-bf87-9e29b42aecae"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NDI_7bdd83b1-9052-4e39-87ce-58194bf9b2da">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7680cb4d42ed478997941e9bf13624ac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfMi0yLTEtMS0w_fc5be4f0-e9da-4f17-8412-f644bdc64ab7"
      unitRef="shares">8397000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7680cb4d42ed478997941e9bf13624ac_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfMi00LTEtMS0w_26a6b191-ce3f-4661-9cc3-2f85e87e3fb5"
      unitRef="usdPerShare">7.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i1c017c3c99f6498daff3ecf3edf83a48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfMy0yLTEtMS0w_f23722a0-3c2d-42a4-ab9d-164c5833838d"
      unitRef="shares">957000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1c017c3c99f6498daff3ecf3edf83a48_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfMy00LTEtMS0w_f66a0da0-52f2-4106-affb-bff3187c845a"
      unitRef="usdPerShare">8.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNC0yLTEtMS0w_892e88a9-e0f3-4f2d-bc4b-bb76b5ed6673"
      unitRef="shares">-109000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNC00LTEtMS0w_ad82af43-0fb5-4d22-8e14-9fec6040cbf3"
      unitRef="usdPerShare">5.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i1c017c3c99f6498daff3ecf3edf83a48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNS0yLTEtMS0w_36df5324-1f2f-48e5-9e50-04bb00141515"
      unitRef="shares">178000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i1c017c3c99f6498daff3ecf3edf83a48_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNS00LTEtMS0w_6195749d-61e6-485c-9338-4992d607f6dc"
      unitRef="usdPerShare">12.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i1c017c3c99f6498daff3ecf3edf83a48_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNi0yLTEtMS0w_a9b03122-c91a-4ad1-ba79-71f367939d08"
      unitRef="shares">31000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i1c017c3c99f6498daff3ecf3edf83a48_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNi00LTEtMS0w_eea6bd36-eb26-4fb8-9cd2-fd381f22a4f1"
      unitRef="usdPerShare">10.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia6aa61cc7aaf43e6bbc474b8505cc3d4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNy0yLTEtMS0w_b56d5d17-e9f4-4f8b-a9ea-5699433b844f"
      unitRef="shares">9036000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia6aa61cc7aaf43e6bbc474b8505cc3d4_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfNy00LTEtMS0w_f814f4b0-c1e0-41db-9171-9b6572b9fe5e"
      unitRef="usdPerShare">7.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ia6aa61cc7aaf43e6bbc474b8505cc3d4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfOC0yLTEtMS0w_b9ac9a57-a425-4bab-a39f-ecee4380e5f6"
      unitRef="shares">5183000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ia6aa61cc7aaf43e6bbc474b8505cc3d4_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOmU3ODg4NzZiMDRhNDRkZGFhOGNjNjJiZWQ0NDBlZmVkL3RhYmxlcmFuZ2U6ZTc4ODg3NmIwNGE0NGRkYWE4Y2M2MmJlZDQ0MGVmZWRfOC00LTEtMS0w_03a48a4a-7b81-420c-bb5c-d102e6145bc0"
      unitRef="usdPerShare">8.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NjE_83333c66-c484-4319-b000-c47b84ebc6ec">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i05f812c6327541b6b09fdc249c90d7f2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfMi0yLTEtMS0w_5ad907d1-5c4c-4624-b249-42f81d0662ce"
      unitRef="shares">2769000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i05f812c6327541b6b09fdc249c90d7f2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfMi00LTEtMS0w_0398db2d-c491-4914-a4c1-ae1c47557a79"
      unitRef="usdPerShare">4.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id5f92e864c7242d5879f8636e1617415_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfMy0yLTEtMS0w_a914e004-fd89-4d30-ac3f-4d8fadb735c6"
      unitRef="shares">631000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id5f92e864c7242d5879f8636e1617415_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfMy00LTEtMS0w_c42cdf2d-fff9-4d0d-a144-dc0d5ab71a88"
      unitRef="usdPerShare">8.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="id5f92e864c7242d5879f8636e1617415_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfNC0yLTEtMS0w_71caaa3e-1273-4be7-9ec9-2d407d0b6f9f"
      unitRef="shares">1154000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="id5f92e864c7242d5879f8636e1617415_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfNC00LTEtMS0w_61eaef09-64ff-4304-9e21-6d7a912d78b5"
      unitRef="usdPerShare">5.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="id5f92e864c7242d5879f8636e1617415_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfNS0yLTEtMS0w_d9c47723-8309-4c89-9aeb-de9d6abe8f25"
      unitRef="shares">33000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="id5f92e864c7242d5879f8636e1617415_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfNS00LTEtMS0w_5d1930cb-b365-4e6d-867d-b7be9520fe4b"
      unitRef="usdPerShare">4.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4c83f6001ecc4b738df4e9c1c3f4412f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfNi0yLTEtMS0w_dfe5caec-6679-4efc-8850-ac6a34519ffa"
      unitRef="shares">2213000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4c83f6001ecc4b738df4e9c1c3f4412f_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RhYmxlOjkyMTE5NjU5M2UyZDQ2OGQ4M2ZkZGRkNjUyZjI2MjUyL3RhYmxlcmFuZ2U6OTIxMTk2NTkzZTJkNDY4ZDgzZmRkZGQ2NTJmMjYyNTJfNi00LTEtMS0w_781f5d25-76c5-4885-ad19-124502fdca9a"
      unitRef="usdPerShare">5.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNC9mcmFnOjIyMzRmZTlkODE3ZDQxMzE4Mjg5YjY3ZDRkYmM5M2NkL3RleHRyZWdpb246MjIzNGZlOWQ4MTdkNDEzMTgyODliNjdkNGRiYzkzY2RfMTQ3NjI_db774248-d1e6-4025-b173-5ac28440a935">Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl8zNy9mcmFnOjYxMWJkMjUyY2FkYzQ2NWQ4NDYxY2U1ZmMxNWJjZmMwL3RleHRyZWdpb246NjExYmQyNTJjYWRjNDY1ZDg0NjFjZTVmYzE1YmNmYzBfMTcyMw_294ebb37-3a79-4e96-b960-76e14e7761de">Recent Accounting PronouncementsIn December 2019, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12, Income Taxes (Topic 740) Simplifying Accounting for Income Taxes, as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, including interim periods therein. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the Company&#x2019;s condensed consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RleHRyZWdpb246MjAzNjQ5OGJiNWUxNDRjMWE2MTdiMDdiYjRjMzM4ZmZfMzQx_40d928a6-6f38-48cd-9706-5237f3d4d483">Cash and Cash Equivalents and Investments&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of cash and cash equivalents and investments held at March&#160;31, 2021 and December&#160;31, 2020 are as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no realized losses during either of the three months ended March&#160;31, 2021 and 2020, respectively.  The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RleHRyZWdpb246MjAzNjQ5OGJiNWUxNDRjMWE2MTdiMDdiYjRjMzM4ZmZfMzI5_563c9944-013a-462e-aed4-23175e42204e">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i5f6b3dae24ed4be1a4420f2bc0f76d2f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMy0yLTEtMS0w_296b5022-3bcf-45ad-a2db-836d2f8b0dc7"
      unitRef="usd">97652000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5f6b3dae24ed4be1a4420f2bc0f76d2f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMy00LTEtMS0w_b5439989-0f8b-4dba-a67b-2397241fc6fe"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5f6b3dae24ed4be1a4420f2bc0f76d2f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMy02LTEtMS0w_75f2c576-5177-4d10-b965-0cc20d96214f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i5f6b3dae24ed4be1a4420f2bc0f76d2f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMy04LTEtMS0w_164219e4-26e2-4c02-aa55-e8163d65c0d0"
      unitRef="usd">97652000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i0c1c834ecce44f16b35b81cf92f8af4c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNS0yLTEtMS0w_5ea7d1d0-90c2-4b8a-9346-0b2c7a4fb9d9"
      unitRef="usd">15243000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0c1c834ecce44f16b35b81cf92f8af4c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNS00LTEtMS0w_f4a5cf97-de2b-44d6-a830-9fbcdb1a6aa9"
      unitRef="usd">2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0c1c834ecce44f16b35b81cf92f8af4c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNS02LTEtMS0w_df88ee13-6baf-46f2-9077-3e8540487d3b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i0c1c834ecce44f16b35b81cf92f8af4c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNS04LTEtMS0w_c1001a33-c48d-4728-a067-7373525f2197"
      unitRef="usd">15245000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i291ed1f6abf04110bd6f3f96dfaf9687_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNi0yLTEtMS0w_3a320026-9297-47ad-b396-6988ad8f57c7"
      unitRef="usd">28461000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i291ed1f6abf04110bd6f3f96dfaf9687_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNi00LTEtMS0w_577d2179-de61-4a77-90ae-c33bc521f138"
      unitRef="usd">10000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i291ed1f6abf04110bd6f3f96dfaf9687_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNi02LTEtMS0w_8693ff7d-b9db-4df5-9ca9-9b4656d3c088"
      unitRef="usd">-7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i291ed1f6abf04110bd6f3f96dfaf9687_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNi04LTEtMS0w_af99e3c3-d9e3-4e1d-9b42-0201c759cd56"
      unitRef="usd">28464000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i4f3856fc70db4f0eb8819a27978a3fb5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNy0yLTEtMS0w_3ee64702-fc6b-4bba-8164-7458f8c6a7d1"
      unitRef="usd">43704000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4f3856fc70db4f0eb8819a27978a3fb5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNy00LTEtMS0w_30c161d0-bfeb-4f55-a2f1-cf9cbca4719d"
      unitRef="usd">12000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4f3856fc70db4f0eb8819a27978a3fb5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNy02LTEtMS0w_a2ed13b5-3f2b-4a4e-a535-6998bab7f439"
      unitRef="usd">7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i4f3856fc70db4f0eb8819a27978a3fb5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfNy04LTEtMS0w_70e57a9c-f3e9-49d5-a1cd-ddc631dac339"
      unitRef="usd">43709000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i25913c0c6d894c7284fdf1a62f452c6a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfOC0yLTEtMS0w_23715b06-371f-4ddc-89c3-4a7559f7e958"
      unitRef="usd">141356000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i25913c0c6d894c7284fdf1a62f452c6a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfOC00LTEtMS0w_c42cf2b9-8873-4d1b-b4c4-9aa46a5d1320"
      unitRef="usd">12000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i25913c0c6d894c7284fdf1a62f452c6a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfOC02LTEtMS0w_9f085a0f-4db4-4f95-891c-756a96bfa6b8"
      unitRef="usd">7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i25913c0c6d894c7284fdf1a62f452c6a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfOC04LTEtMS0w_53a6759b-c90e-4165-816f-3d22954766f3"
      unitRef="usd">141361000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i128725cdccf34310af9e7048fc57e23a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTMtMi0xLTEtMA_601024b8-7a1b-4a0a-b62c-9d672495d720"
      unitRef="usd">126263000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i128725cdccf34310af9e7048fc57e23a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTMtNC0xLTEtMA_204e5124-f56b-4dd8-a118-bc51f99db1bb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i128725cdccf34310af9e7048fc57e23a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTMtNi0xLTEtMA_1c1674bc-7c3a-4287-abf2-16038a98d263"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i128725cdccf34310af9e7048fc57e23a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTMtOC0xLTEtMA_5151e479-de70-4fff-ae49-cae273c198e0"
      unitRef="usd">126263000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="iafe798e7d357475783018b7f99e88eef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTYtMi0xLTEtMA_90adb7b8-c7a6-4680-94e2-e18544aa5614"
      unitRef="usd">26018000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iafe798e7d357475783018b7f99e88eef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTYtNC0xLTEtMA_c41f3d7a-42c9-4914-b644-f5b375a16579"
      unitRef="usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iafe798e7d357475783018b7f99e88eef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTYtNi0xLTEtMA_0e23800a-f6d6-4bd0-85ed-ac885a6b6362"
      unitRef="usd">11000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="iafe798e7d357475783018b7f99e88eef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTYtOC0xLTEtMA_28615ecd-3823-4fa2-820b-ed54e5f6e19b"
      unitRef="usd">26012000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="idce92942910c43e4903e00d0f785c79f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTctMi0xLTEtMA_f7d39b47-11ac-4284-ace0-8c4d7b22fc81"
      unitRef="usd">26018000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idce92942910c43e4903e00d0f785c79f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTctNC0xLTEtMA_f8c5ce2b-9c54-4df7-af7e-a3320a29d6c4"
      unitRef="usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idce92942910c43e4903e00d0f785c79f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTctNi0xLTEtMA_d52d74d4-563b-4622-905a-95988b8dbf41"
      unitRef="usd">11000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="idce92942910c43e4903e00d0f785c79f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTctOC0xLTEtMA_6d6e65da-f154-4279-901b-4c9992e850fe"
      unitRef="usd">26012000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i538c6f098f45484a9093e4c6f76257da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTgtMi0xLTEtMA_4517f1de-fc81-49c8-ac58-e6126d67f1b1"
      unitRef="usd">152281000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i538c6f098f45484a9093e4c6f76257da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTgtNC0xLTEtMA_0919bab1-985a-4314-afd7-687633af3a74"
      unitRef="usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i538c6f098f45484a9093e4c6f76257da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTgtNi0xLTEtMA_27102689-c6ea-42ee-be15-9561502a2cca"
      unitRef="usd">11000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i538c6f098f45484a9093e4c6f76257da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RhYmxlOjQ5NGYzMGM2NTY2NjQ1NmJhOTFhZjllZDhjYmUzNjgxL3RhYmxlcmFuZ2U6NDk0ZjMwYzY1NjY2NDU2YmE5MWFmOWVkOGNiZTM2ODFfMTgtOC0xLTEtMA_d5303031-b9b3-44ed-bea4-8c14fba333b3"
      unitRef="usd">152275000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RleHRyZWdpb246MjAzNjQ5OGJiNWUxNDRjMWE2MTdiMDdiYjRjMzM4ZmZfMTcx_2859c58f-ff8f-4090-9fe5-65e09a1f5e16"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80My9mcmFnOjIwMzY0OThiYjVlMTQ0YzFhNjE3YjA3YmI0YzMzOGZmL3RleHRyZWdpb246MjAzNjQ5OGJiNWUxNDRjMWE2MTdiMDdiYjRjMzM4ZmZfMTcx_767f91c5-f276-4bd0-bc42-75f7f33b15fa"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RleHRyZWdpb246NDIyYTQyZjFhMTQ2NDkzZjkwNDhmMGI1NjM5YmI5NWVfMjE2Nw_7e070745-fc32-4312-946e-3fb783483f3b">Fair Value Measurements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - significant unobservable inputs &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of March&#160;31, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any Level 3 assets or liabilities as of March&#160;31, 2021 or December&#160;31, 2020. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 5, Debt Obligations, for fair value measurements of debt obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RleHRyZWdpb246NDIyYTQyZjFhMTQ2NDkzZjkwNDhmMGI1NjM5YmI5NWVfMjE1Mw_a2c4cd34-6e83-4b97-85ef-fa5c92195b29">&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2f07d12ec62145c8975b2c25813bcab8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNC0yLTEtMS0w_40f14489-c3f3-45e3-90bb-16de555f14f0"
      unitRef="usd">97652000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie788a1a6bb1842ee842bbab7098f63f2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNC00LTEtMS0w_ae1aacb3-a1e2-44e5-b472-2c7bcb70958c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id00ac6a719fe4e628278d8c2ce3383db_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNC02LTEtMS0w_12652c0e-31c9-4a2c-b73b-86317c933415"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNC04LTEtMS0w_08c8d200-d0f2-437c-8ad8-c6ff731098d5"
      unitRef="usd">97652000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i2f07d12ec62145c8975b2c25813bcab8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNS0yLTEtMS0w_c9f01354-1e08-4f76-9d84-290b507ba821"
      unitRef="usd">15245000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ie788a1a6bb1842ee842bbab7098f63f2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNS00LTEtMS0w_67ebb1b0-2044-4552-86e0-204e17e322f4"
      unitRef="usd">28464000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="id00ac6a719fe4e628278d8c2ce3383db_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNS02LTEtMS0w_3a375ce7-2ea2-4667-bc96-f4c260ada7de"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNS04LTEtMS0w_9d73f7fa-9de5-4bf0-9787-37cd94a1e24d"
      unitRef="usd">43709000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2f07d12ec62145c8975b2c25813bcab8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNi0yLTEtMS0w_53d31b92-a0cb-4085-88a3-eb119cb6a848"
      unitRef="usd">112897000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie788a1a6bb1842ee842bbab7098f63f2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNi00LTEtMS0w_8c2d255c-8e65-44f2-96ba-f0e694e2e839"
      unitRef="usd">28464000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id00ac6a719fe4e628278d8c2ce3383db_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNi02LTEtMS0w_7030e007-39f7-4895-85e0-e60e5f9e1a6f"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOjQ2ZWRmNzUyNTRmZTRiMTQ4ZDlkMjk1MTcxN2Y2OWVhL3RhYmxlcmFuZ2U6NDZlZGY3NTI1NGZlNGIxNDhkOWQyOTUxNzE3ZjY5ZWFfNi04LTEtMS0w_a6f94dc6-c406-49b7-a872-d48a70d5463b"
      unitRef="usd">141361000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i01fc13da04a74ba9a24a1954fe5e09d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNC0yLTEtMS0w_2255cb66-90cf-4256-951f-342442f1637b"
      unitRef="usd">126263000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4e16817a1f8b455fa37d4b4d3496642d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNC00LTEtMS0w_58f7472c-dab2-4f56-879d-2ab35c098e11"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia420366f6ef2477b888780f5aa7343c4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNC02LTEtMS0w_ad7287ff-1272-42db-93d2-8e201fbe4c81"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNC04LTEtMS0w_c51b942b-570f-4acf-9fc9-22ea8a686147"
      unitRef="usd">126263000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i01fc13da04a74ba9a24a1954fe5e09d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNS0yLTEtMS0w_4f7ce04d-4a4c-430d-a652-1463beb2a60a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i4e16817a1f8b455fa37d4b4d3496642d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNS00LTEtMS0w_ddf4d82b-5400-47f7-92d8-dd516b4b0656"
      unitRef="usd">26012000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ia420366f6ef2477b888780f5aa7343c4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNS02LTEtMS0w_bea5cbff-3e98-4752-a229-ea3e28d6b795"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNS04LTEtMS0w_20cb257d-bdb0-43e7-9fac-b61126334595"
      unitRef="usd">26012000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i01fc13da04a74ba9a24a1954fe5e09d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNi0yLTEtMS0w_6b887248-1967-4ec3-877d-5921ea16712c"
      unitRef="usd">126263000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4e16817a1f8b455fa37d4b4d3496642d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNi00LTEtMS0w_2675cfbf-266f-49e4-a135-fea68b9e2350"
      unitRef="usd">26012000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia420366f6ef2477b888780f5aa7343c4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNi02LTEtMS0w_3f1206e0-a7eb-4d63-847d-799250eeb4ac"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80Ni9mcmFnOjQyMmE0MmYxYTE0NjQ5M2Y5MDQ4ZjBiNTYzOWJiOTVlL3RhYmxlOmJmNTJlY2Y2ODM5MDQ0MmRhNDE2NDBkYTNhZTI1YWMzL3RhYmxlcmFuZ2U6YmY1MmVjZjY4MzkwNDQyZGE0MTY0MGRhM2FlMjVhYzNfNi04LTEtMS0w_afa88c8f-190f-4d74-9a9f-c3d9b5532ae1"
      unitRef="usd">152275000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfODAwMQ_89160156-33ce-4d63-8582-24412225de66">Debt Obligations&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Debt.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of its 5.25% Convertible Senior Notes due 2021 (the &#x201c;Convertible Notes&#x201d;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#x2019;s condensed consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $75.8 million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principle amount of the Convertible Notes.  As of March&#160;31, 2021, the carrying value of the remaining Convertible Notes was $11.7 million and are included in the current portion of long-term debt, net of deferred issuance costs in the accompanying condensed consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The remaining Convertible Notes are governed by an indenture (the &#x201c;Indenture&#x201d;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bear interest at a rate of 5.25%&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Convertible Notes mature on December&#160;1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially 118.4553 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of $8.442 per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the remaining Convertible Notes was $12.6&#160;million as of March&#160;31, 2021 and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ie2fc5a7556d44214b71b2e8a010774b2_D20141101-20141130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfMTAz_7fd85960-57d0-4f22-9fe3-f4dd71cf5b58"
      unitRef="usd">87500000</us-gaap:ProceedsFromConvertibleDebt>
    <lxrx:ConvDebtInstrumentInterestRateStatedPercentage
      contextRef="icb9c8c0f84be4d2bb3ae691e86ab0e8b_I20141120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfMTQz_815ceef3-6053-48c3-a743-186ee89ea0fa"
      unitRef="number">0.0525</lxrx:ConvDebtInstrumentInterestRateStatedPercentage>
    <lxrx:ConvertibleDebtExchangeTotalPrincipalAmount
      contextRef="i1e1514570bdc407c8e2a1b9524eab9cc_I20200928"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfNTU3_6db3762d-fa16-41bf-a5ca-8f8b6ace1abb"
      unitRef="usd">75800000</lxrx:ConvertibleDebtExchangeTotalPrincipalAmount>
    <lxrx:ConvertibleDebtExchangeRemainingNotes
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfMTI4OA_c59aa68d-2d18-443f-a108-9be005a3870f"
      unitRef="usd">11700000</lxrx:ConvertibleDebtExchangeRemainingNotes>
    <lxrx:ConvDebtInstrumentInterestRateStatedPercentage
      contextRef="icb9c8c0f84be4d2bb3ae691e86ab0e8b_I20141120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfMTkxOA_815ceef3-6053-48c3-a743-186ee89ea0fa"
      unitRef="number">0.0525</lxrx:ConvDebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ie2fc5a7556d44214b71b2e8a010774b2_D20141101-20141130"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfMjY0NQ_e6aec397-f86e-4e1c-b25b-a208690c3a53"
      unitRef="number">118.4553</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="icb9c8c0f84be4d2bb3ae691e86ab0e8b_I20141120"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfMjc2Ng_afa41ad9-8850-45cf-9904-4a57221c50c1"
      unitRef="usdPerShare">8.442</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl80OS9mcmFnOjVjZTdlYWYwMzQ1MzQ5ZDNhZDM1NWY5NzBlZjc1ZTQ0L3RleHRyZWdpb246NWNlN2VhZjAzNDUzNDlkM2FkMzU1Zjk3MGVmNzVlNDRfNDE3Nw_5911f385-25ac-4f44-9ffd-18be40b13762"
      unitRef="usd">12600000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RleHRyZWdpb246YjdhOGU1YzMwMGIyNDhiM2I2ZGYxYjhlOGRiMjE5Y2JfMjgyNQ_84c16a73-11b0-4b09-bbdb-8c6318a04db1">Commitments and Contingencies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating Lease Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;Lexicon&#x2019;s operating leases include office space in The Woodlands, Texas and Basking Ridge, New Jersey that will expire in August 2025 and December 2022, respectively. Under its lease agreements, Lexicon is obligated to pay property taxes, insurance, and maintenance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, the right-of-use assets for the office space leases had a balance of $2.9 million, which is included in other assets in the condensed consolidated balance sheet, and current and non-current liabilities relating to the assets were $1.0 million and $1.7 million, respectively, which are included in accrued liabilities and other long-term liabilities in the condensed consolidated balance sheet, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: short-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against the Company and certain of its officers in the U.S. District Court for the Southern District of Texas, Houston Division.  Our motion to dismiss was granted and the action was dismissed with prejudice by the District Court on August 14, 2020.  The lead plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Fifth Circuit on September 11, 2020 and a brief in support of its appeal on December&#160;17, 2020.  We filed a response brief on February 18, 2021 and the lead plaintiffs filed a reply brief on March 11, 2021.  The lawsuit purports to be a class action brought on behalf of purchasers of our securities during the period from March 11, 2016 through July 29, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from our Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sanofi Arbitration.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  On October 16, 2020, the Company initiated arbitration proceedings against Sanofi-Aventis Deutschland GmbH (&#x201c;Sanofi&#x201d;) seeking to recover damages for breach of contract relating to the Termination and Settlement &lt;/span&gt;&lt;/div&gt;Agreement and Mutual Releases with Sanofi, dated September 9, 2019 (the &#x201c;Termination Agreement&#x201d;).  In September 2020, Sanofi withheld approximately $23.2&#160;million from the final $26&#160;million payment due to the Company under the Termination Agreement, offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by the Company under the terms of the Termination Agreement.  The Company disputes that at least a significant portion of such costs are properly reimbursable by the Company under the terms of the Termination Agreement and asserts that, in any event, Sanofi was not permitted to withhold any of such costs under the terms of the Termination Agreement.  The Company is seeking payment of up to $23.2 million in such disputed costs, together with late interest and attorneys&#x2019; fees and costs.  Sanofi is seeking declaratory judgment that the Company is liable for all disputed costs previously withheld and damages for any additional costs properly reimburseable under the terms of the Termination Agreement in excess of those previously withheld, together with late interest and attorneys&#x2019; fees.In addition, Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RleHRyZWdpb246YjdhOGU1YzMwMGIyNDhiM2I2ZGYxYjhlOGRiMjE5Y2JfMjc0ODc3OTA3ODQzMQ_80c21f17-ddaa-47ac-99dd-616c8634b774"
      unitRef="usd">2900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RleHRyZWdpb246YjdhOGU1YzMwMGIyNDhiM2I2ZGYxYjhlOGRiMjE5Y2JfMjc0ODc3OTA3ODQzNw_22173759-1218-45ab-8796-ac7a7bd80ebe"
      unitRef="usd">1000000.0</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RleHRyZWdpb246YjdhOGU1YzMwMGIyNDhiM2I2ZGYxYjhlOGRiMjE5Y2JfMjc0ODc3OTA3ODQ0MQ_69967cbc-fdf6-4c3d-afa1-ef48a719a2f8"
      unitRef="usd">1700000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfMi0xLTEtMS0zMjc_41107307-c2c7-4c6a-8b48-480d8e2c000b"
      unitRef="usd">644000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfMy0xLTEtMS0zMjc_03f85343-4aae-4a39-989f-9d21d625532d"
      unitRef="usd">1162000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfNC0xLTEtMS0zMjc_bbec3f85-a336-4fa4-a693-f949e3bf3eda"
      unitRef="usd">530000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfNS0xLTEtMS0zMjc_ad1453b3-1ba9-49ac-96d5-47a487ca1c38"
      unitRef="usd">543000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfNi0xLTEtMS0zMjc_15d74e3a-d264-46f2-9c0b-ef77da0fe043"
      unitRef="usd">369000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfOC0xLTEtMS0zMjc_e20af0b5-cc5b-4033-9628-77e7592975d3"
      unitRef="usd">3248000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfOS0xLTEtMS0zMjc_9d2c7120-df7c-422b-ba24-06038e9e00d4"
      unitRef="usd">505000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfMTAtMS0xLTEtMzI3_3bbc3048-ef0d-45c2-bc2e-241650bea0e7"
      unitRef="usd">2743000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfMTEtMS0xLTEtMzI3_894a5d53-23af-49e2-b700-765d6ad22ebb"
      unitRef="usd">-1026000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i87dc4e8dae904d17abf8d61c69bd8c76_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RhYmxlOjczNjI5YTdiMGYwZjQzNTZhOGM0NGVmNTZjZDVjOWU1L3RhYmxlcmFuZ2U6NzM2MjlhN2IwZjBmNDM1NmE4YzQ0ZWY1NmNkNWM5ZTVfMTItMS0xLTEtMzI3_5ff98325-6a5e-4feb-85aa-472de6c6bff2"
      unitRef="usd">1717000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <lxrx:Lxrx_Sanofiterminationcashpayment
      contextRef="i683e05dc441240d9a2492d0fd1aa4361_D20200901-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RleHRyZWdpb246YjdhOGU1YzMwMGIyNDhiM2I2ZGYxYjhlOGRiMjE5Y2JfMTg0OQ_496bba5f-b6e6-4fea-aaa5-5041dfe8d1cf"
      unitRef="usd">23200000</lxrx:Lxrx_Sanofiterminationcashpayment>
    <lxrx:Lxrx_Sanofiterminationcashpayment
      contextRef="i75c9ca72d87c4541bcbf8632f671f7ae_D20200901-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RleHRyZWdpb246YjdhOGU1YzMwMGIyNDhiM2I2ZGYxYjhlOGRiMjE5Y2JfMTg2OA_57f20955-b998-40ea-a629-d11753a92cb1"
      unitRef="usd">26000000</lxrx:Lxrx_Sanofiterminationcashpayment>
    <lxrx:SanofiDisputedCosts
      contextRef="id0d9a71689364f11b5b23e80ebdf0b0e_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81Mi9mcmFnOmI3YThlNWMzMDBiMjQ4YjNiNmRmMWI4ZThkYjIxOWNiL3RleHRyZWdpb246YjdhOGU1YzMwMGIyNDhiM2I2ZGYxYjhlOGRiMjE5Y2JfOTM0NTg0ODg0Nzg2MA_789a1969-b3db-4941-aad2-dd4182dd47c4"
      unitRef="usd">23.2</lxrx:SanofiDisputedCosts>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81NS9mcmFnOmNmOTc3MzZjMWQyODQ1YTVhYjMyNTIzZjM2M2QxNGI4L3RleHRyZWdpb246Y2Y5NzczNmMxZDI4NDVhNWFiMzI1MjNmMzYzZDE0YjhfOTgwNQ_c59f85dc-a23f-4340-96c6-60bde8d17830">Collaboration and License Agreements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ipsen.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#x201c;Ipsen Agreement&#x201d;), with Ipsen for the development and commercialization of XERMELO outside of the United States and Japan (the &#x201c;Licensed Territory&#x201d;).  The Ipsen Agreement was assigned to TerSera in September 2020 in connection with the XERMELO sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the XERMELO sale, Lexicon had earned certain milestone payments and royalties from Ipsen.  Revenue, including royalty revenue, recognized under the Ipsen Agreement was $0.1 million for the three months ended March&#160;31, 2020.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sanofi.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &#x201c;Sanofi Agreement&#x201d;), with Sanofi for the worldwide development of Lexicon&#x2019;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective as of September 9, 2019 (the &#x201c;Settlement Date&#x201d;), Lexicon entered into the Termination Agreement with Sanofi, pursuant to which the Sanofi Agreement was terminated and certain associated disputes between Lexicon and Sanofi were settled.&lt;/span&gt;&lt;/div&gt;Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications. Sanofi paid Lexicon $208 million in September 2019 and $26 million in each of March and September 2020 (less amounts withheld by Sanofi offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by Lexicon under the terms of the Termination Agreement), and neither party will owe any additional payments pursuant to the Sanofi Agreement. The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions.  See Note 6, Commitments and Contingencies, for additional information.  Beginning in March 2020, Lexicon closed out early the clinical studies related to the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease. Subsequent to the Termination Agreement, Lexicon has no remaining performance obligations to Sanofi.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lxrx:IpsenRevenueRecognized
      contextRef="i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81NS9mcmFnOmNmOTc3MzZjMWQyODQ1YTVhYjMyNTIzZjM2M2QxNGI4L3RleHRyZWdpb246Y2Y5NzczNmMxZDI4NDVhNWFiMzI1MjNmMzYzZDE0YjhfMjc0ODc3OTA4NjcxMA_1525b865-cbf7-4520-ae8a-b8bf242d63ea"
      unitRef="usd">100000</lxrx:IpsenRevenueRecognized>
    <lxrx:SettlementPaymentFromTermination
      contextRef="i404c6b80bc36405880a95d223586358a_D20190901-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81NS9mcmFnOmNmOTc3MzZjMWQyODQ1YTVhYjMyNTIzZjM2M2QxNGI4L3RleHRyZWdpb246Y2Y5NzczNmMxZDI4NDVhNWFiMzI1MjNmMzYzZDE0YjhfODc3NA_2ea9840f-adf7-4d03-8740-b052849eecfe"
      unitRef="usd">208000000</lxrx:SettlementPaymentFromTermination>
    <lxrx:Lxrx_sanofiInitialCashPayment
      contextRef="i2747cad63b6941889a2232ada4034c1e_D20200301-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81NS9mcmFnOmNmOTc3MzZjMWQyODQ1YTVhYjMyNTIzZjM2M2QxNGI4L3RleHRyZWdpb246Y2Y5NzczNmMxZDI4NDVhNWFiMzI1MjNmMzYzZDE0YjhfODc5OQ_cab57cdc-a476-4600-9b82-7ed3c3a7856d"
      unitRef="usd">26000000</lxrx:Lxrx_sanofiInitialCashPayment>
    <lxrx:Lxrx_sanofiInitialCashPayment
      contextRef="i75c9ca72d87c4541bcbf8632f671f7ae_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl81NS9mcmFnOmNmOTc3MzZjMWQyODQ1YTVhYjMyNTIzZjM2M2QxNGI4L3RleHRyZWdpb246Y2Y5NzczNmMxZDI4NDVhNWFiMzI1MjNmMzYzZDE0YjhfODc5OQ_f96386bc-0cad-450a-a64f-738db56f4082"
      unitRef="usd">26000000</lxrx:Lxrx_sanofiInitialCashPayment>
    <lxrx:OtherCapitalAgreementsTextBlock
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzkzNDU4NDg4MzY5ODk_1878b2d8-5f52-4b6c-a396-42d2dde07034">Other Capital Agreements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  In 2020, Lexicon entered into an Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;sales agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) relating to the shares of its common stock.  Lexicon may offer and sell common stock having an aggregate sales price of up to $50.0&#160;million from time to time through Jefferies acting as its sales agent.  In 2020, Lexicon sold 3,709,233 shares of its common stock at a price of $1.992 per share pursuant to the sales agreement, resulting in net proceeds of $7.0&#160;million.  In January 2021, Lexicon sold 2,000,000 shares of its common stock at a price of $8.463 per share pursuant to the sales agreement, resulting in net proceeds of $16.4&#160;million.  The net proceeds are reflected as issuance of common stock in the accompanying condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</lxrx:OtherCapitalAgreementsTextBlock>
    <lxrx:ATMOfferingTotal
      contextRef="i0953aa39e2f84e829c3acc2d7f88a6a3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzI3NDg3NzkwNzAxMDQ_64ffa68c-c071-42ab-9676-dfe5eb22e33e"
      unitRef="usd">50000000.0</lxrx:ATMOfferingTotal>
    <lxrx:SharesSoldInNov2020ATMOffering
      contextRef="i0953aa39e2f84e829c3acc2d7f88a6a3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzI3NDg3NzkwNzAxNjI_581888bf-4627-493c-b064-cbf5dde1ea26"
      unitRef="shares">3709233</lxrx:SharesSoldInNov2020ATMOffering>
    <lxrx:SharePriceInNovember20ATMOffering
      contextRef="ie9cf39493d3443c4a790590a54c215b8_D20201001-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzI3NDg3NzkwNzAyMTU_cabc7b0a-866f-465f-8ed6-70a4abd37f7a"
      unitRef="usd">1.992</lxrx:SharePriceInNovember20ATMOffering>
    <lxrx:ProceedsFromNov2020ATMOffering
      contextRef="i0953aa39e2f84e829c3acc2d7f88a6a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzI3NDg3NzkwNzAyOTE_22181dd5-0541-4f23-aaad-6ff8021f70da"
      unitRef="usd">7000000.0</lxrx:ProceedsFromNov2020ATMOffering>
    <lxrx:SharesSoldInJanuary2021ATMOffering
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzI3NDg3NzkwNzAxMTE_aaed9182-4b47-4352-aed0-c1ccffb85b1a"
      unitRef="shares">2000000</lxrx:SharesSoldInJanuary2021ATMOffering>
    <lxrx:SharePriceInJanuary2021ATMOffering
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzI3NDg3NzkwNzAxMTU_509717e2-3156-403e-af5c-b94526dc45ba"
      unitRef="shares">8.463</lxrx:SharePriceInJanuary2021ATMOffering>
    <lxrx:ProceedsFromJanuary2021ATMOffering
      contextRef="i361ed8ee3d41432ca64245bde358c770_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1ODkyZGNjZTI1NTQ3YTE5ZDYzZjA2NGQ0OTY3N2ZmL3NlYzphNTg5MmRjY2UyNTU0N2ExOWQ2M2YwNjRkNDk2NzdmZl84OTQvZnJhZzo1ODcxMDI1ZWE2ZTA0M2Q2OGY1Mzc3ZGYxNGRlYzU4NC90ZXh0cmVnaW9uOjU4NzEwMjVlYTZlMDQzZDY4ZjUzNzdkZjE0ZGVjNTg0XzI3NDg3NzkwNzAxMTk_c2198df8-597d-47b7-a91e-0fcbf72c7daa"
      unitRef="usd">16400000</lxrx:ProceedsFromJanuary2021ATMOffering>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283821194232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8800 Technology Forest Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,387,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283822074168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets-Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 97,652<span></span>
</td>
<td class="nump">$ 126,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">43,709<span></span>
</td>
<td class="nump">26,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,954<span></span>
</td>
<td class="nump">5,049<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">145,416<span></span>
</td>
<td class="nump">157,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $5,851 and $5,815, respectively</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">44,543<span></span>
</td>
<td class="nump">44,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,005<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">193,260<span></span>
</td>
<td class="nump">203,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,926<span></span>
</td>
<td class="nump">5,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">22,409<span></span>
</td>
<td class="nump">29,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net of deferred issuance costs</a></td>
<td class="nump">11,660<span></span>
</td>
<td class="nump">11,646<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">38,995<span></span>
</td>
<td class="nump">46,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,718<span></span>
</td>
<td class="nump">611<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">40,713<span></span>
</td>
<td class="nump">47,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 5,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 225,000 shares authorized; 145,552 and 142,289 shares issued, respectively</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,580,891<span></span>
</td>
<td class="nump">1,561,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,420,976)<span></span>
</td>
<td class="num">(1,400,018)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 1,165 and 793 shares, respectively</a></td>
<td class="num">(7,518)<span></span>
</td>
<td class="num">(4,843)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholder's equity (deficit)</a></td>
<td class="nump">152,547<span></span>
</td>
<td class="nump">156,371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 193,260<span></span>
</td>
<td class="nump">$ 203,788<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283822604664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets Parentheticals - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConsolidatedBalanceSheetsAbstract', window );"><strong>Consolidated Balance Sheets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization, property and equipment</a></td>
<td class="nump">$ 5,851<span></span>
</td>
<td class="nump">$ 5,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">145,552<span></span>
</td>
<td class="nump">142,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">1,165<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Balance Sheets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283821169000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss-Unaudited - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Netproductrevenue', window );">Net product revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaborative agreements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalties and other revenue</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">7,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales (including finite-lived intangible asset amortization)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, including stock-based compensation of $1,286 and $2,176, respectively</a></td>
<td class="nump">12,609<span></span>
</td>
<td class="nump">55,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Sellinggeneralandadministrativeexpenses', window );">Selling, general and administrative, including stock-based compensation of $1,565, and $2,256, respectively</a></td>
<td class="nump">8,257<span></span>
</td>
<td class="nump">14,688<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">20,866<span></span>
</td>
<td class="nump">70,437<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(20,839)<span></span>
</td>
<td class="num">(62,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(5,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,958)<span></span>
</td>
<td class="num">$ (66,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per common share, Basic</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per common share, Basic</a></td>
<td class="nump">143,379<span></span>
</td>
<td class="nump">106,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 776<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(20,947)<span></span>
</td>
<td class="num">(65,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">2,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense', window );">Stock-based compensation expense associated with selling, general and administrative expense</a></td>
<td class="nump">$ 1,565<span></span>
</td>
<td class="nump">$ 2,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Netproductrevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Netproductrevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Sellinggeneralandadministrativeexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Sellinggeneralandadministrativeexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense associated with selling, general and administrative expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283817592664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss Parentheticals - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConsolidatedStatementsOfOperationsAbstract', window );"><strong>Consolidated Statements of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">$ 1,286<span></span>
</td>
<td class="nump">$ 2,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense', window );">Stock-based compensation expense associated with selling, general and administrative expense</a></td>
<td class="nump">$ 1,565<span></span>
</td>
<td class="nump">$ 2,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConsolidatedStatementsOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Statements of Operations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConsolidatedStatementsOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense associated with selling, general and administrative expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283821882584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,958)<span></span>
</td>
<td class="num">$ (66,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,851<span></span>
</td>
<td class="nump">4,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) decrease in accounts receivable</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">26,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">(Increase) decrease in inventory</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other current assets</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="num">(2,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease in other assets</a></td>
<td class="num">(74)<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and other liabilities</a></td>
<td class="num">(8,418)<span></span>
</td>
<td class="nump">15,137<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(25,159)<span></span>
</td>
<td class="num">(22,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(21,686)<span></span>
</td>
<td class="num">(33,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(17,724)<span></span>
</td>
<td class="nump">42,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">16,947<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(2,675)<span></span>
</td>
<td class="num">(923)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt borrowings, net of fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="nump">14,272<span></span>
</td>
<td class="num">(1,244)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(28,611)<span></span>
</td>
<td class="nump">19,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">126,263<span></span>
</td>
<td class="nump">36,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">97,652<span></span>
</td>
<td class="nump">55,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_InitialRecognitionOfRightOfUseAsset', window );">Initial recognition of right of use asset</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">$ 16,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_InitialRecognitionOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial recognition of right of use asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_InitialRecognitionOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283820069192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity/Deficit-Unaudited - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 117,101<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 1,462,172<span></span>
</td>
<td class="num">$ (1,341,444)<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="num">$ (3,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,432<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,432<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(923)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(923)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,611)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(66,611)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">776<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">776<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2020</a></td>
<td class="nump">54,777<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">1,466,604<span></span>
</td>
<td class="num">(1,408,055)<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="num">(4,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">142,289<span></span>
</td>
<td class="nump">142,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 156,371<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">1,561,096<span></span>
</td>
<td class="num">(1,400,018)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(4,843)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,851<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,851<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">16,399<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">16,397<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(2,675)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,958)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,958)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2021</a></td>
<td class="nump">145,552<span></span>
</td>
<td class="nump">145,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 152,547<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">1,580,891<span></span>
</td>
<td class="num">(1,420,976)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(7,518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 547<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283817497800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Notes)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month period ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information, refer to the financial statements and footnotes thereto included in Lexicon&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2020, as filed with the SEC.&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2021, short-term investments consisted of U.S. treasury bills and corporate debt securities.  As of December&#160;31, 2020, short-term investments consisted of corporate debt securities.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.163%"><tr><td style="width:1.0%"/><td style="width:52.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future minimum lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon uses its incremental borrowing rate of 9% at the commencement date in determining the present value of future payments. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Company&#8217;s sale of XERMELO and related assets to TerSera in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (&#8220;Ipsen&#8221;).  Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#8217;s net product revenues reflected the Company&#8217;s best estimates of the amounts of consideration to which it was entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs were considered a fulfillment activity when control transferred to the Company&#8217;s customers and such costs were included in cost of sales.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Agreements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Product shipping and handling costs were included in cost of sales. Cost of sales also included the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#8217;s estimates of the clinical study costs and costs to transition activities from Sanofi for the development of sotagliflozin for type 2 diabetes and heart failure, as well as the wind down of those activities, were based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that conducted and managed the clinical studies on its behalf.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.&#160;&#160;The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the three months ended March&#160;31, 2021 and 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,036&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, Lexicon also granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three annual installments.  The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,213&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283817538536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements Level 1 (Notes)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RecentAccountingPronouncementsAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy</a></td>
<td class="text">Recent Accounting PronouncementsIn December 2019, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, Income Taxes (Topic 740) Simplifying Accounting for Income Taxes, as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, including interim periods therein. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RecentAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recent Accounting Pronouncements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RecentAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283817400136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents Disclosure</a></td>
<td class="text">Cash and Cash Equivalents and Investments<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents and investments held at March&#160;31, 2021 and December&#160;31, 2020 are as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,356&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,361&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no realized losses during either of the three months ended March&#160;31, 2021 and 2020, respectively.  The cost of securities sold is based on the specific identification method.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283817303656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value, Measurement Inputs, Disclosure</a></td>
<td class="text">Fair Value Measurements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - significant unobservable inputs </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of March&#160;31, 2021 and December&#160;31, 2020.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,897&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,464&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,361&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets or liabilities as of March&#160;31, 2021 or December&#160;31, 2020. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5, Debt Obligations, for fair value measurements of debt obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283817607816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure</a></td>
<td class="text">Debt Obligations<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Debt.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of its 5.25% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s condensed consolidated balance sheets.  </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $75.8 million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principle amount of the Convertible Notes.  As of March&#160;31, 2021, the carrying value of the remaining Convertible Notes was $11.7 million and are included in the current portion of long-term debt, net of deferred issuance costs in the accompanying condensed consolidated balance sheet. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The remaining Convertible Notes are governed by an indenture (the &#8220;Indenture&#8221;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bear interest at a rate of 5.25%&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Convertible Notes mature on December&#160;1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.  </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially 118.4553 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of $8.442 per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the remaining Convertible Notes was $12.6&#160;million as of March&#160;31, 2021 and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283817529992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure</a></td>
<td class="text">Commitments and Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Lease Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;Lexicon&#8217;s operating leases include office space in The Woodlands, Texas and Basking Ridge, New Jersey that will expire in August 2025 and December 2022, respectively. Under its lease agreements, Lexicon is obligated to pay property taxes, insurance, and maintenance costs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the right-of-use assets for the office space leases had a balance of $2.9 million, which is included in other assets in the condensed consolidated balance sheet, and current and non-current liabilities relating to the assets were $1.0 million and $1.7 million, respectively, which are included in accrued liabilities and other long-term liabilities in the condensed consolidated balance sheet, respectively.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at March&#160;31, 2021:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"><tr><td style="width:1.0%"/><td style="width:80.632%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,743&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: short-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,717&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against the Company and certain of its officers in the U.S. District Court for the Southern District of Texas, Houston Division.  Our motion to dismiss was granted and the action was dismissed with prejudice by the District Court on August 14, 2020.  The lead plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Fifth Circuit on September 11, 2020 and a brief in support of its appeal on December&#160;17, 2020.  We filed a response brief on February 18, 2021 and the lead plaintiffs filed a reply brief on March 11, 2021.  The lawsuit purports to be a class action brought on behalf of purchasers of our securities during the period from March 11, 2016 through July 29, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from our Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi Arbitration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  On October 16, 2020, the Company initiated arbitration proceedings against Sanofi-Aventis Deutschland GmbH (&#8220;Sanofi&#8221;) seeking to recover damages for breach of contract relating to the Termination and Settlement </span></div>Agreement and Mutual Releases with Sanofi, dated September 9, 2019 (the &#8220;Termination Agreement&#8221;).  In September 2020, Sanofi withheld approximately $23.2&#160;million from the final $26&#160;million payment due to the Company under the Termination Agreement, offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by the Company under the terms of the Termination Agreement.  The Company disputes that at least a significant portion of such costs are properly reimbursable by the Company under the terms of the Termination Agreement and asserts that, in any event, Sanofi was not permitted to withhold any of such costs under the terms of the Termination Agreement.  The Company is seeking payment of up to $23.2 million in such disputed costs, together with late interest and attorneys&#8217; fees and costs.  Sanofi is seeking declaratory judgment that the Company is liable for all disputed costs previously withheld and damages for any additional costs properly reimburseable under the terms of the Termination Agreement in excess of those previously withheld, together with late interest and attorneys&#8217; fees.In addition, Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283817632600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure</a></td>
<td class="text">Collaboration and License Agreements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ipsen.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#8220;Ipsen Agreement&#8221;), with Ipsen for the development and commercialization of XERMELO outside of the United States and Japan (the &#8220;Licensed Territory&#8221;).  The Ipsen Agreement was assigned to TerSera in September 2020 in connection with the XERMELO sale.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the XERMELO sale, Lexicon had earned certain milestone payments and royalties from Ipsen.  Revenue, including royalty revenue, recognized under the Ipsen Agreement was $0.1 million for the three months ended March&#160;31, 2020.   </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &#8220;Sanofi Agreement&#8221;), with Sanofi for the worldwide development of Lexicon&#8217;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of September 9, 2019 (the &#8220;Settlement Date&#8221;), Lexicon entered into the Termination Agreement with Sanofi, pursuant to which the Sanofi Agreement was terminated and certain associated disputes between Lexicon and Sanofi were settled.</span></div>Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications. Sanofi paid Lexicon $208 million in September 2019 and $26 million in each of March and September 2020 (less amounts withheld by Sanofi offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by Lexicon under the terms of the Termination Agreement), and neither party will owe any additional payments pursuant to the Sanofi Agreement. The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions.  See Note 6, Commitments and Contingencies, for additional information.  Beginning in March 2020, Lexicon closed out early the clinical studies related to the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease. Subsequent to the Termination Agreement, Lexicon has no remaining performance obligations to Sanofi.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283817317160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Capital Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OtherCapitalAgreementsTextBlock', window );">Other Capital Agreements</a></td>
<td class="text">Other Capital Agreements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  In 2020, Lexicon entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;sales agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) relating to the shares of its common stock.  Lexicon may offer and sell common stock having an aggregate sales price of up to $50.0&#160;million from time to time through Jefferies acting as its sales agent.  In 2020, Lexicon sold 3,709,233 shares of its common stock at a price of $1.992 per share pursuant to the sales agreement, resulting in net proceeds of $7.0&#160;million.  In January 2021, Lexicon sold 2,000,000 shares of its common stock at a price of $8.463 per share pursuant to the sales agreement, resulting in net proceeds of $16.4&#160;million.  The net proceeds are reflected as issuance of common stock in the accompanying condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OtherCapitalAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Capital Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OtherCapitalAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283822600808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2021, short-term investments consisted of U.S. treasury bills and corporate debt securities.  As of December&#160;31, 2020, short-term investments consisted of corporate debt securities.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Company&#8217;s sale of XERMELO and related assets to TerSera in September 2020, product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (&#8220;Ipsen&#8221;).  Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#8217;s net product revenues reflected the Company&#8217;s best estimates of the amounts of consideration to which it was entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs were considered a fulfillment activity when control transferred to the Company&#8217;s customers and such costs were included in cost of sales.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Agreements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div>The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods and Service [Policy Text Block]</a></td>
<td class="text">Cost of Sales:  Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Product shipping and handling costs were included in cost of sales. Cost of sales also included the amortization of the intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#8217;s estimates of the clinical study costs and costs to transition activities from Sanofi for the development of sotagliflozin for type 2 diabetes and heart failure, as well as the wind down of those activities, were based on estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that conducted and managed the clinical studies on its behalf.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text">Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock', window );">Recognition of Asset and Liability for Lease of Acquiree</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less.</span>Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future minimum lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon uses its incremental borrowing rate of 9% at the commencement date in determining the present value of future payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election not to recognize asset and liability at acquisition for lease with remaining lease term of one year or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 25<br> -Paragraph 28B<br> -URI http://asc.fasb.org/extlink&amp;oid=121564365&amp;loc=SL77931625-128468<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283833242040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Equity Incentive Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract', window );"><strong>Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.163%"><tr><td style="width:1.0%"/><td style="width:52.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,036&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,213&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283817562008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,356&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,361&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283817534584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value, by Balance Sheet Grouping [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,897&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,464&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,361&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,263&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,012&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283821821064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details) - Equity Option [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</a></td>
<td class="nump">105.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283819241240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="num">(109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">9,036<span></span>
</td>
<td class="nump">8,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.16<span></span>
</td>
<td class="nump">$ 7.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="nump">957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 8.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</a></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 12.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 10.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">5,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 8.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">2,213<span></span>
</td>
<td class="nump">2,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 8.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="nump">1,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 5.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 4.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283833292184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Accrued Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedLiabilitiesLineItems', window );"><strong>Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedResearchAndDevelopmentServicesCurrent', window );">Accrued research and development services current</a></td>
<td class="nump">$ 16,505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,962,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedCompensationAndBenefitsCurrent', window );">Accrued compensation and benefits current</a></td>
<td class="nump">3,552,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="nump">1,026,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(553,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Liabilities, Current</a></td>
<td class="nump">1,326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">976,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="nump">$ 22,409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,691,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LexiconIncrementalBorrowingRate', window );">Lexicon incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedCompensationAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation and benefits current - due within 1 year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedCompensationAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedResearchAndDevelopmentServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development services current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedResearchAndDevelopmentServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LexiconIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lexicon incremental borrowing rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LexiconIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283816204184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 97,652<span></span>
</td>
<td class="nump">$ 126,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">97,652<span></span>
</td>
<td class="nump">126,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">15,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">15,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Total Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">43,704<span></span>
</td>
<td class="nump">26,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">43,709<span></span>
</td>
<td class="nump">26,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">141,356<span></span>
</td>
<td class="nump">152,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">141,361<span></span>
</td>
<td class="nump">152,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">28,461<span></span>
</td>
<td class="nump">26,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">$ 28,464<span></span>
</td>
<td class="nump">$ 26,012<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283821001512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized Investment Gains (Losses)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283820192472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 97,652<span></span>
</td>
<td class="nump">$ 126,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">43,709<span></span>
</td>
<td class="nump">26,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">141,361<span></span>
</td>
<td class="nump">152,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">97,652<span></span>
</td>
<td class="nump">126,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">15,245<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">112,897<span></span>
</td>
<td class="nump">126,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">28,464<span></span>
</td>
<td class="nump">26,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">28,464<span></span>
</td>
<td class="nump">26,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283815546904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 28, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 20, 2014 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="nump">$ 87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvDebtInstrumentInterestRateStatedPercentage', window );">Conv Debt Instrument Interest Rate Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt Instrument, Convertible, Conversion Ratio</a></td>
<td class="nump">118.4553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,552<span></span>
</td>
<td class="nump">142,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchangeRemainingNotes', window );">Convertible debt exchange Remaining Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount', window );">Convertible debt exchange - Total Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvDebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvDebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchangeRemainingNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible debt exchange Remaining Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchangeRemainingNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible debt exchange - Total Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchangeTotalPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283819212264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_Sanofiterminationcashpayment', window );">Sanofi termination cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_Sanofiterminationcashpayment', window );">Sanofi termination cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term Debt and Lease Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,717,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Lessee, Operating Lease, Liability, Payments, Due Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,162,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Lessee, Operating Lease, Liability, Payments, Due Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Lessee, Operating Lease, Liability, Payments, Due Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Lessee, Operating Lease, Liability, Payments, Due after Year Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, Operating Lease, Liability, Payments, Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,248,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,743,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCommitmentAmount', window );">Short-term Lease Commitment, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_Sanofiterminationcashpayment', window );">Sanofi termination cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_Sanofiterminationcashpayment', window );">Sanofi termination cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiDisputedCosts', window );">Sanofi Disputed Costs</a></td>
<td class="nump">$ 23.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Lxrx_Sanofiterminationcashpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Lxrx_Sanofiterminationcashpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiDisputedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sanofi Disputed Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiDisputedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918705-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283821813992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_Sanofiterminationcashpayment', window );">Sanofi termination cash payment</a></td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueRecognized', window );">Ipsen Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_sanofiInitialCashPayment', window );">lxrx_sanofi initial cash payment</a></td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SettlementPaymentFromTermination', window );">Settlement Payment from Termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Lxrx_Sanofiterminationcashpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Lxrx_Sanofiterminationcashpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Lxrx_sanofiInitialCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>lxrx_sanofi initial cash payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Lxrx_sanofiInitialCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SettlementPaymentFromTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Payment from Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SettlementPaymentFromTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283845469816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Capital Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ATMOfferingTotal', window );">ATM Offering Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesSoldInNov2020ATMOffering', window );">Shares sold in Nov 2020 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,709,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharePriceInNovember20ATMOffering', window );">Share price in November 20 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ProceedsFromNov2020ATMOffering', window );">Proceeds from Nov 2020 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesSoldInJanuary2021ATMOffering', window );">Shares sold in January 2021 ATM offering</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharePriceInJanuary2021ATMOffering', window );">Share price in January 2021 ATM Offering</a></td>
<td class="nump">8.463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ProceedsFromJanuary2021ATMOffering', window );">Proceeds from January 2021 ATM Offering</a></td>
<td class="nump">$ 16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ATMOfferingTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ATM Offering Total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ATMOfferingTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from January 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromNov2020ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Nov 2020 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromNov2020ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price in January 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInNovember20ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price in November 20 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInNovember20ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesSoldInJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares sold in January 2021 ATM offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesSoldInJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesSoldInNov2020ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares sold in Nov 2020 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesSoldInNov2020ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140283818978984">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_InitialRecognitionOfRightOfUseAsset', window );">Initial recognition of right of use asset</a></td>
<td class="th" style="border-bottom: 0px;">lxrx_InitialRecognitionOfRightOfUseAsset</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_InitialRecognitionOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial recognition of right of use asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_InitialRecognitionOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M.L3".,8C(),69'(AM$!74C_;D)JMM#,Y:A, B0U00%:7=6%+5\Z Q3).&VX
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MRDIC /^OI=3'!S- \[EG^3]02P,$%     @ :(2F4C!).0J; @  8 8  !@
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M    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULG5E1<YLX$/XK&D\?DIFZ1L*
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M47SPV2Y7+3UX\?IEK9?FP;2_UO<-OKU(JQ1V;2IO7:4:LWAU]&9R]_:"QO.
MWZQY\MEG12>9.?>%OGPL7AV=$4&F-/.65M#X]VC>F;*DA4#&[V'-H[0E3<P_
MQ]7_PF?'66;:FW>N_(<MVM6KHYLC59B%[LKVLWOZJPGGN:3UYJ[T_%<]R=C+
MBR,U[WSKUF$R*%C;2O[KKX$/V82;LP,3IF'"E.F6C9C*][K5KU\V[DDU-!JK
MT0<^*L\&<;8BH3RT#7ZUF->^?A!A*+=0#W99V86=ZZI5;^9SUU6MK9;JWI5V
M;HU7QW]WK?$G+U^TV)=FOYB'/=[*'M,#>YRKGUW5KKSZ4!6F&,Y_ 7H3T=-(
M]-OILPO^K)NQ.I^,U/1L.GEFO?/$A'->[_S_SH3_?C/S;0-=^N<S^UZD?2]X
MWXM#^WYKLU_,UU:]+=W\RS_WL?W9U<F<[WRMY^;5$>S5F^;1'/W(4=]J;ST-
MO*?95:O)C.[4+RL#6YJ[=:VK#4WH*MT5MC6%FCL(N/+RR6.=0M/CA:UT-;>Z
M5!Z+&)ATR^O^S7RU&*CN5QKV-3=="V)*/U(?J_E8'?_[O]U,IV<_A5'\;?*3
M<HUJ04'X\9V0$7X\42O]:-3,F$KAR+5NL+NMF-RF  T&UM6NU-)4IM%EN:%?
M3$TTZIX!=6-!;5V"!7!ZF-^:QJZS4]A*G"%[E:I0==?XCKC8.J:MZ6@N_=*8
M95?R0#XP_?A@YEUC6QM&?/@Z7^EJ:11.LK:>?5T\^<.'=_%@8Y904X"^<C.B
MA3:J<*IR+:B9EUT!F91EW&.;P(5S;47&"X)^[RQQ9;;Y,2Z0O$O3FKW"'$-B
MO+&K;46;@HZUKN#4Z><1DZ:+?\&;B>R/23VLYWTPM")B2] &SC3T+!M[PJID
M"T-$5V9NO"?U)9*T6FC;J#K3SDS^@2W%6'VJ<4S>"R/AK.5 1&Z[:HPY79-S
M4AAD7:$,N2@%!S-?)0^CH$?,ZKB_!<]L54!;*:1$KL?5VY5N<?P-Z%#F:XWP
M0S80MMP8W81-WF.U]<PT:9_QKFW]B$5%16C#(MV6F9$F6#QZ6CD(_=0]55C)
M=S-PU^),AL4(70_;*[BYRNNY:"]-GNF2;,@S/TQI$8Z8&EA83QU&CQ4"IEIT
M#2AI<F4<41C'HV G>T\QU%=:P6!XE";ME3F$R?5/-*/J6'UJU[0*!Z5PK29G
MI__Y/5P_@WI"(VR)W]@YL)%^>#=6OWH6[0?H*<@W7ER?^!71-OQZ0!+$$#JV
M;3>RZJ_CA_'W6UPP4Y]9$3%MK;^ \9$>9I7V@%.UR(@53R\6T+B@D,01VF2=
ME 'C3>!R:?7,EKTK*JR?E\YW#1\;!R"J:.?!0%F:U##J_4$Q'J*A,8^FZL*N
M9"%0<*^*CFV?)HDMDL]K1;)B6.!4260N2(<6C5MCL/,91\;JG?:K$?]5'\#"
M1UTF:AY6(.3T%P/=^%@]FN!?[I)Y1#_CV5VM@.9@)*7%*J1U:8*(TS5VB6.7
M$$D;W3FS PY%K07M0/<@2T^"@R>8$TVFIPFGXRE#5S-2GLELB<Q\U^ QP4C,
M865J@<$A++@96Y9R1$0(<)M$4YA9JWP*-7&S/<K_/?L]LRZ91!:$V2 /+$E>
M8UY" 0$Z2"'PY%';4L]*<PI;.?5@3+:VJ#?-T8@*-*$5AP\&=F;$6+P@<_^]
M<T0G8,T7)#&PHKE)T?8 J>J1T#U[PV_0D U@;])YP^:-2$6FX22VD/4AUNNF
M8(G'S5LMA+&*; 9&$_;8P,U4$&1I_\#()9*H8)O.DTW@=+Z#>N04-;E1X3M^
M9(=D.$:[BLE:8'.@1GAZTN@@&58_VO+OX-/!34>">""VX!4>8155(3OG?C@-
MPT.W-L+@N?.R?4\Q @/&^UY@?'[$10*?BA9O&8:R2UT;V#2;_KSIS,!)W>U[
M.%14=D>(;NX)KN1NQ\+V&\&$+4$=6Z+,=1ZG!NR(>Q&ZX 68&?!<I:O9'Q.@
M9E7[DYI<C2[/+O$!!GQ[-4US22!P;CT0FR$ +$CKSD>7EU-U-4+N+(Y)L;F4
M,&F3CK=1D]'9]$I=7IZK3QQ+)Z-S?+^]OMK+"NP_'5V<W=*'V]'5[02^#>ME
M/JXPM WR!.@^8@$[>4IF2#P,\H"C6!L")9J%:VJ)=M#^FD3DBEY>@>EQ(0CN
MFXMB9]O2XT>S\1(D*'4F/\E3D0/3PT["KZZ2BK#"(WP%]!<0&\1F(H@6I"I^
M/$"1=V%)]VB:?%W&R=L+KXVNA"2R8[CR%2QLYN#PC_7)D%0WHU,Q?FJ!_:V$
M]1Z#&]#AUE#P)/,0L084R+:D&L>SK0T* ( 0R+<GC'N!.HB2H*FN:^S?KL#S
M#%(PT*(0R9P/L8M40'S4DRD!7X\GTY.MF)6#9A$:DW7J%J=$2P8B\-$A]I/]
M#96W]U64MXC'H ,$$*FDY!3@A$R%N<"RY@)WV%D.7$8 ^N+_&7MU+8$5Z+-=
M=]%X:KV1<"-A=ZV!B)/L$QR7L<0)#HVL#$APD/C",]+.5M@:#8;]/_D\+"R\
M'"49=,19*P"\8>*!"V:N:=@+R7*@]O;/\;2[Y[2]:28,=."T\7QC]5E@%/[/
M'3)YR<[O&U=T4)O/$6/=PT@2XMZ)U!3NL/9_??C\\X>_?0HY:ZG;:!',1F"F
M!V@#4?E J)6=IZ"'.FR7(-T6;L!!&X&&NI2H'+<*ZO!KQ96#AS8AVC1RUI5?
M5$N<;P<S0=''&KP)=0/U\.8AI<S\0Y\TWV^3]V2"2H)A%/R>5D;HD%(;SB5V
M+0F7.(ZT\PC#+2*!FW/X+\0=%LB$H%^;R..XTA!P9'MN\0Q9)4=,LF!X55*T
M4*V11/41N1D_'3BV40C%G"Y3P)/,C!U@/ JTL8!>CA) )N'.B-$C!8?9+/%E
M_@5?"/DS.J<$#5I6R;.VL;..O7R(=6IA:"Y):4DV5;$&IS49JL!A_FPH-0:C
M[S4"VWL0CK%(8P U:HRVZUG7^#Y58C4@1 M^Y6A>A#5P 6M"%Z7]8LC7<D(1
M  ,?')IK'JD.LT#T<0#RD:"(UF)DHJ2"50U:UV'D)B9<3!.QM@ /&T9L.F2D
M$*!FO4[LG76<HG,%2(P2_UM8<74 %U<,3[<T$AEQ*3YIGX'."%_U'(E!H,^E
M!DI!*B@J"C?VA(-3>&LILQUPL0\ 4K4@GTAUC X)<E/&N@-SRO<VY%>VKN.!
M$6Z+4@;Z-D@J*]1H>*L2.77)7.'*.V?"9&TIQE-Y 9D<C3_@GB*K@V,@:6;[
MY5@TP4YR'A3T2T!V2EGH7&^6R,I$W9);Y+-B6CY.]^-B+85C/\R24M1DL))J
M!9"3\&'X=6CVB*)4!O!#9(J4^9'2 U/[?:X_:':?*1-_D@,AA89X X,E\H1M
M.+"Z66F7(2>14QI-3FLAZ4XZXQT0[TF$0)L!BCL&_F6HH),(?L+H[>'[=XTF
M'1?CF9B:L*?H8%]<DI2-ACV>L"^;4TC<.R@JRO?M+)[J&*OVS(L<954\)ASI
M3W+=4X36_<)*[>G 1D,9L^/F\=:S9$])L@2339E +=F2;&H9&,,/S-BK<]$F
M)^ )4F7%C.AO:.(R/1DVU\:& )CF+)TK&,VE+ 7SHL7YW5#UILU@>T3\HP%=
MA <X*=V_/@ZTMCX4T8@DS=8:)9%E'H)(I5C5'&)Q0I>R)SC'"1"OFK8B*C(B
MB#$%EY4I$<E%U!+CDQ)P6I],:V!P![2.:+4^*6=R6)GS/*"2.WIV2'5]TKQB
M2'O(.?UNJ2\$+?6OKEC&$N'0RB@U*4YUZ2JJ.)1E*#/.15&$F0?HZ5.C+:OZ
M+F4Q!%LEB ?)Y:GSVL)+MZX**4(6.))9$/XS4K,'E112J%:8 F$F-<'Y>3#8
M+\3.1_]Z$$6,U<?%7OO4RF>795%UZ'^#B",F2^D"(\-13-1B8K3WZ '86_]M
MTL?J_7[F)1NBO8/=)5&YE(I&H03?$,*9R2&DV*0HE'"=+ZX(&L&]-0[$CM).
MS\H+TK*@%N 8^E.&A;<$'L>(HN^*:MO4GE-4JJQ(SB(Q]9#"S^@V<\1Z+Q I
MYTSF&@X&B.\RW#?BLDW%^0_3+<4Z)H0+%J.MG4][6Y&\CS@JY1_*"H15:]/[
MIT.61/Z25Y3\C:0$UMHJQ$&[Z._/1N&*3=###KYDO%Z6^S3Q#85(AM79?=X@
MSV>!S+MU%T0"*<Y7IUT=)2#<?^):?KBLR& 8MWH$C!:T.=1YB!EI3[YQ'."U
ML*Y.:.T IJ2J)<=62@+ ;*P.3E/DB)ZS2$%$2C:._=>A,+7K*!-9VY+>KV.9
M21(9>V!Q--ATJ9(>D*&PDW)<(\I*C'VU*0R62[F,91+4 LYEW'PJ64+C-KJD
M^DWN(#)%2[D$%?2@B@EWC[;/4M!>1?#0H:A1."JG0'61]Z_[A(6C:=PXZ' Z
M[S,LC 4D#&^($,*TB:W1%$))@9PS.4%&LFG0 ;M.E'D@))J5U?:$T(U4!^FR
MN?=6Z5%R"NQ$:F3"4B),ST^&89XNC'$^PU@BUK!8B%QS"A+/N$_7/B09ZM,J
MN.,  H(V6+\271P@L+'ZM<9JG*-NLIM6LUVFTR2VH'^1R5SG8.+J5K$#Q0$+
MNH2A-81R@2(R59=Y\M+T]2GBJDZ5++'K&"?V)$UT\MUT)DA64OVDT'!-(2O>
M/DZZ"Q?VLL$DZ6^[A[P4G:-NVIPNX_D8NJ044S+.!]*MN_155&WK4L(VQ2EI
M $FYZJ@Z(7>=G,PB)C7<.R9>N@IU7_+!*Z.+D/%F<((SL^UZV@_DZ<_FS?DI
M=.FSF_< N:#'?PQ*_W"H2#TL<;6OSL=:70^Z.!91#9G:E&+5IB_,I@H5_!A2
M6RC\@D'%Y((O[[G<F5W$Y(#H0[A!OAL.R<-DNF0.@I'*B9=$7VIYL<D%RG#J
M:VIG:$1]G@QUK_BM6L'!:Z%0[(@WCM[T&[&G#>*52JNL<1K]5))YHC?>@88'
M3% D&>N;^:IRI5MNDM=E@^8L,/YF<Z#8P=:X"&FK9X[ BO-(8 \Z0 4M.7.P
M6XXT.4V2UB:J'OHK$<70)^M^VC8W!(0Y%(+ZOJ2L$K^T#:;[/$&4IJ7<F((X
M7,.Q:LU51Z3.ANXEJ<2Y4Z)QS5)707V%MQ+;X:<*1SI&(3(GR;>(?C&PI428
MK]Y\+R1QR>PD>ST&U40)E3UQ=FI-33U410ILB<0LO#:&>FEA-D+.+BV]<C"4
MEGO C 9:N.JX2(^=:YR6W;VI&BHJ])L773,P9-I@L[]RN8,0!U1MHH^JHK<B
MX$(XQO:=MW(CQ 'M05=N85.M(E<]\CT.3(/YE^X/*"D/VM1&36$Y>F;B+0',
MI.%^@!(J.<KME)9\LJ32[BF<C5*0GHC15F%YYW"IIB' )43ED((N0%&Z76)1
MD'/,6P"S>@]Y:@#AEKIZHI;UJ.;S)S%,BBO=/.J%M/P4NVRVTA! 07%F5KI<
M; $(AQA+ZP>)!X'W0!1@%\%2VA-V%A[<_/3R"@C4?&VYO.V\MY(4-ZY;KJ0%
MH.(6'>FHP-)<,T\="D,4+A8\9$5/"A"A>K3X=Z!^W@NJ,#6G6"%AMFM#4<4'
M?TDX3\\W*5\B@BB'M47T(3T%TK71!RG==CZE;LPQO1:)N582!G[B:7^VT:UJ
M+Q -':;,2R!Y@//#(HU=["12?9,C@4Y*OI%Z#2Y#\_9.NJ\4_033'JCGX_0M
MCWN7]1[<[;^*\L,&A>!7XC7G@=;#80LO+="8%37I(T!0 PE;K%_A)"&=B'@S
MSR:X.46YNG?$U$B"#%-VH!^[BH@ LZM8!(#S=!N^@,IO,VR3=07YJ!)YJPVO
M,>J;^_8>.KN?2Z"D;S (N665B"! F'II05Q0K[X2N:<F*^?23]"W*"HYR%Z"
MN,>!QHH;<5T[R%02%O5"2D\]Y65#L,6)]X]O^9W[;7$KY9U%K.+O768KXQ9W
MFE>3Y))5#%.<331U0:+];>E@S;4)I=]>*5(W5%(XZ[- O=71R-J2X=:WI0;7
M'N8K1Y XU@E_V?E%UCZE,@GGRUS]3WV< I3K3B)<-_M7J!IG-=VQ>FOFNO-F
M+U!*BC<\"<,TNLN%SP;_<:BYSVN5\$/2+TGN.VN9)--H-)=K9*51*!X(!:*Y
MJ0*3$2R'R$O1V(9:W$P36F#Z_M-,!)'=Y 2RIM9TO- X/@K1)O2&,Q-];'3/
MNZ^CO7'I3Z['26(E918ZMK"V.VK U:Z]G S8KVL0XP0);-_*/:-00WSHS9*B
M2ANZ0I+2510+GYQ:N;6C3F#7D7]S79U[-/.5&B9"+0>TM*?40$DT"-U2YY>>
M%-9Y@@*/UC5\=T]]LC36<@U.W$^L2F4BZWQ(>%(_C!"I2HDC?P7_@:HI*'/P
MM&$*>>$@R""H[>F+[&:!SS;F](P'/3JJ"')A<[L;<-5OF(_:GZ(+ZT,],@]L
M*;G9M5N)Q5:ZUV"83*0<9;]\>X<=SC;PF"$L94&EO]M]XF3>%*<Z=#WDG.?@
M.+#@&.%B\3_O(-[_,@(4@YIO[GK._M;S[+/U7TX7M,;'V)[YF<25QG(#]/O0
MU+FU-I:,059-SB[5G]79^ )_+_AUF\GT)WS^M(!GB5?R%3Q>LB?); E4W9YA
MX&1,?Z^SJ8/-SO+-;FYYPOG_8J_K:YY*9-YD4W\9R,1RGVS_ZM- LJD]0<I+
MVZ\7^$-ALRYUM?4NR7."NU.?@LC_$31$O0D:\B$:_3U?56QUHG[J6K[6X)I.
MN]O#K6Y&Y[?7ZD_J>CR9JO\(^G1[>:UNQN?7:?%"'4_.;D_4Y?CLG-2!H<OQ
MY/KF1$VFX\M+<H +P]U8Q^<3/#RCY;8VW]+%V]'9^17M>Q6W85>\._!R-+DY
M!XDWXZMS];[O]/\FU_HV.ZY&)6O)''GV!L@^##D>G"%IT ' ^2@-S8&PL+"M
M,%]2J9":'%:M ^O^ORG9 T'O/3K&>J'>DR_X4?V:CJZOJ*GX8GQ^F?3KZGQ"
M^G6C?C-<Z#R>C":7%Z1>T^N!*IV?8.+5]3<T:3J:3DA!H)U3M>_5RA?9.ZYK
MTRSY35Y^)Z1JY777]#2]+/Q&WI'MA\N;QMAZ20W)I5E@ZMGX^O)(ZK[Q2^MJ
M?F-VYMK6K?DCE>5,0P/P.[V?%+_0!ND5ZM?_ U!+ P04    " !HA*923(X6
M7Y0#  "P!P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;)U5;6\B-Q#^
M*Z.M=$HDCF47TN0N@ 2YGAJI%Z&0M!^J?C#K6=8ZK[VQO0?\^\YX@9#HDDK]
M O9ZYGF>>?%XO+'NNZ\0 VQK;?PDJ4)H/J>I+RJLA>_;!@V=E-;5(M#6K5/?
M.!0R.M4ZS0>#7]-:*)-,Q_';PDW'M@U:&5PX\&U="[>;H[:;29(EAP_W:ET%
M_I!.QXU8XQ+#8[-PM$N/*%+5:+RR!AR6DV26?9Z/V#X:_*EPXT_6P)&LK/W.
MFULY208L"#46@1$$_?W &]2:@4C&TQXS.5*RX^GZ@/XUQDZQK(3'&ZO_4C)4
MD^0J 8FE:'6XMYO?<1_/!>,55OOX"YO.=O0I@:+UP=9[9U)0*]/]B^T^#R<.
M5X,W'/*]0QYU=T11Y1<1Q'3L[ 8<6Q,:+V*HT9O$*<-%609'IXK\PO0>"S0!
M9D5A6Q.46</"64/K BGUP<,?^ ,U9'!V9P/Z\W$:B)5]TV+/,.\8\C<8AO#-
MFE!Y^,U(E"_]4U)[E)P?),_S=P&_"=>'8=:#?)!G[^ -CRD81KSA_TW!W[.5
M#X[ZYY]WV$9'ME%D&[W!=D>-^B95#Q96JV+WLRR_#_M?0=P:^$(F]0H=Y2W[
MU(-0(7R=+>>@O&]1GKHN@S!2..GAL9$B()Q]^.4JSP?7L^5C7&77YW!G^Q'I
M8Y;WX-84MD9X$%OT</9@&U7 Y6AP#DM5-UJ5.X8]8:!I\L*G!\)#(UP 6X*B
MG"NC@A)\8R%8NOVR+1#(OM&X56%'YS$ \0SI#Z+[\$ GZU9)0=&#H/BI\:!
M%VA(@52^T-:W#@GVJ55N7^50B0"5D+#"J(LY"="$'M PXS1(L#S.&G0>";$/
M,RD5SQ:A]8X3JOPK6G\JD&-FS<H$=*H&PE%6 I8E32C/@1>5,&OT,3BQ!2TV
MGBD=<7.&C 3?I5.1D?#-P>]5)IBH=*2"!"$CX>N<D-".EO/+YL*85NB])$\I
M6"MC&$N4)/:Y=;*+>.T&/=)8Z%:RR<MX.)'H4)F.4DC;Q/%+,JE[#AUSJ%^I
MG _PU%+E"9UL^$Y3B208R]4@>8+&'1.0/ J>;B'8SO>&ND&8'3=D=GGMJ3NH
MSL9SJ:WQ=(^ZFI7*4,SL3AT2NF+W?W:1TY,I6J-;Q[>"82FMW4 ]?CT^1[-N
M"C^;=V\9C2A*H >-);D.^I<7";CN?>@VP39Q)J]LH D?EQ4]J>C8@,Y+2]-V
MOV&"XR,]_1=02P,$%     @ :(2F4O#"7\^& P  .PD  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&ULQ59M;]LV$/XK!\T8$D"SWFTWLPWDI6_ "@1-
MTWT8]H&6SA91BG1)*F[VZW>D9-5.DZS=/NR#K>.1SW-W?$2>YCNE/YD:T<*7
M1DBS"&IKMV=19,H:&V;&:HN29M9*-\S24&\BL]7(*@]J1)3&\21J&)?!<NY]
MUWHY5ZT57.*U!M,V#=/W%RC4;A$DP=[QGF]JZQS1<KYE&[Q!>[N]UC2*!I:*
M-R@-5Q(TKA?!>7)VD;OU?L%'CCMS8(.K9*74)S=X6RV"V"6$ DOK&!@][O 2
MA7!$E,;GGC,80CK@H;UG?^5KIUI6S."E$K_SRM:+8!9 A6O6"OM>[=Y@7T_A
M^$HEC/^'7;>VR (H6V-5TX,I@X;+[LF^]/MP )C%3P#2'I#ZO+M /LLK9MER
MKM4.M%M-;,[PI7HT)<>E$^7&:IKEA+/+2V9J8+(";[S\W/([)E!:XYUOY1T:
MV[CQ/+(4SH&BLJ>^Z*C3)Z@S>*>DK0V\E!56Q_B(TAQR3?>Y7J3/$KYC>@Q9
M$D(:I\DS?-E0>^;YLO]:._QQOC)6TQOTYS-A\R%L[L/F/QSVBIM2*--J?&RW
M_RWKPV(^U AKQC70@A9!K:'<8[V!#[#\ %NCJ(!9("G*>M#"+[O"$IL5ZKTW
M!J81F(&U$G3TS1F<&Q?L ?2\4=KROY 25\;":ZV,@5M)%XSPWM=TL9AOW;_1
M&.G5,I;3T23'*U?11U_1"9=@:]4:2LN<PN63U8W@Q32<%"D9/_\T2Y/TUR.K
MG[S!LM7<<@I'H<B4&SJDMJ8H2B+<(]-G<#N^&8.E]$B]>S!?(4D1IGD&Z<#K
M'055J[=*4^ITAZSL(2*=A?DD@22&D^EI-\KA@[),@*EILWZQJ)LC54:09^$T
MSLE(7#$.U_M>],COEY@X\B3,BLDQFW=26IV(WXK]_^J8I),PG61/"+F?_2XE
MGQ%F$L;)# HX29+3;I3^DS ]9D2H48<;'2-_2)@B#=-9<LSFG=/"'6LZ;SOW
M)Q4,&RRZ#:ZZ:I&J)=5(07K23R-"T]W2Z&[IQPZVDS<D0K-%WT+%_=C?(:73
MF9@.=L@HNAZX\7VRHCWU41R.KWD)O*(ZG,5\0VZ0Q*W&C]VHT4%#:U!O?-LV
M%+&5MNMM@W?X,CCO&N+7Y=UG!16T<6^>P#5!X_&T"$!WK;H;6+7U[7&E+#5;
M;];T=8/:+:#YM5)V/W !AN^EY=]02P,$%     @ :(2F4F9UY<PI!0  'PT
M !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULK5=;;]LV%/XKA%<,+>#:
MEGS)I4F )%VQ LT6)&GW,.R!DFB+"T4J)&77_?7[#G6)G-O:82\)19[SG>]<
M21]MC+UUN1">?2V4=L>#W/OR<#QV:2X*[D:F%!HG2V,+[O%I5V-76L&SH%2H
M<3R9+,8%EWIP<A3V+NW)D:F\DEI<6N:JHN!V>R:4V1P/HD&[<257N:>-\<E1
MR5?B6OC/Y:7%U[A#R60AM)-&,RN6QX/3Z/!L1O)!X(L4&]=;,_(D,>:6/CYF
MQX,)$1)*I)X0./ZMQ;E0BH! XZ[!''0F2;&_;M$_!-_A2\*=.#?J#YGY_'BP
M/V"96/)*^2NS^54T_LP)+S7*A;]L4\O.I@.65LZ;HE$&@T+J^C__VL2AI[ _
M>48A;A3BP+LV%%B^YYZ?'%FS89:D@4:+X&K0!CFI*2G7WN)40L^??.#2LB]<
M58)=".XJ*Q!Q[X[&'N D,DX;H+,:*'X&:,HNC/:Y8[_H3&2[^F.0ZIC%+;.S
M^$7 "VY';!H-63R)HQ?PIIVGTX W_3%/V9^GB?,6U?'7"T9FG9%9,#+[5R/#
MOA7V49>5=T/V7KI4&=I^*L+?B[WKP$TNV+DI2JZWK'+"L36WTE2.R6 4_U"F
M7EA4C]0KYB&^)*AU@#)+)H/06CA? W*=L:*VX$C<"<:=$SBA-D(KII6U!(5V
MD&[$3NM#4E.2)U))+Z$).6-1"XS[OD'0(0JI09UHAV.LG%$RXQX?"5=<IX*%
MB@:FA20.5L;*;W2\#<I*K(4BZB;YF]I[+?V6.)I4!I2-]'D0;$)0D1UO6J_H
M"'SN28U"$)=&84:18P&_MIY)^.'5%NZH@ T80N:%J9!8<'#5]Y& 8F>1AY$$
MY9WP/HC@(?OYI_TX7KQCGX*_$7O+[BI#V*65J0BIK<<:1H*])0B,:2816"]3
MKOI9';)-+M,<6ZFJ,L$^CZY'S-L0D"USE-,Z;;LV8]@T((DY+E=:+@%+7B=.
MV#5/5.?<ZQJ7@K=+D0@Y64C%[2Z=FC&R;ZU)C TADTV;")^.WCQ@[$BT#(*H
MY\0_SWD*SGVVE7[,]^8^+R!8")^;S"BSVM:U0JPI3^1/SPX5A#:>:0'7'-H,
M=<$U@#)8ZJ64I59DTC,KW>VCDJBC0,BA%0SR?V_B827Z0+JT9BVSNAO[O53T
MYP!,\[)48$(J[41H2LOGZ$*BWZ@\[,JG.ANU11T<:)B'IIL6P06(,06TQ*RI
MCHD%)C?2UH[N4-7O$; B014UNY.=J?&I-S5 JS?HG@1LNZ&MT#;K-\:CYE_7
M4:T<D-V;ULPY=WFPE=)"W%42;H2PO6('>\/%/,:"RBB*W^VLFL/KW%C_EJ;H
MSJB,YL-X-F?Q_G"VF'5:L^EP;W+0\$F?M4R;?;!7+(KBX?[!'E8-8I])-(N&
MTT7T(X%[%/;_/791O!C&B^DSP6M/GXE>*PBI210__/P/X>O(-! [7.;Q,-Z;
M[UR7F<Q"/^><BA<;;3C:^\[NW&A/5B-DGJCN&\NU6PKK6"+\1@C=OU/H9L1X
M^E9W8;A-4E_!6;H#NQ$B;5H5SH?K,+1ORNM[#(>^@0_C H@;$293MW]OMDUX
M*)<FZ5EEVY= *?!6R!PF#.XAC1DU8E<" -3QOV&.LSD>+31M?T^47(49A_E,
MX_&%,13&L[E7&#WULAKW'JV%L*OP-*<ACVNU?K]VN]WK_[1^]-Z+US\=D)&5
MU XA7D)U,MJ;#S!ZPW.\_O"F#$_@Q'@\J,,RQR\884D YTL#5YL/,M#])CKY
M!U!+ P04    " !HA*92.OO(T:X&  "4$   &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6R56-MRVS80_16,FG;:&86ZV(H]C>T9.VFGZ?2227IYZ/0!
M)%<2:A)@ %"*_KYG%R0MQ;*:OEB\ (NSN^?L+GVU=?X^K(FB^EA7-ER/UC$V
MWTXFH5A3K4/F&K)XLW2^UA&W?C4)C2==RJ:ZFLRGTQ>36AL[NKF29V_]S95K
M8V4LO?4JM'6M_>Z.*K>]'LU&_8-W9K6._&!R<]7H%;VG^'OSUN-N,E@I34TV
M&&>5I^7UZ';V[=TYKY<%?QC:AKUKQ9[DSMWSS9OR>C1E0%11$=F"QL^&7E%5
ML2' ^-#9' U'\L;]Z][Z]^([?,EUH%>N^M.4<7T]NARIDI:ZK>([M_V!.G\6
M;*]P59"_:IO6SK&X:$-T=;<9"&ICTZ_^V,5A;\/E](D-\V[#7'"G@P3E:QWU
MS95W6^5Y-:SQA;@JNP'.6$[*^^CQUF!?O'E->52_YI59:8Y2N)I$6.5WDZ*S
M<)<LS)^P<*9^=C:N@_K.EE0>[I\ S0!IWD.ZFY\T^+/VF3J;C=5\.I^=L'<V
MN'@F]LX^TT7UUVT>H@<?_CYA_7RP?B[6ST]9?VU"4;G0>CH6O\\PL _OE;,;
M\M'D%2E^F:DW5OWB-E3GY!&4V?E8_40?30%2%ZYN*HI4*FV56R[)&[O"A7IV
M>9$M0)BJ8NX;T'^U\H0C2#584YA&5TK7KK61EYL8U"*;+[X\./T]6>,\SHX4
M5-F29$1]'=>DOOKB<CZ?OMQ?+<OD^>SE-YGZ#:L*>2T"7I*.B(\J3:FLBZKF
MBL.6"F\B8&N%"J-RLVQ]H9-@ U3_H34>WN4[M2)+7E?5#DHNJ!&?BX(=8)<[
MIRH U;84PX0W_HB[6S%<.%^RB: J9U?/ :&&FI$*G,R[7R&RVN[8G]G%R\"N
ME*A%V(*KX"I3:H:0ZTK;@I0H,$BJ$*3I>-\&(R'VPMCH5*!&>^P=,[(-+N"1
MI96+1@S2QV*M[8J0,$^$\H?,8-?P^-G%(KL<$GLZJPG#)QF2.+,/ID0\)=(;
M7;4<BZ@NP8!NXQ#1_S*8J=O +Z';8CT(-T6@T-[O.#]R1&_"$[<+?OP8'6?G
MV6R673SXB'QJ)!)PJK:4,";;K?<(CVJ<%R]@_#"58\158*-*DY<$A-!*N@H7
M$-?.$--($L6(/B?/B=RGO&"\*TC6VT1>S1J$79' OH#>]$][X8Q5.E!+3!]D
M_V+<23^GN"4Z(*F$Z$]TMJ"^UW[EU)VV]V/U2W:;C=E0]&@D1 GV8[ Y:<_<
M!$=#9!9HQ03E\U--: !@AT6@K-YIWABH-MK:5O3(U07AU3ZP>'YL+:F90'I-
M14(_8UND08]D)J>5L1*Z88.XMW@*8IV*!U8_V$P\ZW>D0-1Z)]4%R89XGA
MF T)0%3\6BR;N).PCP6VA4B-O6=XR]8R:[#%;0QSC\7SA I^<!44%9X6'H-+
M%5$JG_''B-._<DTJ@L@&_(H8A YQ<[^1%.4MP%((?>$:[DL<9^J:2I.*#(:V
M C?PZI'?F?J]D6[2E^O#^K6%$B&B"O.3EPA(*I_-QM/I]&CAZ;Q$O(YXJ&PK
M"<2ZL(900M^ H,(:*##S%/<*E1\F>V<?^D@JG2!U20&M(W^H!X.4'O4>8;-A
MO1M46:;L;':9G2\69WL(#DYGQI_P[[%77W.G0I'C@@30HG<Y;!\'3!64NG-V
M?CZ74P3 I^<_;I^]"Z'-_\% *V>4_T#6W"$X L&!(;21?I&W,>6,I9!3M[)C
MK]2+HO!2\<'NUC;:E(/^I87ILC11:+!T%>9V*8QP&/4.H#PJ+L/I3HMKD-05
M*,<GE?6(4 @KB@9(?"3#":E:BZ34=HT&R'.\M,)>0DR9QXD0A-9V0__6Q#5B
M!K;J3X'+RMXGXXNV#I%+/#?QY0%:U !"517N<D'0''/.K'3D<8<RZ;N;6 [V
M [.G!G/-FKV5]JL#$"$&73[V6MB)PG#L]'W+B5Z#<&;3Z:?-_#.F VS,]ZV6
M*/I5&TY1!GO&PCD,*>C0($O*]FFTJ>XPS9<:'O_/ 6&>O7@8$(Z,'X)S*V6"
MYP'#?9@+XPJC\X8J-0?ZIF6ML(]][42/-CQ];E(P9;!L,9JCZTL;[_EB *J3
M7HY6&SB/^**0XEJQ_:>[P!AL-LQ'D(3E">,Q 6 B!"I8,P9^#A,?;']HW; H
MA?UY22@V8$^++T09&'A-&N?"#B;K[-C'S63O2[$&J>5[F"LO.)$^&H>GPR?W
M;?K2?%B>OM<1;S1QC,^TQ-9I=K$8*9^^@=--=(U\=^8N J-<KDE#*;P [Y<.
M3G4W?,#PCXB;?P%02P,$%     @ :(2F4L^L(]9Z!P  =!   !D   !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&ULI5A=<]NZ$?TK.VJF8\_(DDA)_HKM&=F^
M:6XFN?'$2?/0Z0-(@A(:D& !T++ZZWL6H"C)]SJ=MB\622SV"V?/+GRU-O:'
M6TGIZ;G2M;L>K+QO+L=CEZ]D)=S(-++&2FEL)3Q>[7+L&BM%$395>IQ.)J?C
M2JAZ<',5OCW8FRO3>JUJ^6#)M54E[.96:K.^'B2#[8<O:KGR_&%\<]6(I7R4
M_EOS8/$V[K44JI*U4Z8F*\OKP2*YO)VQ?!#XJY)KM_=,'$EFS ]^^;6X'DS8
M(:EE[EF#P,^3O)-:LR*X\<].YZ WR1OWG[?:WX78$4LFG+PS^KLJ_.IZ<#Z@
M0I:BU?Z+6;^773QSUI<;[<)?6D?9>3J@O'7>5-UF>%"I.OZ*YRX/>QO.)Z]L
M2+L-:? [&@I>W@LO;JZL69-E:6CCAQ!JV WG5,V'\N@M5A7V^9L[4U7*(\O>
MD:@+NC.U5_52UKF2[FKL88(%QWFG[C:J2U]1-Z5/4+!R]$M=R.)P_QBN]?ZE
M6_]NTY\J_"3LB*;)D-))FOQ$W[2/=QKT3?^7>.E>N5P;UUI)?UMDSEN YN\_
ML3KKK<Z"U=G_:?6/$OY3S5RSEZX1N;P>H"B=M$]R\!_,?6ZD%?Q.'R7P3)\S
MK9:":\31);X]J]S4?_[3>9J<O75D>FG-THY4G>NVD&3*4N62@G%\I*\K2=^-
M*30LNB%]E<\B6K\5[@?O_Z**I1S2;ZC4#](ZN2&_$AYXUYKD<Z-L4+-HET ]
M'_<\[+Z7N:PR:?E+.@0/N$:&2M:;$7T#RBPIA!F<([&T4H:XA]M 2"&&&*$L
MR!MJQ(8:RV%Y>"">)615C>R+.H=[;)/)S,N:/U!N'%B/%M!2$M"8KWHX#A&
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M:7Q.'=X.,V#8>-.%OOM@/'7QL&QH;*)E!3JOC/&[#3L8!_'R'U!+ P04
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MU/WM6+!P-LV$DPV7_1X180)/--P3(X1IBUBS*Z26 @5G"H*,9,N@ WY=. M
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M7I[__..);#P_1-?S]73(/KJ6?U*];#P-P/>E<S$_$('R'Q;>_#]02P,$%
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MU_X)FSJV-P@@K[2199-L&91,U"M];G382AC&.Q)(DT \[[J09WE.#9V,E-R
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M965T,C$N>&ULS5E;<]HX&/TK&F8?VID$6S+FTB',D$MW,[-)F-"D#YU]$+;
MFM@6E>20_/N59&.[V"842EH>P!=]\CG?D?0=B^&*\2<1$"+!2Q3&XJP52+G\
M9%G""TB$19LM2:SNS!F/L%2G?&&))2?8-T%1:"';[EH1IG%K-#37)GPT9(D,
M:4PF'(@DBC!_/2<A6YVU8&M]X9XN JDO6*/A$B_(E,B'Y82K,ROOQ:<1B05E
M,>!D?M8:PT\7J*<#3(M'2E:B= PTE1EC3_KDVC]KV1H1"8DG=1=8_3R3"Q*&
MNB>%XWO6:2M_I@XL'Z][_VS(*S(S+,@%"[]27P9GK7X+^&2.DU#>L]4_)"/D
MZOX\%@KS#5996[L%O$1(%F7!"D%$X_07OV2)* 6H?NH#4!: -@,Z#0%.%N 8
MHBDR0^L22SP:<K8"7+=6O>D#DQL3K=C06,LXE5S=I2I.CJ:I?(#-P90N8CJG
M'HXE&'L>2V))XP68L)!ZE @PE<Q[.M4Y\\$%B]1 $MA(L>[CPR61F(8"P(_@
M%/P%+" "S%5D]D-C\"5@B<"Q+X:65.@U!LO+D)ZG2%$#4@?<L%@& ES%/O%_
MC+<4ZYPZ6E,_1UL[O,&\#1QX I"-8 V>B^WAE\3+P^TM<)Q<"<?TYS0IH9-4
ME]XQYSA>$#5W))B]@G*["7XUE\<KS'WP[5_5);B6)!+_;0'4R0%U#*#. 8#$
M5D0GX&ZI(\0)N'HAW*,B'043PBE3=[^:2::BQL^$JT4C;P4FG'JD;HRDD'L&
MLEZBGD=NVW:&UG,-43<GZAY,] ">=3120&Z)QBFT!_4TNCF-[LXT<G@%@S5(
M\.V&1#/"MPV17O[(WI\Q9OLYH/Z[27F72"'56J46P1-PF^B<U4G9KT@YL)UN
M+F6ZE%0;]9U!KU[O0<YU\'NX[C$M!Y5IV6O#S234-D+U28!V4<#L=TO#WRI"
M_K!$W2HGI6JCL@QS0F6BREAMY;*K@\!MD!>62C-\OP6X2FT/F3/ 90G[;:<[
M*'\:6*."-7K'U7A)N8E^8SW.,)4%A+U^ Y6BHD/G/2MH#9?]5'0J*D+4=MT&
MNH5?@(<;AEW9EB;<&\IU*LHYL(%)80C@X8Y@9^%JJ>PGG%L5SFY>0@OC '=W
M#K_( .%92+95S0Q16387]AN,'"S\".S]'B;[J-6K62R[CEWZ- W4PN[ [7[G
MG@BIGJ^!F=<S\!!3-3(_W$\?Q,==G!XLW 8<_!E>#Q6E'QV]]%]]3ZA\!=>Q
MRF.23NL[&1 .9(#C8BS<LOA9I9KXV\8TJKH A*"SX8+J6O6Z#643%68!'6X6
M?GDN*K/"N QPB24!GS'EX!&'2>WD0%4GH5[DT&:NJJTZ;:>A4*'"8J"C6XP=
M<[7INFI34?4>W:82A@KO@0[W'L?A>-"PJ%H393#[.ZR9J+ IZ.@V9<?,/)II
M\H;Z5?\"H=MI(%DX&'3T/8T]21XD?]7@N&W4\"*%"G^#CNYO=DQ&YO7>%+WJ
M?IP&[X,*[X..[GU^CJ5VM >I735(G79W4VVKM+D=$;XP>_X"F/WI=)\[OYK_
MKS VN^E6T3S]4^(&\P55KT\AF:M0N]U3 O!TGS\]D6QIMLIG3$H6F<. 8)]P
MW4#=GS,FUR?Z ?F_+:/_ 5!+ P04    " !HA*92,B+F^.,"  "$"   &0
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MW@UA*/+@>*"@VI2@W94NV,TFR^FR[,<,M5Q;$K1[TB4[?MR;_B;N4C3$0#A
M4IL;G%Q'%Q-CMR==DOVPLML#[H&T:R*[:U;R.?MH:#MW:;]$\/F*0JUSG-T
M_Z\HU/<]&$ _C#I%-L6%"(T'-@/2)HGL)GF^II#!)KN:,L0,: II&T5V&[U
M4S6255.FF"%-(6W%R'[6/%=3J'^0+/L=P2Y+0YSL=SQ436WRR&[R"\KVE$FF
M8$D>Q'G')J0=&L57T(^V4V2WTS/TTW=(- [ZY32$#;^1D+929+?2"]33=TG8
M/<8;8@;Z[6L7]>TN>H%Z_/XAM"L>0\B@>'SMNK[]E'JN>&J8J-/L[O'#%&9X
M(;FM[Q7EQZ*OF#W*YH&4;&6>-XKE*EGU_:4:"+I7GS >J! T4Y<[@C>$E0'R
M^992\30HOXHT7\'F_P!02P,$%     @ :(2F4K%X5O(W @  ( 4  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&ULC53?;]HP$/Y7K&@/K;012!B;JA"I
M0+<AM1("=7N8]F"2"['J'ZGM0+>_?F<G9&D%:"^)[WS?=_?Y?$X.2C^9$L"2
M%\&EF0:EM=5-&)JL!$'-0%4@<:=06E"+IMZ%IM) <P\2/(R&PTDH*)-!FGC?
M2J>)JBUG$E::F%H(JG_/@*O#-!@%1\>:[4KK'&&:5'0'&["/U4JC%78L.1,@
M#5.2:"BFP>WH9CYV\3[@.X.#Z:V)4[)5ZLD9RWP:#%U!P"&SCH'B;P]SX-P1
M81G/+6?0I73 _OK(_L5K1RU;:F"N^ ^6VW(:? Y(#@6MN5VKPS=H]7QT?)GB
MQG_)H8F=C .2U<8JT8*Q L%D\Z<O[3GT ,AS&A"U@.@MX%R&N 7$7FA3F9>U
MH):FB58'HETTLKF%/QN/1C5,NBYNK,9=ACB;SJDI"94Y\8N[YYKM*0=IC7<N
MY1Z,%=Z^6H"EC!L279,/Y'&S(%?OKI/08A&.*LS:A+,F870F84P>E+2E(7<R
MA_PU/L3B.P714<$LNDCX0/6 Q*/W)!I&HQ/US/\?/KQ03MP=:.SYXC-\&YRS
MO.9 5/'J^'[>8R!96A#FUX4TXR[-V*<9GTFS!LK9'^BWB'S%H<4^W2MCP)QL
M3<,Y\9QNOO<I2M[W#^M21%-HV+ML O3.SZ AF:JE;;K6>;LQO_6W^XU_AN/?
M3.L_FN;MP)[LG!0.!5(.!Y]P>'0SCXUA5>6O]%99'!"_+/$) ^T"<+]0RAX-
MEZ![%-._4$L#!!0    ( &B$IE*G2?E$)P,  -(-   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(U+GAM;+57[T_J,!3]5YK%#YJH6[L?@ &2)S[S3)Z)$?5]
MKE#88K=BVX'OOW]M-S=@HVK>_ )M=\_IN7>70SO<,/XB8D(D>$MI)D9.+.7J
MPG7%+"8I%N=L13+U9,%XBJ6:\J4K5IS@N0&EU$6>%[DI3C)G/#1K=WP\9+FD
M24;N.!!YFF+^]Y)0MADYT'E?N$^6L=0+[GBXPDLR)?)Q=<?5S*U8YDE*,I&P
M#'"R&#D_X,4$>1I@(IX2LA%;8Z!3>6;L14]NYB/'TXH()3.I*;#Z6I,)H50S
M*1VO):E3[:F!V^-W]FN3O$KF&0LR8?1/,I?QR.D[8$X6.*?RGFU^D3*A4//-
M&!7F$VR*V$CM.,N%9&D)5O,TR8IO_%868@L @P, 5 +09P%^"?!-HH4RD]85
MEG@\Y&P#N(Y6;'I@:F/0*ILDTZ]Q*KEZFBB<'%_CA(,G3',";@D6.2?J'4D!
MCJ^(Q D5 )Z ,_ XO0+'1R?@""09>(A9+G V%T-7*@6:QYV5NUT6NZ$#N]UB
M?@Y\> J0AV +?&*'7Y%9!?=VX:[*NTH>5<DCP^=_F+R%S*_(?$,6'"";8!$#
M519@!C]?\V2-J:YE6YD*JLA0Z5_:>CSH12$:NNOM:C2C((I0Y%=A.T*#2FA@
M%3J-&9=GDO 4W&1K(F1Z2&7!$V[M'_@];["GLAF%(@^B=I%A)3*TBGQ@$E-P
ML*9F\0/U84,7#* ?P3WY+6$A0KVP77]4Z8^L^NO6.@6_R9I0 "T]UJM8>__?
ML/V*K-]=P_8;56IKV&:4K6$'E=!!1PT[:'N70;BGLAGEM0N$7NVBWG>W:[G#
MCGB(^H/>GOJV.$N1X=8_ ?QBRR)+E\':9&$'+@MKFX4=^FS)U?ZNRWK:0G8U
MU@X+N[)8V.*>_2 *]D5^R61A[;+PVVT6-@VT-8.6,$L&M<_"KQJM;VNSVFEA
M!U8+:Z^%'9HM;/IHHVMM(;L::YN%7?DLM%EH*?#3+HMJET7?[K+E#I%%N36D
M4.YN';CU;4>=:Y=))@ E"X7QSGLJ;5Y<((J)9"MS!G]F4IWHS3!6ER["=8!Z
MOF!,OD_TL;ZZQHW_ 5!+ P04    " !HA*92N[OMPXH#  #1"@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-BYX;6RM5EV/FS@4_2M7:%9JI=GP$4B8*HDT
MD\QH1]IVHZ33?:CZX,!-L ;LK&V26:D_?FT@A$F!=JN^@&U\CL\]OMAW<N3B
M62:("EZRE,FIE2BU?V?;,DHP(W+ ]\CTERT7&5&Z*W:VW LD<0'*4MMSG)&=
M$<JLV:086XK9A.<JI0R7 F2>943\>X<I/TXMUSH-K.@N46; GDWV9(=K5$_[
MI= ]NV:):89,4LY X'9JW;KO'MP"4,SX1/$H&VTPH6PX?S:=QWAJ.481IA@I
M0T'TZX!S3%/#I'7\4Y%:]9H&V&R?V!^*X'4P&R)QSM._::R2J15:$..6Y*E:
M\>,?6 44&+Z(I[)XPK&:ZU@0Y5+QK )K!1EEY9N\5$8T )[; ? J@'<)&'<
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M0GJ \JUNPQTUHC>(HD[:<44[?F?:/X$*3<O;&,<-1HP'I!,2!W5"#3X$,Q$
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M"&\=A$_>K=[Z5!>-?U9_%HQVE19MQ]?^G[3X,9YKH_"J_VQ0[%2*':?8.10
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M>H+Z'C,FCQV]0'73F?P!4$L#!!0    ( &B$IE(Q:!$)U $   P$   9
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;'V4X6Z<, S'7R7* S0<UW93!4@]
MMFF5-O5T5;N/4PX,1 T)2\QQ>_LE@6-L*OU"[,2_/S9V2 9M7FT#@.3<2F53
MVB!V=XS9HH&6VRO=@7(GE38M1^>:FMG. "\#U$H61]$M:[E0-$O"WMYDB>Y1
M"@5[0VS?MMS\WH'40THW]+)Q$'6#?H-E2<=K> )\[O;&>6Q6*44+R@JMB($J
MI?>;NSSV\2'@1<!@%S;QE1RU?O7.0YG2R"<$$@KT"MPM)\A!2B_DTO@U:=+Y
ME1Y<VA?U+Z%V5\N16\BU_"%*;%+ZD9(2*MY+/.CA*TSUW'B]0DL;GF088Z]C
M2HK>HFXGV&70"C6N_#Q]AR6P60'B"8C_ S;;%6 [ =M0Z)A9*.L31YXE1@_$
M^&BGYHWP;0+MJA'*=_$)C3L5CL/L&S^"3!@Z*;_!B@G;O8]]EN!:B6^ ^0C&
M*^ +ESW\BS&7\IQW/.<=!YWK%9T')5!PZ0:IT+6WW4CHBAC?-6_T%@BW%MY*
M<?>^M#R;\\])__!7_K$*(_Y8/5NX7U'.1^7;H.POT"F+$G9:ULD6O?+WY#LW
MM5"62*@<$UU]N*%C%1<'=1?Z<-3HAB&8C;NN8'R .Z^TQHOC)V+^ 61_ %!+
M P04    " !HA*92N9$SS2\#  !0$P  #0   'AL+W-T>6QE<RYX;6S=6%UK
MVS 4_2M&':.#4<?QZL9K'-@"A<$V"NW#WHH2RXE ECQ9Z9+^^NE:CO-1W9#U
M86OFT%BZ1^?<(^FZ5CNLS4JPNSEC)EB60M89F1M3?0S#>CIG):TO5,6D10JE
M2VIL5\_"NM*,YC602A'V>[TD+"F79#24B_*F-'4P50MI,I)TH<#=ON09B9(/
M)'!R8Y6SC#R<O_VY4.;Z3>#N9^_/SGH/[Z[WX^<-\(Z$7M'+(T0O>KBNQ3#I
MY#CI@]JH^-6N>#<>U#9LE#XXRML!9YAPBOC:L=60PW;71\-"R<WFQ\0%K#HM
M6?!(14;&5/")YL J:,G%RH7[$)@JH71@;-79=!%$ZB<'1ZX'!=GJE%PJW>1V
M&=SWI!V^!ZQ[8) +T1GL$Q<8#2MJ#-/RQG::P4WP&12T[?M591W.-%U%_4NR
M(30WFV2B=,YTER8BZ]!H*%@!=C2?S>%N5!4":(PJ;2/G=*8D;3RL&6W#RDZ9
M$'?PM/XH=K27Q=:^]6#79->TAMJFDW$=T-]6<]K;LOT7Z085?U3F\\).1S9]
M*#1VJUG!ETU_670&,/4(5Z=5)5:?!)_)DKG)'YUP-*1K7C!7FC_9;% J4QM@
MF@2/3!L^W8[\TK2Z9TNS+J=E@7ONGZ#GO[O.,R:9IF+;M*W]U[S*+W8<7_TK
MR\UOE7W#7H_M*_BUF[P\!9/)*9@\B9H<G(+)]%6:#-L7^-8I8>>,T$4#.(ME
MY#N<[,0F:3!9<&&X;'MSGN=,/CLJ6'E#)_;/A1U].SYG!5T(<]^!&=FTO[&<
M+\JT&W4+"]&.VK2_PO2BI#L(VEQ<YFS)\G';U;-)TPQLPV9M+R#L(S?-Y4<P
MCL/\"&!8'LP!QG$L+,__-)\!.A^'8=X&7F2 <@8HQ[%\R+CY8'G\G-1>_IFF
M:1PG";:BX['7P1A;MR2!'[\:Y@T86![(]&=KC>\V7B&'ZP#;TT,5@LT4KT1L
MIOA: ^)?-V"DJ7^WL3S P'8!JQW([\\#->7GQ#'L*N8->X)Q)$TQ!&K17Z-)
M@JQ. A___F!/21RGJ1\!S.\@CC$$GD8<P1R !PR)X^8]N/<^"M?OJ7#S/[31
M;U!+ P04    " !HA*92EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y
M;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI
M0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:W
MO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:
M>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%B
MM/XU@LD/['X 4$L#!!0    ( &B$IE+ZKF9 *0,  /(4   /    >&PO=V]R
M:V)O;VLN>&ULQ9A;3]LP%(#_BI4G]L#2N*5<1)$8A:T2&X@.7B?7.6TM'+NS
M'6Z_?B?)RMPACO;B]2FQG3A??#F?[>-'Z^YGUMZSITH;/\J6(:R.\MS+)53"
M?[0K,%@RMZX2 9-ND?N5 U'Z)4"H=,Y[O6%>"66RD^-U7=<NCQ,V@ S*&LQL
M,NX4//H_Y4V2/2BO9DJK\#S*VGL-&:N4495Z@7*4]3+FE_;QBW7JQ9H@]%0Z
MJ_4H*[J".W!!R3?9TP;RNYCY-B>(V8U D%$V[&&%<^5\:)]HZQ?(^ #X<)>J
M@[U0.H ;BP"?G:U7RBR::O O\N@WVG987[M&/'+_THQV/E<2QE;6%9C0M:,#
MW0 :OU0KGS$C*AAEZT>8,"4[-P$;B4U,5Q4^V_PI?GI2=G\=$#=J0W>DL,!-
MRA8\'>09IJU6)7Z]9)^$%D8":QO7[]X:$4%R I)O#9)="Q=!]@G(_G^$G#80
MS0N>V3D[L]4J@AP0D(,M0O[@$>0> ;FW/4CAEQ'DD( <;@UR&JR,(/<)R/VT
MD-.ZJH1[;J'4PBA\36! .I72UAB0(L@# O(@+>0-2(B@S(*A>@S>R[9)(\A#
M O(P<7?CP&L#>7MS_K-6#T*W'=YD3N)@WJ.B>2\MYH50CMT)70/["L+7KAN5
M,1XIF\2V&<,LL*N95HNN+.:B_%(D%TQ5J5"]]B=.[F8@@I$*-B IOQ3)!:.U
MF%G7EK28E_BB\<!.%PX@QJ0,4R16S%58@L-ILE*XW.O0WHQ!2BY%8KN0,7%#
M@06EER*Q7VC,?HQ)":9(;!@R+FZV)J68(K%CWHF+; ?W#7ISBE.2*1);AN[T
M0;P:IRS#$UN&QMR+,2G;\,2VH3&',2:YN4DM'W(*Q3.=4_KAJ?5#8FZ,34H_
M/+%^WIWI8PA"Z1B3LA!/;*&_5T)K/O\A)J0$Q)-O<(@U$=N),2D!\=0"HE9%
M&P+BE(!X8@&]MRKZW>\Q)B4@GEA MT;BEQ?-<1UN:R>XJ?5LE^DG][3+>VTP
M?SUIH034;P64K\_82I@K ^4W_(3'?"FTO':LN70K_\%>8]UYK?49YEV92RO*
M]9'=^KCQY!=02P,$%     @ :(2F4F2$U7I7 0  D1(  !H   !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<\W8S8Z",!2&X5LAO0#+.2CJ1%S-QNW$&R!8
M?B)00CL9O?LAN,#/S&(VIF=%6L+INWH@'+Y,F_O&]JYN!A?=NK9WF:J]'SZT
M=D5MNMRM[&#ZZ4YIQR[WTW*L]) 7U[PRFN,XU>/S#'4\/,^,SO?!_&>B+<NF
M,)^V^.Y,[_\8K'_L>'6U,5Y%YWRLC,^4OK7+MM/SA5;39!6=+ID:3Q=2.G00
M0Q"'#TH@* D?M(:@=?B@#01MP@>E$)2&#]I"T#9\T Z"=N&#]A"T#Q]$,<H8
M"TAZP5J UH1<DP"O"<$F 6(3DDT"S"9$FP2H3<@V"7";$&X2(#<AW23 ;D*\
M28#>C'JS +T9]68!>O/+Q[8 O1GU9@%Z,^K- O1FU)L%Z,VH-PO0FU%O%J W
MH]XL0&]&O5F W@GJG;Q3;^?OK7%+SV.-Y[^3:C\]:Y;CY^5C$]\7R8RSAC]0
MQU]02P,$%     @ :(2F4CEI(W6" 0  3!,  !,   !;0V]N=&5N=%]4>7!E
M<UTN>&ULS9C+3L,P$$5_)<H6-:Y=* ^UW0!;Z((?,,FDL>J7/&YI_QXG?4B@
M$E$5B=G$2CQS[[5'.HM,WK8>,-L8;7&:-S'Z!\:P;,!(+)P'FW9J%XR,Z34L
MF)?E4BZ B>%PS$IG(]@XB*U&/IL\02U7.F;/F_09E;/3/(#&/'O<%;9>TUQZ
MKU4I8]IG:UM]<QGL'8K4V=5@HSQ>I8*<G71H=WXVV/>]KB$$54$VER&^2).J
MV$8SC%L-6/1+G,CHZEJ54+ER95)+@3Z K+ !B$87.]&K?N>8;AAV3WZQ?R?3
M9Y@JY\%Y3!,+<+[=821M]\ G(0A1]1_QZ)BD+SX?M-.NH/JE=[K>#Q>6W3R0
M=<OE=_QUQD?],W,((CE&1')<$\EQ0R3'F$B.6R(Y[HCDN">2@P^I!*%"5$X%
MJ9P*4SD5J'(J5.54L,JI<)53 2NG0E9!A:R""ED%%;(**F055,@JJ)!54"&K
MH$)6086L@@I91_])UG?GEG_]?Z=="R.5/?BS[B?:[!-02P$"% ,4    " !H
MA*92!T%-8H$   "Q    $               @ $     9&]C4')O<',O87!P
M+GAM;%!+ 0(4 Q0    ( &B$IE(Q>Y;X[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( &B$IE*97)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ :(2F4E5",J8[!0  @!4  !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &B$IE+PS1G'J04
M *@5   8              " @7X-  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " !HA*92D97$Q P#   B"@  &               @(%=
M$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ :(2F4M^0
M*9T"!0  ^A$  !@              ("!GQ8  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( &B$IE(P23D*FP(  & &   8
M  " @=<;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !H
MA*92,>J<&4\&   @&   &               @(&H'@  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ :(2F4AV.//4:!@  )!T  !@
M         ("!+24  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( &B$IE(&5SM-1A4  $X]   8              " @7TK  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !HA*923(X67Y0#  "P!P
M&               @('Y0   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ :(2F4O#"7\^& P  .PD  !D              ("!PT0  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !HA*929G7ES"D%
M   ?#0  &0              @(& 2   >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( &B$IE(Z^\C1K@8  )00   9              "
M@>!-  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ :(2F
M4L^L(]9Z!P  =!   !D              ("!Q50  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " !HA*92RQ..%[P$   >"P  &0
M        @(%V7   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( &B$IE)M ":Z/@,  )0'   9              " @6EA  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ :(2F4I9B: E]$   O#
M !D              ("!WF0  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " !HA*92W3I)I(($  "."P  &0              @(&2=0
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( &B$IE+97[$;
M-@,  "L(   9              " @4MZ  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ :(2F4NO957S< @  "0<  !D
M ("!N'T  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !H
MA*92\Y7D35H#  "I#@  &0              @('+@   >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( &B$IE(Y'U3:Q@0  'D9   9
M          " @5R$  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#
M%     @ :(2F4C(BYOCC @  A @  !D              ("!68D  'AL+W=O
M<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !HA*92_E!P@@\$   1
M$P  &0              @(%SC   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM
M;%!+ 0(4 Q0    ( &B$IE*Q>%;R-P(  " %   9              " @;F0
M  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ :(2F4J=)
M^40G P  T@T  !D              ("!)Y,  'AL+W=O<FMS:&5E=',O<VAE
M970R-2YX;6Q02P$"% ,4    " !HA*92N[OMPXH#  #1"@  &0
M    @(&%E@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M &B$IE*+X>'M#00   T0   9              " @4::  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ :(2F4D?G^KVX @  [0<  !D
M             ("!BIX  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " !HA*92?,'LM.<"  #U"   &0              @(%YH0  >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( &B$IE(Q:!$)U $
M  P$   9              " @9>D  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ :(2F4KF1,\TO P  4!,   T              ( !
MHJ8  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !HA*92EXJ[',     3 @
M"P              @ '\J0  7W)E;',O+G)E;'-02P$"% ,4    " !HA*92
M^JYF0"D#  #R%   #P              @ 'EJ@  >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ :(2F4F2$U7I7 0  D1(  !H              ( !.ZX
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ :(2F4CEI
M(W6" 0  3!,  !,              ( !RJ\  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&     "8 )@!!"@  ?;$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>71</ContextCount>
  <ElementCount>268</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>17</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes</Role>
      <ShortName>Summary of Significant Accounting Policies (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2109102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes</Role>
      <ShortName>Recent Accounting Pronouncements Level 1 (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Cash and Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</Role>
      <ShortName>Cash and Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Debt Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligations</Role>
      <ShortName>Debt Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Other Capital Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OtherCapitalAgreements</Role>
      <ShortName>Other Capital Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables</Role>
      <ShortName>Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsDetails</Role>
      <ShortName>Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/DebtObligations</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Collaboration and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails</Role>
      <ShortName>Collaboration and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CollaborationandLicenseAgreements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Other Capital Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OtherCapitalAgreementsDetails</Role>
      <ShortName>Other Capital Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/OtherCapitalAgreements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lxrx-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - lxrx-20210331.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - lxrx-20210331.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="lxrx-20210331.htm">lxrx-20210331.htm</File>
    <File>exh311certificationofprinc.htm</File>
    <File>exh312certificationofprinc.htm</File>
    <File>exh321certificationofprinc.htm</File>
    <File>lxrx-20210331.xsd</File>
    <File>lxrx-20210331_cal.xml</File>
    <File>lxrx-20210331_def.xml</File>
    <File>lxrx-20210331_lab.xml</File>
    <File>lxrx-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>47
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20210331.htm": {
   "axisCustom": 0,
   "axisStandard": 5,
   "contextCount": 71,
   "dts": {
    "calculationLink": {
     "local": [
      "lxrx-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lxrx-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "lxrx-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20210331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 314,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 32,
   "keyStandard": 236,
   "memberCustom": 0,
   "memberStandard": 17,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.lexpharma.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Cash and Cash Equivalents and Investments",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments",
     "shortName": "Cash and Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Fair Value Measurements",
     "role": "http://www.lexpharma.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Debt Obligations",
     "role": "http://www.lexpharma.com/role/DebtObligations",
     "shortName": "Debt Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Commitments and Contingencies",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:OtherCapitalAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Other Capital Agreements",
     "role": "http://www.lexpharma.com/role/OtherCapitalAgreements",
     "shortName": "Other Capital Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:OtherCapitalAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables",
     "shortName": "Summary of Significant Accounting Policies Equity Incentive Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Cash and Cash Equivalents and Investments (Tables)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables",
     "shortName": "Cash and Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i87dc4e8dae904d17abf8d61c69bd8c76_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets-Unaudited",
     "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
     "shortName": "Consolidated Balance Sheets-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i87dc4e8dae904d17abf8d61c69bd8c76_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "icef415129a23469b9ec147c98cb56572_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails",
     "shortName": "Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "icef415129a23469b9ec147c98cb56572_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
     "shortName": "Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i87dc4e8dae904d17abf8d61c69bd8c76_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:AccruedResearchAndDevelopmentServicesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails",
     "shortName": "Summary of Significant Accounting Policies Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i87dc4e8dae904d17abf8d61c69bd8c76_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:AccruedResearchAndDevelopmentServicesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i5f6b3dae24ed4be1a4420f2bc0f76d2f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
     "shortName": "Cash and Cash Equivalents and Investments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i5f6b3dae24ed4be1a4420f2bc0f76d2f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2",
     "shortName": "Cash and Cash Equivalents and Investments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i87dc4e8dae904d17abf8d61c69bd8c76_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i87dc4e8dae904d17abf8d61c69bd8c76_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "ie2fc5a7556d44214b71b2e8a010774b2_D20141101-20141130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Debt Obligations (Details)",
     "role": "http://www.lexpharma.com/role/DebtObligationsDetails",
     "shortName": "Debt Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "ie2fc5a7556d44214b71b2e8a010774b2_D20141101-20141130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i75c9ca72d87c4541bcbf8632f671f7ae_D20200901-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:Lxrx_Sanofiterminationcashpayment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i87dc4e8dae904d17abf8d61c69bd8c76_I20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtAndCapitalLeaseObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i75c9ca72d87c4541bcbf8632f671f7ae_D20200901-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:Lxrx_Sanofiterminationcashpayment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Collaboration and License Agreements (Details)",
     "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
     "shortName": "Collaboration and License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i4be4c6376df74ca9aaba4f35cb69abb5_D20200101-20200331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "lxrx:IpsenRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i0953aa39e2f84e829c3acc2d7f88a6a3_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ATMOfferingTotal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Other Capital Agreements (Details)",
     "role": "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails",
     "shortName": "Other Capital Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i0953aa39e2f84e829c3acc2d7f88a6a3_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ATMOfferingTotal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i87dc4e8dae904d17abf8d61c69bd8c76_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets Parentheticals",
     "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals",
     "shortName": "Consolidated Balance Sheets Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i87dc4e8dae904d17abf8d61c69bd8c76_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:Netproductrevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
     "shortName": "Consolidated Statements of Comprehensive Loss-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:Netproductrevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
     "shortName": "Consolidated Statements of Comprehensive Loss Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i2dca67dbb6624abeb8141b5923482d81_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
     "shortName": "Consolidated Statements of Stockholders' Equity/Deficit-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i2dca67dbb6624abeb8141b5923482d81_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes",
     "shortName": "Summary of Significant Accounting Policies (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)",
     "role": "http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes",
     "shortName": "Recent Accounting Pronouncements Level 1 (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "i361ed8ee3d41432ca64245bde358c770_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:InitialRecognitionOfRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - lxrx-20210331.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - lxrx-20210331.htm",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210331.htm",
      "contextRef": "if0c05bbf9b164905b6ce0c6e3dc95aea_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:InitialRecognitionOfRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 17,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lxrx_ATMOfferingTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Offering Total",
        "label": "ATM Offering Total",
        "terseLabel": "ATM Offering Total"
       }
      }
     },
     "localname": "ATMOfferingTotal",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedCompensationAndBenefitsCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued compensation and benefits current - due within 1 year",
        "label": "Accrued compensation and benefits current",
        "terseLabel": "Accrued compensation and benefits current"
       }
      }
     },
     "localname": "AccruedCompensationAndBenefitsCurrent",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedInterestOnConvertible": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "accrued interest on convertible",
        "label": "accrued interest on convertible",
        "terseLabel": "accrued interest on convertible"
       }
      }
     },
     "localname": "AccruedInterestOnConvertible",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedLiabilitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "accrued liabilities",
        "label": "accrued liabilities [Axis]",
        "terseLabel": "Accrued Liabilities [Axis]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAxis",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lxrx_AccruedLiabilitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities",
        "label": "Accrued Liabilities [Domain]",
        "terseLabel": "Accrued Liabilities [Domain]"
       }
      }
     },
     "localname": "AccruedLiabilitiesDomain",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lxrx_AccruedLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities",
        "label": "Accrued Liabilities [Line Items]",
        "terseLabel": "Accrued Liabilities [Line Items]"
       }
      }
     },
     "localname": "AccruedLiabilitiesLineItems",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lxrx_AccruedLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "accrued liabilities [Table]",
        "label": "accrued liabilities [Table]",
        "terseLabel": "Accrued Liabilities [Table]"
       }
      }
     },
     "localname": "AccruedLiabilitiesTable",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lxrx_AccruedResearchAndDevelopmentServicesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development services current",
        "label": "Accrued research and development services current",
        "terseLabel": "Accrued research and development services current"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentServicesCurrent",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_CashAndCashEquivalentsAndInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Cash Equivalents and Investments [Abstract]",
        "label": "Cash and Cash Equivalents and Investments [Abstract]",
        "terseLabel": "Cash and Cash Equivalents and Investments [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestmentsAbstract",
     "nsuri": "http://www.lexpharma.com/20210331",
     "xbrltype": "stringItemType"
    },
    "lxrx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and License Agreements [Abstract]",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.lexpharma.com/20210331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Balance Sheets [Abstract]",
        "label": "Consolidated Balance Sheets [Abstract]",
        "terseLabel": "Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.lexpharma.com/20210331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Cash Flows [Abstract]",
        "label": "Consolidated Statements of Cash Flows [Abstract]",
        "terseLabel": "Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfCashFlowsAbstract",
     "nsuri": "http://www.lexpharma.com/20210331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Operations [Abstract]",
        "label": "Consolidated Statements of Operations [Abstract]",
        "terseLabel": "Consolidated Statements of Operations [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfOperationsAbstract",
     "nsuri": "http://www.lexpharma.com/20210331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "label": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "terseLabel": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfStockholdersEquityAbstract",
     "nsuri": "http://www.lexpharma.com/20210331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConvDebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement",
        "label": "Conv Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Conv Debt Instrument Interest Rate Stated Percentage"
       }
      }
     },
     "localname": "ConvDebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ConvertibleDebtExchange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange",
        "label": "Convertible debt exchange",
        "terseLabel": "Convertible debt exchange"
       }
      }
     },
     "localname": "ConvertibleDebtExchange",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeRemainingNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange Remaining Notes",
        "label": "Convertible debt exchange Remaining Notes",
        "terseLabel": "Convertible debt exchange Remaining Notes"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeRemainingNotes",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeSeptemberCashPortion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange- September cash portion",
        "label": "Convertible debt exchange- September cash portion",
        "terseLabel": "Convertible debt exchange- September cash portion"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeSeptemberCashPortion",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeSeptemberSharePayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange - September share payment",
        "label": "Convertible debt exchange - September share payment",
        "terseLabel": "Convertible debt exchange - September share payment"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeSeptemberSharePayment",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_ConvertibleDebtExchangeTotalPrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange - Total Principal Amount",
        "label": "Convertible debt exchange - Total Principal Amount",
        "terseLabel": "Convertible debt exchange - Total Principal Amount"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeTotalPrincipalAmount",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DebtObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Obligations [Abstract]",
        "label": "Debt Obligations [Abstract]",
        "terseLabel": "Debt Obligations [Abstract]"
       }
      }
     },
     "localname": "DebtObligationsAbstract",
     "nsuri": "http://www.lexpharma.com/20210331",
     "xbrltype": "stringItemType"
    },
    "lxrx_FairValueMeasurementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Measurements [Abstract]",
        "label": "Fair Value Measurements [Abstract]",
        "terseLabel": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "localname": "FairValueMeasurementsAbstract",
     "nsuri": "http://www.lexpharma.com/20210331",
     "xbrltype": "stringItemType"
    },
    "lxrx_FutureConvertibleDebtExchange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "future convertible debt exchange",
        "label": "future convertible debt exchange",
        "terseLabel": "future convertible debt exchange"
       }
      }
     },
     "localname": "FutureConvertibleDebtExchange",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_FutureConvertibleDebtExchangeShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Convertible debt exchange shares",
        "label": "Future Convertible debt exchange shares",
        "terseLabel": "Future Convertible debt exchange shares"
       }
      }
     },
     "localname": "FutureConvertibleDebtExchangeShares",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_GainOnSaleOfNonFinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on sale of non-financial assets",
        "label": "Gain on sale of non-financial assets",
        "negatedTerseLabel": "Gain on sale of non-financial assets",
        "terseLabel": "Gain on sale of non-financial assets"
       }
      }
     },
     "localname": "GainOnSaleOfNonFinancialAssets",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_InitialRecognitionOfRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial recognition of right of use asset",
        "label": "Initial recognition of right of use asset",
        "terseLabel": "Initial recognition of right of use asset"
       }
      }
     },
     "localname": "InitialRecognitionOfRightOfUseAsset",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMaximumSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.",
        "label": "Ipsen Maximum Sales Milestones",
        "terseLabel": "Ipsen Maximum Sales Milestones"
       }
      }
     },
     "localname": "IpsenMaximumSalesMilestones",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.",
        "label": "Ipsen Milestone Payment",
        "terseLabel": "Ipsen Milestone Payment"
       }
      }
     },
     "localname": "IpsenMilestonePayment",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.",
        "label": "Ipsen Milestone Payment Received",
        "terseLabel": "Ipsen Milestone Payment Received"
       }
      }
     },
     "localname": "IpsenMilestonePaymentReceived",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.",
        "label": "Ipsen Revenue Allocated to Development Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to Development Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoDevelopmentDeliverable",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.",
        "label": "Ipsen Revenue Recognized",
        "terseLabel": "Ipsen Revenue Recognized"
       }
      }
     },
     "localname": "IpsenRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenTotalPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.",
        "label": "Ipsen Total Payments",
        "terseLabel": "Ipsen Total Payments"
       }
      }
     },
     "localname": "IpsenTotalPayments",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_LexiconIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lexicon incremental borrowing rate",
        "label": "Lexicon incremental borrowing rate",
        "terseLabel": "Lexicon incremental borrowing rate"
       }
      }
     },
     "localname": "LexiconIncrementalBorrowingRate",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_LiabilitiesAssumedByTerSera": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities assumed by TerSera",
        "label": "Liabilities assumed by TerSera",
        "terseLabel": "Liabilities assumed by TerSera"
       }
      }
     },
     "localname": "LiabilitiesAssumedByTerSera",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Lxrx_Sanofiterminationcashpayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance",
        "label": "lxrx_Sanofi termination cash payment",
        "terseLabel": "Sanofi termination cash payment"
       }
      }
     },
     "localname": "Lxrx_Sanofiterminationcashpayment",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Lxrx_sanofiInitialCashPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "lxrx_sanofi initial cash payment",
        "label": "lxrx_sanofi initial cash payment",
        "terseLabel": "lxrx_sanofi initial cash payment"
       }
      }
     },
     "localname": "Lxrx_sanofiInitialCashPayment",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtBalloonPayment_LXRX": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.",
        "label": "Mortgage Debt Balloon Payment_LXRX",
        "terseLabel": "Mortgage Debt Balloon Payment_LXRX"
       }
      }
     },
     "localname": "MortgageDebtBalloonPayment_LXRX",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtInstrument_Revere_LXRX": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral",
        "label": "Mortgage Debt Instrument_Revere_LXRX",
        "terseLabel": "Mortgage Debt Instrument_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInstrument_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%",
        "label": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX",
        "terseLabel": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInterestRateBasePlus_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_MortgageDebtInterestRate_Base_Revere_LXRX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%",
        "label": "Mortgage Debt Interest Rate_Base_Revere_LXRX",
        "terseLabel": "Mortgage Debt Interest Rate_Base_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInterestRate_Base_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_Netproductrevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.",
        "label": "Net product revenue",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "Netproductrevenue",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_OtherCapitalAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Capital Agreements",
        "label": "Other Capital Agreements [Text Block]",
        "terseLabel": "Other Capital Agreements"
       }
      }
     },
     "localname": "OtherCapitalAgreementsTextBlock",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lxrx_PrincipalAmountOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "principal amount of convertible notes",
        "label": "principal amount of convertible notes",
        "terseLabel": "principal amount of convertible notes"
       }
      }
     },
     "localname": "PrincipalAmountOfConvertibleNotes",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromJanuary2021ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from January 2021 ATM Offering",
        "label": "Proceeds from January 2021 ATM Offering",
        "terseLabel": "Proceeds from January 2021 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromNov2020ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Nov 2020 ATM Offering",
        "label": "Proceeds from Nov 2020 ATM Offering",
        "terseLabel": "Proceeds from Nov 2020 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromNov2020ATMOffering",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_RecentAccountingPronouncementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recent Accounting Pronouncements [Abstract]",
        "label": "Recent Accounting Pronouncements [Abstract]",
        "terseLabel": "Recent Accounting Pronouncements [Abstract]"
       }
      }
     },
     "localname": "RecentAccountingPronouncementsAbstract",
     "nsuri": "http://www.lexpharma.com/20210331",
     "xbrltype": "stringItemType"
    },
    "lxrx_SanofiDisputedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Disputed Costs",
        "label": "Sanofi Disputed Costs",
        "terseLabel": "Sanofi Disputed Costs"
       }
      }
     },
     "localname": "SanofiDisputedCosts",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.",
        "label": "Sanofi Revenue Recognized",
        "terseLabel": "Sanofi Revenue Recognized"
       }
      }
     },
     "localname": "SanofiRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]"
       }
      }
     },
     "localname": "ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract",
     "nsuri": "http://www.lexpharma.com/20210331",
     "xbrltype": "stringItemType"
    },
    "lxrx_Sellinggeneralandadministrativeexpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.",
        "label": "Selling, general and administrative expenses",
        "terseLabel": "Selling, general and administrative, including stock-based compensation of $1,565, and $2,256, respectively"
       }
      }
     },
     "localname": "Sellinggeneralandadministrativeexpenses",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SettlementPaymentFromTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Payment from Termination",
        "label": "Settlement Payment from Termination",
        "terseLabel": "Settlement Payment from Termination"
       }
      }
     },
     "localname": "SettlementPaymentFromTermination",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_SharePriceInJanuary2021ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price in January 2021 ATM Offering",
        "label": "Share price in January 2021 ATM Offering",
        "terseLabel": "Share price in January 2021 ATM Offering"
       }
      }
     },
     "localname": "SharePriceInJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharePriceInNovember20ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price in November 20 ATM Offering",
        "label": "Share price in November 20 ATM Offering",
        "terseLabel": "Share price in November 20 ATM Offering"
       }
      }
     },
     "localname": "SharePriceInNovember20ATMOffering",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SharesSoldInJanuary2021ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in January 2021 ATM offering",
        "label": "Shares sold in January 2021 ATM offering",
        "terseLabel": "Shares sold in January 2021 ATM offering"
       }
      }
     },
     "localname": "SharesSoldInJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInNov2020ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in Nov 2020 ATM Offering",
        "label": "Shares sold in Nov 2020 ATM Offering",
        "terseLabel": "Shares sold in Nov 2020 ATM Offering"
       }
      }
     },
     "localname": "SharesSoldInNov2020ATMOffering",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense included in research and development expense.",
        "label": "Stock-based compensation expense associated with research and development expense",
        "terseLabel": "Stock-based compensation expense associated with research and development expense"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense associated with selling, general and administrative expense",
        "label": "Stock-based compensation expense associated with selling, general and administrative expense",
        "terseLabel": "Stock-based compensation expense associated with selling, general and administrative expense"
       }
      }
     },
     "localname": "Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense",
     "nsuri": "http://www.lexpharma.com/20210331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SummaryOfSignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Significant Accounting Policies [Abstract]",
        "label": "Summary of Significant Accounting Policies [Abstract]",
        "terseLabel": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "nsuri": "http://www.lexpharma.com/20210331",
     "xbrltype": "stringItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r175",
      "r184",
      "r186",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r175",
      "r184",
      "r186",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r158",
      "r185",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Statement, Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r18",
      "r140",
      "r141"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r279",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r26",
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation and amortization, property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r44",
      "r45",
      "r46",
      "r291",
      "r307",
      "r308"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r43",
      "r46",
      "r47",
      "r86",
      "r87",
      "r88",
      "r231",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r216"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r187",
      "r189",
      "r217",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r74",
      "r253"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r74",
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset Impairment Charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r83",
      "r126",
      "r129",
      "r135",
      "r144",
      "r228",
      "r232",
      "r242",
      "r273",
      "r290"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r41",
      "r83",
      "r144",
      "r228",
      "r232",
      "r242"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available-for-sale Securities, Amortized Cost Basis",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.",
        "label": "Available-for-sale Securities, Current",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r191",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r191",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r25",
      "r76"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash and Cash Equivalents Disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r77",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r82",
      "r83",
      "r100",
      "r101",
      "r102",
      "r104",
      "r106",
      "r112",
      "r113",
      "r114",
      "r144",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r223",
      "r224",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Arrangement Disclosure"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r157",
      "r280",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies Disclosure"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 225,000 shares authorized; 145,552 and 142,289 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r56",
      "r282",
      "r298"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r176",
      "r183",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r58",
      "r271"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales (including finite-lived intangible asset amortization)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Goods and Service [Policy Text Block]"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt Disclosure"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r11",
      "r13",
      "r14",
      "r274",
      "r275",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r33",
      "r164",
      "r165",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt Instrument, Convertible, Conversion Ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt Instrument, Fair Value Disclosure"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r34",
      "r84",
      "r164",
      "r166",
      "r167",
      "r168",
      "r251",
      "r252",
      "r254",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r74",
      "r125"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r57",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r99",
      "r100",
      "r104",
      "r105",
      "r106",
      "r109",
      "r110",
      "r283",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income (loss) per common share, Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r90",
      "r96",
      "r98",
      "r111",
      "r145",
      "r163",
      "r169",
      "r213",
      "r214",
      "r215",
      "r220",
      "r221",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r236",
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r236",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table Text Block]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r237",
      "r261",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r176",
      "r177",
      "r182",
      "r183",
      "r237",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r176",
      "r177",
      "r182",
      "r183",
      "r237",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r237",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value, Measurement Inputs, Disclosure"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r261",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r146",
      "r147",
      "r272"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfRealEstate": {
     "auth_ref": [
      "r74",
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value.",
        "label": "Impairment of Real Estate",
        "terseLabel": "Impairment of Real Estate"
       }
      }
     },
     "localname": "ImpairmentOfRealEstate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Decrease in accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "(Increase) decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "(Increase) decrease in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Decrease in other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "(Increase) decrease in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r148",
      "r149"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "verboseLabel": "Intangible Assets, Net (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r53",
      "r124",
      "r250",
      "r253",
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r69",
      "r71",
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Total Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held for their financial return, rather than for the entity's operations.",
        "label": "Investments [Member]",
        "terseLabel": "Total Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Year Five"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Four"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Three"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Two"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30",
      "r83",
      "r130",
      "r144",
      "r229",
      "r232",
      "r233",
      "r242"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r83",
      "r144",
      "r242",
      "r276",
      "r293"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32",
      "r83",
      "r144",
      "r229",
      "r232",
      "r233",
      "r242"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term Debt and Lease Obligation"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt, net of deferred issuance costs"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r34",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r70",
      "r72",
      "r75"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r48",
      "r50",
      "r55",
      "r75",
      "r83",
      "r89",
      "r91",
      "r92",
      "r93",
      "r94",
      "r97",
      "r98",
      "r103",
      "r126",
      "r128",
      "r131",
      "r134",
      "r136",
      "r144",
      "r242",
      "r281",
      "r297"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements, Policy"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r126",
      "r128",
      "r131",
      "r134",
      "r136"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating Lease, Liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Operating Lease, Liability, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other Accrued Liabilities, Current"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r42",
      "r44"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r191",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value; 5,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from Convertible Debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from Sale of Productive Assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r152",
      "r294"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation and amortization of $5,851 and $5,815, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized Investment Gains (Losses)"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy election not to recognize asset and liability at acquisition for lease with remaining lease term of one year or less.",
        "label": "Recognition of Asset and Liability for Lease of Acquiree [Policy Text Block]",
        "terseLabel": "Recognition of Asset and Liability for Lease of Acquiree"
       }
      }
     },
     "localname": "RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of debt borrowings, net of fees"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r219",
      "r326"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, including stock-based compensation of $1,286 and $2,176, respectively"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r79",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r169",
      "r216",
      "r292",
      "r306",
      "r308"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r90",
      "r96",
      "r98",
      "r145",
      "r213",
      "r214",
      "r215",
      "r220",
      "r221",
      "r303",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r122",
      "r123",
      "r127",
      "r132",
      "r133",
      "r137",
      "r138",
      "r139",
      "r172",
      "r173",
      "r271"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaborative agreements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r54",
      "r83",
      "r122",
      "r123",
      "r127",
      "r132",
      "r133",
      "r137",
      "r138",
      "r139",
      "r144",
      "r242",
      "r285"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalties and other revenue"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of cash and cash equivalents and investments",
        "verboseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r191",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r194",
      "r207",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r196",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r188",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r79",
      "r191",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r12",
      "r277",
      "r278",
      "r289"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Total Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCommitmentAmount": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease commitment.",
        "label": "Short-term Lease Commitment, Amount",
        "terseLabel": "Short-term Lease Commitment, Amount"
       }
      }
     },
     "localname": "ShortTermLeaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r82",
      "r83",
      "r100",
      "r101",
      "r102",
      "r104",
      "r106",
      "r112",
      "r113",
      "r114",
      "r144",
      "r163",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r38",
      "r86",
      "r87",
      "r88",
      "r90",
      "r96",
      "r98",
      "r111",
      "r145",
      "r163",
      "r169",
      "r213",
      "r214",
      "r215",
      "r220",
      "r221",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r111",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r163",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r163",
      "r169",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r163",
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r169",
      "r190",
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r22",
      "r23",
      "r83",
      "r142",
      "r144",
      "r242"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholder's equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r83",
      "r86",
      "r87",
      "r88",
      "r90",
      "r96",
      "r144",
      "r145",
      "r169",
      "r213",
      "r214",
      "r215",
      "r220",
      "r221",
      "r226",
      "r227",
      "r234",
      "r242",
      "r243",
      "r244",
      "r248",
      "r304",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, value",
        "periodStartLabel": "Balance, value"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r249",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r249",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r249",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingActivityByTypeAxis": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of trading activity.",
        "label": "Trading Activity [Axis]",
        "terseLabel": "Trading Activity, by Type [Axis]"
       }
      }
     },
     "localname": "TradingActivityByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingActivityByTypeDomain": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit).",
        "label": "Trading Activity, by Type [Domain]",
        "terseLabel": "Trading Activity, by Type [Domain]"
       }
      }
     },
     "localname": "TradingActivityByTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r37",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r37",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r37",
      "r170",
      "r171"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost, 1,165 and 793 shares, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r163",
      "r169",
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r176",
      "r183",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r99",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in computing net loss per common share, Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28B",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121564365&loc=SL77931625-128468"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624186-113959"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918705-209980"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611133-123010"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r327": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r328": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r329": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r331": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r332": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>48
<FILENAME>0001062822-21-000035-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-21-000035-xbrl.zip
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M07^/\,G?[!$^>WV:!]S_8>F*\?)9[<M@:E+"37AE=U>AS!<#6_04<JFN#!I
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M/$Z=R+4O9); #1S577;A0Z"W\@]W>>@#DP<_MZG_QH]_PF=(I_\#4$L#!!0
M   ( &B$IE)>B>QG.@4  ,(8   >    97AH,S(Q8V5R=&EF:6-A=&EO;F]F
M<')I;F,N:'1M[5GK;]LV$/^^O^+J8&D"6&\_93= ZCBHAS1Q$W?!/@VT2$5$
M95$CZ3C>7[\39>?MU,G:U!N:#X:DX[U_=T<RW3<')[W1'\,^)'J2PO#S^Z-!
M#RJ6XYP'/<<Y&!W A]''(ZC9K@<C23+%-1<921VG?UR!2J)U'CK.;#:S9X$M
MY(4S.G4*434G%4(QFVI:V>L67_"7$;KW2_>-9<&!B*83EFF()".:49@JGEW
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M*2FW+CI-.'$"''*N:= DVPLQSV$OHU['@^R)#7\-\+*3HV;#-_K5V'+PBM"
M;X?!X%'X<O5+'[J>[]G\SR SP4[KJ-.&7WOK)PV8K,:7P>>M3OM+O^._#Y_U
M]S<WON)\U,Y;<B]#!F[\"$.^)!J!8S2$@2QB A<*.P'R"#(2#5,D$+(7(YKU
M$!HYCFJ;'VTC;+7?VJ-&WS871$PZ!:]\DBIJQ8,0)B5.L,/6P32#^<NQH,^Q
M;QOM&#9MM]UH'_061#XL"AT9 :!CF"NIC<;$.XN3HI*:(%Z,?-:]'[0&S;P0
MMMVOQVZ^KAOK^6D_XE;;=UIQ040F$E:4.YQLU%Q+F(F$,\%+"E:FO7 O1F0[
MW8(&G2[2M(2MQ%()Z1E-W"BJA34"YB0CK?7,\><3SJQ&0 5F38HQ$*%X!">+
M)F*DX42FF BE,^":BTR>9D^"P5O&#$@P9])R1XV%V4(Z9SU/W'NK7YY GXUR
MS5ZX3 GO<X2/>L83B88QJ1GS) 8<K4HO3[A/3]1F+U6LM)/.6)J\X<QBH[@
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M<X'FR@@E'2WIZ-SWJ*2CKY2. @.TE29T+U:L]T!'<Z7!4#"T[G(%6G_3IQ5
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M' '#!0D8!M5;1]U8A^MR&H@/G5[O$C*@R@ZH5JQ4.T5VALUB7^(5),GH\6#
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M,GQAL8M_N=($#6T6DV513;[1/UV>-)RB[J^O9ST>CC98C8N5K']=T L8]=
M&,O%YRNIVVD5=9-&EGCM'=T[O@,T&>[-QZ[@FT;K",PH%'98B/XGH+%X:+G>
M[(/-'-0KQ[$RPHNA-(<5J[)%#P]7P&BF45TK4)W\[4\P:TB*;*_3SO:S?*M
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M!UKG;N#NOEAT4Q=?S'(/DR0&'2,+G'!&O96<<N%"9$)[I?"WC6+]'/Z''E(
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MR\6;O)P&3;JO\L^+%UL:]*R7!$M;?YRM7U MSJ.UUF,4I+"()PMFSD5$ >-
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M^-'A^CG>&_'J3?EYU]A*4YZ:*5\XN=&DJ T3*#!)8>ZD&"B=8(AP2GBT,J_
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MW3:,6V_\WC^SKI]/7KB<O.XP>>U=VIQ.%5;>6!24"@BDI&$:DP:IP(@P7L1
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M;8]IAE<NO4<T65YZG6S4;F^$NM+/5:H^7>65G]74O;7CWK_M8!:?,42_M?V
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M!,K&&XI<"!91@P,5RGG)LU67;$I]/NFL..V?A!S?I]>^R/$:Y7@E6\)H$5-
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M/7,\"S,Q19@[)\SM)@>>))RT0L8FA[@)'KE@%(J*)\^#)M3)C6TF-PEY@BU
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MQCD-;ER7FKS6+.3U'L1IO(G.<EZPKL+P[D4<O[O5WPRKV1R=](=Y)F%RX9;
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MPQHAS9W.1:.%-X$+X4AN)M2EOK?/P3"RGS.GBO&CFRSCZN0BK^+YH,B"6C=
MK7[;\*&4=B1J%)QRB#O/D9.)H,0,]9K)J!+-Y(+=GEP4PT=W)7AMY**(Z1K%
M=$DN% LZ1!<1<3$BSA5'%M8'$:$CBTIZ247NS=HE(7UNK<HN")A^B/B=U:"[
M"SH1/MMFM>N?H">#__? X"X]%5X.P]YHZ,L1<?TCHATXI*DF7&;CD"!P1 !A
M0YK*A!B))E(GM<7 Y"C=Y-BL205=GR1U/.RH8&K!U"XY$PNFWB6FMFAW#)'
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M.#>_>;:G 9%!%(7$8ZAOJ!V$-**$1X+8;N0&XM4-MM<C&4USMN[NFG;&VW0
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MCNOH!KPM9-T"TTZ,;1,*.,MBW&.^'<:22H\$Q ]$P F7CA,X(FJ!:2>!B53
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M)6+FNL()@X"P5]=L+IL\*(JH%E\G8W!3^!JX\C8=*L\&W26<V HI'P7D#H:
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MK#1B<$*U\Z.<G"1;AG'E1^E(^SMC=<(RAH[.SC5&0!6.1!.88)GGI8]2_5O
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M+-/W7.$Q08A$DF6[8Y%%#HG6#GL(N*HNV*R-4VNJE+9R:UNY=;=,U@TO ;:
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M[-"AZH%/$]"UMA69+@YM,.D7[#^8XJ'(0A=ZF$OY [!D1L[4S%28J^02B4C
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M*0'[,%GUZBV5K-41O)DCVM$DRR=,UW/74K9\QJ&#C65J9@F"+9!RG5U1G3R
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MYW?9)XE>^<P>R])ABDY=P=KR!'=:5F:!J6 3NHC-_=(<GC:OM1PJ<6K4"4I
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M]0+0/^5LLS[ <#7E'+P!EE00N49B06.2Z@'H@GF?IX-1+QU.C0..DP'V\Q8
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M9PK.77B5I?K7XJB"^7/?FV'_+LTHN1@\E>IQL86!=4\LGJELSDS!>D&8H'Z
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MQS[8U<I0L.[=5M7.-;3L*G^STU&.<80\D4O<J<RUH:]H!?5F-<OE;V116R&
MF:8R65:MO=QH&VN=D:KC1#Q0J0;=)\%=G,08O%$\0LI -D2Q*@NYK7?=3F]7
M>6.T \,F)%F0"!CIV%M"88:(+!U4L1\5'1\Y*>KLC%4Z1T4."7/"#JPJSULF
MQ&XS=-M1]G:'9^_PN:+'J>RGNBCUEJJE9<ZP4-X%*1MI7*-HG-5$(H VU8
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MT-,QYQN1W(I(IGM?'D(Y<<X&%*WM@;:U=6*K!D@-5%M*M&J@50-K5@.]I=1
MT?2Z50.K5@.]UAIHU< SJX'>4ZT!)O:>J1[26OUP>G#<ZH>%PREN]_+7F_5I
MB&W ?:Y+26QB2O_ST]<KYS)BDG/G(A[D")M84<YC]V7YYOR?K2SOE"Q_$P]P
M0XPFH/TS)(=%DG+L*"!:X:X*]_G952O<6YF47DR^SQ5T%/]]%43?$<S62GM5
MVB\^?6ZE_05(NW,A_2 *6FF?*^U79S^UTOX"I/U*W,JPE?.9<G[]]5,KYR]
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M/.!X-CQ@_S;V)O!_PVP4_N/_ 5!+ P04    " !HA*92&LOC] $-  "/B
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M^_+)RT(4@/*R[O<'R'G\[ MX5N\1H21XA#1 .+DL"\:,4^#PBY8'?'GA5[X
MX*)53HB1-&+RSB^GD;PH+-_$<AY"BHC[J"[RNA%-VL;?C>-+>Q<MAT(7R9<6
M1*)SQ"/9Z'=*HO"B%;=$' 8M*[X.'#\)"!8 T^=;\8WDOGQOP,:8[^1_(K0E
M'KJ5<PU\64)/AE$XX!*JQHXV_PK(*.<*R# 9>'8*XL'$,[ -)Y-I,1B_8"^2
MAPJCOXFX, Q"\IF\N"X$D6G\Q[DS!2+W>!#&2,9L!8A7HBT?8/QZ%3-\F>)>
M87R?".43,%&BW6(.!16_%]!\OP0,?K^'0G3X_>[;_;?"41IPV/=8<11(:GG>
MH\)0\UW%(YSS2U\LP,(!EM+M?8W&KX0ZYVD7%0:7'%E+ 1CAS+(K')F>R "M
MGVM^EZ?RAHQ% 70OGX7C>( 4%!M?'4U3!ZI,Q.7Z*=DAI=)^R*:7S\LFB2-1
M]RH6^REJK*$J-WZ<A] 1AG=&9%0AIN)9+$GX,0A]\@PU1NSG"K%_53(R$;>A
MB-8^(9'9<@%3,AIYH S-Y*7)@BDJH6JL9U>X?:$B,[S%?P <"2KY[I7AXZ>1
MYT'I(/6KHH3TI5QW5=?V.T!XA!^ #T?>9X)O1&")'1%VQ2<Y"X=61M98.(L<
ML=3,+W[$=O+F^4SJ=>B%;P(Q"40+".N..XNB1A@*VK&,1T3N(+#2I5A&/!KM
M!!-+\YG,E."]KJF-*J#<09==./[%//^?"Z<K%5I,@I@9RH;8%58N=<'7B(JV
MA/[D>,!0M)JCA+U.P3UB/VY$4I$UMHW 9BO!ZD8&^KY0[ G$(K 7BNH"-T 8
MR<F2MX[A7$Z*+MBM2M]4PU%F\F.;6%*I,F-2<P%#?Y6D+!*H2EUW.)!S$8X$
M(E M&E=Q^Y<J5KB*?X6AB"EV('29K/<*MRS?UEK%FY>1-54C57%SPR9_C"V)
M,+=$Y!;" _Z%^/0>,@BH,Q76]5K>42*A9)4T+;99>^N@J5,H[5&<CX@)4"_!
MS/HD54EVO\0^0F0N6K-FPJ;VY";/"-]#J69BQ2<7[LQ,^#KU]D'_KQ?^RKVE
MFLI=:UV_D#-)B2HMKLSY@&'.T8/R#+HR@[I=IZK.R:H%CL3Z=\@$H_^5%?-R
MFC>V[%.@ZH^$ U]DO]A!(?"'@0QP3,U%/H]&5PK8 _'=[<J9):1UES.3D"[?
MAS] .A,JR*XB2G6AO1F3IB*MMM(?U%8Z7YX8< ";AE4VX?64C55T99EBE8QE
M+?9B>4V;"F96]PSR@3*RNM6UZ+##2(@07P#8]KA$'H>ZG6RL4M>(A1&7H1/3
M+,[<MDW-/>*]/3!'013(/2&VV.<KT;XBFL::%^UIE>W.N#0VP5B[U%.FB87-
MZU:[;%'$,.2I0MILI5S;<#?;GF^P(F[6[H9SQ*I7^N+6>UB:+C]W42#?FAXG
ME=OZAI=*J1NQ36(D4/V9?^Y5ZS+[5T)4MQ5<ODW0R>"9;-: 1054_LE+5FF#
M1U]KW6]/3;6QV8,@E\#W"<&)*E0_0))+U]0\)./Y5.94G$-O-&PJAB^^'YR:
MN/IVI)<2U+SUG/CAE6%B]U*HOX=XU;I,&753=4?^05XW\B'Q%)KC=325W1S%
M*"[>XYQ!MLP![8]_[;[J)6*/:S1#+L1N8\Z.;"58W6='7GH":MI\*A"AYMDN
M*FXM_F;0MM6Q' 9UZWQV2VDH(B)'RLQ)IO)^#7T1$U*@NZQAR*6QZ>UGR$-*
MW,CA-!Y,X8AS6C9V5'=PCAR1@6$G3H^ ?TDH)4]BA4C%*]Z0**.K]Q3"9G7A
M#F$H"0T*$AF2NE5Q4[C'=:73C^717+N*JRO39XE$-(:[5%?BMUF/2EZD7A9@
M&7*I&\?D!FVR02\YC[Q[-)GRD?>5Q6\(+S:D56@;6KB6WFVX\4[0X<H[04L]
MIQ&/NI$VW9#XU;8BUHY7B !F.0#]&:\*E$W-%U=O&:7'\;:XH)1/VM1AQSN?
MU<\B%;:O/PQ2[X=@(BT/P(<W_P=02P,$%     @ :(2F4A9QX83V$0  )JP
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MS18Q/_2;KLW?UURE7:,U\;:5S1:D6:/5UI)J1Z;IU(?9L("+G;[JXJ*Z_&B
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MP=X&27MK,F0NP5E)"@Z:9(.<U-MKRWPQDF%MPY:*DTHVRG*Z!]5CT(/^V-[
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MN*BB2B(7!HBQ3BTGF)E'%E*PPG)9S\Y;J-*]J)[4J4>I-9EMN&Z:DC99$K#
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M8#;;H(O*62Z?SW82^SVO?'32[XN]=Y7 -E&""O+-Z'RV!-3JQ1V64G5"8X+
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MDCXE3 ]I7;=7[?^(IQ\IW[I+[)>AC<YZWE]&'(O.X9^&<QB]1)CAC88=@R3
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MXKI):M:F0+]'C=I80#TV6-@4[[-"X<0"]/ S#H2)B7Q!Q62M,M)0-(O<.Z9
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M/%=KV'L#_.7F6K]$F.%__MO_!U!+ P04    " !HA*92>7/[9Q.3   &)@8
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M^K GK?F=@4Q6;F;?!:#M#+O^X!M83S8G8[N<@H95\-V*V>_[L^/L4.G34KM
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M+L?MO02RK-('T^@$B/674IA*4-]1H+=.<^Q@$OAR!2K]<&D  H\FT>E[4.6
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MVVC<< GCWCHT7"0TK"5?-ZO4:V\>)#02,F(P"",/8H6IMN!) $G,$/5"ZN$
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M@%'JF9P,Q4R1C5!HU\%GD 1*FPY1'$;<J?'I&3I34PEU)O8U:>JGL+2S!GI
M:.C;H'UPP)=!CGHOX-!W<OHI4J,GI[?(>RHYO>WQ;FI@D^2^4PFTW/SR/U)9
MZ"'OGU<-/ 5'(O0Y@V% ),38$S").8<J05'L2>%AY-0*U8GZU%3&ME;#;+>.
M:KE7Q6$C0\<NJF[S8Z=P!D-]8#5T$E83;O?^YD\#=&+M!%.?6LJ-@5%U5R=L
M#C5:MT&Z%N'(N92B_%F+LJ[K]$'M1,7-0T$3E% "8^51B*/0G)D2!!."8I\D
M'N;(J6S/18I3TV=KAH&9[NW)2*XV'> -UZZE.2[!;J>R>@5S8#6UC^/;'1QW
M8U[[+-AAB4V_=3LN$1VY?(<E!L=5/&Q?[)H ;QK(FI#^6SW :IM6* Q#A!5$
M82!-V9\$)J;S=*3M)^F')$8R=E$UIXA,3;ML>>QH"9U$TDY[7(O/P K#!9H.
MV>SG9>\WD_T$G9&SV,]+>IS!WO)LEP 9656+VH!9U5(U^L2<XJ99$U7 8R_@
M7 K(N# MYJ6"#$?:D9*A\KP(>4%D5;O4BMK4UOZ6WTUI\WIOW&'9):+C$M;M
M2J%W! ?6#B.#YQ(,TR.(8X7"7 &F8Q2,)3CM,3"7!ADQ L92GOWX%]N7W"^V
M;O1PHAYR0>_F6H.&"?(]B"+$(&9(0B(5@QZ- Y:$GA\(JX"7HY&GIDHWS '#
MG?U-U3Y<EZ^F.H,PL#:TE-_IZNFDK%?<->V/-]KETDDQ=F^33C_0S:]Y0XO,
MU*OZ*(LFR.T@[CUB-%(24<B]4$%LD@V8T'Z.BO0?*DR"B#B=IER@-[5ENF;7
MM/)L"G7VEV]P"7H[GZA'0 =>\CUAZ>PY62+4IQ-UB>2H_I2E_(>NE>UK?11=
M;]IETL"+J':P8!BB$&(>,TA9@F",D AX&"KN.14I.$%C:OKE,[^78KF0QW7P
M=LJ)E]V:D9Z"V$ZG7 G<T(Y4/YA=671]L,:EI\B\8+'UUA:F;8]V[#[<M=_-
MF[\MT^IYYP/X4-W+XO:>9JM.R7_40U2;)LE_7C6ZNGF2!;V3]3^^II7<]B:0
M/B<Q4@+*P)0G##T&281]R&64((']4#HV/IZ*9)/3@==WUFL@VEO^-4B@TBAM
MV[,W0&T[L\_ &BRP0JMY!!B\=F[_'9M 3V6B;?M/3X7?*>TQO]UOTKT7]]3F
MO]<VX),1;MP.Y),1^XSE,#T&N]X+E])$MYA^5/))+O)'PY1IM)>5*Y=I[H4)
M3P(/09](DU+M4Y@@A*$@OJ(AXH$G(K=KXHLTI[;'KUENFJ]MF08KKOL[5;&9
M$-O;YEYA'OSR>0"$.]Q26V/6[Z7U9;(CWV%;XW!\I6W_:C>==5M0L6T.\?S3
M\TX@1J1$$)@$(H]*!'% "4PDC2!+F/2D0(%*K&I(6=":FHY:L;IN@/(\,P:>
M8;=CH$L;S'8:J"?P!M8\5^#FK%\L$.E3K[21&U6?6,A]J$=L7NE:F&JA_YH7
MU%1 W3'93J7.("^(_2@0T.=,0)QP!DD844@(\E$88%^$3KU^'6A/3;_LL;[G
M2';-5W*9"#N-,Q"\ VL@&V0'2G;J %B_9:[LR8]<]<H9E^,B6.Y#]-JI[VWV
M),MJKXW6IJL'ELQ+P@1#$DBMUT*&(?5I"./88SA1<81])SO)G87)J3?3Y4/5
M73Z:Q(,UZSN-^_[02^>^MGFQ4W/#HCVPMKO0R6\CQ$XGOU[[KEP/X@C-_=JX
MF$*3/PN4+)O]V8QT=1>!O6:\B <XXEC"*%#8I)8CR#RA_ZJX]!(?LT@XVG0G
MZ4Q.P>WU%+BBS_$Y7%7H,<5B!0/.?8@%\S6NA.N_$BFYEU 9A//'^ECS<T6+
M:C1T#VD.A_%/=&$R=];P]H,K9R'W A[# ,4<8H]J7/T0PR#FB4P81A[!*US?
M9)9=*GM#=4WQ-X:IK3MQ-4J#NPZ[[2L:)@?M7S%T(^YSI%ZJFX5-"^Y+CW?<
MOO1F>9,)\X>Y-'JB"W-==*,WT:)XUOME<T<NO#".XU!!GL0FXIQ1F"@<02&]
M@":>Y-AWV\QLJ$YN:S/FI+DXJ%MORRW?CLK""G'E8^$KXD$12@HQ)0@2[DE(
M19@0GQ,2A%Z';:YOW,?;],ZB#V@%F+Q+,Q.(:<+=&IX&F10N6<CT5 @A]*1X
M3$]*%(304\(/(\]72,7.>^0P4S+\CMDZ(5+_?M"IL-Q:^P9WZ(UVC6G]PP[+
M,P/JFNN^8UN<4.IU&[8B/.ZF[(+%T1;M]'*'S-O=!/XS];T#J@*MHGP8AG$
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M9ABL!U8Z%T*RMCKIYC+,?<5AM2 V0OS5*>I3B+MJ0<4RWJIMA"X5)\VM=YU
MS'<2(663[D/+,N<IK:3XFE;WI5SH4>[N9*8YT-^?H.(AS5(3ZV5"9%?OS%6
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MC$@J0TYXPD.C3)Q3$\SM6U*+"%H9026DC6/B"(8FCI[+D!G;FS,"*#8NF<O
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M@(G O#K]P?!SXPT=.-I("!H1+3[WA^@9V#X783(R$;B&P\+\N0B6B>R?(_
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MT]Q8A=2R[KH'YZMNWV";\^8^? U\T:Y0&YE%)@+,YK#>$7 3.:Z' FAYBF\
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MAHF.SRN/%&874"#"/]="D47Z^_M/)+?5FY-U??M<<_"))=_'7 Q02B+!,"7
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MH1B<$9@]DQ92*58CXS*R)K4Q=Y,T3AO>1G@92/(]^)*SG/]M^%X3_O/PG.G
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M%&;K5)I(<F$A@_.A<+( FU.3-\NW2>DDJS].QS<SM.,$W@%DMA1_6D[L2X'
M!:L/=UPU)<_!*,DR2YFLJ=$=_D'32MN_+1G0PQPFY0YP<N4L8C.%:'5:93"Q
MVF#BDM5'IQY4T1$\TG8=O7.!&VT";_)P[@YZ.G$R!ZKY[O.?@V7>S9N0V]?#
M%-C/3G(M4JES@TA#Z_5R&D_6U=H^+%XO*.Z?KXD6^L2/YT7 $Q71F>(#".V)
M=^<8^,@U9(]>B:"Y:7-0/0SYG5R)# //$33:#9JO#9FYXX1M8[/QYK2V=TBB
M6DW7^!Z77Z<)3RNTKI0LGS[&890"28D<-+>*HA)=($A,P*4WN5"V&V2CH]&V
MC'62- QC 5VAH(,@X8[RP]/-Z[+^,%.@+7VDB#NKVBDJ&0@6'6@AE,^8M!9-
M8H;=R.LDZ!S01P^KD7YQ=J/,E6=I5 D!8HAD/)@9!)Y-[5=AO+?,%]\N5.B\
M%OE14':$/CH V;7#Q TK9YU#<YUH^3=<?UKDB::5>5'DENN+-%52 5?;R$LA
MF&4Z.*N:C$W9A;CNGC ? ['!M='/:)1KHPDG440NN&%$N5%U.D8"%^D[[WP,
M*I.#+DV\UC4JNGN0? QT#I=O%R44=]V(_3XGDYA-_POSOU(.1DZW#D:M++Z9
MO\=46\C65T=+BC+G'Z]Z91+'F_(A?)L8QV/)(@&BJB>5BD-(=2 ;)DNVDUVC
MSFZM&-H)M.Z)@+8+K7>P"]]U!B:9$SJA!%6[H2A;.R 'Z4#83-%KO0<N30ZI
MCSEW]$\$>T/(O)<&(<.<4>44>#24@AM;ATI'[< A+^#1JBA022V;N,I'/'7D
M[(F@<P25]@+F:HR_W#Q*>K9<AOG'C8!_^7[Y*V<-0Y_]$9;YS9=-#_F_TB^N
M5R_GISO")(BL"ZM]P052TL]8!)>U!!X9HR#)"R&:U.T.R\9NX'XJ5SXCJKB#
MS?Z^<X3MDIE@G;NJ:OQ2:M.JI!/X&#V@BI'GP)/Q\;$/>;:3NAM0G]3E3SM5
M=?OL_/W)Y\]A^7U1WD\_SJ=EFNK,K-/YEYL-:#9-%("_7JQQ=9V7W=Z9[_/Q
MPSPL/YBA(5Z2GRW^YO[%+]X1&VY,,5S7ZV[*W;U"<,XA""F2C!2/9ID>DO !
MZQ[MUNY;Y /)\9=9[=_MM.>H*:B.1I*1)"' )VE!Y:"$,T47;!-D[D3>B"_.
M&Z+DEEL;7E5/W)6=_]G.FUVL\)@.;3M;(_@T9ZTRW$?(D1. )&V-T2:DB(T9
M@U+I$EV'/NVR"P1I://AWR_-0V17'V0KHM)38,&\(@L,$JQQ1A@52F[S@.(^
MHIZ._]H'$;>/;@922P?9P.]UP,6OJ_7T,T6NJTDQSD6)##(3 93#6O56^_B1
MN*+U/@O5Y&+D.AGC5' ]-HR.$'T'P+FCB_L-:]#<6*93J?W:*1T1Q%0,]4VW
MH73$:,9=:1)N[43=.&52C^ZM!E=4!^A[AU]Q?H)7:KEN,A13-MGS .FT\U]Q
M$'.I?;=9";2M*\V;W%T\2-DXI4^/C;IA%=0!XFH%! F.K.>6[22>M3>2$A7%
MB1,6"KC:[X;EB$YP2H7:S%Z_FZ1Q"I\>/PX;1"4=@.L=*8@(J'[Z!1G.;+$9
M#?_KMWJNAZ>\3= QD0I)2D=50(7:VLUX!QDUMSY(Z6R3*J@=:!NG".KQ7=JP
M2NH =]L/D4^O.8C-E_-$'$Z_XMM9F)_9V,2R4GC1&H32FSG>#H*A<(%G%9*M
M[9A5F]Z,^],Z3H758^.RM1([P.EY4XRWN-QP>]/=%VO09Q/!HI%5? &<Y;7>
M1J.4.6 L32ZH'J!KG&*IQ\;?D,KI &O7!AMLFLV3$9WW&/_^VV*YZ4=/_W1:
M&GN+7;^I;! *6*FS\@3%M2%P#;+DJ)P/3*8F1RA'TCU.<=7C[^&/I]PG?B=Q
M4?9SNGML"B!6FU?:#:\I[EOT,6\N=F9^D,N,] GSR0R)IHMW;%?+3C9E &>U
M)_7N_]0JZZB#TY]=6$:R*466/(1LR;^&VBRJ:,JK/<L:/1:ARD-Z&I2BH^/3
M,SJJ0:;E">8KLQXVVKBTS*RC42YE8)Z^*&X3!!T8J&Q($#[HW.@ATLXDCGDY
M,@;";L6I;9390<APR=GVNK&'Q'N#>QL5J_/$@0M7^S!S?SK;AHML4W:266R3
M80W*QIB7.'W!_=%!T:E)7$U/KW)_-FCZ^PV.*5N0A<<,-D4.JMZ*U=,5L#7$
M\YI)E1M[]$-)'_-BJ5?H-U1^5W!_O9A_Q=4:\SOZNIRFS0 /XNAWRCKN8I;K
M) +WM5]>IDU.\=J.3R(@*QYS<"6[)A/FCJ)ZS'NLOD#>6N5//)'<R.)6<XX+
MO;RHC6]G#7/*'==_S/3R$)&,4#:'TD11B]511U='"FGP.6=P"65@+BC+Y&[Y
MY..6 C^P_5QYZ;&ZZZG':3LZGKD2H@@0R6N@;SEXCP)DT;0OY1@#MGF],Q0'
M3Z<@;Q^L[1MOM%%X!V%'O=)Y'3[CIL>FB3X9E2Q(5TNR78@0 HE1"OJ:9-#$
M4PNP7B5BY-: X^!@,9!2.@+4^?PFC*AB'>',N025O(%H2YVRZWTN*DA^<VSV
ML)#JH:GMX>J\ Q<'R+8#9&R,XT58G\H!<_'*> %1%PI?L53[,!0XNQ!4L45[
MT:2N\QH5(S=Z[,+9'*Z6GC!U9A*T_Z-C-2GRA6( 8374>GFP#)G0W%HG=YG*
M=SBJ>O W1VCT+FP<(-Y>T/&!?GDCB!)5Y)Q2=1F(@\UX"H<N@)(V*YV*\;H=
M-LZI&+FQ9C\>YR"U=("IPP5WR?8\W]C) ^<N1B&!"UOJW$Q&=N4](4IK26(F
M2VO3R[T!,QWXOL.PM6^/A]:*[@'LE\>@YW-:A-$^L-KEM@ZEM\J"*R4"+SE%
M2=L#_;@)4F]2,G*>.#HXMC5Z.%A374#MKLD?@L=D+7>0E-/U(L="I!^!,!:Y
M-DEQT:AWR#$3==JU'NYB#Q]&71W@;LMLF"2]EU(C),VP%IE&B-EEH)\ES5D1
MLDVWV*<SC&<O'3\\C&<?@8\\$/Y=M:V-#*3GRHN8(<HZDE-Q\M98RTEY,(%%
M;J39I<9FIP'P%ZN.W(]Z5-=SN/A[P,S9KFSILXE3BD@YAMJ<44)DA@/G160R
M*R?<+N/A=D?-F-'2$1J[J?,#Q-?!YO)ON*I75:>Y"%K-)=,@?8W'ZDR@2%0!
MAF(I&DLYZB8U>5=H&+G5>!>!RZ$JZ0=-9YNFEBZC<INS.+/I"TQ[,)E"\06S
M5DY%T^0 _1H5XP8H!^MR.R8.$&P'J#BX%^6KBPZ#*1-?5CKP(=?IXLZ"-Z$^
M3(FL!*ZT;#-]\GC21^Z WX5'>V0 C CYTZJ00]G]+4R7IR,I+NOXZMOK6FWW
M=3&CCZDON):4\_SZ^<ML\1UQ-3$82/J80/O:4#N2:PE%:DB\*.E2LM'>L(R[
MZI<>D>K.C\8&AN/B*6#CAS*:=]/5WW];(IXWZ7YW12P3X:06)!'*Y;,BJ3 #
MSA@$)M [@5HI8Q[?8NXC>>0B@!_%7 9#Q0]E*^=.Y ,N/U^Z#J^E#J09\ DC
M*.\9Q"J8$&U@1A?A](.ERX]$Z\@7UC^*=1R/@Q_2+%Y,OTXSSO.[:SNK4\9S
MYC(8GVH+<N%K\4JDA,P'SJTKSHUH'EMI'OE.Z$<SD^-Q\4.:R[]=A*)5,&]*
MF2:B]MD\OU[,S\7T8KJDWUTL5Y/(4TFRSMG3@<2E0JYOA0HDR;,-TJG =NS#
M/CHO(]][_&CFU0Y'/Y39;0MI'Q)6<9MKB 0\A_K*VB)XEPU8SH5F*2?R57WD
M/T.87+O+@A_%Y%ICZ(<RN*M1\D-"RMHJHQ,#VO8-"0DYQ-HPW6;EA5&BW!HI
M]-@YU! &UN[L^D<QL%:8^2$-ZVI<_9"PD&G)4'NPP5%R:G*]$3,%2N9")E=$
MM".<Y!W R<@39W\T0VN%H1^R2<'9?WOV'I]?Y[5]CX*;RX_?HN!>@8S0H< :
MIIR/MG: ]*"R=^"29&!R?:@9:+O@8C<O]T0[%"CEE1(>@061:]4Y.1=F/4@7
M7?':2L]NM/S[1X>"1\!:NPX%^RB\@_J6:Z^G(TN%"0Q0ZEL>Q3@%<#;48T M
MA(U)VIL7)__H4# (#N[K4+"/4CH"U%FYES>&VWJFA=:*VA:/@8_)@11)9:%U
MX:+)V[N>7LT=KL[[.Q3L(]L.D'']X309@%)!"XB>OJCB:X?[@+7#??(E2E1M
MNJ'\D!T*CG$VAZNE)TQ=,8DBG03'L@:EZRS[@@ZXC\)BLB68)H^+.NY0L)=&
M'^A0L(]X>T''Q7-E:15WQ"[([&,E/D&@[!D,:I%E9-:5)G6X/V2'@J,]SD%J
MZ0!33=XF"U.L+T6!YV2>*BL/010#T@KF%9.:B29NZT?O4+ 7MAZC0\$^BNX
M[.='CEO>O\OH7= 97&!U5Y'\]/T[BYYG9F2.KLE[JSLIZKPLNSE8;@[]&41S
M'4!P6\_>=^]_/V,FRB@3SP4"UA*_5%N09!;!)V^X84+IT.1X[5ZJ.B]Y?FPH
M#J?!#N!X]ZM]I;,@1CQ8GNI@\41[38X)'.:(:#=)?Y,]_$=OI'%,J#F,NCK
MW9:^#BXQSZ.1D(TDFXPE4' C!03G=&:.24K*6@#NZ332V$O'#S?2V$?@/31%
M.&TF(K3SDF)>)VL(;&K?YB2(<F6M]88B8-PEM?AS-M(XQ/4<+OX>,'.V*VL4
MK,[I@RSK08]/!9P-O'(OC=,J)_^C-M+82V-W--+81WP=;"Y77_K[X$O@64#*
MNH!2C.(Q(RC2HZB,/"9FOU/CG7\TTC@N<#E4)?V@Z;S[5. B8*BM;*.H<P,8
M!*\L1._)1%BTI4WW@TX;:>RERWL;:>PCV Y0,4"A7JZY(%<*1-04SBDK@9RQ
M (LJN!"2#:Y-+<T_&FD,D8H]+@">,N3/1F.].5FOUF&>R>9?GVSB"@S2FF"1
MX@I+<85)'&+! %R%;%W((N8V_6&'YJ3ST]J!H3B4)0R"BQ_+,/X=IQ\_K3$_
M^XK+\!%__8;+-%WAV^4TX833SNA+JM/ D9242P$?%8(/JDC:>Y&7<1I_#\-?
MY^?,3\:(!L/0#V!:?Z5?7*]>SM_B<KK($Q[06:<*Q.CJZ!O+H&[S4(H)VM76
MM(+W:$'7V7CR73;&-)0C$/$4[.'.B'<K^_>ZBE)0>:L];<",=N$8(E"R%R$Y
ME65B7G'7V9R)O7E\\HTXFEK22%CZ$<SLG/O=I,-X9B6'!)GI2)MR".2$T$**
MD6LI> UZN[2TO=A\\FTY1C6V=HCJP=[JM>3+U>H$\XN397T-M6%Q(Y#5U?':
MYUSFB> A."V(PWH=H9A!B$E+RA%YXHI%45BC01_[DOKD>V,<A?NVFNT!NT<&
MI+]^^S)=;OZ;RZA4A: PD@A4M C*9MHN.<D^6,]$9H[[TN3E6@->GGSCBC&3
ME6.Q\13,X^&-[Y8,[M_Z9$#MDP+C$@/E-S-S$VU]7$ATQB3TX_0G'YC1)]^H
M8N1PJAVJGH+5/2">WQ;+@M/UR?(RWIQ(([0-]2R>6XHI(ZF*_I; ,+3"2,N\
M-CUN2EMXV<EV_)_5=AICXRF8QT/N8XL,[G4?5GJ7-,\U%>.@"I*^8BE@N54Z
MI\*%&2>@&YC1W2Y"V9_5LL:$U5,PN]W.0&KMQME-L=!!8\H:C'24*SJ5P*NH
M2%M"J<*-")T-H[F+D]T,YQ\E!"V \6-9QKT.0UI>+&H+5M7!5X*07>MW04JI
M-&>BZ#;O'!^)O]VLZ!\U!(\'HJ=L6[_^Y\ET_?WE?+5>GFQV[S?K3[C\\"G,
MSP3V>C'_BBL2TYG3T;3G:AE4K9.G[1AE@%"R!9Y**5J8Z$1?&=*^'.YF7_\H
M/7A,(/TY+.R&0]I</==.+A>]1R>Q*!\LB8OI'$#Q)"!&%2"79+4V*; V'9AZ
M8'XWN_S3%C+T!K\?VF1O%%AA#$Y$3N&W)9TJA@Q"D!ERY")&]$PV>D?^2 SN
M9GI_VK*&,6#T)S*OA_V28HH+7UV2*IH288V4")/TG(H",87,_1/;%O>4P&X&
M^L/67_2BAKV ^$-;\+]M(HH+SV:-LB+E",PG"THJ$HEG&;P1W"3E92Q/;(.\
MSN!N]O>/"I!'A-&?R+P>]DLD.+3UYD1$18)+NL88(H 7*AAE+..BKRN$H26P
MFX'^:2M)N@3B#VW!9[>@5YQ;/09311;R9HB@HD=PTEC(QELGN.5&V*=EH[=X
MW,T*_U&3\KA@^C/86:TV>-@[>9.RBRE#**AK?*'!AR! ZN@=T[YH[.OQ\:#L
M[_8V^4];U](?!/\$\\%NM-QZ[/E@HKOY8#<$,L)\,!:$ME)*4)CHB]$%(GH.
MW&'1R28MLWM(0T]Z/I@42EOD$;2/NK87<."XYE#2:3-FAJQ)$\\_X7RP?;#6
M;C[8/@KO()BZ-KM(V6 DAMI/E2M06B!$6WN9Q>A%45DYV61,P8\X'VPO'-PW
M'VP?I70$J+,N=K84AKJ8TQ[TRH0,42!%+)GI8'A6WLN6D.JA/^#AZKQ_/M@^
MLNT &=='=ZALC7480 1'<BA,@8M:0-%69&]*%J&3:3U/8#[8,<[F<+5T@*G#
M!7?/,(22D\E!1# L^CHPFNQ*<@^H0_"2\<S].%WXGOBTGKVP]1C3>O91= ]@
MO[,1?D#-DHJ4^0M)C' EP(DL07//&<LL!MVH]\,QLRF>P!BT8QSK,.KJ '=;
M1B6(C*4XPR'6L@45"T4Q.FNPQ4:?BT?BIP7@GLYLBKUT_/!LBGT$WL.<@5.'
M[[0L*"T8G0LY?,K(0RUXR<B54<$AA;\[H*3!;(HG,!;G$-=SN/A[P,S9< 5!
M%B.CT'5B6<V0BH808VV-)KPKW!L7=GD:_!1G4^REL3MF4^PCO@XVEP%N<ESP
M0J%UP+&VK&3*0DB*@1;.).L,T[S-&>O1I/\H<W2."I,>%P!/_!Z,?K(\(8JG
M(4YGTS7]Y.RNI]W=U]U+/N9]UXZ,'WG'=9&XWGW-4-!+G^JH1.,);(8GPGJQ
MX%!Z0WXWE38]^H>_[=I<LMR6ZZE)AR2S%=: 1>,H-RX!HJ>=*2;M6:"4W9K=
M;N[N6&#D@XEA]'ONRP:3Y(@;\AT\G$ZUR0D3UQY(-O6DF<()SRPYV&3K4/B@
M\.:;B9W!,-Z=SW!*NQ\%>TNP/Q"<):%:QY3KE:I4V8 *W$ L,D"A+%24I++U
MA_J$,9/YP?1V/PX.$&)_2+@,NA)F:7Q@8$V53'V<[53Q(#2FHHV-QK$#P;!?
M?#SX_<QC.8;#9-D))MZ1+HB(3\_F^05^Q=GB2PW,W^/RZS3AZOG)LDIX(DR2
MC%-B(+T4M;0T0D#*33U&,BQ7ZS7"/B#9:=6NO,B!2MZ"G.$EW@F4KN5]\_P+
MSK%,UQ<<>2>CS9@@;ZH<M2*+DQHI/G:.)?*DFMM],'3_<EVYG.' ,Z",.S@T
M>O,%:Z_2^<=7&.@CSP3V_9R;HHN7L@[Q<;[4,78%?"%A18],1V0\QR:U!?>3
M-<Z=6!-D-=##_JCRIZB:X\>PQOQA.'#5DNS;$CMG*F(V*A0'0=19;,$8R@^=
M ^9BMB4*ITR3_/]^LL:Y]6@+KN'TT('+NI,1\L:O%_-TOGTGP7SB' 263(Y8
M,C(9%8%%P2(JBZE-O=QNY(US7MT490WT,G98]0J_3=-B_G*>EIL#]##[9;%<
M+OX@/_V.7.6$LMCD:_5A,*J6O<0"(:4(.:HDDF;,R >/CG=9:)PY'^U"J2'E
M^L2O(5[24O./4TJ(GZU6N&Y_"7'7@H]Y!;$3T^TO(-#RZ'.@/:]V"Z%8O5!
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M"-86_Z'.+#7*2N>,:#(O[2!JQVWD, (<!U%;!]B\@[V)T4Q8M *TQPP4_U(
MG*4&%A5F4W3.OLE<CSOH&;G'0QN #2'[#B#T_M-BN:Y'HALV+J5T9A!&9V>+
M*""*B*"TJJV>59U*$((6+!B9FIP0WD_6R%TBV@!J0$UT@*OKYO%N^O'3^DWY
M?87/R"VO)TX5K3UIOH3:43>B@\BUAT#B<R%:9=KD"_=2-7*7B<=P4\?H8>PK
MV-,+PA?3U9<3VK:?+U;KU22'Z'A6=8P!)V?KJK.-.H!AVD;KO11NM\X26SY\
MY#X2#>Y9CY5@Q_7_,T++8KGYI##/KZ8)YX3QCTO<3.X^L/S_H0\=JOI_+^*'
M&+QZ;<EG6Y:\*,&5-@KCN +ZIKY$(9C%A D$9F]XCH%+N9.![;SD\8^7+A;Z
MBL^6R_J^KRZP[?&+TDD;(30X'NN@@#H;B95:).6<Y@DU#TVZ!.]!XXC#7-N@
MY/9[I3;Z>KK.ZO )V;M^]",YKD93M!]<]Z@W7SM^]B.)L-GL[=V-FPO/2_("
MDH@*E!64>)C_O[IKV6WK!J+[_@L!OA^; @':A0LX*>#LA2$Y# 0H4FK+0=*O
MS_!*22S7DJGH7O%VHX4ED)S#X^&0G#D4GG'/$X4A7,KFPO.)EX#6HJ*00P3G
MF(G!5'$;S8*P6!7+?0XB42C<]H;*3#/U)IS?<\NWSD!Z'MN+J@F\?B1OE#8?
MULM_,2]DY$($2 Q3+4(R4K' (S*ON1;*H<ZV3?'R2 =]TNRNQ9$Q4.W-C)M/
M-"4[T9K]-<9"2TEH*,Y$X0,>D@*1P%F5A.">..Z?E[4<(<5_V^Z3XW8M/ER(
MY2RH< M?EA\?/]X!!3>W2_K8;M;XL$#.BQ5*$":)MN4"# M9!T:V!)64,]JU
M%0>?Z*1/MME5R3$"NO-@R?>Q?Y>3*1K1%,-90:SL=HE!\(8YC,DK:Y0W< 8_
MGC7?)_/KNLRX!-%9<F)75D7+(4?PZ.KAOJE)0D(G%A$$4SX;):*WP-N*1TYV
MTR<?JRM'?@GA67!E'S.]60T_QKS=_$%_66T^#8<CN"*K[G?%68 07?6',5?
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M9$; =/I3B_T7]2/" _[^VS=02P$"% ,4    " !HA*92WCS-6=8'  !B)0
M'@              @ $     97AH,S$Q8V5R=&EF:6-A=&EO;F]F<')I;F,N
M:'1M4$L! A0#%     @ :(2F4F@?M#38!P  X20  !X              ( !
M$@@  &5X:#,Q,F-E<G1I9FEC871I;VYO9G!R:6YC+FAT;5!+ 0(4 Q0    (
M &B$IE)>B>QG.@4  ,(8   >              "  280  !E>&@S,C%C97)T
M:69I8V%T:6]N;V9P<FEN8RYH=&U02P$"% ,4    " !HA*92#WX1#U09 0 Z
M3 P $0              @ &<%0  ;'AR>"TR,#(Q,#,S,2YH=&U02P$"% ,4
M    " !HA*92&LOC] $-  "/B   $0              @ $?+P$ ;'AR>"TR
M,#(Q,#,S,2YX<V102P$"% ,4    " !HA*92%G'AA/81   FK   %0
M        @ %// $ ;'AR>"TR,#(Q,#,S,5]C86PN>&UL4$L! A0#%     @
M:(2F4L*LP_7U0   $]8" !4              ( !>$X! &QX<G@M,C R,3 S
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( &B$IE)Y<_MG$Y,   8F!@ 5
M      "  :"/ 0!L>')X+3(P,C$P,S,Q7VQA8BYX;6Q02P$"% ,4    " !H
MA*92PD\5E!=2  #SL , %0              @ 'F(@( ;'AR>"TR,#(Q,#,S
?,5]P<F4N>&UL4$L%!@     )  D ;@(  #!U @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
